_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,e1,e2,expdec,rel-type,sent_id,sentence,term1,term2
503460850,7/16/2014 13:28:58,,1324253054,7/16/2014 13:28:50,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],Comparison,N/A,98,73,109,84,1,RO-may_treat,907590-FS1,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
503460850,7/16/2014 13:37:28,,1324256675,7/16/2014 13:36:52,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",Comparison of,N/A,98,73,109,84,1,RO-may_treat,907590-FS1,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
503460850,7/16/2014 13:39:01,,1324257280,7/16/2014 13:38:42,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],in essential,N/A,98,73,109,84,1,RO-may_treat,907590-FS1,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
503460850,7/16/2014 13:45:47,,1324259709,7/16/2014 13:45:26,instagc,1,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],Comparison of enalapril and PROPRANOLOL in,N/a,98,73,109,84,1,RO-may_treat,907590-FS1,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
503460850,7/16/2014 13:51:11,,1324261539,7/16/2014 13:50:58,instagc,1,28301350,GBR,K4,Plymouth,92.28.208.109,[TREATS],[TREATS],in,N/A,98,73,109,84,1,RO-may_treat,907590-FS1,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
503460850,7/16/2014 13:53:55,,1324262577,7/16/2014 13:52:53,vivatic,1,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],Comparison in essential,N/A,98,73,109,84,1,RO-may_treat,907590-FS1,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
503460850,7/16/2014 13:56:21,,1324263580,7/16/2014 13:56:06,instagc,1,14378608,USA,NY,Brooklyn,24.189.101.95,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]",Geyskes Comparison enalapril,N/A,98,73,109,84,1,RO-may_treat,907590-FS1,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
503460850,7/16/2014 15:41:19,,1324302561,7/16/2014 15:38:50,prodege,1,27990290,GBR,I9,Bury Saint Edmunds,86.142.231.81,[TREATS],[TREATS],Comparison,enalapril and PROPRANOLOL treats hypertension and these are being compared.,98,73,109,84,1,RO-may_treat,907590-FS1,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
503460850,7/16/2014 16:10:43,,1324317983,7/16/2014 16:09:38,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PROPRANOLOL,n/a,98,73,109,84,1,RO-may_treat,907590-FS1,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
503460850,7/16/2014 17:05:16,,1324339771,7/16/2014 17:04:46,prodege,1,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,98,73,109,84,1,RO-may_treat,907590-FS1,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
503460850,7/16/2014 17:09:24,,1324341179,7/16/2014 17:08:11,neodev,1,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[SYMPTOM],[SYMPTOM],PROPRANOLOL in essential HYPERTENSION,N/A,98,73,109,84,1,RO-may_treat,907590-FS1,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
503460850,7/16/2014 18:25:12,,1324400042,7/16/2014 18:24:57,gifthulk,1,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],PROPRANOLOL in HYPERTENSION,N/A,98,73,109,84,1,RO-may_treat,907590-FS1,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
503460850,7/16/2014 18:37:42,,1324405914,7/16/2014 18:36:13,zoombucks,1,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],Comparison of,na,98,73,109,84,1,RO-may_treat,907590-FS1,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
503460850,7/16/2014 18:48:36,,1324411609,7/16/2014 18:47:23,prodege,1,9378607,GBR,H9,London,90.201.89.10,[SYMPTOM],[SYMPTOM],Comparison of PROPRANOLOL essential HYPERTENSION,n/a,98,73,109,84,1,RO-may_treat,907590-FS1,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
503460850,7/16/2014 19:52:11,,1324445226,7/16/2014 19:49:52,prodege,1,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],in essential,N/A,98,73,109,84,1,RO-may_treat,907590-FS1,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
503460851,7/16/2014 13:28:54,,1324253045,7/16/2014 13:28:22,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],A case of Leigh's DISEASE DYSTONIA paraparesis the presence of low attenuation,N/A,127,18,134,68,1,RO-has_manifestation,906024-FS1,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
503460851,7/16/2014 13:50:52,,1324261449,7/16/2014 13:50:09,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],features as,N/A,127,18,134,68,1,RO-has_manifestation,906024-FS1,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
503460851,7/16/2014 13:53:44,,1324262492,7/16/2014 13:53:16,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is reported,N/A,127,18,134,68,1,RO-has_manifestation,906024-FS1,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
503460851,7/16/2014 13:58:28,,1324264496,7/16/2014 13:57:49,elite,1,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) DYSTONIA the presence of low attenuation areas,N/A,127,18,134,68,1,RO-has_manifestation,906024-FS1,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
503460851,7/16/2014 14:58:12,,1324287300,7/16/2014 14:57:39,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,[SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]",such noteworthy features as,N/A,127,18,134,68,1,RO-has_manifestation,906024-FS1,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
503460851,7/16/2014 15:33:48,,1324299569,7/16/2014 15:33:18,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[IS_A],[IS_A],Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY),n/a,127,18,134,68,1,RO-has_manifestation,906024-FS1,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
503460851,7/16/2014 15:40:39,,1324302203,7/16/2014 15:40:14,elite,1,28276268,USA,MI,Fenton,68.188.185.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is reported with,[DIAGNOSE_BY_TEST_OR_DRUG],127,18,134,68,1,RO-has_manifestation,906024-FS1,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
503460851,7/16/2014 16:23:30,,1324323360,7/16/2014 16:23:05,prodege,1,23541832,USA,AZ,Tempe,149.169.143.104,[SYMPTOM],[SYMPTOM],reported with features as,N/A,127,18,134,68,1,RO-has_manifestation,906024-FS1,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
503460851,7/16/2014 16:26:54,,1324324573,7/16/2014 16:26:02,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],(SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) DYSTONIA,n/a,127,18,134,68,1,RO-has_manifestation,906024-FS1,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
503460851,7/16/2014 16:55:41,,1324336614,7/16/2014 16:55:08,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) DYSTONIA,n/a,127,18,134,68,1,RO-has_manifestation,906024-FS1,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
503460851,7/16/2014 18:30:25,,1324402257,7/16/2014 18:29:57,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[SYMPTOM],[SYMPTOM],Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with features DYSTONIA,N/A,127,18,134,68,1,RO-has_manifestation,906024-FS1,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
503460851,7/16/2014 19:44:29,,1324441471,7/16/2014 19:43:58,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[PART_OF],[PART_OF],"early onset,",N/A,127,18,134,68,1,RO-has_manifestation,906024-FS1,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
503460851,7/16/2014 20:10:02,,1324452750,7/16/2014 20:07:07,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[SYMPTOM],[SYMPTOM],noteworthy features,n/a,127,18,134,68,1,RO-has_manifestation,906024-FS1,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
503460851,7/16/2014 20:27:37,,1324461100,7/16/2014 20:26:57,elite,1,28466071,CAN,AB,Edmonton,68.150.39.46,[SYMPTOM],[SYMPTOM],reported with such noteworthy features as,N/A,127,18,134,68,1,RO-has_manifestation,906024-FS1,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
503460851,7/16/2014 20:53:19,,1324471714,7/16/2014 20:52:42,clixsense,1,16827630,GBR,A7,Birmingham,86.146.169.103,[NONE],[NONE],N/A,NONE,127,18,134,68,1,RO-has_manifestation,906024-FS1,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
503460852,7/16/2014 13:32:42,,1324254751,7/16/2014 13:32:30,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],suppressed the,N/A,81,116,91,124,1,RO-may_treat,908049-FS1,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
503460852,7/16/2014 13:36:18,,1324256282,7/16/2014 13:36:00,clixsense,1,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],suppressed,N/A,81,116,91,124,1,RO-may_treat,908049-FS1,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
503460852,7/16/2014 13:38:41,,1324257141,7/16/2014 13:38:24,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],suppressed,N/A,81,116,91,124,1,RO-may_treat,908049-FS1,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
503460852,7/16/2014 13:47:50,,1324260380,7/16/2014 13:47:24,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],suppressed the,N/A,81,116,91,124,1,RO-may_treat,908049-FS1,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
503460852,7/16/2014 13:55:25,,1324263141,7/16/2014 13:54:28,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],suppressed the,N/A,81,116,91,124,1,RO-may_treat,908049-FS1,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
503460852,7/16/2014 13:55:53,,1324263348,7/16/2014 13:55:42,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[TREATS] [CAUSES],"[TREATS]
[CAUSES]",inhibited atropine reduced BRADYCARDIA combination,N/A,81,116,91,124,1,RO-may_treat,908049-FS1,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
503460852,7/16/2014 14:50:39,,1324284685,7/16/2014 14:50:06,neodev,1,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],the combination of ATROPINE and tertatolol suppressed,N/A,81,116,91,124,1,RO-may_treat,908049-FS1,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
503460852,7/16/2014 15:27:23,,1324297428,7/16/2014 15:26:58,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],reduced the,n/a,81,116,91,124,1,RO-may_treat,908049-FS1,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
503460852,7/16/2014 15:55:12,,1324308395,7/16/2014 15:54:13,prodege,1.0,27990290,GBR,I9,Bury Saint Edmunds,86.142.231.81,[TREATS],[TREATS],combination suppressed bradycardia.,the combination of ATROPINE and tertatolol suppressed the bradycardia.,81,116,91,124,1,RO-may_treat,908049-FS1,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
503460852,7/16/2014 18:21:19,,1324398581,7/16/2014 18:20:49,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,N/A,81,116,91,124,1,RO-may_treat,908049-FS1,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
503460852,7/16/2014 18:24:17,,1324399705,7/16/2014 18:23:39,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],only reduced the,na,81,116,91,124,1,RO-may_treat,908049-FS1,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
503460852,7/16/2014 19:02:27,,1324419926,7/16/2014 19:01:38,tremorgames,1,19721342,CAN,ON,Ottawa,99.246.56.98,[CONTRAINDICATES],[CONTRAINDICATES],combination,N/A,81,116,91,124,1,RO-may_treat,908049-FS1,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
503460852,7/16/2014 19:22:30,,1324430794,7/16/2014 19:22:00,clixsense,1,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],suppressed,N/A,81,116,91,124,1,RO-may_treat,908049-FS1,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
503460852,7/16/2014 20:04:37,,1324450354,7/16/2014 20:03:30,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],suppressed,n/a,81,116,91,124,1,RO-may_treat,908049-FS1,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
503460852,7/16/2014 20:36:58,,1324465032,7/16/2014 20:35:06,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],suppressed the,N/A,81,116,91,124,1,RO-may_treat,908049-FS1,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
503460853,7/16/2014 13:37:40,,1324256764,7/16/2014 13:37:27,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[CAUSES],[CAUSES],causative agent,n/a,0,85,24,96,1,RO-has_causative_agent,903552-FS1,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
503460853,7/16/2014 13:46:43,,1324259995,7/16/2014 13:46:31,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[CAUSES],[CAUSES],causative,N/A,0,85,24,96,1,RO-has_causative_agent,903552-FS1,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
503460853,7/16/2014 13:52:22,,1324261935,7/16/2014 13:51:51,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],is the causative of,N/A,0,85,24,96,1,RO-has_causative_agent,903552-FS1,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
503460853,7/16/2014 13:57:11,,1324263947,7/16/2014 13:56:55,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],BURKHOLDERIA PSEUDOMALLEI is causative agent of MELIOIDOSIS,N/A,0,85,24,96,1,RO-has_causative_agent,903552-FS1,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
503460853,7/16/2014 14:57:07,,1324286901,7/16/2014 14:56:40,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES],[CAUSES],is the causative agent of,N/A,0,85,24,96,1,RO-has_causative_agent,903552-FS1,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
503460853,7/16/2014 16:13:26,,1324319166,7/16/2014 16:12:38,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],BURKHOLDERIA PSEUDOMALLEI MELIOIDOSIS,n/a,0,85,24,96,1,RO-has_causative_agent,903552-FS1,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
503460853,7/16/2014 16:21:20,,1324322499,7/16/2014 16:21:02,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[CAUSES],[CAUSES],is the causative agent,N/A,0,85,24,96,1,RO-has_causative_agent,903552-FS1,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
503460853,7/16/2014 16:50:02,,1324334656,7/16/2014 16:49:30,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],BURKHOLDERIA PSEUDOMALLEI is causative of MELIOIDOSIS,N/A,0,85,24,96,1,RO-has_causative_agent,903552-FS1,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
503460853,7/16/2014 16:51:05,,1324334987,7/16/2014 16:50:39,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[CAUSES],[CAUSES],causative agent,N/A,0,85,24,96,1,RO-has_causative_agent,903552-FS1,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
503460853,7/16/2014 17:03:37,,1324339250,7/16/2014 17:03:32,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,0,85,24,96,1,RO-has_causative_agent,903552-FS1,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
503460853,7/16/2014 17:12:28,,1324342296,7/16/2014 17:11:15,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[CAUSES],[CAUSES],causative agent,N\A,0,85,24,96,1,RO-has_causative_agent,903552-FS1,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
503460853,7/16/2014 18:28:48,,1324401712,7/16/2014 18:28:19,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],is a gram negative bacillus that the causative of,na,0,85,24,96,1,RO-has_causative_agent,903552-FS1,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
503460853,7/16/2014 18:33:37,,1324403849,7/16/2014 18:33:19,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[CAUSES],[CAUSES],BURKHOLDERIA PSEUDOMALLEI is the causative agent of MELIOIDOSIS,N/A,0,85,24,96,1,RO-has_causative_agent,903552-FS1,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
503460853,7/16/2014 18:42:57,,1324408578,7/16/2014 18:42:33,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[CAUSES],[CAUSES],BURKHOLDERIA PSEUDOMALLEI causative agent of MELIOIDOSIS,n/a,0,85,24,96,1,RO-has_causative_agent,903552-FS1,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
503460853,7/16/2014 18:59:28,,1324418010,7/16/2014 18:59:18,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],causative,N/A,0,85,24,96,1,RO-has_causative_agent,903552-FS1,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
503460854,7/16/2014 13:27:53,,1324252610,7/16/2014 13:27:42,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],dose efficacy study,N/A,161,117,180,127,1,RO-may_treat,907513-FS1,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
503460854,7/16/2014 13:28:10,,1324252726,7/16/2014 13:27:59,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],atorvastatin,N/A,161,117,180,127,1,RO-may_treat,907513-FS1,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
503460854,7/16/2014 13:32:02,,1324254510,7/16/2014 13:31:35,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],dose efficacy fluvastatin in patients with,N/A,161,117,180,127,1,RO-may_treat,907513-FS1,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
503460854,7/16/2014 13:35:07,,1324255835,7/16/2014 13:34:34,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[MANIFESTATION],[MANIFESTATION],in patients with,n/a,161,117,180,127,1,RO-may_treat,907513-FS1,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
503460854,7/16/2014 13:38:37,,1324257112,7/16/2014 13:38:14,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HYPERCHOLESTEROLEMIA,asd,161,117,180,127,1,RO-may_treat,907513-FS1,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
503460854,7/16/2014 13:44:45,,1324259355,7/16/2014 13:44:32,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],dose,Na,161,117,180,127,1,RO-may_treat,907513-FS1,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
503460854,7/16/2014 13:49:02,,1324260780,7/16/2014 13:48:43,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],dose efficacy study,N/A,161,117,180,127,1,RO-may_treat,907513-FS1,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
503460854,7/16/2014 13:54:21,,1324262774,7/16/2014 13:53:46,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[TREATS] [CAUSES] [LOCATION],"[TREATS]
[CAUSES]
[LOCATION]","atorvastatin versus lovastatin, CURVES","Due to one, the other may occur.",161,117,180,127,1,RO-may_treat,907513-FS1,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
503460854,7/16/2014 13:55:21,,1324263114,7/16/2014 13:54:31,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],dose efficacy LOVASTATIN in patients with HYPERCHOLESTEROLEMIA,N/A,161,117,180,127,1,RO-may_treat,907513-FS1,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
503460854,7/16/2014 14:47:55,,1324283818,7/16/2014 14:47:24,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS],[TREATS],Comparative dose efficacy study,N/A,161,117,180,127,1,RO-may_treat,907513-FS1,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
503460854,7/16/2014 15:08:39,,1324291489,7/16/2014 15:08:06,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],dose study of,na,161,117,180,127,1,RO-may_treat,907513-FS1,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
503460854,7/16/2014 15:32:33,,1324299203,7/16/2014 15:32:18,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],dose efficacy,n/a,161,117,180,127,1,RO-may_treat,907513-FS1,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
503460854,7/16/2014 16:22:05,,1324322791,7/16/2014 16:21:21,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,161,117,180,127,1,RO-may_treat,907513-FS1,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
503460854,7/16/2014 16:38:53,,1324330043,7/16/2014 16:38:02,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LOVASTATIN HYPERCHOLESTEROLEMIA,n/a,161,117,180,127,1,RO-may_treat,907513-FS1,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
503460854,7/16/2014 16:54:38,,1324336213,7/16/2014 16:54:04,instagc,1,23149109,USA,NC,Cary,24.206.38.18,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",efficacy study of LOVASTATIN in patients with HYPERCHOLESTEROLEMIA,N/A,161,117,180,127,1,RO-may_treat,907513-FS1,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
503460855,7/16/2014 13:34:42,,1324255719,7/16/2014 13:34:10,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[CAUSES],[CAUSES],results in,na,64,18,80,36,1,RO-has_finding_site,905456-FS1,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
503460855,7/16/2014 13:36:38,,1324256407,7/16/2014 13:36:19,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],in,N/A,64,18,80,36,1,RO-has_finding_site,905456-FS1,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
503460855,7/16/2014 13:38:26,,1324257050,7/16/2014 13:38:08,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],results in a,n/a,64,18,80,36,1,RO-has_finding_site,905456-FS1,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
503460855,7/16/2014 15:44:50,,1324304080,7/16/2014 15:44:28,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],results in,n/a,64,18,80,36,1,RO-has_finding_site,905456-FS1,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
503460855,7/16/2014 16:20:32,,1324322183,7/16/2014 16:19:56,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],total loss,na,64,18,80,36,1,RO-has_finding_site,905456-FS1,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
503460855,7/16/2014 16:40:37,,1324331002,7/16/2014 16:39:40,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[CAUSES],[CAUSES],CATARACT FORMATION results LENS TRANSPARENCY,N/A,64,18,80,36,1,RO-has_finding_site,905456-FS1,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
503460855,7/16/2014 16:59:43,,1324338037,7/16/2014 16:59:09,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[SYMPTOM],[SYMPTOM],results in a total loss of LENS TRANSPARENCY,N/A,64,18,80,36,1,RO-has_finding_site,905456-FS1,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
503460855,7/16/2014 18:18:58,,1324397435,7/16/2014 18:18:28,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],results in a total loss of,na,64,18,80,36,1,RO-has_finding_site,905456-FS1,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
503460855,7/16/2014 19:57:51,,1324447721,7/16/2014 19:57:35,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[MANIFESTATION],[MANIFESTATION],last stage,n/a,64,18,80,36,1,RO-has_finding_site,905456-FS1,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
503460855,7/16/2014 20:58:51,,1324473886,7/16/2014 20:58:33,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[CAUSES],[CAUSES],FORMATION,NONE,64,18,80,36,1,RO-has_finding_site,905456-FS1,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
503460855,7/16/2014 20:59:13,,1324474039,7/16/2014 20:58:48,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],results,N/A,64,18,80,36,1,RO-has_finding_site,905456-FS1,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
503460855,7/16/2014 21:08:33,,1324479429,7/16/2014 21:07:50,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CAUSES],[CAUSES],CATARACT FORMATION results total loss LENS TRANSPARENCY,n/a,64,18,80,36,1,RO-has_finding_site,905456-FS1,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
503460855,7/16/2014 21:08:51,,1324479620,7/16/2014 21:07:56,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[MANIFESTATION],[MANIFESTATION],results in a total loss,n/a,64,18,80,36,1,RO-has_finding_site,905456-FS1,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
503460855,7/16/2014 21:14:59,,1324483570,7/16/2014 21:13:35,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[CAUSES],[CAUSES],CATARACT FORMATION results in loss of LENS TRANSPARENCY,N/A,64,18,80,36,1,RO-has_finding_site,905456-FS1,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
503460855,7/16/2014 21:26:00,,1324488494,7/16/2014 21:25:36,clixsense,1,19500241,USA,NC,Greensboro,174.98.255.13,[CAUSES],[CAUSES],results in,N/A,64,18,80,36,1,RO-has_finding_site,905456-FS1,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
503460856,7/16/2014 13:59:32,,1324265071,7/16/2014 13:59:07,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],such as,N/A,97,43,109,58,-1,RO-cause_of,900166-FS1,"One suggestion for why some people develop ATOPIC DISEASES such as allergic rhinitis, asthma and ATOPIC ECZEMA is that there are alterations in their intestinal microflora not seen in those without such conditions.",ATOPIC ECZEMA,ATOPIC DISEASES
503460856,7/16/2014 14:18:07,,1324272754,7/16/2014 14:17:57,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],develop,N/A,97,43,109,58,-1,RO-cause_of,900166-FS1,"One suggestion for why some people develop ATOPIC DISEASES such as allergic rhinitis, asthma and ATOPIC ECZEMA is that there are alterations in their intestinal microflora not seen in those without such conditions.",ATOPIC ECZEMA,ATOPIC DISEASES
503460856,7/16/2014 15:40:17,,1324302090,7/16/2014 15:40:04,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ATOPIC DISEASES ATOPIC,N/A,97,43,109,58,-1,RO-cause_of,900166-FS1,"One suggestion for why some people develop ATOPIC DISEASES such as allergic rhinitis, asthma and ATOPIC ECZEMA is that there are alterations in their intestinal microflora not seen in those without such conditions.",ATOPIC ECZEMA,ATOPIC DISEASES
503460856,7/16/2014 16:36:34,,1324328446,7/16/2014 16:36:02,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[IS_A],[IS_A],ATOPIC DISEASES such as ATOPIC ECZEMA,N/A,97,43,109,58,-1,RO-cause_of,900166-FS1,"One suggestion for why some people develop ATOPIC DISEASES such as allergic rhinitis, asthma and ATOPIC ECZEMA is that there are alterations in their intestinal microflora not seen in those without such conditions.",ATOPIC ECZEMA,ATOPIC DISEASES
503460856,7/16/2014 16:46:31,,1324333350,7/16/2014 16:45:30,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[IS_A],[IS_A],ATOPIC DISEASES such as,N/A,97,43,109,58,-1,RO-cause_of,900166-FS1,"One suggestion for why some people develop ATOPIC DISEASES such as allergic rhinitis, asthma and ATOPIC ECZEMA is that there are alterations in their intestinal microflora not seen in those without such conditions.",ATOPIC ECZEMA,ATOPIC DISEASES
503460856,7/16/2014 16:50:32,,1324334802,7/16/2014 16:49:50,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[PART_OF],[PART_OF],ATOPIC DISEASES such as ATOPIC ECZEMA,N/A,97,43,109,58,-1,RO-cause_of,900166-FS1,"One suggestion for why some people develop ATOPIC DISEASES such as allergic rhinitis, asthma and ATOPIC ECZEMA is that there are alterations in their intestinal microflora not seen in those without such conditions.",ATOPIC ECZEMA,ATOPIC DISEASES
503460856,7/16/2014 17:09:46,,1324341330,7/16/2014 17:09:26,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[IS_A],[IS_A],ATOPIC DISEASES such as ATOPIC ECZEMA,N/A,97,43,109,58,-1,RO-cause_of,900166-FS1,"One suggestion for why some people develop ATOPIC DISEASES such as allergic rhinitis, asthma and ATOPIC ECZEMA is that there are alterations in their intestinal microflora not seen in those without such conditions.",ATOPIC ECZEMA,ATOPIC DISEASES
503460856,7/16/2014 18:27:01,,1324400880,7/16/2014 18:25:57,prodege,1.0,20349329,USA,CA,El Cajon,68.7.51.119,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"develop ATOPIC DISEASES such as allergic rhinitis, asthma and ATOPIC ECZEMA",N/A,97,43,109,58,-1,RO-cause_of,900166-FS1,"One suggestion for why some people develop ATOPIC DISEASES such as allergic rhinitis, asthma and ATOPIC ECZEMA is that there are alterations in their intestinal microflora not seen in those without such conditions.",ATOPIC ECZEMA,ATOPIC DISEASES
503460856,7/16/2014 18:33:02,,1324403509,7/16/2014 18:32:15,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[IS_A],[IS_A],"such as allergic rhinitis, asthma and",na,97,43,109,58,-1,RO-cause_of,900166-FS1,"One suggestion for why some people develop ATOPIC DISEASES such as allergic rhinitis, asthma and ATOPIC ECZEMA is that there are alterations in their intestinal microflora not seen in those without such conditions.",ATOPIC ECZEMA,ATOPIC DISEASES
503460856,7/16/2014 18:44:55,,1324409613,7/16/2014 18:43:54,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[IS_A],[IS_A],ATOPIC DISEASES such as ATOPIC ECZEMA,n/a,97,43,109,58,-1,RO-cause_of,900166-FS1,"One suggestion for why some people develop ATOPIC DISEASES such as allergic rhinitis, asthma and ATOPIC ECZEMA is that there are alterations in their intestinal microflora not seen in those without such conditions.",ATOPIC ECZEMA,ATOPIC DISEASES
503460856,7/16/2014 19:06:12,,1324422333,7/16/2014 19:05:30,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]",and,N/A,97,43,109,58,-1,RO-cause_of,900166-FS1,"One suggestion for why some people develop ATOPIC DISEASES such as allergic rhinitis, asthma and ATOPIC ECZEMA is that there are alterations in their intestinal microflora not seen in those without such conditions.",ATOPIC ECZEMA,ATOPIC DISEASES
503460856,7/16/2014 20:28:29,,1324461516,7/16/2014 20:28:14,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",such as,N/A,97,43,109,58,-1,RO-cause_of,900166-FS1,"One suggestion for why some people develop ATOPIC DISEASES such as allergic rhinitis, asthma and ATOPIC ECZEMA is that there are alterations in their intestinal microflora not seen in those without such conditions.",ATOPIC ECZEMA,ATOPIC DISEASES
503460856,7/16/2014 20:59:53,,1324474405,7/16/2014 20:59:29,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[LOCATION],[LOCATION],ATOPIC DISEASES,NONE,97,43,109,58,-1,RO-cause_of,900166-FS1,"One suggestion for why some people develop ATOPIC DISEASES such as allergic rhinitis, asthma and ATOPIC ECZEMA is that there are alterations in their intestinal microflora not seen in those without such conditions.",ATOPIC ECZEMA,ATOPIC DISEASES
503460856,7/16/2014 21:01:04,,1324475211,7/16/2014 21:00:49,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[IS_A],[IS_A],such as,N/A,97,43,109,58,-1,RO-cause_of,900166-FS1,"One suggestion for why some people develop ATOPIC DISEASES such as allergic rhinitis, asthma and ATOPIC ECZEMA is that there are alterations in their intestinal microflora not seen in those without such conditions.",ATOPIC ECZEMA,ATOPIC DISEASES
503460856,7/16/2014 21:12:47,,1324482347,7/16/2014 21:12:06,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ATOPIC DISEASES such as ATOPIC ECZEMA,n/a,97,43,109,58,-1,RO-cause_of,900166-FS1,"One suggestion for why some people develop ATOPIC DISEASES such as allergic rhinitis, asthma and ATOPIC ECZEMA is that there are alterations in their intestinal microflora not seen in those without such conditions.",ATOPIC ECZEMA,ATOPIC DISEASES
503460857,7/16/2014 13:33:01,,1324254877,7/16/2014 13:32:54,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],against,N/A,120,4,131,23,1,RO-may_diagnose,906700-FS1,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
503460857,7/16/2014 13:36:54,,1324256527,7/16/2014 13:36:22,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],indicates the status of,N/A,120,4,131,23,1,RO-may_diagnose,906700-FS1,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
503460857,7/16/2014 13:43:27,,1324258909,7/16/2014 13:43:11,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],indicates immunity,Na,120,4,131,23,1,RO-may_diagnose,906700-FS1,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
503460857,7/16/2014 14:34:07,,1324279245,7/16/2014 14:33:16,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[ASSOCIATED_WITH],[ASSOCIATED_WITH],indicates the status,N/A,120,4,131,23,1,RO-may_diagnose,906700-FS1,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
503460857,7/16/2014 15:01:02,,1324288332,7/16/2014 15:00:08,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[SYMPTOM],[SYMPTOM],which indicates,na,120,4,131,23,1,RO-may_diagnose,906700-FS1,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
503460857,7/16/2014 15:27:50,,1324297536,7/16/2014 15:27:14,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"reaction, against",n\a,120,4,131,23,1,RO-may_diagnose,906700-FS1,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
503460857,7/16/2014 15:39:36,,1324301833,7/16/2014 15:39:22,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],immunity against,N/A,120,4,131,23,1,RO-may_diagnose,906700-FS1,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
503460857,7/16/2014 16:22:16,,1324322845,7/16/2014 16:21:51,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[CONTRAINDICATES],[CONTRAINDICATES],indicates immunity against,N/A,120,4,131,23,1,RO-may_diagnose,906700-FS1,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
503460857,7/16/2014 16:58:29,,1324337581,7/16/2014 16:58:01,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULIN RESPONSE TUBERCULOSIS,n/a,120,4,131,23,1,RO-may_diagnose,906700-FS1,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
503460857,7/16/2014 18:16:26,,1324395033,7/16/2014 18:16:04,clixsense,1.0,6621167,USA,"","",66.87.78.42,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,Na,120,4,131,23,1,RO-may_diagnose,906700-FS1,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
503460857,7/16/2014 18:20:28,,1324398224,7/16/2014 18:19:47,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[OTHER],[OTHER],TUBERCULIN RESPONSE indicates the status of cellular immunity against TUBERCULOSIS,N/A,120,4,131,23,1,RO-may_diagnose,906700-FS1,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
503460857,7/16/2014 19:27:16,,1324433092,7/16/2014 19:26:48,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",immunity against,N/A,120,4,131,23,1,RO-may_diagnose,906700-FS1,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
503460857,7/16/2014 19:58:34,,1324448037,7/16/2014 19:58:21,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],cellular immunity against,N/A,120,4,131,23,1,RO-may_diagnose,906700-FS1,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
503460857,7/16/2014 20:28:06,,1324461356,7/16/2014 20:26:53,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"reaction, indicates the status",n/a,120,4,131,23,1,RO-may_diagnose,906700-FS1,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
503460857,7/16/2014 20:42:32,,1324467258,7/16/2014 20:42:05,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[PREVENTS],[PREVENTS],indicates the status of cellular immunity,N/A,120,4,131,23,1,RO-may_diagnose,906700-FS1,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
503460858,7/16/2014 13:26:58,,1324252236,7/16/2014 13:26:37,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[PART_OF]",is characterized by an,N/A,28,0,51,4,1,RO-disease_may_have_finding,902982-FS1,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
503460858,7/16/2014 13:37:30,,1324256690,7/16/2014 13:37:09,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],described SMZL,asd,28,0,51,4,1,RO-disease_may_have_finding,902982-FS1,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
503460858,7/16/2014 13:48:48,,1324260715,7/16/2014 13:48:29,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[SYMPTOM],[SYMPTOM],characterized,N/A,28,0,51,4,1,RO-disease_may_have_finding,902982-FS1,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
503460858,7/16/2014 13:48:51,,1324260724,7/16/2014 13:47:57,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],characterized,N/A,28,0,51,4,1,RO-disease_may_have_finding,902982-FS1,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
503460858,7/16/2014 13:58:22,,1324264473,7/16/2014 13:58:12,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[MANIFESTATION] [CAUSES],"[CAUSES]
[MANIFESTATION]",characterized CLINICAL previous,N/A,28,0,51,4,1,RO-disease_may_have_finding,902982-FS1,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
503460858,7/16/2014 14:15:21,,1324271637,7/16/2014 14:15:04,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],characterized,N/A,28,0,51,4,1,RO-disease_may_have_finding,902982-FS1,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
503460858,7/16/2014 14:43:17,,1324282554,7/16/2014 14:42:24,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",characterized by,N/A,28,0,51,4,1,RO-disease_may_have_finding,902982-FS1,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
503460858,7/16/2014 15:41:09,,1324302469,7/16/2014 15:40:35,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[SYMPTOM],[SYMPTOM],characterized by,n/a,28,0,51,4,1,RO-disease_may_have_finding,902982-FS1,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
503460858,7/16/2014 16:42:32,,1324331957,7/16/2014 16:42:08,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],described,na,28,0,51,4,1,RO-disease_may_have_finding,902982-FS1,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
503460858,7/16/2014 16:49:19,,1324334446,7/16/2014 16:48:05,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[SYMPTOM],[SYMPTOM],characterized by,N/A,28,0,51,4,1,RO-disease_may_have_finding,902982-FS1,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
503460858,7/16/2014 16:52:10,,1324335370,7/16/2014 16:51:44,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],characterized,NONE,28,0,51,4,1,RO-disease_may_have_finding,902982-FS1,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
503460858,7/16/2014 17:11:14,,1324341864,7/16/2014 17:10:18,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],SMZL is characterized by an INDOLENT CLINICAL COURSE,N/A,28,0,51,4,1,RO-disease_may_have_finding,902982-FS1,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
503460858,7/16/2014 18:19:46,,1324397922,7/16/2014 18:19:07,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[MANIFESTATION],[MANIFESTATION],SMZL is characterized by an INDOLENT CLINICAL COURSE,N/A,28,0,51,4,1,RO-disease_may_have_finding,902982-FS1,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
503460858,7/16/2014 19:03:57,,1324420877,7/16/2014 19:03:17,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[SYMPTOM],[SYMPTOM],is characterized by,N/A,28,0,51,4,1,RO-disease_may_have_finding,902982-FS1,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
503460858,7/16/2014 19:16:34,,1324428042,7/16/2014 19:16:12,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[SYMPTOM],[SYMPTOM],characterized by,N/A,28,0,51,4,1,RO-disease_may_have_finding,902982-FS1,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
503460859,7/16/2014 13:29:06,,1324253128,7/16/2014 13:28:58,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],disease.,N/A,78,157,99,166,1,RO-may_diagnose,906943-FS1,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
503460859,7/16/2014 13:36:33,,1324256371,7/16/2014 13:36:12,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],currently used to,n/a,78,157,99,166,1,RO-may_diagnose,906943-FS1,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
503460859,7/16/2014 13:46:11,,1324259802,7/16/2014 13:45:55,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tests,N/A,78,157,99,166,1,RO-may_diagnose,906943-FS1,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
503460859,7/16/2014 13:46:41,,1324260006,7/16/2014 13:45:58,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],caffeine tests,na,78,157,99,166,1,RO-may_diagnose,906943-FS1,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
503460859,7/16/2014 14:13:37,,1324270994,7/16/2014 14:13:22,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detect,N/A,78,157,99,166,1,RO-may_diagnose,906943-FS1,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
503460859,7/16/2014 14:41:25,,1324282049,7/16/2014 14:40:30,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],be added to the,N/A,78,157,99,166,1,RO-may_diagnose,906943-FS1,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
503460859,7/16/2014 16:41:57,,1324331731,7/16/2014 16:40:52,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MALIGNANT HYPERTHERMIA HALOTHANE tests,N/A,78,157,99,166,1,RO-may_diagnose,906943-FS1,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
503460859,7/16/2014 16:47:23,,1324333723,7/16/2014 16:46:33,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],tests currently used,N/A,78,157,99,166,1,RO-may_diagnose,906943-FS1,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
503460859,7/16/2014 17:03:56,,1324339393,7/16/2014 17:03:50,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,78,157,99,166,1,RO-may_diagnose,906943-FS1,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
503460859,7/16/2014 18:05:19,,1324383231,7/16/2014 18:04:44,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tests,na,78,157,99,166,1,RO-may_diagnose,906943-FS1,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
503460859,7/16/2014 18:29:57,,1324402103,7/16/2014 18:29:22,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],be added to the and caffeine tests currently used to detect this disease.,na,78,157,99,166,1,RO-may_diagnose,906943-FS1,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
503460859,7/16/2014 19:36:52,,1324437573,7/16/2014 19:36:08,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tests currently used to detect,N/A,78,157,99,166,1,RO-may_diagnose,906943-FS1,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
503460859,7/16/2014 20:22:15,,1324458673,7/16/2014 20:21:10,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],used to detect this disease.,N/A,78,157,99,166,1,RO-may_diagnose,906943-FS1,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
503460859,7/16/2014 20:44:20,,1324467883,7/16/2014 20:44:04,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tests,N/A,78,157,99,166,1,RO-may_diagnose,906943-FS1,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
503460859,7/16/2014 20:59:31,,1324474213,7/16/2014 20:58:57,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE tests,N/A,78,157,99,166,1,RO-may_diagnose,906943-FS1,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
503460860,7/16/2014 13:28:12,,1324252731,7/16/2014 13:27:53,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],samples from patients with and seven serial samples from one patient with,N/A,219,283,231,307,-1,RO-has_manifestation,906428-FS1,"In this study, a previously unpublished ELISA test for FVIII inhibitor screening (Genetic Testing Institute [GTI] FVIII inhibitor, Brookfield, WI, USA) was evaluated in 131 blood samples (124 samples from patients with HAEMOPHILIA A and seven serial samples from one patient with an ACQUIRED FVIII INHIBITOR.",HAEMOPHILIA A,ACQUIRED FVIII INHIBITOR
503460860,7/16/2014 13:35:42,,1324256053,7/16/2014 13:35:25,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],screening,Na,219,283,231,307,-1,RO-has_manifestation,906428-FS1,"In this study, a previously unpublished ELISA test for FVIII inhibitor screening (Genetic Testing Institute [GTI] FVIII inhibitor, Brookfield, WI, USA) was evaluated in 131 blood samples (124 samples from patients with HAEMOPHILIA A and seven serial samples from one patient with an ACQUIRED FVIII INHIBITOR.",HAEMOPHILIA A,ACQUIRED FVIII INHIBITOR
503460860,7/16/2014 13:35:50,,1324256102,7/16/2014 13:34:53,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,UNRELATED CONDITIONS.,219,283,231,307,-1,RO-has_manifestation,906428-FS1,"In this study, a previously unpublished ELISA test for FVIII inhibitor screening (Genetic Testing Institute [GTI] FVIII inhibitor, Brookfield, WI, USA) was evaluated in 131 blood samples (124 samples from patients with HAEMOPHILIA A and seven serial samples from one patient with an ACQUIRED FVIII INHIBITOR.",HAEMOPHILIA A,ACQUIRED FVIII INHIBITOR
503460860,7/16/2014 13:39:38,,1324257490,7/16/2014 13:38:55,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,i don't see the relation,219,283,231,307,-1,RO-has_manifestation,906428-FS1,"In this study, a previously unpublished ELISA test for FVIII inhibitor screening (Genetic Testing Institute [GTI] FVIII inhibitor, Brookfield, WI, USA) was evaluated in 131 blood samples (124 samples from patients with HAEMOPHILIA A and seven serial samples from one patient with an ACQUIRED FVIII INHIBITOR.",HAEMOPHILIA A,ACQUIRED FVIII INHIBITOR
503460860,7/16/2014 13:43:08,,1324258788,7/16/2014 13:42:50,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[TREATS],[TREATS],HAEMOPHILIA,asd,219,283,231,307,-1,RO-has_manifestation,906428-FS1,"In this study, a previously unpublished ELISA test for FVIII inhibitor screening (Genetic Testing Institute [GTI] FVIII inhibitor, Brookfield, WI, USA) was evaluated in 131 blood samples (124 samples from patients with HAEMOPHILIA A and seven serial samples from one patient with an ACQUIRED FVIII INHIBITOR.",HAEMOPHILIA A,ACQUIRED FVIII INHIBITOR
503460860,7/16/2014 13:52:46,,1324262109,7/16/2014 13:52:13,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[ASSOCIATED_WITH],[ASSOCIATED_WITH],evaluated in 131 blood samples,N/A,219,283,231,307,-1,RO-has_manifestation,906428-FS1,"In this study, a previously unpublished ELISA test for FVIII inhibitor screening (Genetic Testing Institute [GTI] FVIII inhibitor, Brookfield, WI, USA) was evaluated in 131 blood samples (124 samples from patients with HAEMOPHILIA A and seven serial samples from one patient with an ACQUIRED FVIII INHIBITOR.",HAEMOPHILIA A,ACQUIRED FVIII INHIBITOR
503460860,7/16/2014 14:07:23,,1324268289,7/16/2014 14:06:22,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],(124 samples patients with HAEMOPHILIA seven samples patient with ACQUIRED FVIII INHIBITOR.,N/A,219,283,231,307,-1,RO-has_manifestation,906428-FS1,"In this study, a previously unpublished ELISA test for FVIII inhibitor screening (Genetic Testing Institute [GTI] FVIII inhibitor, Brookfield, WI, USA) was evaluated in 131 blood samples (124 samples from patients with HAEMOPHILIA A and seven serial samples from one patient with an ACQUIRED FVIII INHIBITOR.",HAEMOPHILIA A,ACQUIRED FVIII INHIBITOR
503460860,7/16/2014 15:28:04,,1324297637,7/16/2014 15:27:41,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,219,283,231,307,-1,RO-has_manifestation,906428-FS1,"In this study, a previously unpublished ELISA test for FVIII inhibitor screening (Genetic Testing Institute [GTI] FVIII inhibitor, Brookfield, WI, USA) was evaluated in 131 blood samples (124 samples from patients with HAEMOPHILIA A and seven serial samples from one patient with an ACQUIRED FVIII INHIBITOR.",HAEMOPHILIA A,ACQUIRED FVIII INHIBITOR
503460860,7/16/2014 16:21:40,,1324322636,7/16/2014 16:20:34,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[ASSOCIATED_WITH]",patient with,na,219,283,231,307,-1,RO-has_manifestation,906428-FS1,"In this study, a previously unpublished ELISA test for FVIII inhibitor screening (Genetic Testing Institute [GTI] FVIII inhibitor, Brookfield, WI, USA) was evaluated in 131 blood samples (124 samples from patients with HAEMOPHILIA A and seven serial samples from one patient with an ACQUIRED FVIII INHIBITOR.",HAEMOPHILIA A,ACQUIRED FVIII INHIBITOR
503460860,7/16/2014 19:02:40,,1324420067,7/16/2014 19:02:28,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[NONE],[NONE],N/A,Separate,219,283,231,307,-1,RO-has_manifestation,906428-FS1,"In this study, a previously unpublished ELISA test for FVIII inhibitor screening (Genetic Testing Institute [GTI] FVIII inhibitor, Brookfield, WI, USA) was evaluated in 131 blood samples (124 samples from patients with HAEMOPHILIA A and seven serial samples from one patient with an ACQUIRED FVIII INHIBITOR.",HAEMOPHILIA A,ACQUIRED FVIII INHIBITOR
503460860,7/16/2014 19:27:44,,1324433344,7/16/2014 19:27:17,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"In this study,",N/A,219,283,231,307,-1,RO-has_manifestation,906428-FS1,"In this study, a previously unpublished ELISA test for FVIII inhibitor screening (Genetic Testing Institute [GTI] FVIII inhibitor, Brookfield, WI, USA) was evaluated in 131 blood samples (124 samples from patients with HAEMOPHILIA A and seven serial samples from one patient with an ACQUIRED FVIII INHIBITOR.",HAEMOPHILIA A,ACQUIRED FVIII INHIBITOR
503460860,7/16/2014 19:47:00,,1324442724,7/16/2014 19:46:36,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],with an,N/A,219,283,231,307,-1,RO-has_manifestation,906428-FS1,"In this study, a previously unpublished ELISA test for FVIII inhibitor screening (Genetic Testing Institute [GTI] FVIII inhibitor, Brookfield, WI, USA) was evaluated in 131 blood samples (124 samples from patients with HAEMOPHILIA A and seven serial samples from one patient with an ACQUIRED FVIII INHIBITOR.",HAEMOPHILIA A,ACQUIRED FVIII INHIBITOR
503460860,7/16/2014 20:30:52,,1324462605,7/16/2014 20:28:28,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different conditions,219,283,231,307,-1,RO-has_manifestation,906428-FS1,"In this study, a previously unpublished ELISA test for FVIII inhibitor screening (Genetic Testing Institute [GTI] FVIII inhibitor, Brookfield, WI, USA) was evaluated in 131 blood samples (124 samples from patients with HAEMOPHILIA A and seven serial samples from one patient with an ACQUIRED FVIII INHIBITOR.",HAEMOPHILIA A,ACQUIRED FVIII INHIBITOR
503460860,7/16/2014 20:34:36,,1324464062,7/16/2014 20:33:44,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was evaluated in blood samples with,N/A,219,283,231,307,-1,RO-has_manifestation,906428-FS1,"In this study, a previously unpublished ELISA test for FVIII inhibitor screening (Genetic Testing Institute [GTI] FVIII inhibitor, Brookfield, WI, USA) was evaluated in 131 blood samples (124 samples from patients with HAEMOPHILIA A and seven serial samples from one patient with an ACQUIRED FVIII INHIBITOR.",HAEMOPHILIA A,ACQUIRED FVIII INHIBITOR
503460860,7/16/2014 20:41:43,,1324466979,7/16/2014 20:41:08,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],patients with HAEMOPHILIA A and one patient with an ACQUIRED FVIII INHIBITOR.,N/A,219,283,231,307,-1,RO-has_manifestation,906428-FS1,"In this study, a previously unpublished ELISA test for FVIII inhibitor screening (Genetic Testing Institute [GTI] FVIII inhibitor, Brookfield, WI, USA) was evaluated in 131 blood samples (124 samples from patients with HAEMOPHILIA A and seven serial samples from one patient with an ACQUIRED FVIII INHIBITOR.",HAEMOPHILIA A,ACQUIRED FVIII INHIBITOR
503460861,7/16/2014 13:27:28,,1324252449,7/16/2014 13:27:19,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],especially,N/A,101,47,118,55,-1,RO-has_definitional_manifestation,904527-FS1,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
503460861,7/16/2014 13:34:19,,1324255509,7/16/2014 13:33:16,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],inducing,N/A,101,47,118,55,-1,RO-has_definitional_manifestation,904527-FS1,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
503460861,7/16/2014 13:41:02,,1324257997,7/16/2014 13:40:30,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],especially in the setting of a high lifetime,N/A,101,47,118,55,-1,RO-has_definitional_manifestation,904527-FS1,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
503460861,7/16/2014 13:45:56,,1324259735,7/16/2014 13:45:31,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[CAUSES],[CAUSES],to occur,na,101,47,118,55,-1,RO-has_definitional_manifestation,904527-FS1,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
503460861,7/16/2014 13:46:52,,1324260069,7/16/2014 13:46:35,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SIDE_EFFECT],[SIDE_EFFECT],especially the setting of high lifetime,n/a,101,47,118,55,-1,RO-has_definitional_manifestation,904527-FS1,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
503460861,7/16/2014 13:50:56,,1324261484,7/16/2014 13:50:32,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[CAUSES],[CAUSES],high NUMBER,N/A,101,47,118,55,-1,RO-has_definitional_manifestation,904527-FS1,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
503460861,7/16/2014 14:15:56,,1324271873,7/16/2014 14:15:38,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[PART_OF],[PART_OF],NUMBER OF SEIZURES,N/A,101,47,118,55,-1,RO-has_definitional_manifestation,904527-FS1,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
503460861,7/16/2014 15:05:08,,1324290284,7/16/2014 15:04:19,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[SYMPTOM],[SYMPTOM],in the setting of,na,101,47,118,55,-1,RO-has_definitional_manifestation,904527-FS1,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
503460861,7/16/2014 15:46:11,,1324304685,7/16/2014 15:45:44,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[SYMPTOM],[SYMPTOM],the setting of a high lifetime NUMBER OF SEIZURES,n/a,101,47,118,55,-1,RO-has_definitional_manifestation,904527-FS1,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
503460861,7/16/2014 16:33:07,,1324326800,7/16/2014 16:32:45,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[SIDE_EFFECT],[SIDE_EFFECT],with especially,N/A,101,47,118,55,-1,RO-has_definitional_manifestation,904527-FS1,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
503460861,7/16/2014 16:43:27,,1324332285,7/16/2014 16:42:47,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,none,101,47,118,55,-1,RO-has_definitional_manifestation,904527-FS1,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
503460861,7/16/2014 17:44:01,,1324360993,7/16/2014 17:43:42,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],especially in the setting of,n/a,101,47,118,55,-1,RO-has_definitional_manifestation,904527-FS1,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
503460861,7/16/2014 19:17:33,,1324428486,7/16/2014 19:16:48,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES,N/A,101,47,118,55,-1,RO-has_definitional_manifestation,904527-FS1,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
503460861,7/16/2014 19:36:06,,1324437269,7/16/2014 19:35:18,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],tends to occur,N/A,101,47,118,55,-1,RO-has_definitional_manifestation,904527-FS1,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
503460861,7/16/2014 19:47:42,,1324443105,7/16/2014 19:45:00,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[MANIFESTATION],[MANIFESTATION],EPILEPSY especially high lifetime NUMBER OF SEIZURES,N/A,101,47,118,55,-1,RO-has_definitional_manifestation,904527-FS1,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
503460862,7/16/2014 13:30:27,,1324253715,7/16/2014 13:29:41,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],important factor for predicting,N/A,142,180,148,188,-1,RO-has_definitional_manifestation,904923-FS1,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
503460862,7/16/2014 13:40:19,,1324257783,7/16/2014 13:39:39,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],for predicting SEIZURE prognosis was the severity of EPILEPSY,n/a,142,180,148,188,-1,RO-has_definitional_manifestation,904923-FS1,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
503460862,7/16/2014 15:38:42,,1324301442,7/16/2014 15:38:19,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],found to have,N/A,142,180,148,188,-1,RO-has_definitional_manifestation,904923-FS1,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
503460862,7/16/2014 16:19:55,,1324321956,7/16/2014 16:19:18,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]",SEIZURE prognosis,na,142,180,148,188,-1,RO-has_definitional_manifestation,904923-FS1,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
503460862,7/16/2014 16:27:57,,1324324951,7/16/2014 16:24:34,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[SIDE_EFFECT],[SIDE_EFFECT],predicting SEIZURE prognosis severity of EPILEPSY prepregnancy.,N/A,142,180,148,188,-1,RO-has_definitional_manifestation,904923-FS1,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
503460862,7/16/2014 16:34:50,,1324327541,7/16/2014 16:33:28,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[MANIFESTATION],[MANIFESTATION],Epileptic women have seizure,N/A,142,180,148,188,-1,RO-has_definitional_manifestation,904923-FS1,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
503460862,7/16/2014 17:31:19,,1324350298,7/16/2014 17:30:45,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],for predicting SEIZURE prognosis was the severity of,n/a,142,180,148,188,-1,RO-has_definitional_manifestation,904923-FS1,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
503460862,7/16/2014 18:28:17,,1324401443,7/16/2014 18:27:13,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[MANIFESTATION],[MANIFESTATION],prognosis was the severity of prepregnancy.,na,142,180,148,188,-1,RO-has_definitional_manifestation,904923-FS1,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
503460862,7/16/2014 19:26:02,,1324432537,7/16/2014 19:25:26,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were found to have,N/A,142,180,148,188,-1,RO-has_definitional_manifestation,904923-FS1,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
503460862,7/16/2014 19:39:07,,1324438680,7/16/2014 19:38:55,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURE,N/A,142,180,148,188,-1,RO-has_definitional_manifestation,904923-FS1,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
503460862,7/16/2014 20:35:05,,1324464235,7/16/2014 20:34:37,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[SYMPTOM],[SYMPTOM],prognosis was the severity of,N/A,142,180,148,188,-1,RO-has_definitional_manifestation,904923-FS1,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
503460862,7/16/2014 20:36:59,,1324465033,7/16/2014 20:36:06,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],SEIZURE prognosis of EPILEPSY,Manifestation,142,180,148,188,-1,RO-has_definitional_manifestation,904923-FS1,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
503460862,7/16/2014 20:44:58,,1324468131,7/16/2014 20:44:21,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prognosis severity of,N/A,142,180,148,188,-1,RO-has_definitional_manifestation,904923-FS1,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
503460862,7/16/2014 20:53:35,,1324471813,7/16/2014 20:53:09,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[CAUSES],[CAUSES],factor for predicting,n/a,142,180,148,188,-1,RO-has_definitional_manifestation,904923-FS1,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
503460862,7/16/2014 20:55:44,,1324472579,7/16/2014 20:54:23,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[LOCATION],[LOCATION],prepregnancy.,NONE,142,180,148,188,-1,RO-has_definitional_manifestation,904923-FS1,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
503460863,7/16/2014 13:28:21,,1324252798,7/16/2014 13:28:13,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],radiotherapy,N/A,128,158,139,182,-1,RO-disease_may_have_finding,902504-FS1,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460863,7/16/2014 13:37:07,,1324256596,7/16/2014 13:36:52,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],treatment,Na,128,158,139,182,-1,RO-disease_may_have_finding,902504-FS1,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460863,7/16/2014 13:43:18,,1324258843,7/16/2014 13:42:49,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatment,N/A,128,158,139,182,-1,RO-disease_may_have_finding,902504-FS1,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460863,7/16/2014 13:54:28,,1324262819,7/16/2014 13:53:46,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],combined treatment of,N/A,128,158,139,182,-1,RO-disease_may_have_finding,902504-FS1,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460863,7/16/2014 14:00:14,,1324265285,7/16/2014 14:00:00,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[TREATS] [CAUSES],"[TREATS]
[CAUSES]","current survival, evaluation",N/A,128,158,139,182,-1,RO-disease_may_have_finding,902504-FS1,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460863,7/16/2014 14:10:46,,1324269813,7/16/2014 14:10:21,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],treatment of,N/A,128,158,139,182,-1,RO-disease_may_have_finding,902504-FS1,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460863,7/16/2014 15:31:42,,1324298938,7/16/2014 15:31:13,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treatment,n/a,128,158,139,182,-1,RO-disease_may_have_finding,902504-FS1,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460863,7/16/2014 15:40:02,,1324302019,7/16/2014 15:39:51,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],for unresectable,N/A,128,158,139,182,-1,RO-disease_may_have_finding,902504-FS1,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460863,7/16/2014 15:48:13,,1324305489,7/16/2014 15:47:35,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],treatment,n/a,128,158,139,182,-1,RO-disease_may_have_finding,902504-FS1,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460863,7/16/2014 16:33:26,,1324326915,7/16/2014 16:32:45,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[TREATS],[TREATS],treatment,N/A,128,158,139,182,-1,RO-disease_may_have_finding,902504-FS1,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460863,7/16/2014 16:40:16,,1324330804,7/16/2014 16:39:43,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[LOCATION] [SYMPTOM] [MANIFESTATION] [DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[SYMPTOM]
[MANIFESTATION]",combined treatment,na,128,158,139,182,-1,RO-disease_may_have_finding,902504-FS1,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460863,7/16/2014 16:54:58,,1324336321,7/16/2014 16:54:13,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPERTHERMIA HEPATOCELLULAR CARCINOMA,n/a,128,158,139,182,-1,RO-disease_may_have_finding,902504-FS1,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460863,7/16/2014 17:13:46,,1324342649,7/16/2014 17:13:13,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],for,NONE,128,158,139,182,-1,RO-disease_may_have_finding,902504-FS1,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460863,7/16/2014 18:26:06,,1324400481,7/16/2014 18:25:14,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA,N/A,128,158,139,182,-1,RO-disease_may_have_finding,902504-FS1,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460863,7/16/2014 19:19:02,,1324429234,7/16/2014 19:18:14,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[TREATS],[TREATS],treatment of,N/A,128,158,139,182,-1,RO-disease_may_have_finding,902504-FS1,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460864,7/16/2014 13:57:22,,1324264014,7/16/2014 13:56:21,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],primary targets,N/A,0,87,27,100,1,RO-disease_has_primary_anatomic_site,902071-FS1,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
503460864,7/16/2014 15:31:12,,1324298753,7/16/2014 15:30:47,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],primary targets,n/a,0,87,27,100,1,RO-disease_has_primary_anatomic_site,902071-FS1,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
503460864,7/16/2014 16:22:51,,1324323069,7/16/2014 16:22:34,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[PART_OF],[PART_OF],primary targets,N/A,0,87,27,100,1,RO-disease_has_primary_anatomic_site,902071-FS1,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
503460864,7/16/2014 17:01:38,,1324338695,7/16/2014 17:01:07,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[LOCATION],[LOCATION],BREAST EPITHELIAL STEM CELLS BREAST CANCER,n/a,0,87,27,100,1,RO-disease_has_primary_anatomic_site,902071-FS1,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
503460864,7/16/2014 17:03:49,,1324339332,7/16/2014 17:03:44,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,0,87,27,100,1,RO-disease_has_primary_anatomic_site,902071-FS1,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
503460864,7/16/2014 19:26:47,,1324432851,7/16/2014 19:26:03,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],the aetiology,N/A,0,87,27,100,1,RO-disease_has_primary_anatomic_site,902071-FS1,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
503460864,7/16/2014 19:37:54,,1324438077,7/16/2014 19:37:46,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],CELLS,N/A,0,87,27,100,1,RO-disease_has_primary_anatomic_site,902071-FS1,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
503460864,7/16/2014 19:58:20,,1324447910,7/16/2014 19:58:01,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],in the aetiology of,N/A,0,87,27,100,1,RO-disease_has_primary_anatomic_site,902071-FS1,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
503460864,7/16/2014 20:30:49,,1324462588,7/16/2014 20:29:41,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[LOCATION],[LOCATION],thought to be the primary targets,N/A,0,87,27,100,1,RO-disease_has_primary_anatomic_site,902071-FS1,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
503460864,7/16/2014 20:43:11,,1324467480,7/16/2014 20:42:50,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],targets,N/A,0,87,27,100,1,RO-disease_has_primary_anatomic_site,902071-FS1,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
503460864,7/16/2014 21:07:49,,1324478948,7/16/2014 21:07:03,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CAUSES] [LOCATION],"[CAUSES]
[LOCATION]",BREAST EPITHELIAL STEM CELLS primary targets BREAST CANCER,n/a,0,87,27,100,1,RO-disease_has_primary_anatomic_site,902071-FS1,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
503460864,7/16/2014 21:09:23,,1324479956,7/16/2014 21:08:53,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[LOCATION],[LOCATION],primary targets,n/a,0,87,27,100,1,RO-disease_has_primary_anatomic_site,902071-FS1,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
503460864,7/16/2014 21:12:15,,1324481988,7/16/2014 21:10:29,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[CAUSES],[CAUSES],BREAST EPITHELIAL STEM CELLS in the aetiology of BREAST CANCER,N/A,0,87,27,100,1,RO-disease_has_primary_anatomic_site,902071-FS1,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
503460864,7/16/2014 21:25:34,,1324488268,7/16/2014 21:24:21,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],primary targets in the,N/A,0,87,27,100,1,RO-disease_has_primary_anatomic_site,902071-FS1,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
503460864,7/16/2014 21:53:55,,1324499591,7/16/2014 21:53:30,neodev,1,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION],[LOCATION],are thought to be the primary targets,N/A,0,87,27,100,1,RO-disease_has_primary_anatomic_site,902071-FS1,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
503460865,7/16/2014 13:27:00,,1324252243,7/16/2014 13:26:52,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],females),N/A,85,145,113,161,1,RO-may_treat,908298-FS1,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
503460865,7/16/2014 13:31:34,,1324254243,7/16/2014 13:31:15,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],hypergranular type,asd,85,145,113,161,1,RO-may_treat,908298-FS1,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
503460865,7/16/2014 13:35:24,,1324255943,7/16/2014 13:34:44,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[TREATS],[TREATS],were treated,na,85,145,113,161,1,RO-may_treat,908298-FS1,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
503460865,7/16/2014 13:35:33,,1324256019,7/16/2014 13:34:50,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treated,N/A,85,145,113,161,1,RO-may_treat,908298-FS1,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
503460865,7/16/2014 13:54:41,,1324262897,7/16/2014 13:54:22,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[TREATS] [LOCATION] [SYMPTOM],"[TREATS]
[LOCATION]
[SYMPTOM]",type treated intravenous,They were treated.,85,145,113,161,1,RO-may_treat,908298-FS1,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
503460865,7/16/2014 14:12:48,,1324270696,7/16/2014 14:12:26,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],treated with,N/A,85,145,113,161,1,RO-may_treat,908298-FS1,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
503460865,7/16/2014 14:17:46,,1324272622,7/16/2014 14:17:35,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],treated,N/A,85,145,113,161,1,RO-may_treat,908298-FS1,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
503460865,7/16/2014 14:50:05,,1324284511,7/16/2014 14:49:45,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],were treated with,N/A,85,145,113,161,1,RO-may_treat,908298-FS1,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
503460865,7/16/2014 15:01:08,,1324288381,7/16/2014 15:00:49,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS],[TREATS],were treated with,N/A,85,145,113,161,1,RO-may_treat,908298-FS1,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
503460865,7/16/2014 15:03:43,,1324289637,7/16/2014 15:03:14,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],treated with,na,85,145,113,161,1,RO-may_treat,908298-FS1,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
503460865,7/16/2014 15:34:48,,1324299962,7/16/2014 15:34:37,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,unclear,85,145,113,161,1,RO-may_treat,908298-FS1,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
503460865,7/16/2014 16:37:38,,1324329172,7/16/2014 16:37:07,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],PROMYELOCYTIC LEUKEMIA were treated with ARSENIC TRIOXIDE,N/A,85,145,113,161,1,RO-may_treat,908298-FS1,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
503460865,7/16/2014 16:39:43,,1324330484,7/16/2014 16:39:15,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",treated with intravenous,na,85,145,113,161,1,RO-may_treat,908298-FS1,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
503460865,7/16/2014 16:45:58,,1324333187,7/16/2014 16:45:27,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[TREATS],[TREATS],PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE,N/A,85,145,113,161,1,RO-may_treat,908298-FS1,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
503460865,7/16/2014 16:57:30,,1324337259,7/16/2014 16:56:59,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[TREATS],[TREATS],PROMYELOCYTIC LEUKEMIA (APML) ARSENIC TRIOXIDE,n/a,85,145,113,161,1,RO-may_treat,908298-FS1,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
503460866,7/16/2014 13:27:56,,1324252636,7/16/2014 13:27:31,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],characterised by,n/a,142,0,153,30,1,RO-has_finding_site,905340-FS1,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
503460866,7/16/2014 13:38:36,,1324257108,7/16/2014 13:38:18,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[LOCATION],[LOCATION],characterised repetitive collapse of the upper airway,n/a,142,0,153,30,1,RO-has_finding_site,905340-FS1,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
503460866,7/16/2014 13:46:19,,1324259842,7/16/2014 13:45:49,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],collapse of the in,N/A,142,0,153,30,1,RO-has_finding_site,905340-FS1,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
503460866,7/16/2014 13:48:37,,1324260634,7/16/2014 13:47:51,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[MANIFESTATION],[MANIFESTATION],owing to a sleep related decrement in muscle activity,N/A,142,0,153,30,1,RO-has_finding_site,905340-FS1,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
503460866,7/16/2014 13:49:26,,1324260883,7/16/2014 13:49:03,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],in,N/A,142,0,153,30,1,RO-has_finding_site,905340-FS1,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
503460866,7/16/2014 13:56:20,,1324263561,7/16/2014 13:55:27,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],in UPPER AIRWAY muscle activity,N/A,142,0,153,30,1,RO-has_finding_site,905340-FS1,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
503460866,7/16/2014 16:37:51,,1324329294,7/16/2014 16:37:19,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],consequent failure,na,142,0,153,30,1,RO-has_finding_site,905340-FS1,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
503460866,7/16/2014 16:45:25,,1324333014,7/16/2014 16:44:38,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],characterised,none,142,0,153,30,1,RO-has_finding_site,905340-FS1,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
503460866,7/16/2014 16:52:27,,1324335435,7/16/2014 16:51:49,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised related decrement in UPPER AIRWAY muscle activity,N/A,142,0,153,30,1,RO-has_finding_site,905340-FS1,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
503460866,7/16/2014 18:29:55,,1324402091,7/16/2014 18:29:04,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[LOCATION],[LOCATION],OBSTRUCTIVE SLEEP APNOEA (OSA) characterised by repetitive collapse of UPPER AIRWAY,N/A,142,0,153,30,1,RO-has_finding_site,905340-FS1,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
503460866,7/16/2014 19:38:46,,1324438514,7/16/2014 19:38:38,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],AIRWAY,N/A,142,0,153,30,1,RO-has_finding_site,905340-FS1,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
503460866,7/16/2014 19:56:17,,1324447110,7/16/2014 19:55:46,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[LOCATION],[LOCATION],in,n/a,142,0,153,30,1,RO-has_finding_site,905340-FS1,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
503460866,7/16/2014 20:24:03,,1324459432,7/16/2014 20:23:23,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[LOCATION],[LOCATION],related decrement in,N/A,142,0,153,30,1,RO-has_finding_site,905340-FS1,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
503460866,7/16/2014 20:50:29,,1324470576,7/16/2014 20:47:42,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],UPPER AIRWAY muscle activity,N/A,142,0,153,30,1,RO-has_finding_site,905340-FS1,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
503460866,7/16/2014 20:51:01,,1324470793,7/16/2014 20:49:47,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION] [CAUSES],"[CAUSES]
[LOCATION]",OBSTRUCTIVE SLEEP APNOEA repetitive collapse upper airway UPPER AIRWAY,Location / causes,142,0,153,30,1,RO-has_finding_site,905340-FS1,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
503460867,7/16/2014 13:30:49,,1324253868,7/16/2014 13:30:41,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],RHEUMATOID,N/A,227,302,255,330,-1,RO-has_manifestation,906154-FS1,BC]  Specific recommendation: ? Note if the patient carries a diagnosis that indicates susceptibility to uveitis or any signs or symptoms of these diseases: ? Ankylosing spondylitis ? Reactive arthritis ? Psoriatic arthritis ? JUVENILE RHEUMATOID ARTHRITIS ? Inflammatory bowel disease ? Sarcoidosis ? SYSTEMIC LUPUS ERYTHEMATOSUS ? Behcet's disease ? Wegener granulomatosis ? Relapsing polychondritis ? Systemic or cerebral vasculitis ? Multiple sclerosis ? Tubular interstitial nephritis ? Juvenile xanthogranuloma ? Toxoplasmosis ? Syphilis ? Herpes zoster ophthalmicus ? Lyme disease ? Tuberculosis ? West Nile virus ? Whipple disease ? HTLV 1 infection.,JUVENILE RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS
503460867,7/16/2014 13:35:50,,1324256105,7/16/2014 13:32:22,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,this is written poorly and makes no sense,227,302,255,330,-1,RO-has_manifestation,906154-FS1,BC]  Specific recommendation: ? Note if the patient carries a diagnosis that indicates susceptibility to uveitis or any signs or symptoms of these diseases: ? Ankylosing spondylitis ? Reactive arthritis ? Psoriatic arthritis ? JUVENILE RHEUMATOID ARTHRITIS ? Inflammatory bowel disease ? Sarcoidosis ? SYSTEMIC LUPUS ERYTHEMATOSUS ? Behcet's disease ? Wegener granulomatosis ? Relapsing polychondritis ? Systemic or cerebral vasculitis ? Multiple sclerosis ? Tubular interstitial nephritis ? Juvenile xanthogranuloma ? Toxoplasmosis ? Syphilis ? Herpes zoster ophthalmicus ? Lyme disease ? Tuberculosis ? West Nile virus ? Whipple disease ? HTLV 1 infection.,JUVENILE RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS
503460867,7/16/2014 13:37:44,,1324256772,7/16/2014 13:37:06,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,TWO UNRELATED CONDITIONS.,227,302,255,330,-1,RO-has_manifestation,906154-FS1,BC]  Specific recommendation: ? Note if the patient carries a diagnosis that indicates susceptibility to uveitis or any signs or symptoms of these diseases: ? Ankylosing spondylitis ? Reactive arthritis ? Psoriatic arthritis ? JUVENILE RHEUMATOID ARTHRITIS ? Inflammatory bowel disease ? Sarcoidosis ? SYSTEMIC LUPUS ERYTHEMATOSUS ? Behcet's disease ? Wegener granulomatosis ? Relapsing polychondritis ? Systemic or cerebral vasculitis ? Multiple sclerosis ? Tubular interstitial nephritis ? Juvenile xanthogranuloma ? Toxoplasmosis ? Syphilis ? Herpes zoster ophthalmicus ? Lyme disease ? Tuberculosis ? West Nile virus ? Whipple disease ? HTLV 1 infection.,JUVENILE RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS
503460867,7/16/2014 13:40:24,,1324257814,7/16/2014 13:40:08,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Inflammatory,Na,227,302,255,330,-1,RO-has_manifestation,906154-FS1,BC]  Specific recommendation: ? Note if the patient carries a diagnosis that indicates susceptibility to uveitis or any signs or symptoms of these diseases: ? Ankylosing spondylitis ? Reactive arthritis ? Psoriatic arthritis ? JUVENILE RHEUMATOID ARTHRITIS ? Inflammatory bowel disease ? Sarcoidosis ? SYSTEMIC LUPUS ERYTHEMATOSUS ? Behcet's disease ? Wegener granulomatosis ? Relapsing polychondritis ? Systemic or cerebral vasculitis ? Multiple sclerosis ? Tubular interstitial nephritis ? Juvenile xanthogranuloma ? Toxoplasmosis ? Syphilis ? Herpes zoster ophthalmicus ? Lyme disease ? Tuberculosis ? West Nile virus ? Whipple disease ? HTLV 1 infection.,JUVENILE RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS
503460867,7/16/2014 13:50:45,,1324261432,7/16/2014 13:50:26,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[NONE],[NONE],N/A,"Different, unrelated conditions",227,302,255,330,-1,RO-has_manifestation,906154-FS1,BC]  Specific recommendation: ? Note if the patient carries a diagnosis that indicates susceptibility to uveitis or any signs or symptoms of these diseases: ? Ankylosing spondylitis ? Reactive arthritis ? Psoriatic arthritis ? JUVENILE RHEUMATOID ARTHRITIS ? Inflammatory bowel disease ? Sarcoidosis ? SYSTEMIC LUPUS ERYTHEMATOSUS ? Behcet's disease ? Wegener granulomatosis ? Relapsing polychondritis ? Systemic or cerebral vasculitis ? Multiple sclerosis ? Tubular interstitial nephritis ? Juvenile xanthogranuloma ? Toxoplasmosis ? Syphilis ? Herpes zoster ophthalmicus ? Lyme disease ? Tuberculosis ? West Nile virus ? Whipple disease ? HTLV 1 infection.,JUVENILE RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS
503460867,7/16/2014 13:58:12,,1324264382,7/16/2014 13:57:59,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",RHEUMATOID ? disease Wegener polychondritis Herpes,N/A,227,302,255,330,-1,RO-has_manifestation,906154-FS1,BC]  Specific recommendation: ? Note if the patient carries a diagnosis that indicates susceptibility to uveitis or any signs or symptoms of these diseases: ? Ankylosing spondylitis ? Reactive arthritis ? Psoriatic arthritis ? JUVENILE RHEUMATOID ARTHRITIS ? Inflammatory bowel disease ? Sarcoidosis ? SYSTEMIC LUPUS ERYTHEMATOSUS ? Behcet's disease ? Wegener granulomatosis ? Relapsing polychondritis ? Systemic or cerebral vasculitis ? Multiple sclerosis ? Tubular interstitial nephritis ? Juvenile xanthogranuloma ? Toxoplasmosis ? Syphilis ? Herpes zoster ophthalmicus ? Lyme disease ? Tuberculosis ? West Nile virus ? Whipple disease ? HTLV 1 infection.,JUVENILE RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS
503460867,7/16/2014 15:04:00,,1324289757,7/16/2014 15:02:53,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],JUVENILE RHEUMATOID ARTHRITIS SYSTEMIC LUPUS ERYTHEMATOSUS,n/a,227,302,255,330,-1,RO-has_manifestation,906154-FS1,BC]  Specific recommendation: ? Note if the patient carries a diagnosis that indicates susceptibility to uveitis or any signs or symptoms of these diseases: ? Ankylosing spondylitis ? Reactive arthritis ? Psoriatic arthritis ? JUVENILE RHEUMATOID ARTHRITIS ? Inflammatory bowel disease ? Sarcoidosis ? SYSTEMIC LUPUS ERYTHEMATOSUS ? Behcet's disease ? Wegener granulomatosis ? Relapsing polychondritis ? Systemic or cerebral vasculitis ? Multiple sclerosis ? Tubular interstitial nephritis ? Juvenile xanthogranuloma ? Toxoplasmosis ? Syphilis ? Herpes zoster ophthalmicus ? Lyme disease ? Tuberculosis ? West Nile virus ? Whipple disease ? HTLV 1 infection.,JUVENILE RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS
503460867,7/16/2014 15:30:46,,1324298612,7/16/2014 15:30:20,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],susceptibility to,n/a,227,302,255,330,-1,RO-has_manifestation,906154-FS1,BC]  Specific recommendation: ? Note if the patient carries a diagnosis that indicates susceptibility to uveitis or any signs or symptoms of these diseases: ? Ankylosing spondylitis ? Reactive arthritis ? Psoriatic arthritis ? JUVENILE RHEUMATOID ARTHRITIS ? Inflammatory bowel disease ? Sarcoidosis ? SYSTEMIC LUPUS ERYTHEMATOSUS ? Behcet's disease ? Wegener granulomatosis ? Relapsing polychondritis ? Systemic or cerebral vasculitis ? Multiple sclerosis ? Tubular interstitial nephritis ? Juvenile xanthogranuloma ? Toxoplasmosis ? Syphilis ? Herpes zoster ophthalmicus ? Lyme disease ? Tuberculosis ? West Nile virus ? Whipple disease ? HTLV 1 infection.,JUVENILE RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS
503460867,7/16/2014 15:43:18,,1324303309,7/16/2014 15:42:49,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[NONE],[NONE],N/A,This is just a list of unrelated diseases.,227,302,255,330,-1,RO-has_manifestation,906154-FS1,BC]  Specific recommendation: ? Note if the patient carries a diagnosis that indicates susceptibility to uveitis or any signs or symptoms of these diseases: ? Ankylosing spondylitis ? Reactive arthritis ? Psoriatic arthritis ? JUVENILE RHEUMATOID ARTHRITIS ? Inflammatory bowel disease ? Sarcoidosis ? SYSTEMIC LUPUS ERYTHEMATOSUS ? Behcet's disease ? Wegener granulomatosis ? Relapsing polychondritis ? Systemic or cerebral vasculitis ? Multiple sclerosis ? Tubular interstitial nephritis ? Juvenile xanthogranuloma ? Toxoplasmosis ? Syphilis ? Herpes zoster ophthalmicus ? Lyme disease ? Tuberculosis ? West Nile virus ? Whipple disease ? HTLV 1 infection.,JUVENILE RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS
503460867,7/16/2014 15:45:42,,1324304484,7/16/2014 15:45:05,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Inflammatory bowel disease,[DIAGNOSE_BY_TEST_OR_DRUG],227,302,255,330,-1,RO-has_manifestation,906154-FS1,BC]  Specific recommendation: ? Note if the patient carries a diagnosis that indicates susceptibility to uveitis or any signs or symptoms of these diseases: ? Ankylosing spondylitis ? Reactive arthritis ? Psoriatic arthritis ? JUVENILE RHEUMATOID ARTHRITIS ? Inflammatory bowel disease ? Sarcoidosis ? SYSTEMIC LUPUS ERYTHEMATOSUS ? Behcet's disease ? Wegener granulomatosis ? Relapsing polychondritis ? Systemic or cerebral vasculitis ? Multiple sclerosis ? Tubular interstitial nephritis ? Juvenile xanthogranuloma ? Toxoplasmosis ? Syphilis ? Herpes zoster ophthalmicus ? Lyme disease ? Tuberculosis ? West Nile virus ? Whipple disease ? HTLV 1 infection.,JUVENILE RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS
503460867,7/16/2014 16:38:19,,1324329626,7/16/2014 16:37:52,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],symptoms,na,227,302,255,330,-1,RO-has_manifestation,906154-FS1,BC]  Specific recommendation: ? Note if the patient carries a diagnosis that indicates susceptibility to uveitis or any signs or symptoms of these diseases: ? Ankylosing spondylitis ? Reactive arthritis ? Psoriatic arthritis ? JUVENILE RHEUMATOID ARTHRITIS ? Inflammatory bowel disease ? Sarcoidosis ? SYSTEMIC LUPUS ERYTHEMATOSUS ? Behcet's disease ? Wegener granulomatosis ? Relapsing polychondritis ? Systemic or cerebral vasculitis ? Multiple sclerosis ? Tubular interstitial nephritis ? Juvenile xanthogranuloma ? Toxoplasmosis ? Syphilis ? Herpes zoster ophthalmicus ? Lyme disease ? Tuberculosis ? West Nile virus ? Whipple disease ? HTLV 1 infection.,JUVENILE RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS
503460867,7/16/2014 16:53:16,,1324335785,7/16/2014 16:52:31,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],these diseases: JUVENILE RHEUMATOID ARTHRITIS SYSTEMIC LUPUS ERYTHEMATOSUS,N/A,227,302,255,330,-1,RO-has_manifestation,906154-FS1,BC]  Specific recommendation: ? Note if the patient carries a diagnosis that indicates susceptibility to uveitis or any signs or symptoms of these diseases: ? Ankylosing spondylitis ? Reactive arthritis ? Psoriatic arthritis ? JUVENILE RHEUMATOID ARTHRITIS ? Inflammatory bowel disease ? Sarcoidosis ? SYSTEMIC LUPUS ERYTHEMATOSUS ? Behcet's disease ? Wegener granulomatosis ? Relapsing polychondritis ? Systemic or cerebral vasculitis ? Multiple sclerosis ? Tubular interstitial nephritis ? Juvenile xanthogranuloma ? Toxoplasmosis ? Syphilis ? Herpes zoster ophthalmicus ? Lyme disease ? Tuberculosis ? West Nile virus ? Whipple disease ? HTLV 1 infection.,JUVENILE RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS
503460867,7/16/2014 16:54:48,,1324336259,7/16/2014 16:54:04,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],diseases:,NONE,227,302,255,330,-1,RO-has_manifestation,906154-FS1,BC]  Specific recommendation: ? Note if the patient carries a diagnosis that indicates susceptibility to uveitis or any signs or symptoms of these diseases: ? Ankylosing spondylitis ? Reactive arthritis ? Psoriatic arthritis ? JUVENILE RHEUMATOID ARTHRITIS ? Inflammatory bowel disease ? Sarcoidosis ? SYSTEMIC LUPUS ERYTHEMATOSUS ? Behcet's disease ? Wegener granulomatosis ? Relapsing polychondritis ? Systemic or cerebral vasculitis ? Multiple sclerosis ? Tubular interstitial nephritis ? Juvenile xanthogranuloma ? Toxoplasmosis ? Syphilis ? Herpes zoster ophthalmicus ? Lyme disease ? Tuberculosis ? West Nile virus ? Whipple disease ? HTLV 1 infection.,JUVENILE RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS
503460867,7/16/2014 18:02:33,,1324380506,7/16/2014 17:59:47,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diagnosis that indicates,na,227,302,255,330,-1,RO-has_manifestation,906154-FS1,BC]  Specific recommendation: ? Note if the patient carries a diagnosis that indicates susceptibility to uveitis or any signs or symptoms of these diseases: ? Ankylosing spondylitis ? Reactive arthritis ? Psoriatic arthritis ? JUVENILE RHEUMATOID ARTHRITIS ? Inflammatory bowel disease ? Sarcoidosis ? SYSTEMIC LUPUS ERYTHEMATOSUS ? Behcet's disease ? Wegener granulomatosis ? Relapsing polychondritis ? Systemic or cerebral vasculitis ? Multiple sclerosis ? Tubular interstitial nephritis ? Juvenile xanthogranuloma ? Toxoplasmosis ? Syphilis ? Herpes zoster ophthalmicus ? Lyme disease ? Tuberculosis ? West Nile virus ? Whipple disease ? HTLV 1 infection.,JUVENILE RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS
503460867,7/16/2014 18:25:23,,1324400096,7/16/2014 18:24:56,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,227,302,255,330,-1,RO-has_manifestation,906154-FS1,BC]  Specific recommendation: ? Note if the patient carries a diagnosis that indicates susceptibility to uveitis or any signs or symptoms of these diseases: ? Ankylosing spondylitis ? Reactive arthritis ? Psoriatic arthritis ? JUVENILE RHEUMATOID ARTHRITIS ? Inflammatory bowel disease ? Sarcoidosis ? SYSTEMIC LUPUS ERYTHEMATOSUS ? Behcet's disease ? Wegener granulomatosis ? Relapsing polychondritis ? Systemic or cerebral vasculitis ? Multiple sclerosis ? Tubular interstitial nephritis ? Juvenile xanthogranuloma ? Toxoplasmosis ? Syphilis ? Herpes zoster ophthalmicus ? Lyme disease ? Tuberculosis ? West Nile virus ? Whipple disease ? HTLV 1 infection.,JUVENILE RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS
503460868,7/16/2014 13:29:45,,1324253390,7/16/2014 13:29:31,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA,N/A,339,306,366,317,1,RO-may_treat,908334-FS1,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
503460868,7/16/2014 13:32:48,,1324254805,7/16/2014 13:32:30,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],for the treatment of,N/A,339,306,366,317,1,RO-may_treat,908334-FS1,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
503460868,7/16/2014 13:56:07,,1324263464,7/16/2014 13:55:53,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],PILOCARPINE for treatment of RADIATION INDUCED XEROSTOMIA,N/A,339,306,366,317,1,RO-may_treat,908334-FS1,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
503460868,7/16/2014 14:45:35,,1324283125,7/16/2014 14:45:12,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS],[TREATS],for the treatment of,N/A,339,306,366,317,1,RO-may_treat,908334-FS1,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
503460868,7/16/2014 15:34:21,,1324299739,7/16/2014 15:34:03,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,unclear,339,306,366,317,1,RO-may_treat,908334-FS1,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
503460868,7/16/2014 15:43:59,,1324303688,7/16/2014 15:43:46,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[TREATS],[TREATS],for the treatment of,N/A,339,306,366,317,1,RO-may_treat,908334-FS1,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
503460868,7/16/2014 16:51:48,,1324335245,7/16/2014 16:51:22,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[TREATS],[TREATS],efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA,N/A,339,306,366,317,1,RO-may_treat,908334-FS1,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
503460868,7/16/2014 17:04:31,,1324339551,7/16/2014 17:04:20,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,339,306,366,317,1,RO-may_treat,908334-FS1,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
503460868,7/16/2014 19:07:52,,1324423322,7/16/2014 19:07:40,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[TREATS],[TREATS],treatment,N/A,339,306,366,317,1,RO-may_treat,908334-FS1,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
503460868,7/16/2014 19:20:11,,1324429717,7/16/2014 19:19:49,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],and efficacy,IS TREATED BY,339,306,366,317,1,RO-may_treat,908334-FS1,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
503460868,7/16/2014 19:36:46,,1324437540,7/16/2014 19:36:36,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],treatment,N/A,339,306,366,317,1,RO-may_treat,908334-FS1,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
503460868,7/16/2014 19:45:14,,1324441883,7/16/2014 19:44:51,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],for the treatment of,N/A,339,306,366,317,1,RO-may_treat,908334-FS1,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
503460868,7/16/2014 20:28:55,,1324461701,7/16/2014 20:28:31,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],for the treatment of,N/A,339,306,366,317,1,RO-may_treat,908334-FS1,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
503460868,7/16/2014 20:42:00,,1324467077,7/16/2014 20:41:44,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[TREATS],[TREATS],treatment,N/A,339,306,366,317,1,RO-may_treat,908334-FS1,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
503460868,7/16/2014 20:43:29,,1324467571,7/16/2014 20:42:33,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],PILOCARPINE treatment of RADIATION INDUCED XEROSTOMIA,Treats,339,306,366,317,1,RO-may_treat,908334-FS1,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
503460869,7/16/2014 13:38:39,,1324257130,7/16/2014 13:37:51,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,na,106,125,119,140,-1,RO-has_manifestation,906314-FS1,"Clinically significant anaerobic pleuropulmonary infection was not found in our patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS and occurred in only some of our patients with empyema and lung abscess.",BRONCHIECTASIS,CYSTIC FIBROSIS
503460869,7/16/2014 13:42:53,,1324258716,7/16/2014 13:42:32,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS",N/A,106,125,119,140,-1,RO-has_manifestation,906314-FS1,"Clinically significant anaerobic pleuropulmonary infection was not found in our patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS and occurred in only some of our patients with empyema and lung abscess.",BRONCHIECTASIS,CYSTIC FIBROSIS
503460869,7/16/2014 13:42:58,,1324258724,7/16/2014 13:42:42,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,106,125,119,140,-1,RO-has_manifestation,906314-FS1,"Clinically significant anaerobic pleuropulmonary infection was not found in our patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS and occurred in only some of our patients with empyema and lung abscess.",BRONCHIECTASIS,CYSTIC FIBROSIS
503460869,7/16/2014 14:11:59,,1324270356,7/16/2014 14:11:49,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,106,125,119,140,-1,RO-has_manifestation,906314-FS1,"Clinically significant anaerobic pleuropulmonary infection was not found in our patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS and occurred in only some of our patients with empyema and lung abscess.",BRONCHIECTASIS,CYSTIC FIBROSIS
503460869,7/16/2014 14:46:07,,1324283263,7/16/2014 14:45:41,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[NONE],[NONE],N/A,separate conditions,106,125,119,140,-1,RO-has_manifestation,906314-FS1,"Clinically significant anaerobic pleuropulmonary infection was not found in our patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS and occurred in only some of our patients with empyema and lung abscess.",BRONCHIECTASIS,CYSTIC FIBROSIS
503460869,7/16/2014 16:29:58,,1324325703,7/16/2014 16:29:06,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BRONCHIECTASIS CYSTIC FIBROSIS,n/a,106,125,119,140,-1,RO-has_manifestation,906314-FS1,"Clinically significant anaerobic pleuropulmonary infection was not found in our patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS and occurred in only some of our patients with empyema and lung abscess.",BRONCHIECTASIS,CYSTIC FIBROSIS
503460869,7/16/2014 16:41:11,,1324331358,7/16/2014 16:40:42,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",occurred in,na,106,125,119,140,-1,RO-has_manifestation,906314-FS1,"Clinically significant anaerobic pleuropulmonary infection was not found in our patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS and occurred in only some of our patients with empyema and lung abscess.",BRONCHIECTASIS,CYSTIC FIBROSIS
503460869,7/16/2014 18:16:01,,1324394534,7/16/2014 18:15:25,clixsense,1.0,6621167,USA,"","",66.87.78.42,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,106,125,119,140,-1,RO-has_manifestation,906314-FS1,"Clinically significant anaerobic pleuropulmonary infection was not found in our patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS and occurred in only some of our patients with empyema and lung abscess.",BRONCHIECTASIS,CYSTIC FIBROSIS
503460869,7/16/2014 18:33:19,,1324403685,7/16/2014 18:32:50,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS",N/A,106,125,119,140,-1,RO-has_manifestation,906314-FS1,"Clinically significant anaerobic pleuropulmonary infection was not found in our patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS and occurred in only some of our patients with empyema and lung abscess.",BRONCHIECTASIS,CYSTIC FIBROSIS
503460869,7/16/2014 19:05:36,,1324421930,7/16/2014 19:05:25,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,106,125,119,140,-1,RO-has_manifestation,906314-FS1,"Clinically significant anaerobic pleuropulmonary infection was not found in our patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS and occurred in only some of our patients with empyema and lung abscess.",BRONCHIECTASIS,CYSTIC FIBROSIS
503460869,7/16/2014 19:08:50,,1324423841,7/16/2014 19:08:10,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BRONCHIECTASIS and CYSTIC FIBROSIS and occurred,N/A,106,125,119,140,-1,RO-has_manifestation,906314-FS1,"Clinically significant anaerobic pleuropulmonary infection was not found in our patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS and occurred in only some of our patients with empyema and lung abscess.",BRONCHIECTASIS,CYSTIC FIBROSIS
503460869,7/16/2014 19:58:00,,1324447788,7/16/2014 19:57:44,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],and,N/A,106,125,119,140,-1,RO-has_manifestation,906314-FS1,"Clinically significant anaerobic pleuropulmonary infection was not found in our patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS and occurred in only some of our patients with empyema and lung abscess.",BRONCHIECTASIS,CYSTIC FIBROSIS
503460869,7/16/2014 20:48:53,,1324469929,7/16/2014 20:47:13,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[PREVENTS],[PREVENTS],infection,NONE,106,125,119,140,-1,RO-has_manifestation,906314-FS1,"Clinically significant anaerobic pleuropulmonary infection was not found in our patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS and occurred in only some of our patients with empyema and lung abscess.",BRONCHIECTASIS,CYSTIC FIBROSIS
503460869,7/16/2014 20:58:56,,1324473942,7/16/2014 20:58:26,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],BRONCHIECTASIS and CYSTIC FIBROSIS occurred in only some of our patients with empyema and lung abscess.,N/A,106,125,119,140,-1,RO-has_manifestation,906314-FS1,"Clinically significant anaerobic pleuropulmonary infection was not found in our patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS and occurred in only some of our patients with empyema and lung abscess.",BRONCHIECTASIS,CYSTIC FIBROSIS
503460869,7/16/2014 21:00:48,,1324475080,7/16/2014 21:00:22,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],"not found in our patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS",N/A,106,125,119,140,-1,RO-has_manifestation,906314-FS1,"Clinically significant anaerobic pleuropulmonary infection was not found in our patients with bronchitis, BRONCHIECTASIS and CYSTIC FIBROSIS and occurred in only some of our patients with empyema and lung abscess.",BRONCHIECTASIS,CYSTIC FIBROSIS
503460870,7/16/2014 13:28:19,,1324252792,7/16/2014 13:28:11,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],significant,N/A,97,17,123,49,-1,RO-cause_of,900330-FS1,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
503460870,7/16/2014 13:36:18,,1324256292,7/16/2014 13:35:54,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[CAUSES],[CAUSES],account for,na,97,17,123,49,-1,RO-cause_of,900330-FS1,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
503460870,7/16/2014 13:43:35,,1324258956,7/16/2014 13:43:12,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[PREVENTS],[PREVENTS],LATE SYSTEMIC ALLERGIC REACTIONS,asd,97,17,123,49,-1,RO-cause_of,900330-FS1,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
503460870,7/16/2014 13:45:44,,1324259700,7/16/2014 13:44:59,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],account for significant percent of the total NUMBER,n/a,97,17,123,49,-1,RO-cause_of,900330-FS1,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
503460870,7/16/2014 13:53:29,,1324262391,7/16/2014 13:53:11,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],account for a significant percent of the total,N/a,97,17,123,49,-1,RO-cause_of,900330-FS1,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
503460870,7/16/2014 13:58:50,,1324264687,7/16/2014 13:58:41,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",account significant immunotherapy.,N/A,97,17,123,49,-1,RO-cause_of,900330-FS1,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
503460870,7/16/2014 14:11:55,,1324270329,7/16/2014 14:11:21,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],account for a significant percent of the total,N/A,97,17,123,49,-1,RO-cause_of,900330-FS1,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
503460870,7/16/2014 14:14:15,,1324271323,7/16/2014 14:14:03,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],account for,N/A,97,17,123,49,-1,RO-cause_of,900330-FS1,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
503460870,7/16/2014 14:45:40,,1324283151,7/16/2014 14:45:06,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],NUMBER OF SYSTEMIC ALLERGIC reactions,N/A,97,17,123,49,-1,RO-cause_of,900330-FS1,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
503460870,7/16/2014 15:33:16,,1324299400,7/16/2014 15:32:35,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],significant percent the total NUMBER,n/a,97,17,123,49,-1,RO-cause_of,900330-FS1,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
503460870,7/16/2014 15:40:18,,1324302091,7/16/2014 15:39:44,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[ASSOCIATED_WITH],[ASSOCIATED_WITH],significant percent,N/A,97,17,123,49,-1,RO-cause_of,900330-FS1,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
503460870,7/16/2014 16:36:42,,1324328529,7/16/2014 16:35:29,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],significant percent,na,97,17,123,49,-1,RO-cause_of,900330-FS1,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
503460870,7/16/2014 16:42:38,,1324331995,7/16/2014 16:41:30,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],SYSTEMIC ALLERGIC REACTIONS,N/A,97,17,123,49,-1,RO-cause_of,900330-FS1,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
503460870,7/16/2014 16:46:50,,1324333480,7/16/2014 16:45:47,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[IS_A],[IS_A],LATE SYSTEMIC ALLERGIC REACTIONS account for NUMBER OF SYSTEMIC ALLERGIC,N/A,97,17,123,49,-1,RO-cause_of,900330-FS1,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
503460870,7/16/2014 19:24:56,,1324431945,7/16/2014 19:24:27,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],We conclude,N/A,97,17,123,49,-1,RO-cause_of,900330-FS1,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
503460871,7/16/2014 13:29:31,,1324253326,7/16/2014 13:28:45,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],reduce cardiac events,n/a,84,44,85,51,1,RO-may_prevent,907404-FS1,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
503460871,7/16/2014 13:31:48,,1324254377,7/16/2014 13:31:35,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],reduces the incidence of,N/A,84,44,85,51,1,RO-may_prevent,907404-FS1,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
503460871,7/16/2014 13:45:25,,1324259605,7/16/2014 13:45:08,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",reduces the incidence of,N/a,84,44,85,51,1,RO-may_prevent,907404-FS1,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
503460871,7/16/2014 13:57:48,,1324264225,7/16/2014 13:57:34,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[PREVENTS] [CAUSES] [CONTRAINDICATES],"[PREVENTS]
[CAUSES]
[CONTRAINDICATES]",combination ASPIRIN the during revascularization,N/A,84,44,85,51,1,RO-may_prevent,907404-FS1,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
503460871,7/16/2014 14:02:37,,1324266179,7/16/2014 14:02:20,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],ASPIRIN reduces incidence of MI,N/A,84,44,85,51,1,RO-may_prevent,907404-FS1,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
503460871,7/16/2014 15:04:17,,1324289884,7/16/2014 15:03:43,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[PREVENTS],[PREVENTS],reduces the incidence of,N/A,84,44,85,51,1,RO-may_prevent,907404-FS1,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
503460871,7/16/2014 15:42:41,,1324303081,7/16/2014 15:42:14,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PREVENTS],[PREVENTS],reduces the incidence of,n/a,84,44,85,51,1,RO-may_prevent,907404-FS1,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
503460871,7/16/2014 15:42:48,,1324303125,7/16/2014 15:42:14,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[OTHER] [TREATS],"[TREATS]
[OTHER]",reduces the incidence of,N/A,84,44,85,51,1,RO-may_prevent,907404-FS1,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
503460871,7/16/2014 15:51:54,,1324307045,7/16/2014 15:50:33,prodege,1.0,27990290,GBR,I9,Bury Saint Edmunds,86.142.231.81,[PREVENTS],[PREVENTS],reduces incidence,the combination of heparin and aspirin reduces the incidence of MI.,84,44,85,51,1,RO-may_prevent,907404-FS1,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
503460871,7/16/2014 16:30:34,,1324325954,7/16/2014 16:30:19,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],reduces,N/A,84,44,85,51,1,RO-may_prevent,907404-FS1,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
503460871,7/16/2014 16:41:57,,1324331730,7/16/2014 16:40:56,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASPIRIN MI,n/a,84,44,85,51,1,RO-may_prevent,907404-FS1,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
503460871,7/16/2014 16:56:19,,1324336829,7/16/2014 16:55:44,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH] [PREVENTS],"[PREVENTS]
[ASSOCIATED_WITH]",ASPIRIN MI,n/a,84,44,85,51,1,RO-may_prevent,907404-FS1,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
503460871,7/16/2014 17:06:46,,1324340207,7/16/2014 17:06:37,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,84,44,85,51,1,RO-may_prevent,907404-FS1,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
503460871,7/16/2014 17:16:00,,1324343280,7/16/2014 17:15:33,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[OTHER],[OTHER],ASPIRIN reduces incidence MI,n/a,84,44,85,51,1,RO-may_prevent,907404-FS1,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
503460871,7/16/2014 19:06:46,,1324422668,7/16/2014 19:06:13,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[PREVENTS],[PREVENTS],ASPIRIN in ACS reduces the incidence of MI,N/A,84,44,85,51,1,RO-may_prevent,907404-FS1,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
503460872,7/16/2014 13:34:51,,1324255743,7/16/2014 13:34:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],BLADDER lies,N/A,150,150,156,164,1,RO-has_finding_site,905349-FS1,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
503460872,7/16/2014 13:37:49,,1324256795,7/16/2014 13:37:15,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[LOCATION],[LOCATION],because the BLADDER,na,150,150,156,164,1,RO-has_finding_site,905349-FS1,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
503460872,7/16/2014 13:42:19,,1324258548,7/16/2014 13:41:49,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[PREVENTS],[PREVENTS],BLADDER INJURY,asd,150,150,156,164,1,RO-has_finding_site,905349-FS1,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
503460872,7/16/2014 13:44:31,,1324259310,7/16/2014 13:44:18,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[LOCATION],[LOCATION],abdomen.,Na,150,150,156,164,1,RO-has_finding_site,905349-FS1,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
503460872,7/16/2014 13:55:59,,1324263387,7/16/2014 13:55:27,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[LOCATION],[LOCATION],lies in,N/A,150,150,156,164,1,RO-has_finding_site,905349-FS1,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
503460872,7/16/2014 14:38:45,,1324281176,7/16/2014 14:38:22,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[LOCATION],[LOCATION],in,N/A,150,150,156,164,1,RO-has_finding_site,905349-FS1,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
503460872,7/16/2014 15:03:20,,1324289483,7/16/2014 15:02:46,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION],[LOCATION],lies in,N/A,150,150,156,164,1,RO-has_finding_site,905349-FS1,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
503460872,7/16/2014 16:54:46,,1324336238,7/16/2014 16:54:07,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[LOCATION],[LOCATION],BLADDER INJURY because the BLADDER lies in abdomen.,N/A,150,150,156,164,1,RO-has_finding_site,905349-FS1,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
503460872,7/16/2014 16:56:36,,1324336917,7/16/2014 16:56:01,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[LOCATION],[LOCATION],BLADDER INJURY,N/A,150,150,156,164,1,RO-has_finding_site,905349-FS1,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
503460872,7/16/2014 17:04:02,,1324339428,7/16/2014 17:03:57,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,150,150,156,164,1,RO-has_finding_site,905349-FS1,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
503460872,7/16/2014 17:49:36,,1324366916,7/16/2014 17:49:13,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[LOCATION],[LOCATION],is the most common BLADDER INJURY,n/a,150,150,156,164,1,RO-has_finding_site,905349-FS1,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
503460872,7/16/2014 18:31:15,,1324402681,7/16/2014 18:30:37,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],in children because the lies in the abdomen.,na,150,150,156,164,1,RO-has_finding_site,905349-FS1,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
503460872,7/16/2014 19:16:51,,1324428201,7/16/2014 19:16:34,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[LOCATION],[LOCATION],bladder dome;,N/A,150,150,156,164,1,RO-has_finding_site,905349-FS1,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
503460872,7/16/2014 19:20:03,,1324429632,7/16/2014 19:19:42,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[LOCATION],[LOCATION],in children because the lies in the abdomen.,N/A,150,150,156,164,1,RO-has_finding_site,905349-FS1,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
503460872,7/16/2014 19:37:26,,1324437896,7/16/2014 19:37:19,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],BLADDER,N/A,150,150,156,164,1,RO-has_finding_site,905349-FS1,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
503460873,7/16/2014 13:26:59,,1324252242,7/16/2014 13:26:34,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[MANIFESTATION],[MANIFESTATION],dermatologic manifestation of,n/a,0,56,16,72,-1,RO-cause_of,900179-FS1,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
503460873,7/16/2014 13:31:07,,1324254031,7/16/2014 13:30:56,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],manifestation of the,N/A,0,56,16,72,-1,RO-cause_of,900179-FS1,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
503460873,7/16/2014 13:41:27,,1324258167,7/16/2014 13:41:03,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[MANIFESTATION],[MANIFESTATION],the dermatologic manifestation of the,N/A,0,56,16,72,-1,RO-cause_of,900179-FS1,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
503460873,7/16/2014 13:45:48,,1324259712,7/16/2014 13:45:28,instagc,1.0,13763729,USA,"","",75.182.89.225,[MANIFESTATION],[MANIFESTATION],dermatologic manifestation of,N/A,0,56,16,72,-1,RO-cause_of,900179-FS1,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
503460873,7/16/2014 13:49:00,,1324260774,7/16/2014 13:48:49,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[SYMPTOM],[SYMPTOM],manifestation,N/A,0,56,16,72,-1,RO-cause_of,900179-FS1,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
503460873,7/16/2014 13:53:32,,1324262398,7/16/2014 13:53:11,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],ATOPIC DERMATITIS dermatologic manifestation of ATOPIC DIATHESIS,N/A,0,56,16,72,-1,RO-cause_of,900179-FS1,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
503460873,7/16/2014 14:16:42,,1324272153,7/16/2014 14:16:32,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],manifestation,N/A,0,56,16,72,-1,RO-cause_of,900179-FS1,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
503460873,7/16/2014 14:48:39,,1324284047,7/16/2014 14:47:50,prodege,1.0,15508331,USA,OK,Stillwater,139.78.139.193,[MANIFESTATION],[MANIFESTATION],ATOPIC DERMATITIS the dermatologic manifestation of ATOPIC DIATHESIS,N/A,0,56,16,72,-1,RO-cause_of,900179-FS1,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
503460873,7/16/2014 15:19:38,,1324295010,7/16/2014 15:19:26,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],manifestation of,N/A,0,56,16,72,-1,RO-cause_of,900179-FS1,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
503460873,7/16/2014 15:56:03,,1324308782,7/16/2014 15:55:14,prodege,1.0,27990290,GBR,I9,Bury Saint Edmunds,86.142.231.81,[MANIFESTATION],[MANIFESTATION],manifestation,atopic dermatitis is a manifestation of atopic diathesis.,0,56,16,72,-1,RO-cause_of,900179-FS1,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
503460873,7/16/2014 16:46:25,,1324333314,7/16/2014 16:46:00,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[MANIFESTATION],[MANIFESTATION],ATOPIC DERMATITIS dermatologic manifestation of ATOPIC DIATHESIS,N/A,0,56,16,72,-1,RO-cause_of,900179-FS1,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
503460873,7/16/2014 17:04:45,,1324339655,7/16/2014 17:04:39,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,0,56,16,72,-1,RO-cause_of,900179-FS1,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
503460873,7/16/2014 17:43:41,,1324360679,7/16/2014 17:42:40,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[MANIFESTATION],[MANIFESTATION],the dermatologic manifestation of,n/a,0,56,16,72,-1,RO-cause_of,900179-FS1,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
503460873,7/16/2014 18:24:56,,1324399923,7/16/2014 18:24:33,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[MANIFESTATION],[MANIFESTATION],ATOPIC DERMATITIS the dermatologic manifestation of ATOPIC DIATHESIS,N/A,0,56,16,72,-1,RO-cause_of,900179-FS1,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
503460873,7/16/2014 19:37:07,,1324437729,7/16/2014 19:36:58,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[MANIFESTATION],[MANIFESTATION],manifestation,N/A,0,56,16,72,-1,RO-cause_of,900179-FS1,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
503460874,7/16/2014 13:28:39,,1324252941,7/16/2014 13:28:30,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,77,141,84,159,-1,RO-has_definitional_manifestation,904933-FS1,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
503460874,7/16/2014 13:35:05,,1324255796,7/16/2014 13:34:40,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],onset of the,N/A,77,141,84,159,-1,RO-has_definitional_manifestation,904933-FS1,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
503460874,7/16/2014 13:38:32,,1324257080,7/16/2014 13:38:11,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],and subtype of,N/A,77,141,84,159,-1,RO-has_definitional_manifestation,904933-FS1,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
503460874,7/16/2014 13:47:24,,1324260227,7/16/2014 13:47:07,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[PART_OF],[PART_OF],subtype,N/A,77,141,84,159,-1,RO-has_definitional_manifestation,904933-FS1,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
503460874,7/16/2014 13:49:44,,1324260977,7/16/2014 13:49:26,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],SEIZURES,N/A,77,141,84,159,-1,RO-has_definitional_manifestation,904933-FS1,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
503460874,7/16/2014 13:49:58,,1324261073,7/16/2014 13:49:18,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],included:,N/A,77,141,84,159,-1,RO-has_definitional_manifestation,904933-FS1,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
503460874,7/16/2014 14:44:37,,1324282900,7/16/2014 14:44:03,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURES EPILEPTIC SEIZURES,n/a,77,141,84,159,-1,RO-has_definitional_manifestation,904933-FS1,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
503460874,7/16/2014 15:05:08,,1324290279,7/16/2014 15:03:29,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[MANIFESTATION],[MANIFESTATION],of,N/A,77,141,84,159,-1,RO-has_definitional_manifestation,904933-FS1,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
503460874,7/16/2014 15:42:26,,1324302987,7/16/2014 15:41:40,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",the clinical subgroup of,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],77,141,84,159,-1,RO-has_definitional_manifestation,904933-FS1,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
503460874,7/16/2014 16:24:07,,1324323573,7/16/2014 16:23:54,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[PART_OF],[PART_OF],subtype of,N/A,77,141,84,159,-1,RO-has_definitional_manifestation,904933-FS1,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
503460874,7/16/2014 16:42:45,,1324332035,7/16/2014 16:42:15,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],subtype,none,77,141,84,159,-1,RO-has_definitional_manifestation,904933-FS1,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
503460874,7/16/2014 17:19:09,,1324344147,7/16/2014 17:17:59,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[OTHER],[OTHER],SEIZURES subgroup EPILEPTIC SEIZURES,n/a,77,141,84,159,-1,RO-has_definitional_manifestation,904933-FS1,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
503460874,7/16/2014 18:20:48,,1324398339,7/16/2014 18:20:29,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[IS_A],[IS_A],SEIZURES the clinical subgroup of EPILEPTIC SEIZURES,N/A,77,141,84,159,-1,RO-has_definitional_manifestation,904933-FS1,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
503460874,7/16/2014 19:13:30,,1324426366,7/16/2014 19:13:10,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",and subtype of,N/A,77,141,84,159,-1,RO-has_definitional_manifestation,904933-FS1,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
503460874,7/16/2014 19:47:57,,1324443212,7/16/2014 19:47:40,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],and subtype of,N/A,77,141,84,159,-1,RO-has_definitional_manifestation,904933-FS1,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
503460875,7/16/2014 13:35:23,,1324255937,7/16/2014 13:34:51,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients with a history of,N/A,161,112,183,130,-1,RO-disease_may_have_finding,902513-FS1,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503460875,7/16/2014 13:44:17,,1324259231,7/16/2014 13:43:59,clixsense,1,20614047,USA,MO,Maryville,174.32.162.147,[TREATS],[TREATS],POSTMENOPAUSAL BLEEDING,asd,161,112,183,130,-1,RO-disease_may_have_finding,902513-FS1,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503460875,7/16/2014 13:52:11,,1324261876,7/16/2014 13:51:53,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with a history,N/A,161,112,183,130,-1,RO-disease_may_have_finding,902513-FS1,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503460875,7/16/2014 13:57:22,,1324264004,7/16/2014 13:57:12,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[CAUSES] [TREATS],"[TREATS]
[CAUSES]",role three dimensional dimensional BLEEDING,N/A,161,112,183,130,-1,RO-disease_may_have_finding,902513-FS1,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503460875,7/16/2014 14:02:20,,1324266050,7/16/2014 14:01:24,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],a history of,N/A,161,112,183,130,-1,RO-disease_may_have_finding,902513-FS1,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503460875,7/16/2014 14:17:09,,1324272371,7/16/2014 14:16:57,zoombucks,1,5919735,USA,PA,Doylestown,173.49.91.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosing,N/A,161,112,183,130,-1,RO-disease_may_have_finding,902513-FS1,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503460875,7/16/2014 14:44:38,,1324282902,7/16/2014 14:44:14,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[SYMPTOM],[SYMPTOM],with a history,N/A,161,112,183,130,-1,RO-disease_may_have_finding,902513-FS1,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503460875,7/16/2014 14:55:20,,1324286152,7/16/2014 14:54:30,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TVUS ENDOMETRIAL CANCER,n/a,161,112,183,130,-1,RO-disease_may_have_finding,902513-FS1,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503460875,7/16/2014 15:30:18,,1324298436,7/16/2014 15:29:47,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[SYMPTOM],[SYMPTOM],history of,n/a,161,112,183,130,-1,RO-disease_may_have_finding,902513-FS1,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503460875,7/16/2014 15:43:47,,1324303584,7/16/2014 15:43:18,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],in patients with a history,[DIAGNOSE_BY_TEST_OR_DRUG],161,112,183,130,-1,RO-disease_may_have_finding,902513-FS1,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503460875,7/16/2014 18:06:04,,1324383986,7/16/2014 18:05:20,bitcoinget,1,28222930,USA,IL,Mattoon,206.166.56.30,[SYMPTOM],[SYMPTOM],patients with,na,161,112,183,130,-1,RO-disease_may_have_finding,902513-FS1,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503460875,7/16/2014 18:22:57,,1324399186,7/16/2014 18:21:59,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[SYMPTOM],[SYMPTOM],in diagnosing in patients with a history,na,161,112,183,130,-1,RO-disease_may_have_finding,902513-FS1,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503460875,7/16/2014 19:56:58,,1324447335,7/16/2014 19:56:33,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[SYMPTOM],[SYMPTOM],in patients with,N/A,161,112,183,130,-1,RO-disease_may_have_finding,902513-FS1,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503460875,7/16/2014 20:32:10,,1324463105,7/16/2014 20:31:23,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients with history,n/a,161,112,183,130,-1,RO-disease_may_have_finding,902513-FS1,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503460875,7/16/2014 20:44:28,,1324467951,7/16/2014 20:43:57,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[CAUSES],[CAUSES],in patients with a history of,N/A,161,112,183,130,-1,RO-disease_may_have_finding,902513-FS1,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503460876,7/16/2014 13:30:22,,1324253657,7/16/2014 13:30:09,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],INDOCYANINE GREEN (ICG UPTAKE EXCRETION,N/A,137,70,149,109,1,RO-may_diagnose,906957-FS1,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
503460876,7/16/2014 13:47:18,,1324260195,7/16/2014 13:46:43,clixsense,1,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[SIDE_EFFECT],[SIDE_EFFECT],disturbance,naa,137,70,149,109,1,RO-may_diagnose,906957-FS1,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
503460876,7/16/2014 13:49:46,,1324260988,7/16/2014 13:49:21,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],disturbance of INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,N/A,137,70,149,109,1,RO-may_diagnose,906957-FS1,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
503460876,7/16/2014 13:53:14,,1324262283,7/16/2014 13:52:24,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[LOCATION],[LOCATION],is to clarify,N/A,137,70,149,109,1,RO-may_diagnose,906957-FS1,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
503460876,7/16/2014 14:48:09,,1324283881,7/16/2014 14:47:14,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[CAUSES],[CAUSES],mechanism in patients with,N/A,137,70,149,109,1,RO-may_diagnose,906957-FS1,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
503460876,7/16/2014 16:32:44,,1324326678,7/16/2014 16:31:13,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,137,70,149,109,1,RO-may_diagnose,906957-FS1,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
503460876,7/16/2014 17:29:48,,1324349194,7/16/2014 17:29:22,zapbux,1,27754872,USA,SC,Graniteville,24.145.86.46,[SIDE_EFFECT],[SIDE_EFFECT],disturbance of the,n/a,137,70,149,109,1,RO-may_diagnose,906957-FS1,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
503460876,7/16/2014 18:34:35,,1324404320,7/16/2014 18:33:58,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,N/A,137,70,149,109,1,RO-may_diagnose,906957-FS1,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
503460876,7/16/2014 19:07:39,,1324423160,7/16/2014 19:07:22,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CONTRAINDICATES],[CONTRAINDICATES],disturbance,N/A,137,70,149,109,1,RO-may_diagnose,906957-FS1,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
503460876,7/16/2014 19:14:09,,1324426682,7/16/2014 19:13:31,tremorgames,1,16681597,USA,IL,Chicago,76.193.178.111,[SYMPTOM] [ASSOCIATED_WITH] [SIDE_EFFECT],"[SYMPTOM]
[ASSOCIATED_WITH]
[SIDE_EFFECT]",disturbance of the mechanism in patients with,N/A,137,70,149,109,1,RO-may_diagnose,906957-FS1,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
503460876,7/16/2014 20:52:47,,1324471576,7/16/2014 20:51:30,neodev,1,21405167,USA,MD,Glen Burnie,69.137.237.73,[PART_OF],[PART_OF],mechanism in patients with LIVER DISEASE,N/A,137,70,149,109,1,RO-may_diagnose,906957-FS1,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
503460876,7/16/2014 20:56:44,,1324472992,7/16/2014 20:56:02,instagc,1,18611009,GBR,Q4,Pershore,31.50.159.84,[MANIFESTATION],[MANIFESTATION],INDOCYANINE,NONE,137,70,149,109,1,RO-may_diagnose,906957-FS1,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
503460876,7/16/2014 21:06:52,,1324478440,7/16/2014 21:06:06,eup_slw,1,20900720,USA,ID,Boise,97.121.0.39,[PART_OF],[PART_OF],INDOCYANINE GREEN in patients with LIVER DISEASE,N/A,137,70,149,109,1,RO-may_diagnose,906957-FS1,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
503460876,7/16/2014 21:12:05,,1324481846,7/16/2014 21:11:10,neodev,1,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",INDOCYANINE GREEN (ICG UPTAKE EXCRETION LIVER DISEASE,n/a,137,70,149,109,1,RO-may_diagnose,906957-FS1,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
503460876,7/16/2014 21:20:50,,1324486175,7/16/2014 21:19:42,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,[MANIFESTATION],[MANIFESTATION],clarify the disturbance,n/a,137,70,149,109,1,RO-may_diagnose,906957-FS1,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
503460877,7/16/2014 13:27:48,,1324252596,7/16/2014 13:27:38,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],containing,N/A,0,0,7,21,1,RO-has_causative_agent,903967-FS1,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
503460877,7/16/2014 13:31:35,,1324254245,7/16/2014 13:31:21,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ALUMINUM INTOXICATION ALUMINUM,N/A,0,0,7,21,1,RO-has_causative_agent,903967-FS1,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
503460877,7/16/2014 13:34:51,,1324255749,7/16/2014 13:34:36,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],absorption aluminum,Na,0,0,7,21,1,RO-has_causative_agent,903967-FS1,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
503460877,7/16/2014 13:39:52,,1324257567,7/16/2014 13:39:30,instagc,1,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],ALUMINUM INTOXICATION ALUMINUM,N/A,0,0,7,21,1,RO-has_causative_agent,903967-FS1,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
503460877,7/16/2014 13:49:49,,1324261000,7/16/2014 13:49:23,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[CAUSES],[CAUSES],because of absorption of,na,0,0,7,21,1,RO-has_causative_agent,903967-FS1,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
503460877,7/16/2014 15:18:35,,1324294685,7/16/2014 15:18:20,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],from,N/A,0,0,7,21,1,RO-has_causative_agent,903967-FS1,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
503460877,7/16/2014 15:41:54,,1324302807,7/16/2014 15:41:18,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[CAUSES],[CAUSES],is common because of absorption,N/A,0,0,7,21,1,RO-has_causative_agent,903967-FS1,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
503460877,7/16/2014 16:40:48,,1324331125,7/16/2014 16:39:22,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],ALUMINUM INTOXICATION is common with ALUMINUM,N/A,0,0,7,21,1,RO-has_causative_agent,903967-FS1,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
503460877,7/16/2014 16:48:29,,1324334133,7/16/2014 16:47:52,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ALUMINUM INTOXICATION is dialysis from ALUMINUM,N/A,0,0,7,21,1,RO-has_causative_agent,903967-FS1,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
503460877,7/16/2014 16:57:11,,1324337146,7/16/2014 16:56:38,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[CAUSES],[CAUSES],because of absorption of aluminum,N/A,0,0,7,21,1,RO-has_causative_agent,903967-FS1,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
503460877,7/16/2014 17:13:12,,1324342460,7/16/2014 17:12:38,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[CAUSES],[CAUSES],from,NONE,0,0,7,21,1,RO-has_causative_agent,903967-FS1,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
503460877,7/16/2014 18:03:18,,1324381200,7/16/2014 18:02:34,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[CAUSES],[CAUSES],containing,na,0,0,7,21,1,RO-has_causative_agent,903967-FS1,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
503460877,7/16/2014 18:24:04,,1324399597,7/16/2014 18:21:41,prodege,1.0,20349329,USA,CA,El Cajon,68.7.51.119,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ALUMINUM INTOXICATION is common in patients with chronic renal failure,N/A,0,0,7,21,1,RO-has_causative_agent,903967-FS1,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
503460877,7/16/2014 19:35:17,,1324436922,7/16/2014 19:34:31,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is common in patients with,N/A,0,0,7,21,1,RO-has_causative_agent,903967-FS1,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
503460877,7/16/2014 19:38:04,,1324438137,7/16/2014 19:37:55,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[CAUSES],[CAUSES],ALUMINUM INTOXICATION,N/A,0,0,7,21,1,RO-has_causative_agent,903967-FS1,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
503460878,7/16/2014 13:36:39,,1324256426,7/16/2014 13:36:21,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],for the treatment of,N/A,189,116,196,127,1,RO-may_treat,907928-FS1,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
503460878,7/16/2014 13:43:40,,1324258973,7/16/2014 13:43:20,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],treatment of,N/A,189,116,196,127,1,RO-may_treat,907928-FS1,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
503460878,7/16/2014 13:46:23,,1324259876,7/16/2014 13:46:06,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],randomized placebo controlled trial,n/a,189,116,196,127,1,RO-may_treat,907928-FS1,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
503460878,7/16/2014 14:00:42,,1324265413,7/16/2014 14:00:26,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],RISPERIDONE for treatment of DEMENTIA,N/A,189,116,196,127,1,RO-may_treat,907928-FS1,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
503460878,7/16/2014 14:12:37,,1324270635,7/16/2014 14:12:25,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],treatment,N/A,189,116,196,127,1,RO-may_treat,907928-FS1,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
503460878,7/16/2014 15:30:56,,1324298695,7/16/2014 15:29:19,prodege,1.0,27990290,GBR,I9,Bury Saint Edmunds,86.142.231.81,[TREATS],[TREATS],treatment,Risperidone is used to treat Dementia.,189,116,196,127,1,RO-may_treat,907928-FS1,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
503460878,7/16/2014 15:34:04,,1324299665,7/16/2014 15:33:33,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],treatment,n\a,189,116,196,127,1,RO-may_treat,907928-FS1,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
503460878,7/16/2014 15:38:54,,1324301522,7/16/2014 15:38:44,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],treatment,N/A,189,116,196,127,1,RO-may_treat,907928-FS1,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
503460878,7/16/2014 16:43:23,,1324332270,7/16/2014 16:42:39,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],treatment of,N/A,189,116,196,127,1,RO-may_treat,907928-FS1,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
503460878,7/16/2014 16:48:57,,1324334352,7/16/2014 16:48:18,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],RISPERIDONE treatment psychosis of DEMENTIA,N/A,189,116,196,127,1,RO-may_treat,907928-FS1,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
503460878,7/16/2014 17:30:44,,1324349840,7/16/2014 17:29:49,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],for the treatment of,n/a,189,116,196,127,1,RO-may_treat,907928-FS1,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
503460878,7/16/2014 20:37:50,,1324465322,7/16/2014 20:36:59,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],for the treatment of,N/A,189,116,196,127,1,RO-may_treat,907928-FS1,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
503460878,7/16/2014 20:53:08,,1324471670,7/16/2014 20:52:54,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],treatment,n/a,189,116,196,127,1,RO-may_treat,907928-FS1,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
503460878,7/16/2014 20:58:30,,1324473698,7/16/2014 20:58:19,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[LOCATION],[LOCATION],placebo,NONE,189,116,196,127,1,RO-may_treat,907928-FS1,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
503460878,7/16/2014 20:58:47,,1324473856,7/16/2014 20:58:34,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[TREATS],[TREATS],treatment,N/A,189,116,196,127,1,RO-may_treat,907928-FS1,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
503460879,7/16/2014 13:38:20,,1324257011,7/16/2014 13:38:02,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,82,105,94,149,-1,RO-disease_has_finding,901702-FS1,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
503460879,7/16/2014 13:53:10,,1324262248,7/16/2014 13:52:22,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],"differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection),",Different types of brucellosis,82,105,94,149,-1,RO-disease_has_finding,901702-FS1,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
503460879,7/16/2014 14:12:25,,1324270543,7/16/2014 14:11:56,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],includes,N/A,82,105,94,149,-1,RO-disease_has_finding,901702-FS1,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
503460879,7/16/2014 14:40:06,,1324281682,7/16/2014 14:39:36,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[NONE],[NONE],N/A,different types of infection,82,105,94,149,-1,RO-disease_has_finding,901702-FS1,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
503460879,7/16/2014 15:26:57,,1324297325,7/16/2014 15:26:33,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],includes,n/a,82,105,94,149,-1,RO-disease_has_finding,901702-FS1,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
503460879,7/16/2014 15:32:54,,1324299307,7/16/2014 15:32:43,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,82,105,94,149,-1,RO-disease_has_finding,901702-FS1,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
503460879,7/16/2014 16:12:10,,1324318663,7/16/2014 16:11:38,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]","malaria,",[SYMPTOM] [CAUSES],82,105,94,149,-1,RO-disease_has_finding,901702-FS1,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
503460879,7/16/2014 16:44:37,,1324332748,7/16/2014 16:43:28,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],includes,none,82,105,94,149,-1,RO-disease_has_finding,901702-FS1,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
503460879,7/16/2014 17:17:58,,1324343834,7/16/2014 17:16:01,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diagnosis includes ENTERIC FEVER INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS,n/a,82,105,94,149,-1,RO-disease_has_finding,901702-FS1,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
503460879,7/16/2014 19:53:58,,1324446121,7/16/2014 19:52:11,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],"malaria,",N/A,82,105,94,149,-1,RO-disease_has_finding,901702-FS1,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
503460879,7/16/2014 20:36:06,,1324464646,7/16/2014 20:35:15,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"diagnosis brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV]",Associated With,82,105,94,149,-1,RO-disease_has_finding,901702-FS1,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
503460879,7/16/2014 20:55:23,,1324472500,7/16/2014 20:55:02,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[NONE],[NONE],N/A,N/A,82,105,94,149,-1,RO-disease_has_finding,901702-FS1,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
503460879,7/16/2014 20:57:35,,1324473292,7/16/2014 20:57:14,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],diagnosis of brucellosis includes,N/A,82,105,94,149,-1,RO-disease_has_finding,901702-FS1,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
503460879,7/16/2014 21:18:36,,1324485319,7/16/2014 21:17:27,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[ASSOCIATED_WITH],[ASSOCIATED_WITH],differential diagnosis,n/a,82,105,94,149,-1,RO-disease_has_finding,901702-FS1,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
503460879,7/16/2014 21:19:35,,1324485661,7/16/2014 21:18:31,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[NONE],[NONE],"differential diagnosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS",ENTERIC FEVER malaria and INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS are two separate diseases often with similar symptoms,82,105,94,149,-1,RO-disease_has_finding,901702-FS1,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
503460880,7/16/2014 13:36:11,,1324256234,7/16/2014 13:35:49,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],CAUSED BY system disease or damage,n/a,146,201,173,217,1,RO-has_definitional_manifestation,904937-FS1,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
503460880,7/16/2014 13:36:51,,1324256504,7/16/2014 13:36:14,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],CAUSED BY,N/A,146,201,173,217,1,RO-has_definitional_manifestation,904937-FS1,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
503460880,7/16/2014 13:38:40,,1324257124,7/16/2014 13:38:22,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],CAUSED,N/A,146,201,173,217,1,RO-has_definitional_manifestation,904937-FS1,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
503460880,7/16/2014 13:41:32,,1324258184,7/16/2014 13:40:55,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],3 broad categories:,na,146,201,173,217,1,RO-has_definitional_manifestation,904937-FS1,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
503460880,7/16/2014 13:42:27,,1324258614,7/16/2014 13:42:07,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],chronic pain,Na,146,201,173,217,1,RO-has_definitional_manifestation,904937-FS1,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
503460880,7/16/2014 13:58:53,,1324264707,7/16/2014 13:58:30,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[NONE],[NONE],N/A,Different pain categories,146,201,173,217,1,RO-has_definitional_manifestation,904937-FS1,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
503460880,7/16/2014 14:39:34,,1324281476,7/16/2014 14:38:45,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[NONE],[NONE],N/A,different types of pain,146,201,173,217,1,RO-has_definitional_manifestation,904937-FS1,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
503460880,7/16/2014 15:33:49,,1324299577,7/16/2014 15:33:34,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[LOCATION],[LOCATION],somatic background.,N/A,146,201,173,217,1,RO-has_definitional_manifestation,904937-FS1,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
503460880,7/16/2014 16:46:55,,1324333528,7/16/2014 16:46:20,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[CAUSES],[CAUSES],BY,none,146,201,173,217,1,RO-has_definitional_manifestation,904937-FS1,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
503460880,7/16/2014 16:50:38,,1324334851,7/16/2014 16:50:02,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],chronic pain,N/A,146,201,173,217,1,RO-has_definitional_manifestation,904937-FS1,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
503460880,7/16/2014 19:40:58,,1324439684,7/16/2014 19:40:38,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],PAIN,N/A,146,201,173,217,1,RO-has_definitional_manifestation,904937-FS1,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
503460880,7/16/2014 20:38:58,,1324465821,7/16/2014 20:37:52,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[PART_OF],[PART_OF],system disease or damage,N/A,146,201,173,217,1,RO-has_definitional_manifestation,904937-FS1,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
503460880,7/16/2014 20:46:14,,1324468702,7/16/2014 20:44:49,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],classification chronic pain 3 broad categories: PAIN CAUSED BY SOMATOSENSORY (NEUROPATHIC PAIN,N/a,146,201,173,217,1,RO-has_definitional_manifestation,904937-FS1,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
503460880,7/16/2014 20:56:00,,1324472650,7/16/2014 20:55:45,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[SYMPTOM],[SYMPTOM],(nociceptive,NONE,146,201,173,217,1,RO-has_definitional_manifestation,904937-FS1,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
503460880,7/16/2014 20:57:05,,1324473082,7/16/2014 20:54:48,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[IS_A],[IS_A],PAIN CAUSED BY SOMATOSENSORY system or (NEUROPATHIC PAIN,N/A,146,201,173,217,1,RO-has_definitional_manifestation,904937-FS1,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
503460881,7/16/2014 13:31:30,,1324254208,7/16/2014 13:31:21,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[SIDE_EFFECT],[SIDE_EFFECT],common,N/A,32,0,42,15,1,RO-has_finding_site,905071-FS1,DERMATOFIBROMAS are very common SKIN TUMORS.,SKIN TUMORS,DERMATOFIBROMAS
503460881,7/16/2014 13:32:17,,1324254621,7/16/2014 13:32:09,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],are very common,N/A,32,0,42,15,1,RO-has_finding_site,905071-FS1,DERMATOFIBROMAS are very common SKIN TUMORS.,SKIN TUMORS,DERMATOFIBROMAS
503460881,7/16/2014 13:33:45,,1324255253,7/16/2014 13:33:29,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],are,N/A,32,0,42,15,1,RO-has_finding_site,905071-FS1,DERMATOFIBROMAS are very common SKIN TUMORS.,SKIN TUMORS,DERMATOFIBROMAS
503460881,7/16/2014 13:38:45,,1324257175,7/16/2014 13:38:28,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[IS_A],[IS_A],are very common,n/a,32,0,42,15,1,RO-has_finding_site,905071-FS1,DERMATOFIBROMAS are very common SKIN TUMORS.,SKIN TUMORS,DERMATOFIBROMAS
503460881,7/16/2014 13:40:06,,1324257659,7/16/2014 13:39:41,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CONTRAINDICATES],[CONTRAINDICATES],DERMATOFIBROMAS TUMORS.,asd,32,0,42,15,1,RO-has_finding_site,905071-FS1,DERMATOFIBROMAS are very common SKIN TUMORS.,SKIN TUMORS,DERMATOFIBROMAS
503460881,7/16/2014 13:47:07,,1324260128,7/16/2014 13:46:54,instagc,1.0,18960682,GBR,"","",86.29.147.112,[IS_A],[IS_A],DERMATOFIBROMAS are very common,N/a,32,0,42,15,1,RO-has_finding_site,905071-FS1,DERMATOFIBROMAS are very common SKIN TUMORS.,SKIN TUMORS,DERMATOFIBROMAS
503460881,7/16/2014 14:00:24,,1324265330,7/16/2014 14:00:12,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],DERMATOFIBROMAS are common SKIN TUMORS.,N/A,32,0,42,15,1,RO-has_finding_site,905071-FS1,DERMATOFIBROMAS are very common SKIN TUMORS.,SKIN TUMORS,DERMATOFIBROMAS
503460881,7/16/2014 14:53:45,,1324285617,7/16/2014 14:53:11,prodege,1,15508331,USA,OK,Stillwater,139.78.139.193,[IS_A],[IS_A],DERMATOFIBROMAS are SKIN TUMORS.,N/A,32,0,42,15,1,RO-has_finding_site,905071-FS1,DERMATOFIBROMAS are very common SKIN TUMORS.,SKIN TUMORS,DERMATOFIBROMAS
503460881,7/16/2014 15:05:37,,1324290484,7/16/2014 15:05:14,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A],[IS_A],are very common,N/A,32,0,42,15,1,RO-has_finding_site,905071-FS1,DERMATOFIBROMAS are very common SKIN TUMORS.,SKIN TUMORS,DERMATOFIBROMAS
503460881,7/16/2014 15:38:47,,1324301469,7/16/2014 15:38:22,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[MANIFESTATION],[MANIFESTATION],are,n/a,32,0,42,15,1,RO-has_finding_site,905071-FS1,DERMATOFIBROMAS are very common SKIN TUMORS.,SKIN TUMORS,DERMATOFIBROMAS
503460881,7/16/2014 16:54:04,,1324336062,7/16/2014 16:53:39,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",DERMATOFIBROMAS are very common SKIN TUMORS.,N/A,32,0,42,15,1,RO-has_finding_site,905071-FS1,DERMATOFIBROMAS are very common SKIN TUMORS.,SKIN TUMORS,DERMATOFIBROMAS
503460881,7/16/2014 17:00:11,,1324338161,7/16/2014 16:59:43,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[IS_A],[IS_A],DERMATOFIBROMAS are very common SKIN TUMORS.,N/A,32,0,42,15,1,RO-has_finding_site,905071-FS1,DERMATOFIBROMAS are very common SKIN TUMORS.,SKIN TUMORS,DERMATOFIBROMAS
503460881,7/16/2014 17:02:13,,1324338875,7/16/2014 17:01:59,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,32,0,42,15,1,RO-has_finding_site,905071-FS1,DERMATOFIBROMAS are very common SKIN TUMORS.,SKIN TUMORS,DERMATOFIBROMAS
503460881,7/16/2014 17:33:26,,1324351826,7/16/2014 17:33:04,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[IS_A],[IS_A],are,n/a,32,0,42,15,1,RO-has_finding_site,905071-FS1,DERMATOFIBROMAS are very common SKIN TUMORS.,SKIN TUMORS,DERMATOFIBROMAS
503460881,7/16/2014 19:13:09,,1324426173,7/16/2014 19:12:49,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[IS_A],[IS_A],are very common,N/A,32,0,42,15,1,RO-has_finding_site,905071-FS1,DERMATOFIBROMAS are very common SKIN TUMORS.,SKIN TUMORS,DERMATOFIBROMAS
503460882,7/16/2014 13:31:15,,1324254094,7/16/2014 13:30:29,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],"too low,",N/A,43,84,64,90,1,RO-may_treat,908185-FS1,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
503460882,7/16/2014 13:36:05,,1324256191,7/16/2014 13:35:44,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[MANIFESTATION],[MANIFESTATION],DECOMPRESSION SICKNESS,asd,43,84,64,90,1,RO-may_treat,908185-FS1,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
503460882,7/16/2014 13:36:40,,1324256432,7/16/2014 13:36:17,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"oxygen is too low, incidence DECOMPRESSION SICKNESS increases;",n/a,43,84,64,90,1,RO-may_treat,908185-FS1,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
503460882,7/16/2014 13:40:07,,1324257664,7/16/2014 13:39:49,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],"OXYGEN high,",Na,43,84,64,90,1,RO-may_treat,908185-FS1,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
503460882,7/16/2014 13:46:32,,1324259935,7/16/2014 13:45:54,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],"is too low, the incidence of",N/A,43,84,64,90,1,RO-may_treat,908185-FS1,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
503460882,7/16/2014 13:51:04,,1324261501,7/16/2014 13:50:26,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],"oxygen is too low, DECOMPRESSION SICKNESS increases;",N/a,43,84,64,90,1,RO-may_treat,908185-FS1,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
503460882,7/16/2014 14:01:23,,1324265669,7/16/2014 14:00:28,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS] [CAUSES],"[TREATS]
[CAUSES]","too low, increases; too high, poisoning becomes a",N/A,43,84,64,90,1,RO-may_treat,908185-FS1,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
503460882,7/16/2014 15:03:29,,1324289572,7/16/2014 15:02:31,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],"oxygen low, SICKNESS increases;",N/A,43,84,64,90,1,RO-may_treat,908185-FS1,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
503460882,7/16/2014 16:22:10,,1324322834,7/16/2014 16:21:41,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",increases;,na,43,84,64,90,1,RO-may_treat,908185-FS1,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
503460882,7/16/2014 17:04:38,,1324339603,7/16/2014 17:04:32,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,43,84,64,90,1,RO-may_treat,908185-FS1,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
503460882,7/16/2014 17:10:17,,1324341527,7/16/2014 17:09:47,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"oxygen low, incidence DECOMPRESSION SICKNESS increases;",N/A,43,84,64,90,1,RO-may_treat,908185-FS1,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
503460882,7/16/2014 17:14:17,,1324342782,7/16/2014 17:13:48,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],if,NONE,43,84,64,90,1,RO-may_treat,908185-FS1,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
503460882,7/16/2014 17:48:29,,1324365774,7/16/2014 17:47:59,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[CAUSES],[CAUSES],"If the oxygen is too low,",n/a,43,84,64,90,1,RO-may_treat,908185-FS1,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
503460882,7/16/2014 18:06:54,,1324384874,7/16/2014 18:06:05,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[PREVENTS],[PREVENTS],"oxygen is too low,",na,43,84,64,90,1,RO-may_treat,908185-FS1,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
503460882,7/16/2014 18:59:52,,1324418329,7/16/2014 18:59:29,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[NONE],[NONE],N/A,Separate entities,43,84,64,90,1,RO-may_treat,908185-FS1,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
503460883,7/16/2014 13:33:53,,1324255312,7/16/2014 13:33:41,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],develop,N/A,162,113,177,138,1,RO-may_prevent,907131-FS1,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
503460883,7/16/2014 13:37:19,,1324256636,7/16/2014 13:36:46,instagc,1.0,13763729,USA,"","",75.182.89.225,[NONE],[NONE],N/A,Partial words are presented.,162,113,177,138,1,RO-may_prevent,907131-FS1,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
503460883,7/16/2014 13:38:23,,1324257024,7/16/2014 13:37:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],break through,N/A,162,113,177,138,1,RO-may_prevent,907131-FS1,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
503460883,7/16/2014 13:46:36,,1324259955,7/16/2014 13:46:01,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],develop,N/A,162,113,177,138,1,RO-may_prevent,907131-FS1,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
503460883,7/16/2014 13:47:48,,1324260357,7/16/2014 13:47:09,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,"this included only a small portion of a word, which on its own is not a word",162,113,177,138,1,RO-may_prevent,907131-FS1,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
503460883,7/16/2014 14:05:13,,1324267365,7/16/2014 14:04:02,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[PREVENTS],[PREVENTS],would break through and develop,N/A,162,113,177,138,1,RO-may_prevent,907131-FS1,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
503460883,7/16/2014 14:11:37,,1324270181,7/16/2014 14:11:21,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[SYMPTOM],[SYMPTOM],develop,N/A,162,113,177,138,1,RO-may_prevent,907131-FS1,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
503460883,7/16/2014 15:39:50,,1324301937,7/16/2014 15:39:37,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,unclear,162,113,177,138,1,RO-may_prevent,907131-FS1,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
503460883,7/16/2014 16:40:50,,1324331143,7/16/2014 16:39:57,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LOW DOSE HEPARIN PROPHYLAxis thromboeMBOLISM AFTER MAjor,n/a,162,113,177,138,1,RO-may_prevent,907131-FS1,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
503460883,7/16/2014 17:01:04,,1324338484,7/16/2014 17:00:35,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[SYMPTOM],[SYMPTOM],LOW DOSE HEPARIN PROPHYLAxis thromboeMBOLISM AFTER MAjor,n/a,162,113,177,138,1,RO-may_prevent,907131-FS1,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
503460883,7/16/2014 17:01:58,,1324338811,7/16/2014 17:01:19,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,162,113,177,138,1,RO-may_prevent,907131-FS1,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
503460883,7/16/2014 17:14:06,,1324342728,7/16/2014 17:12:29,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[OTHER],[OTHER],break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM,n\a,162,113,177,138,1,RO-may_prevent,907131-FS1,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
503460883,7/16/2014 19:03:34,,1324420647,7/16/2014 19:03:10,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[NONE],[NONE],N/A,Poor wording,162,113,177,138,1,RO-may_prevent,907131-FS1,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
503460883,7/16/2014 19:55:43,,1324446885,7/16/2014 19:55:06,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],and develop,N/A,162,113,177,138,1,RO-may_prevent,907131-FS1,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
503460883,7/16/2014 20:22:47,,1324458947,7/16/2014 20:22:15,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and develop,N/A,162,113,177,138,1,RO-may_prevent,907131-FS1,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
503460884,7/16/2014 13:39:13,,1324257341,7/16/2014 13:38:56,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],induced by,N/A,167,206,193,216,1,RO-may_diagnose,906561-FS1,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
503460884,7/16/2014 13:40:39,,1324257888,7/16/2014 13:40:20,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],induced by,n/a,167,206,193,216,1,RO-may_diagnose,906561-FS1,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
503460884,7/16/2014 13:41:24,,1324258147,7/16/2014 13:40:58,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SIDE_EFFECT] [MANIFESTATION],"[MANIFESTATION]
[SIDE_EFFECT]",VASOSPASTIC ANGINA PECTORIS ERGONOVINE,asd,167,206,193,216,1,RO-may_diagnose,906561-FS1,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
503460884,7/16/2014 13:48:23,,1324260535,7/16/2014 13:48:12,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],induced by,N/A,167,206,193,216,1,RO-may_diagnose,906561-FS1,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
503460884,7/16/2014 13:48:28,,1324260585,7/16/2014 13:48:16,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[CAUSES],[CAUSES],induced,N/A,167,206,193,216,1,RO-may_diagnose,906561-FS1,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
503460884,7/16/2014 13:50:34,,1324261305,7/16/2014 13:49:50,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[CAUSES],[CAUSES],induced by,na,167,206,193,216,1,RO-may_diagnose,906561-FS1,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
503460884,7/16/2014 13:55:25,,1324263144,7/16/2014 13:55:11,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[TREATS] [PREVENTS] [CAUSES] [MANIFESTATION] [CONTRAINDICATES],"[TREATS]
[PREVENTS]
[CAUSES]
[MANIFESTATION]
[CONTRAINDICATES]",characteristic ventricular ventricular arrhythmias ANGINA,N/A,167,206,193,216,1,RO-may_diagnose,906561-FS1,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
503460884,7/16/2014 13:59:48,,1324265148,7/16/2014 13:59:35,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE,N/A,167,206,193,216,1,RO-may_diagnose,906561-FS1,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
503460884,7/16/2014 14:15:04,,1324271547,7/16/2014 14:14:53,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[CAUSES],[CAUSES],induced,N/A,167,206,193,216,1,RO-may_diagnose,906561-FS1,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
503460884,7/16/2014 14:51:23,,1324284882,7/16/2014 14:50:15,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES] [OTHER],"[CAUSES]
[OTHER]",induced by,N/A,167,206,193,216,1,RO-may_diagnose,906561-FS1,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
503460884,7/16/2014 15:39:11,,1324301697,7/16/2014 15:37:54,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[ASSOCIATED_WITH] [OTHER],"[ASSOCIATED_WITH]
[OTHER]",induced by,N/A,167,206,193,216,1,RO-may_diagnose,906561-FS1,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
503460884,7/16/2014 15:46:47,,1324304856,7/16/2014 15:46:22,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[CAUSES],[CAUSES],induced by,[CAUSES],167,206,193,216,1,RO-may_diagnose,906561-FS1,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
503460884,7/16/2014 15:51:02,,1324306671,7/16/2014 15:50:30,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[CAUSES],[CAUSES],induced by,n/a,167,206,193,216,1,RO-may_diagnose,906561-FS1,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
503460884,7/16/2014 16:44:16,,1324332612,7/16/2014 16:43:40,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE,N/A,167,206,193,216,1,RO-may_diagnose,906561-FS1,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
503460884,7/16/2014 16:59:55,,1324338075,7/16/2014 16:59:21,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],VASOSPASTIC ANGINA PECTORIS ERGONOVINE,n/a,167,206,193,216,1,RO-may_diagnose,906561-FS1,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
503460885,7/16/2014 13:41:46,,1324258282,7/16/2014 13:41:27,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],Chga null mice,asdd,137,208,160,220,-1,RO-has_definitional_manifestation,904540-FS1,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
503460885,7/16/2014 13:53:14,,1324262272,7/16/2014 13:52:47,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[SYMPTOM],[SYMPTOM],indicating a direct role in preventing,N/A,137,208,160,220,-1,RO-has_definitional_manifestation,904540-FS1,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
503460885,7/16/2014 14:54:49,,1324285946,7/16/2014 14:53:43,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A] [SYMPTOM],"[SYMPTOM]
[IS_A]",indicating a direct role in preventing,N/A,137,208,160,220,-1,RO-has_definitional_manifestation,904540-FS1,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
503460885,7/16/2014 15:38:21,,1324301229,7/16/2014 15:37:16,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,n/a,137,208,160,220,-1,RO-has_definitional_manifestation,904540-FS1,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
503460885,7/16/2014 15:43:14,,1324303284,7/16/2014 15:42:53,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[PREVENTS],[PREVENTS],in preventing,[PREVENTS],137,208,160,220,-1,RO-has_definitional_manifestation,904540-FS1,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
503460885,7/16/2014 15:50:31,,1324306495,7/16/2014 15:48:09,prodege,1.0,27990290,GBR,I9,Bury Saint Edmunds,86.142.231.81,[MANIFESTATION],[MANIFESTATION],preventing,blood pressure elevation is a symptom of hypertension.,137,208,160,220,-1,RO-has_definitional_manifestation,904540-FS1,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
503460885,7/16/2014 16:24:10,,1324323599,7/16/2014 16:23:55,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[PREVENTS],[PREVENTS],preventing,N/A,137,208,160,220,-1,RO-has_definitional_manifestation,904540-FS1,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
503460885,7/16/2014 18:35:28,,1324404848,7/16/2014 18:34:05,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[IS_A],[IS_A],indicating a direct role of Cts in,na,137,208,160,220,-1,RO-has_definitional_manifestation,904540-FS1,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
503460885,7/16/2014 19:12:48,,1324425948,7/16/2014 19:12:24,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[CAUSES],[CAUSES],indicating a direct role of Cts in preventing,N/A,137,208,160,220,-1,RO-has_definitional_manifestation,904540-FS1,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
503460885,7/16/2014 20:47:12,,1324469127,7/16/2014 20:46:47,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HYPERTENSION,NONE,137,208,160,220,-1,RO-has_definitional_manifestation,904540-FS1,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
503460885,7/16/2014 20:57:25,,1324473195,7/16/2014 20:56:31,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],BLOOD PRESSURE ELEVATION indicating a direct role in HYPERTENSION,N/A,137,208,160,220,-1,RO-has_definitional_manifestation,904540-FS1,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
503460885,7/16/2014 20:59:49,,1324474344,7/16/2014 20:58:37,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[IS_A],[IS_A],BLOOD PRESSURE ELEVATION indicating HYPERTENSION,N/A,137,208,160,220,-1,RO-has_definitional_manifestation,904540-FS1,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
503460885,7/16/2014 21:00:21,,1324474680,7/16/2014 21:00:03,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],indicating a direct role of Cts in preventing HYPERTENSION,N/A,137,208,160,220,-1,RO-has_definitional_manifestation,904540-FS1,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
503460885,7/16/2014 21:05:52,,1324477880,7/16/2014 21:04:57,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[CAUSES],[CAUSES],indicating a direct role,n/a,137,208,160,220,-1,RO-has_definitional_manifestation,904540-FS1,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
503460885,7/16/2014 21:10:31,,1324480680,7/16/2014 21:09:47,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[PREVENTS],[PREVENTS],BLOOD PRESSURE ELEVATION indicating preventing HYPERTENSION,n/a,137,208,160,220,-1,RO-has_definitional_manifestation,904540-FS1,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
503460886,7/16/2014 13:36:16,,1324256270,7/16/2014 13:35:51,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"CLUSTER HEADACHE PAIN is episodic and unilateral,",n/a,70,53,73,69,-1,RO-has_definitional_manifestation,904783-FS1,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
503460886,7/16/2014 13:39:09,,1324257313,7/16/2014 13:38:40,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SYMPTOM],[SYMPTOM],HEADACHE PAIN,asd,70,53,73,69,-1,RO-has_definitional_manifestation,904783-FS1,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
503460886,7/16/2014 13:39:53,,1324257587,7/16/2014 13:38:41,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],PAIN,N/A,70,53,73,69,-1,RO-has_definitional_manifestation,904783-FS1,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
503460886,7/16/2014 13:45:40,,1324259676,7/16/2014 13:45:19,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[CAUSES],[CAUSES],"excruciating,",N/A,70,53,73,69,-1,RO-has_definitional_manifestation,904783-FS1,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
503460886,7/16/2014 13:52:44,,1324262096,7/16/2014 13:52:25,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],CLUSTER HEADACHE PAIN is episodic,N/a,70,53,73,69,-1,RO-has_definitional_manifestation,904783-FS1,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
503460886,7/16/2014 14:16:18,,1324272002,7/16/2014 14:15:56,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[PART_OF],[PART_OF],CLUSTER HEADACHE PAIN,N/A,70,53,73,69,-1,RO-has_definitional_manifestation,904783-FS1,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
503460886,7/16/2014 14:40:28,,1324281757,7/16/2014 14:40:07,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[SYMPTOM],[SYMPTOM],CLUSTER HEADACHE PAIN,n/a,70,53,73,69,-1,RO-has_definitional_manifestation,904783-FS1,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
503460886,7/16/2014 16:10:34,,1324317863,7/16/2014 16:09:26,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[MANIFESTATION]","both disorders is excruciating,",[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [MANIFESTATION],70,53,73,69,-1,RO-has_definitional_manifestation,904783-FS1,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
503460886,7/16/2014 16:30:18,,1324325848,7/16/2014 16:29:19,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[SIDE_EFFECT],[SIDE_EFFECT],CLUSTER HEADACHE PAIN,N/A,70,53,73,69,-1,RO-has_definitional_manifestation,904783-FS1,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
503460886,7/16/2014 16:49:28,,1324334489,7/16/2014 16:48:59,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[SYMPTOM] [PART_OF],"[SYMPTOM]
[PART_OF]",CLUSTER HEADACHE PAIN,N/A,70,53,73,69,-1,RO-has_definitional_manifestation,904783-FS1,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
503460886,7/16/2014 16:54:02,,1324336058,7/16/2014 16:53:18,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is,NONE,70,53,73,69,-1,RO-has_definitional_manifestation,904783-FS1,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
503460886,7/16/2014 19:07:21,,1324423028,7/16/2014 19:07:02,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SYMPTOM],[SYMPTOM],"excruciating,",N/A,70,53,73,69,-1,RO-has_definitional_manifestation,904783-FS1,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
503460886,7/16/2014 19:56:32,,1324447179,7/16/2014 19:56:18,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[PART_OF],[PART_OF],CLUSTER HEADACHE PAIN,N/A,70,53,73,69,-1,RO-has_definitional_manifestation,904783-FS1,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
503460886,7/16/2014 20:29:39,,1324462065,7/16/2014 20:28:56,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[SYMPTOM],[SYMPTOM],usually limited to the tissues,N/A,70,53,73,69,-1,RO-has_definitional_manifestation,904783-FS1,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
503460886,7/16/2014 20:49:46,,1324470349,7/16/2014 20:48:54,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM],[SYMPTOM],"excruciating, CLUSTER HEADACHE PAIN",n/a,70,53,73,69,-1,RO-has_definitional_manifestation,904783-FS1,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
503460887,7/16/2014 13:30:40,,1324253815,7/16/2014 13:30:31,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],HYPERTHERMIA,N/A,85,141,96,165,-1,RO-disease_may_have_finding,902641-FS1,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460887,7/16/2014 13:40:46,,1324257922,7/16/2014 13:39:53,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],treating,N/A,85,141,96,165,-1,RO-disease_may_have_finding,902641-FS1,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460887,7/16/2014 13:42:05,,1324258479,7/16/2014 13:41:32,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],treating,Na,85,141,96,165,-1,RO-disease_may_have_finding,902641-FS1,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460887,7/16/2014 13:54:37,,1324262855,7/16/2014 13:54:20,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[TREATS],[TREATS],treating,N/A,85,141,96,165,-1,RO-disease_may_have_finding,902641-FS1,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460887,7/16/2014 15:41:17,,1324302530,7/16/2014 15:40:58,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[TREATS],[TREATS],effective for treating,N/A,85,141,96,165,-1,RO-disease_may_have_finding,902641-FS1,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460887,7/16/2014 16:36:43,,1324328538,7/16/2014 16:36:06,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[TREATS],[TREATS],HYPERTHERMIA effective for treating HEPATOCELLULAR CARCINOMA,N/A,85,141,96,165,-1,RO-disease_may_have_finding,902641-FS1,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460887,7/16/2014 16:39:21,,1324330300,7/16/2014 16:38:46,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],HYPERTHERMIA for treating HEPATOCELLULAR CARCINOMA,N/A,85,141,96,165,-1,RO-disease_may_have_finding,902641-FS1,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460887,7/16/2014 16:43:53,,1324332458,7/16/2014 16:43:24,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[TREATS],[TREATS],effective for treating,N/A,85,141,96,165,-1,RO-disease_may_have_finding,902641-FS1,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460887,7/16/2014 17:00:31,,1324338301,7/16/2014 16:59:58,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPERTHERMIA HEPATOCELLULAR CARCINOMA,n/a,85,141,96,165,-1,RO-disease_may_have_finding,902641-FS1,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460887,7/16/2014 18:18:49,,1324397365,7/16/2014 18:17:23,clixsense,1.0,6621167,USA,"","",66.87.78.42,[SIDE_EFFECT],[SIDE_EFFECT],for,Na,85,141,96,165,-1,RO-disease_may_have_finding,902641-FS1,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460887,7/16/2014 18:28:01,,1324401311,7/16/2014 18:27:34,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,N/A,85,141,96,165,-1,RO-disease_may_have_finding,902641-FS1,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460887,7/16/2014 18:29:21,,1324401859,7/16/2014 18:28:49,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],may be effective for treating unresectable,na,85,141,96,165,-1,RO-disease_may_have_finding,902641-FS1,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460887,7/16/2014 19:37:55,,1324438094,7/16/2014 19:36:53,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],for treating,N/A,85,141,96,165,-1,RO-disease_may_have_finding,902641-FS1,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460887,7/16/2014 19:43:11,,1324440752,7/16/2014 19:42:57,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],plus,N/A,85,141,96,165,-1,RO-disease_may_have_finding,902641-FS1,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460887,7/16/2014 19:46:20,,1324442426,7/16/2014 19:46:01,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[TREATS],[TREATS],for treating,N/A,85,141,96,165,-1,RO-disease_may_have_finding,902641-FS1,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
503460888,7/16/2014 13:31:19,,1324254122,7/16/2014 13:31:11,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],treatment,N/A,53,0,71,11,1,RO-may_treat,907536-FS1,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
503460888,7/16/2014 13:41:31,,1324258191,7/16/2014 13:41:18,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],treatment of,N/A,53,0,71,11,1,RO-may_treat,907536-FS1,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
503460888,7/16/2014 13:46:18,,1324259834,7/16/2014 13:45:52,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],treatment of,N/A,53,0,71,11,1,RO-may_treat,907536-FS1,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
503460888,7/16/2014 13:49:55,,1324261065,7/16/2014 13:49:40,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[TREATS],[TREATS],treatment,N/A,53,0,71,11,1,RO-may_treat,907536-FS1,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
503460888,7/16/2014 13:53:45,,1324262515,7/16/2014 13:53:27,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[TREATS],[TREATS],metronidazole treatment,Results with the treatment.,53,0,71,11,1,RO-may_treat,907536-FS1,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
503460888,7/16/2014 13:56:24,,1324263605,7/16/2014 13:56:09,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],CLINDAMYCIN in treatment of BACTERIAL VAGINOSIS,N/A,53,0,71,11,1,RO-may_treat,907536-FS1,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
503460888,7/16/2014 14:17:56,,1324272700,7/16/2014 14:17:47,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],treatment,N/A,53,0,71,11,1,RO-may_treat,907536-FS1,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
503460888,7/16/2014 15:48:48,,1324305731,7/16/2014 15:48:14,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],treatment,n/a,53,0,71,11,1,RO-may_treat,907536-FS1,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
503460888,7/16/2014 16:36:45,,1324328555,7/16/2014 16:36:04,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],CLINDAMYCIN BACTERIAL VAGINOSIS,n/a,53,0,71,11,1,RO-may_treat,907536-FS1,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
503460888,7/16/2014 16:42:13,,1324331813,7/16/2014 16:41:28,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],treatment,none,53,0,71,11,1,RO-may_treat,907536-FS1,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
503460888,7/16/2014 16:52:30,,1324335464,7/16/2014 16:52:03,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],CLINDAMYCIN in treatment of BACTERIAL VAGINOSIS,N/A,53,0,71,11,1,RO-may_treat,907536-FS1,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
503460888,7/16/2014 17:06:53,,1324340293,7/16/2014 17:06:46,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,53,0,71,11,1,RO-may_treat,907536-FS1,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
503460888,7/16/2014 17:32:23,,1324351035,7/16/2014 17:32:00,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],in the treatment of,n/a,53,0,71,11,1,RO-may_treat,907536-FS1,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
503460888,7/16/2014 18:31:09,,1324402593,7/16/2014 18:30:54,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],CLINDAMYCIN in the treatment of BACTERIAL VAGINOSIS,N/A,53,0,71,11,1,RO-may_treat,907536-FS1,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
503460888,7/16/2014 19:01:03,,1324419094,7/16/2014 19:00:43,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CONTRAINDICATES],[CONTRAINDICATES],treatment,N/A,53,0,71,11,1,RO-may_treat,907536-FS1,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
503460889,7/16/2014 13:50:11,,1324261155,7/16/2014 13:49:55,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[PART_OF],[PART_OF],frequently present in,N/A,33,86,59,109,1,RO-disease_has_finding,901556-FS1,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
503460889,7/16/2014 14:13:11,,1324270824,7/16/2014 14:12:58,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],present,N/A,33,86,59,109,1,RO-disease_has_finding,901556-FS1,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
503460889,7/16/2014 14:13:15,,1324270848,7/16/2014 14:12:49,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is frequently present in,N/A,33,86,59,109,1,RO-disease_has_finding,901556-FS1,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
503460889,7/16/2014 14:53:41,,1324285596,7/16/2014 14:52:57,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION] [SYMPTOM],"[LOCATION]
[SYMPTOM]",is frequently present in,N/A,33,86,59,109,1,RO-disease_has_finding,901556-FS1,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
503460889,7/16/2014 15:33:19,,1324299417,7/16/2014 15:33:07,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[SYMPTOM],[SYMPTOM],frequently present,N/A,33,86,59,109,1,RO-disease_has_finding,901556-FS1,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
503460889,7/16/2014 16:34:04,,1324327205,7/16/2014 16:33:08,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[LOCATION],[LOCATION],present,N/A,33,86,59,109,1,RO-disease_has_finding,901556-FS1,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
503460889,7/16/2014 16:49:18,,1324334447,7/16/2014 16:48:29,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",MICROVASCULAR PROLIFERATION frequently present in GLIOBLASTOMA MULTIFORME,N/A,33,86,59,109,1,RO-disease_has_finding,901556-FS1,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
503460889,7/16/2014 18:32:14,,1324403082,7/16/2014 18:31:46,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],is frequently present in,na,33,86,59,109,1,RO-disease_has_finding,901556-FS1,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
503460889,7/16/2014 19:00:26,,1324418772,7/16/2014 19:00:11,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],present,N/A,33,86,59,109,1,RO-disease_has_finding,901556-FS1,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
503460889,7/16/2014 19:37:18,,1324437808,7/16/2014 19:37:08,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],frequently present,N/A,33,86,59,109,1,RO-disease_has_finding,901556-FS1,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
503460889,7/16/2014 20:42:29,,1324467228,7/16/2014 20:42:01,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],present in,N/A,33,86,59,109,1,RO-disease_has_finding,901556-FS1,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
503460889,7/16/2014 20:46:52,,1324469015,7/16/2014 20:46:15,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],MICROVASCULAR PROLIFERATION frequently present GLIOBLASTOMA MULTIFORME,n/a,33,86,59,109,1,RO-disease_has_finding,901556-FS1,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
503460889,7/16/2014 20:47:20,,1324469182,7/16/2014 20:46:08,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[SYMPTOM],[SYMPTOM],is frequently present in,N/A,33,86,59,109,1,RO-disease_has_finding,901556-FS1,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
503460889,7/16/2014 20:58:24,,1324473657,7/16/2014 20:57:27,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME,N/A,33,86,59,109,1,RO-disease_has_finding,901556-FS1,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
503460889,7/16/2014 21:00:28,,1324474794,7/16/2014 21:00:07,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[LOCATION],[LOCATION],PROLIFERATION,NONE,33,86,59,109,1,RO-disease_has_finding,901556-FS1,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
503460890,7/16/2014 13:32:18,,1324254618,7/16/2014 13:31:40,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of,na,28,77,42,102,1,RO-disease_has_finding,901958-FS1,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
503460890,7/16/2014 13:42:48,,1324258703,7/16/2014 13:42:13,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,28,77,42,102,1,RO-disease_has_finding,901958-FS1,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
503460890,7/16/2014 14:02:18,,1324266049,7/16/2014 14:02:00,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],PSAMMOMA BODIES is important in diagnosis of DUODENAL SOMATOSTATINOMAS,N/A,28,77,42,102,1,RO-disease_has_finding,901958-FS1,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
503460890,7/16/2014 15:39:20,,1324301731,7/16/2014 15:39:11,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,28,77,42,102,1,RO-disease_has_finding,901958-FS1,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
503460890,7/16/2014 15:40:12,,1324302079,7/16/2014 15:39:38,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],in the diagnosis of,[DIAGNOSE_BY_TEST_OR_DRUG],28,77,42,102,1,RO-disease_has_finding,901958-FS1,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
503460890,7/16/2014 16:37:17,,1324328877,7/16/2014 16:36:44,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,na,28,77,42,102,1,RO-disease_has_finding,901958-FS1,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
503460890,7/16/2014 18:30:52,,1324402471,7/16/2014 18:30:26,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,N/A,28,77,42,102,1,RO-disease_has_finding,901958-FS1,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
503460890,7/16/2014 18:31:45,,1324402873,7/16/2014 18:31:16,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is important in the diagnosis of,na,28,77,42,102,1,RO-disease_has_finding,901958-FS1,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
503460890,7/16/2014 19:07:19,,1324423010,7/16/2014 19:06:47,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",is important in the diagnosis of,N/A,28,77,42,102,1,RO-disease_has_finding,901958-FS1,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
503460890,7/16/2014 19:22:07,,1324430638,7/16/2014 19:21:53,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of,N/A,28,77,42,102,1,RO-disease_has_finding,901958-FS1,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
503460890,7/16/2014 19:39:52,,1324439079,7/16/2014 19:39:33,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],BODIES,N/A,28,77,42,102,1,RO-disease_has_finding,901958-FS1,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
503460890,7/16/2014 20:21:20,,1324458227,7/16/2014 20:18:42,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[SYMPTOM],[SYMPTOM],finding,n/a,28,77,42,102,1,RO-disease_has_finding,901958-FS1,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
503460890,7/16/2014 20:43:56,,1324467731,7/16/2014 20:43:23,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[MANIFESTATION],[MANIFESTATION],is important in the diagnosis of,N/A,28,77,42,102,1,RO-disease_has_finding,901958-FS1,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
503460890,7/16/2014 20:57:10,,1324473089,7/16/2014 20:56:59,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[LOCATION],[LOCATION],DUODENAL,NONE,28,77,42,102,1,RO-disease_has_finding,901958-FS1,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
503460890,7/16/2014 20:58:02,,1324473438,7/16/2014 20:57:36,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[MANIFESTATION],[MANIFESTATION],diagnosis,N/A,28,77,42,102,1,RO-disease_has_finding,901958-FS1,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
503460891,7/16/2014 13:27:09,,1324252310,7/16/2014 13:27:01,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DEPENDENT,N/A,139,43,159,69,1,RO-cause_of,900071-FS1,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
503460891,7/16/2014 13:29:40,,1324253351,7/16/2014 13:29:02,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],very high specific incidence of,N/A,139,43,159,69,1,RO-cause_of,900071-FS1,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
503460891,7/16/2014 13:43:07,,1324258786,7/16/2014 13:42:15,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],revealed a very high specific incidence,n/a,139,43,159,69,1,RO-cause_of,900071-FS1,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
503460891,7/16/2014 13:48:11,,1324260493,7/16/2014 13:47:43,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],revealed a very high specific incidence,N/a,139,43,159,69,1,RO-cause_of,900071-FS1,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
503460891,7/16/2014 14:17:22,,1324272444,7/16/2014 14:17:09,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],incidence,N/A,139,43,159,69,1,RO-cause_of,900071-FS1,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
503460891,7/16/2014 15:33:32,,1324299477,7/16/2014 15:30:39,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],incidence,n/a,139,43,159,69,1,RO-cause_of,900071-FS1,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
503460891,7/16/2014 16:13:33,,1324319241,7/16/2014 16:11:48,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION],[MANIFESTATION],revealed,na,139,43,159,69,1,RO-cause_of,900071-FS1,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
503460891,7/16/2014 16:29:02,,1324325361,7/16/2014 16:27:58,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],INSULIN DEPENDENT DIABETES DIABETIC KETOACIDOSIS,n/a,139,43,159,69,1,RO-cause_of,900071-FS1,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
503460891,7/16/2014 17:03:13,,1324339131,7/16/2014 17:03:07,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,139,43,159,69,1,RO-cause_of,900071-FS1,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
503460891,7/16/2014 17:21:10,,1324344705,7/16/2014 17:20:02,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[SIDE_EFFECT],[SIDE_EFFECT],Analysis of INSULIN DEPENDENT DIABETES revealed high incidence DIABETIC KETOACIDOSIS,n/a,139,43,159,69,1,RO-cause_of,900071-FS1,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
503460891,7/16/2014 18:27:15,,1324401015,7/16/2014 18:26:40,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[CAUSES],[CAUSES],Analysis of children with INSULIN DEPENDENT DIABETES revealed a high incidence of DIABETIC KETOACIDOSIS,N/A,139,43,159,69,1,RO-cause_of,900071-FS1,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
503460891,7/16/2014 19:11:52,,1324425400,7/16/2014 19:10:56,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",the principal cause of lethal outcomes,N/A,139,43,159,69,1,RO-cause_of,900071-FS1,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
503460891,7/16/2014 19:35:36,,1324437076,7/16/2014 19:35:24,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],specific incidence,N/A,139,43,159,69,1,RO-cause_of,900071-FS1,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
503460891,7/16/2014 20:18:41,,1324457122,7/16/2014 20:17:28,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],high incidence,n/a,139,43,159,69,1,RO-cause_of,900071-FS1,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
503460891,7/16/2014 20:42:04,,1324467099,7/16/2014 20:41:20,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[SYMPTOM],[SYMPTOM],revealed a very high specific incidence of,N/A,139,43,159,69,1,RO-cause_of,900071-FS1,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
503460892,7/16/2014 13:33:46,,1324255262,7/16/2014 13:33:27,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[PREVENTS],[PREVENTS],Galactosialidosis Mucolipidosis,asd,297,249,332,296,-1,RO-has_manifestation,906211-FS1,"Keratan sulfate Dermatan sulfate  Dermatan sulfate, heparan sulfate, chondroitin 4 sulfate, chondroitin 6 sulfate Glycoproteinoses Mannosidosis  Fucosidosis  Aspartylglucosaminuria  Sialidosis  Galactosialidosis    Mucolipidosis II (I cell disease) MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR); locus: 19cen q12 Locus: 1p34  Locus: 4q32 q33  Locus: 6p21.3  Locus: 20q13    Locus: 4q21 q23.",MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR),MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY)
503460892,7/16/2014 13:34:27,,1324255569,7/16/2014 13:34:04,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[PART_OF],[PART_OF],MUCOLIPIDOSIS,N/A,297,249,332,296,-1,RO-has_manifestation,906211-FS1,"Keratan sulfate Dermatan sulfate  Dermatan sulfate, heparan sulfate, chondroitin 4 sulfate, chondroitin 6 sulfate Glycoproteinoses Mannosidosis  Fucosidosis  Aspartylglucosaminuria  Sialidosis  Galactosialidosis    Mucolipidosis II (I cell disease) MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR); locus: 19cen q12 Locus: 1p34  Locus: 4q32 q33  Locus: 6p21.3  Locus: 20q13    Locus: 4q21 q23.",MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR),MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY)
503460892,7/16/2014 13:39:54,,1324257597,7/16/2014 13:39:13,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Keratan,n/a,297,249,332,296,-1,RO-has_manifestation,906211-FS1,"Keratan sulfate Dermatan sulfate  Dermatan sulfate, heparan sulfate, chondroitin 4 sulfate, chondroitin 6 sulfate Glycoproteinoses Mannosidosis  Fucosidosis  Aspartylglucosaminuria  Sialidosis  Galactosialidosis    Mucolipidosis II (I cell disease) MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR); locus: 19cen q12 Locus: 1p34  Locus: 4q32 q33  Locus: 6p21.3  Locus: 20q13    Locus: 4q21 q23.",MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR),MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY)
503460892,7/16/2014 13:43:55,,1324259072,7/16/2014 13:43:22,instagc,1.0,18960682,GBR,"","",86.29.147.112,[OTHER],[OTHER],MUCOLIPIDOSIS III MUCOLIPIDOSIS IV,N/a,297,249,332,296,-1,RO-has_manifestation,906211-FS1,"Keratan sulfate Dermatan sulfate  Dermatan sulfate, heparan sulfate, chondroitin 4 sulfate, chondroitin 6 sulfate Glycoproteinoses Mannosidosis  Fucosidosis  Aspartylglucosaminuria  Sialidosis  Galactosialidosis    Mucolipidosis II (I cell disease) MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR); locus: 19cen q12 Locus: 1p34  Locus: 4q32 q33  Locus: 6p21.3  Locus: 20q13    Locus: 4q21 q23.",MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR),MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY)
503460892,7/16/2014 15:10:42,,1324292190,7/16/2014 15:08:41,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[NONE],[NONE],na,just a list of disorders; it is not a sentence.,297,249,332,296,-1,RO-has_manifestation,906211-FS1,"Keratan sulfate Dermatan sulfate  Dermatan sulfate, heparan sulfate, chondroitin 4 sulfate, chondroitin 6 sulfate Glycoproteinoses Mannosidosis  Fucosidosis  Aspartylglucosaminuria  Sialidosis  Galactosialidosis    Mucolipidosis II (I cell disease) MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR); locus: 19cen q12 Locus: 1p34  Locus: 4q32 q33  Locus: 6p21.3  Locus: 20q13    Locus: 4q21 q23.",MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR),MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY)
503460892,7/16/2014 16:21:49,,1324322686,7/16/2014 16:21:08,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR);,n/a,297,249,332,296,-1,RO-has_manifestation,906211-FS1,"Keratan sulfate Dermatan sulfate  Dermatan sulfate, heparan sulfate, chondroitin 4 sulfate, chondroitin 6 sulfate Glycoproteinoses Mannosidosis  Fucosidosis  Aspartylglucosaminuria  Sialidosis  Galactosialidosis    Mucolipidosis II (I cell disease) MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR); locus: 19cen q12 Locus: 1p34  Locus: 4q32 q33  Locus: 6p21.3  Locus: 20q13    Locus: 4q21 q23.",MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR),MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY)
503460892,7/16/2014 16:24:31,,1324323712,7/16/2014 16:24:11,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[IS_A],[IS_A],MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR);,N/A,297,249,332,296,-1,RO-has_manifestation,906211-FS1,"Keratan sulfate Dermatan sulfate  Dermatan sulfate, heparan sulfate, chondroitin 4 sulfate, chondroitin 6 sulfate Glycoproteinoses Mannosidosis  Fucosidosis  Aspartylglucosaminuria  Sialidosis  Galactosialidosis    Mucolipidosis II (I cell disease) MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR); locus: 19cen q12 Locus: 1p34  Locus: 4q32 q33  Locus: 6p21.3  Locus: 20q13    Locus: 4q21 q23.",MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR),MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY)
503460892,7/16/2014 16:36:04,,1324328196,7/16/2014 16:35:12,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR);,N/A,297,249,332,296,-1,RO-has_manifestation,906211-FS1,"Keratan sulfate Dermatan sulfate  Dermatan sulfate, heparan sulfate, chondroitin 4 sulfate, chondroitin 6 sulfate Glycoproteinoses Mannosidosis  Fucosidosis  Aspartylglucosaminuria  Sialidosis  Galactosialidosis    Mucolipidosis II (I cell disease) MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR); locus: 19cen q12 Locus: 1p34  Locus: 4q32 q33  Locus: 6p21.3  Locus: 20q13    Locus: 4q21 q23.",MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR),MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY)
503460892,7/16/2014 18:26:28,,1324400645,7/16/2014 18:26:01,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,297,249,332,296,-1,RO-has_manifestation,906211-FS1,"Keratan sulfate Dermatan sulfate  Dermatan sulfate, heparan sulfate, chondroitin 4 sulfate, chondroitin 6 sulfate Glycoproteinoses Mannosidosis  Fucosidosis  Aspartylglucosaminuria  Sialidosis  Galactosialidosis    Mucolipidosis II (I cell disease) MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR); locus: 19cen q12 Locus: 1p34  Locus: 4q32 q33  Locus: 6p21.3  Locus: 20q13    Locus: 4q21 q23.",MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR),MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY)
503460892,7/16/2014 18:26:49,,1324400757,7/16/2014 18:24:55,gifthulk,1.0,24076843,GBR,K6,Portsmouth,86.6.112.248,[NONE],[NONE],N/A,"This is not a sentence, in that a sentence by definition has to MAKE SENSE.",297,249,332,296,-1,RO-has_manifestation,906211-FS1,"Keratan sulfate Dermatan sulfate  Dermatan sulfate, heparan sulfate, chondroitin 4 sulfate, chondroitin 6 sulfate Glycoproteinoses Mannosidosis  Fucosidosis  Aspartylglucosaminuria  Sialidosis  Galactosialidosis    Mucolipidosis II (I cell disease) MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR); locus: 19cen q12 Locus: 1p34  Locus: 4q32 q33  Locus: 6p21.3  Locus: 20q13    Locus: 4q21 q23.",MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR),MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY)
503460892,7/16/2014 18:28:25,,1324401484,7/16/2014 18:28:03,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[NONE],[NONE],N/A,No relation - this is just a list.,297,249,332,296,-1,RO-has_manifestation,906211-FS1,"Keratan sulfate Dermatan sulfate  Dermatan sulfate, heparan sulfate, chondroitin 4 sulfate, chondroitin 6 sulfate Glycoproteinoses Mannosidosis  Fucosidosis  Aspartylglucosaminuria  Sialidosis  Galactosialidosis    Mucolipidosis II (I cell disease) MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR); locus: 19cen q12 Locus: 1p34  Locus: 4q32 q33  Locus: 6p21.3  Locus: 20q13    Locus: 4q21 q23.",MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR),MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY)
503460892,7/16/2014 19:21:03,,1324430152,7/16/2014 19:20:37,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[PART_OF],[PART_OF],MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR);,all same term,297,249,332,296,-1,RO-has_manifestation,906211-FS1,"Keratan sulfate Dermatan sulfate  Dermatan sulfate, heparan sulfate, chondroitin 4 sulfate, chondroitin 6 sulfate Glycoproteinoses Mannosidosis  Fucosidosis  Aspartylglucosaminuria  Sialidosis  Galactosialidosis    Mucolipidosis II (I cell disease) MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR); locus: 19cen q12 Locus: 1p34  Locus: 4q32 q33  Locus: 6p21.3  Locus: 20q13    Locus: 4q21 q23.",MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR),MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY)
503460892,7/16/2014 19:42:31,,1324440444,7/16/2014 19:42:19,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MUCOLIPIDOSIS MUCOLIPIDOSIS,N/A,297,249,332,296,-1,RO-has_manifestation,906211-FS1,"Keratan sulfate Dermatan sulfate  Dermatan sulfate, heparan sulfate, chondroitin 4 sulfate, chondroitin 6 sulfate Glycoproteinoses Mannosidosis  Fucosidosis  Aspartylglucosaminuria  Sialidosis  Galactosialidosis    Mucolipidosis II (I cell disease) MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR); locus: 19cen q12 Locus: 1p34  Locus: 4q32 q33  Locus: 6p21.3  Locus: 20q13    Locus: 4q21 q23.",MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR),MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY)
503460892,7/16/2014 20:52:53,,1324471628,7/16/2014 20:52:13,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],II III IV,different conditions,297,249,332,296,-1,RO-has_manifestation,906211-FS1,"Keratan sulfate Dermatan sulfate  Dermatan sulfate, heparan sulfate, chondroitin 4 sulfate, chondroitin 6 sulfate Glycoproteinoses Mannosidosis  Fucosidosis  Aspartylglucosaminuria  Sialidosis  Galactosialidosis    Mucolipidosis II (I cell disease) MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR); locus: 19cen q12 Locus: 1p34  Locus: 4q32 q33  Locus: 6p21.3  Locus: 20q13    Locus: 4q21 q23.",MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR),MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY)
503460892,7/16/2014 20:58:33,,1324473732,7/16/2014 20:58:03,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER] [PART_OF] [IS_A],"[IS_A]
[PART_OF]
[OTHER]",MUCOLIPIDOSIS MUCOLIPIDOSIS,N/A,297,249,332,296,-1,RO-has_manifestation,906211-FS1,"Keratan sulfate Dermatan sulfate  Dermatan sulfate, heparan sulfate, chondroitin 4 sulfate, chondroitin 6 sulfate Glycoproteinoses Mannosidosis  Fucosidosis  Aspartylglucosaminuria  Sialidosis  Galactosialidosis    Mucolipidosis II (I cell disease) MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY) MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR); locus: 19cen q12 Locus: 1p34  Locus: 4q32 q33  Locus: 6p21.3  Locus: 20q13    Locus: 4q21 q23.",MUCOLIPIDOSIS IV (SIALOLIPIDOSIS AR),MUCOLIPIDOSIS III (PSEUDO HURLER POLYDYSTROPHY)
503460893,7/16/2014 13:27:37,,1324252521,7/16/2014 13:27:29,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],MELLITUS,N/A,77,50,97,67,1,RO-cause_of,900074-FS1,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
503460893,7/16/2014 13:40:59,,1324257985,7/16/2014 13:40:39,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,n/a,77,50,97,67,1,RO-cause_of,900074-FS1,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
503460893,7/16/2014 14:08:49,,1324268895,7/16/2014 14:08:24,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],begin as,N/A,77,50,97,67,1,RO-cause_of,900074-FS1,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
503460893,7/16/2014 15:45:05,,1324304198,7/16/2014 15:44:52,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],begin as,n/a,77,50,97,67,1,RO-cause_of,900074-FS1,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
503460893,7/16/2014 17:03:06,,1324339111,7/16/2014 17:03:01,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,77,50,97,67,1,RO-cause_of,900074-FS1,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
503460893,7/16/2014 17:37:15,,1324354678,7/16/2014 17:36:25,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],begin as,n/a,77,50,97,67,1,RO-cause_of,900074-FS1,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
503460893,7/16/2014 19:01:22,,1324419271,7/16/2014 19:01:03,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[MANIFESTATION],[MANIFESTATION],begin,N/A,77,50,97,67,1,RO-cause_of,900074-FS1,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
503460893,7/16/2014 19:23:24,,1324431195,7/16/2014 19:22:44,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER] [IS_A],"[IS_A]
[OTHER]",begin as,is caused by,77,50,97,67,1,RO-cause_of,900074-FS1,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
503460893,7/16/2014 19:39:31,,1324438867,7/16/2014 19:39:16,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[MANIFESTATION],[MANIFESTATION],begin,N/A,77,50,97,67,1,RO-cause_of,900074-FS1,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
503460893,7/16/2014 19:58:26,,1324447951,7/16/2014 19:57:52,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],begin as,n/a,77,50,97,67,1,RO-cause_of,900074-FS1,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
503460893,7/16/2014 20:57:13,,1324473105,7/16/2014 20:56:58,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",begin as,N/A,77,50,97,67,1,RO-cause_of,900074-FS1,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
503460893,7/16/2014 20:58:36,,1324473760,7/16/2014 20:57:07,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[CAUSES],[CAUSES],DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,N/A,77,50,97,67,1,RO-cause_of,900074-FS1,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
503460893,7/16/2014 21:00:05,,1324474519,7/16/2014 20:59:54,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[CAUSES],[CAUSES],DIABETES,NONE,77,50,97,67,1,RO-cause_of,900074-FS1,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
503460893,7/16/2014 21:00:12,,1324474578,7/16/2014 20:59:32,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,N/A,77,50,97,67,1,RO-cause_of,900074-FS1,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
503460893,7/16/2014 21:07:54,,1324479003,7/16/2014 21:07:07,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[SYMPTOM],[SYMPTOM],begin as,n/a,77,50,97,67,1,RO-cause_of,900074-FS1,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
503460894,7/16/2014 13:28:49,,1324252992,7/16/2014 13:28:41,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],reduced,N/A,30,40,35,49,1,RO-may_prevent,907302-FS1,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
503460894,7/16/2014 13:38:11,,1324256962,7/16/2014 13:37:58,instagc,1.0,13763729,USA,"","",75.182.89.225,[PREVENTS],[PREVENTS],inhibition of,N/A,30,40,35,49,1,RO-may_prevent,907302-FS1,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
503460894,7/16/2014 13:38:17,,1324256983,7/16/2014 13:37:41,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PREVENTS],[PREVENTS],the inhibition of CARIES by FLUORIDES,n/a,30,40,35,49,1,RO-may_prevent,907302-FS1,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
503460894,7/16/2014 13:47:57,,1324260423,7/16/2014 13:47:20,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[PREVENTS],[PREVENTS],inhibition,na,30,40,35,49,1,RO-may_prevent,907302-FS1,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
503460894,7/16/2014 13:57:43,,1324264209,7/16/2014 13:57:23,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[PREVENTS],[PREVENTS],inhibition of,N/A,30,40,35,49,1,RO-may_prevent,907302-FS1,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
503460894,7/16/2014 15:03:42,,1324289636,7/16/2014 15:03:21,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[PREVENTS],[PREVENTS],the inhibition of,N/A,30,40,35,49,1,RO-may_prevent,907302-FS1,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
503460894,7/16/2014 15:09:32,,1324291803,7/16/2014 15:08:50,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],inhibition by,N/A,30,40,35,49,1,RO-may_prevent,907302-FS1,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
503460894,7/16/2014 15:43:26,,1324303399,7/16/2014 15:43:00,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PREVENTS],[PREVENTS],inhibition of,n/a,30,40,35,49,1,RO-may_prevent,907302-FS1,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
503460894,7/16/2014 15:44:50,,1324304071,7/16/2014 15:44:38,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[PREVENTS],[PREVENTS],inhibition of,N/A,30,40,35,49,1,RO-may_prevent,907302-FS1,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
503460894,7/16/2014 16:08:12,,1324316361,7/16/2014 16:07:50,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],by,[ASSOCIATED_WITH],30,40,35,49,1,RO-may_prevent,907302-FS1,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
503460894,7/16/2014 16:35:02,,1324327605,7/16/2014 16:34:41,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],ascribed,N/A,30,40,35,49,1,RO-may_prevent,907302-FS1,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
503460894,7/16/2014 16:42:43,,1324332022,7/16/2014 16:42:02,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CARIES FLUORIDES,n/a,30,40,35,49,1,RO-may_prevent,907302-FS1,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
503460894,7/16/2014 18:13:20,,1324391346,7/16/2014 18:12:48,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],inhibition by,na,30,40,35,49,1,RO-may_prevent,907302-FS1,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
503460894,7/16/2014 18:19:53,,1324397956,7/16/2014 18:19:35,clixsense,1.0,6621167,USA,"","",66.87.78.42,[ASSOCIATED_WITH],[ASSOCIATED_WITH],by,Na,30,40,35,49,1,RO-may_prevent,907302-FS1,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
503460894,7/16/2014 18:32:28,,1324403166,7/16/2014 18:31:55,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],the inhibition of CARIES by FLUORIDES,N/A,30,40,35,49,1,RO-may_prevent,907302-FS1,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
503460895,7/16/2014 14:10:20,,1324269599,7/16/2014 14:09:34,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",documented by venography,N/A,18,104,33,121,1,RO-has_finding_site,905367-FS1,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
503460895,7/16/2014 15:45:44,,1324304491,7/16/2014 15:45:22,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],presence of,n/a,18,104,33,121,1,RO-has_finding_site,905367-FS1,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
503460895,7/16/2014 15:46:31,,1324304795,7/16/2014 15:45:42,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[SYMPTOM],[SYMPTOM],presence of,n/a,18,104,33,121,1,RO-has_finding_site,905367-FS1,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
503460895,7/16/2014 16:22:54,,1324323072,7/16/2014 16:21:54,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[LOCATION],[LOCATION],THROMBOSED VEINS VENOUS THROMBOSIS,n/a,18,104,33,121,1,RO-has_finding_site,905367-FS1,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
503460895,7/16/2014 18:13:19,,1324391345,7/16/2014 18:12:36,clixsense,1.0,6621167,USA,"","",66.87.78.42,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,18,104,33,121,1,RO-has_finding_site,905367-FS1,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
503460895,7/16/2014 19:00:10,,1324418592,7/16/2014 18:59:53,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],presence,N/A,18,104,33,121,1,RO-has_finding_site,905367-FS1,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
503460895,7/16/2014 19:21:52,,1324430503,7/16/2014 19:21:30,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],substantiated by the findings.,N/A,18,104,33,121,1,RO-has_finding_site,905367-FS1,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
503460895,7/16/2014 19:36:57,,1324437597,7/16/2014 19:36:47,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],VEINS,N/A,18,104,33,121,1,RO-has_finding_site,905367-FS1,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
503460895,7/16/2014 19:57:25,,1324447511,7/16/2014 19:56:58,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],the presence of,N/A,18,104,33,121,1,RO-has_finding_site,905367-FS1,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
503460895,7/16/2014 20:26:52,,1324460725,7/16/2014 20:24:17,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],presence of,n/a,18,104,33,121,1,RO-has_finding_site,905367-FS1,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
503460895,7/16/2014 20:31:37,,1324462900,7/16/2014 20:30:50,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[LOCATION],[LOCATION],the presence of,N/A,18,104,33,121,1,RO-has_finding_site,905367-FS1,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
503460895,7/16/2014 20:54:29,,1324472169,7/16/2014 20:52:48,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[SYMPTOM],[SYMPTOM],THROMBOSED VEINS substantiated by the,N/A,18,104,33,121,1,RO-has_finding_site,905367-FS1,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
503460895,7/16/2014 20:55:00,,1324472401,7/16/2014 20:54:19,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[PART_OF],[PART_OF],THROMBOSED VEINS documented by venography the presence of VENOUS THROMBOSIS was substantiated,N/A,18,104,33,121,1,RO-has_finding_site,905367-FS1,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
503460895,7/16/2014 21:04:55,,1324477262,7/16/2014 21:03:31,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[NONE],[NONE],n/a,no words used to express that there is a relationship between the 2 conditions,18,104,33,121,1,RO-has_finding_site,905367-FS1,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
503460895,7/16/2014 21:08:31,,1324479414,7/16/2014 21:06:53,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"In three patients THROMBOSED VEINS and in all five cases, VENOUS THROMBOSIS",N/A,18,104,33,121,1,RO-has_finding_site,905367-FS1,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
503460896,7/16/2014 13:27:31,,1324252487,7/16/2014 13:26:58,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was induced by,N/A,35,0,61,19,1,RO-has_finding_site,905126-FS1,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
503460896,7/16/2014 13:29:25,,1324253258,7/16/2014 13:29:16,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],whereas,N/A,35,0,61,19,1,RO-has_finding_site,905126-FS1,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
503460896,7/16/2014 13:34:09,,1324255427,7/16/2014 13:33:43,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[CAUSES],[CAUSES],induced by,na,35,0,61,19,1,RO-has_finding_site,905126-FS1,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
503460896,7/16/2014 13:35:24,,1324255942,7/16/2014 13:35:11,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],induced,Na,35,0,61,19,1,RO-has_finding_site,905126-FS1,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
503460896,7/16/2014 13:36:55,,1324256525,7/16/2014 13:36:38,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],induced,N/A,35,0,61,19,1,RO-has_finding_site,905126-FS1,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
503460896,7/16/2014 13:38:11,,1324256942,7/16/2014 13:37:55,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],PORTAL HYPERTENSION,asd,35,0,61,19,1,RO-has_finding_site,905126-FS1,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
503460896,7/16/2014 13:38:51,,1324257202,7/16/2014 13:38:33,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],was induced by,N/A,35,0,61,19,1,RO-has_finding_site,905126-FS1,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
503460896,7/16/2014 13:45:07,,1324259490,7/16/2014 13:44:50,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],was induced by,N/a,35,0,61,19,1,RO-has_finding_site,905126-FS1,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
503460896,7/16/2014 13:46:35,,1324259983,7/16/2014 13:46:24,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was induced by,n/a,35,0,61,19,1,RO-has_finding_site,905126-FS1,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
503460896,7/16/2014 13:47:26,,1324260232,7/16/2014 13:47:10,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],induced by,N/A,35,0,61,19,1,RO-has_finding_site,905126-FS1,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
503460896,7/16/2014 13:55:11,,1324263050,7/16/2014 13:54:42,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[PREVENTS] [LOCATION],"[PREVENTS]
[LOCATION]",induced GRADED PORTAL STENOSIS controls,N/A,35,0,61,19,1,RO-has_finding_site,905126-FS1,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
503460896,7/16/2014 14:52:55,,1324285315,7/16/2014 14:52:34,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[CAUSES],[CAUSES],was induced by,N/A,35,0,61,19,1,RO-has_finding_site,905126-FS1,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
503460896,7/16/2014 15:05:13,,1324290295,7/16/2014 15:04:19,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[OTHER],[OTHER],was induced by,N/A,35,0,61,19,1,RO-has_finding_site,905126-FS1,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
503460896,7/16/2014 15:49:11,,1324305841,7/16/2014 15:48:49,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[CAUSES],[CAUSES],induced,n/a,35,0,61,19,1,RO-has_finding_site,905126-FS1,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
503460896,7/16/2014 16:09:24,,1324317116,7/16/2014 16:08:45,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[CAUSES],[CAUSES],was induced by,[CAUSES],35,0,61,19,1,RO-has_finding_site,905126-FS1,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
503460897,7/16/2014 13:33:28,,1324255096,7/16/2014 13:33:12,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test to screen for,n/a,232,199,254,212,1,RO-may_diagnose,906699-FS1,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
503460897,7/16/2014 13:49:16,,1324260837,7/16/2014 13:49:01,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test,N/A,232,199,254,212,1,RO-may_diagnose,906699-FS1,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
503460897,7/16/2014 13:54:05,,1324262649,7/16/2014 13:53:52,instagc,1.0,18960682,GBR,"","",86.29.147.112,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DEXAMETHASONE test to screen for,N/a,232,199,254,212,1,RO-may_diagnose,906699-FS1,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
503460897,7/16/2014 13:54:27,,1324262809,7/16/2014 13:53:56,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test to screen for,N/A,232,199,254,212,1,RO-may_diagnose,906699-FS1,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
503460897,7/16/2014 14:49:54,,1324284444,7/16/2014 14:49:24,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DEXAMETHASONE LATENT HYPERCORTISOLISM,n/a,232,199,254,212,1,RO-may_diagnose,906699-FS1,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
503460897,7/16/2014 16:14:30,,1324319713,7/16/2014 16:13:32,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DEXAMETHASONE LATENT HYPERCORTISOLISM,n/a,232,199,254,212,1,RO-may_diagnose,906699-FS1,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
503460897,7/16/2014 18:59:17,,1324417903,7/16/2014 18:59:06,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],screen,N/A,232,199,254,212,1,RO-may_diagnose,906699-FS1,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
503460897,7/16/2014 20:42:31,,1324467253,7/16/2014 20:41:45,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DEXAMETHASONE test screen for LATENT HYPERCORTISOLISM,Diagnosed by test or drug,232,199,254,212,1,RO-may_diagnose,906699-FS1,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
503460897,7/16/2014 20:56:29,,1324472904,7/16/2014 20:55:25,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM,N/A,232,199,254,212,1,RO-may_diagnose,906699-FS1,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
503460897,7/16/2014 21:00:01,,1324474475,7/16/2014 20:59:37,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",1mg overnight DEXAMETHASONE test to screen for,N/A,232,199,254,212,1,RO-may_diagnose,906699-FS1,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
503460897,7/16/2014 21:01:08,,1324475266,7/16/2014 21:00:29,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[MANIFESTATION],[MANIFESTATION],HYPERCORTISOLISM,NONE,232,199,254,212,1,RO-may_diagnose,906699-FS1,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
503460897,7/16/2014 21:13:35,,1324482808,7/16/2014 21:12:16,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM,N/A,232,199,254,212,1,RO-may_diagnose,906699-FS1,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
503460897,7/16/2014 21:19:40,,1324485696,7/16/2014 21:18:37,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test to screen for,n/a,232,199,254,212,1,RO-may_diagnose,906699-FS1,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
503460897,7/16/2014 21:26:37,,1324488779,7/16/2014 21:26:01,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],to screen for,N/A,232,199,254,212,1,RO-may_diagnose,906699-FS1,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
503460897,7/16/2014 21:53:29,,1324499383,7/16/2014 21:53:09,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test to screen,N/A,232,199,254,212,1,RO-may_diagnose,906699-FS1,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
503460898,7/16/2014 13:26:56,,1324252216,7/16/2014 13:26:16,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],curing by,N/A,91,79,111,87,1,RO-disease_has_primary_anatomic_site,902134-FS1,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
503460898,7/16/2014 13:30:47,,1324253864,7/16/2014 13:30:27,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],"induced,",asd,91,79,111,87,1,RO-disease_has_primary_anatomic_site,902134-FS1,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
503460898,7/16/2014 13:41:48,,1324258308,7/16/2014 13:41:28,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],to curing by,N/A,91,79,111,87,1,RO-disease_has_primary_anatomic_site,902134-FS1,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
503460898,7/16/2014 13:44:25,,1324259262,7/16/2014 13:43:52,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PREVENTS],[PREVENTS],curing,n/a,91,79,111,87,1,RO-disease_has_primary_anatomic_site,902134-FS1,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
503460898,7/16/2014 13:46:00,,1324259759,7/16/2014 13:45:33,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],curing,N/A,91,79,111,87,1,RO-disease_has_primary_anatomic_site,902134-FS1,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
503460898,7/16/2014 13:48:27,,1324260583,7/16/2014 13:48:08,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],curing by,N/A,91,79,111,87,1,RO-disease_has_primary_anatomic_site,902134-FS1,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
503460898,7/16/2014 13:49:53,,1324261044,7/16/2014 13:49:30,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],curing DIABETES by ISLET CELL NEOGENESIS,N/a,91,79,111,87,1,RO-disease_has_primary_anatomic_site,902134-FS1,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
503460898,7/16/2014 13:56:33,,1324263650,7/16/2014 13:56:23,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[MANIFESTATION],[MANIFESTATION],"be induced, major hurdle",N/A,91,79,111,87,1,RO-disease_has_primary_anatomic_site,902134-FS1,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
503460898,7/16/2014 14:00:10,,1324265262,7/16/2014 13:59:49,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],curing DIABETES by ISLET CELL NEOGENESIS,N/A,91,79,111,87,1,RO-disease_has_primary_anatomic_site,902134-FS1,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
503460898,7/16/2014 14:50:05,,1324284512,7/16/2014 14:48:40,prodege,1.0,15508331,USA,OK,Stillwater,139.78.139.193,[TREATS],[TREATS],curing DIABETES by ISLET CELL NEOGENESIS,N/A,91,79,111,87,1,RO-disease_has_primary_anatomic_site,902134-FS1,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
503460898,7/16/2014 15:45:21,,1324304300,7/16/2014 15:45:06,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],curing by,n/a,91,79,111,87,1,RO-disease_has_primary_anatomic_site,902134-FS1,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
503460898,7/16/2014 16:11:03,,1324318125,7/16/2014 16:10:38,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[CAUSES],[CAUSES],by,[CAUSES],91,79,111,87,1,RO-disease_has_primary_anatomic_site,902134-FS1,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
503460898,7/16/2014 16:31:12,,1324326187,7/16/2014 16:30:47,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],by,N/A,91,79,111,87,1,RO-disease_has_primary_anatomic_site,902134-FS1,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
503460898,7/16/2014 16:33:10,,1324326832,7/16/2014 16:32:02,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],curing DIABETES by ISLET CELL NEOGENESIS,N/A,91,79,111,87,1,RO-disease_has_primary_anatomic_site,902134-FS1,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
503460898,7/16/2014 18:29:11,,1324401784,7/16/2014 18:28:05,prodege,1.0,20349329,USA,CA,El Cajon,68.7.51.119,[TREATS],[TREATS],curing DIABETES by ISLET CELL NEOGENESIS,N/A,91,79,111,87,1,RO-disease_has_primary_anatomic_site,902134-FS1,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
503460899,7/16/2014 13:27:18,,1324252386,7/16/2014 13:27:10,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],and,N/A,56,112,59,127,1,RO-disease_has_primary_anatomic_site,902135-FS1,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
503460899,7/16/2014 13:39:11,,1324257321,7/16/2014 13:38:47,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[LOCATION],[LOCATION],specimens from a variety of animals with suspected,n/a,56,112,59,127,1,RO-disease_has_primary_anatomic_site,902135-FS1,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
503460899,7/16/2014 13:39:38,,1324257470,7/16/2014 13:39:13,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],SKIN,asd,56,112,59,127,1,RO-disease_has_primary_anatomic_site,902135-FS1,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
503460899,7/16/2014 13:48:41,,1324260658,7/16/2014 13:48:24,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],specimens,N/A,56,112,59,127,1,RO-disease_has_primary_anatomic_site,902135-FS1,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
503460899,7/16/2014 13:58:11,,1324264366,7/16/2014 13:57:43,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],specimens from animals with suspected,N/A,56,112,59,127,1,RO-disease_has_primary_anatomic_site,902135-FS1,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
503460899,7/16/2014 14:42:06,,1324282238,7/16/2014 14:41:11,prodege,1.0,15508331,USA,OK,Stillwater,139.78.139.193,[LOCATION],[LOCATION],"SKIN specimens were studied,",N/A,56,112,59,127,1,RO-disease_has_primary_anatomic_site,902135-FS1,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
503460899,7/16/2014 14:48:00,,1324283853,7/16/2014 14:47:24,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SKIN DERMATOPHYTOSES,n/a,56,112,59,127,1,RO-disease_has_primary_anatomic_site,902135-FS1,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
503460899,7/16/2014 14:57:38,,1324287107,7/16/2014 14:57:08,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION],[LOCATION],specimens from,N/A,56,112,59,127,1,RO-disease_has_primary_anatomic_site,902135-FS1,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
503460899,7/16/2014 15:33:05,,1324299349,7/16/2014 15:32:55,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,unclear,56,112,59,127,1,RO-disease_has_primary_anatomic_site,902135-FS1,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
503460899,7/16/2014 15:45:57,,1324304584,7/16/2014 15:45:44,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[LOCATION],[LOCATION],specimens with suspected,N/A,56,112,59,127,1,RO-disease_has_primary_anatomic_site,902135-FS1,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
503460899,7/16/2014 16:38:06,,1324329421,7/16/2014 16:37:26,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[LOCATION],[LOCATION],SKIN specimens with DERMATOPHYTOSES,N/A,56,112,59,127,1,RO-disease_has_primary_anatomic_site,902135-FS1,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
503460899,7/16/2014 17:09:13,,1324341108,7/16/2014 17:08:07,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],with,NONE,56,112,59,127,1,RO-disease_has_primary_anatomic_site,902135-FS1,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
503460899,7/16/2014 19:42:18,,1324440384,7/16/2014 19:42:05,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],SKIN,N/A,56,112,59,127,1,RO-disease_has_primary_anatomic_site,902135-FS1,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
503460899,7/16/2014 19:55:06,,1324446647,7/16/2014 19:54:47,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],with suspected,N/A,56,112,59,127,1,RO-disease_has_primary_anatomic_site,902135-FS1,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
503460899,7/16/2014 19:57:13,,1324447439,7/16/2014 19:56:48,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[LOCATION],[LOCATION],specimens,n/a,56,112,59,127,1,RO-disease_has_primary_anatomic_site,902135-FS1,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
503460900,7/16/2014 13:30:20,,1324253633,7/16/2014 13:30:13,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],serum,N/A,289,328,306,346,-1,RO-cause_of,900233-FS1,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
503460900,7/16/2014 13:42:41,,1324258689,7/16/2014 13:42:28,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],caused,Na,289,328,306,346,-1,RO-cause_of,900233-FS1,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
503460900,7/16/2014 13:43:58,,1324259097,7/16/2014 13:43:12,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],or may be caused by,N/A,289,328,306,346,-1,RO-cause_of,900233-FS1,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
503460900,7/16/2014 13:47:09,,1324260148,7/16/2014 13:46:53,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],phenomenon contributing to ALLERGIC DISORDERS caused ALLERGIC REACTIONS,n/a,289,328,306,346,-1,RO-cause_of,900233-FS1,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
503460900,7/16/2014 13:47:20,,1324260198,7/16/2014 13:47:06,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],contributing,N/A,289,328,306,346,-1,RO-cause_of,900233-FS1,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
503460900,7/16/2014 13:51:43,,1324261691,7/16/2014 13:51:28,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or may be,N/a,289,328,306,346,-1,RO-cause_of,900233-FS1,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
503460900,7/16/2014 15:03:14,,1324289376,7/16/2014 15:02:31,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[PART_OF],[PART_OF],contributing to,na,289,328,306,346,-1,RO-cause_of,900233-FS1,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
503460900,7/16/2014 15:13:15,,1324293010,7/16/2014 15:12:07,prodege,1,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],ALLERGIC,N/A,289,328,306,346,-1,RO-cause_of,900233-FS1,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
503460900,7/16/2014 15:25:55,,1324297060,7/16/2014 15:25:33,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],caused by,n/a,289,328,306,346,-1,RO-cause_of,900233-FS1,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
503460900,7/16/2014 15:40:33,,1324302187,7/16/2014 15:39:55,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,[CAUSES],[CAUSES],caused by,n/a,289,328,306,346,-1,RO-cause_of,900233-FS1,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
503460900,7/16/2014 16:34:52,,1324327564,7/16/2014 16:34:15,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],ALLERGIC DISORDERS ALLERGIC REACTIONS,n/a,289,328,306,346,-1,RO-cause_of,900233-FS1,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
503460900,7/16/2014 16:35:29,,1324327838,7/16/2014 16:32:18,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[TREATS],[TREATS],determine,na,289,328,306,346,-1,RO-cause_of,900233-FS1,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
503460900,7/16/2014 16:36:44,,1324328542,7/16/2014 16:36:24,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],caused,N/A,289,328,306,346,-1,RO-cause_of,900233-FS1,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
503460900,7/16/2014 16:41:26,,1324331489,7/16/2014 16:40:07,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[CAUSES],[CAUSES],caused,none,289,328,306,346,-1,RO-cause_of,900233-FS1,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
503460900,7/16/2014 16:51:14,,1324335035,7/16/2014 16:50:43,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",ALLERGIC DISORDERS caused ALLERGIC REACTIONS,N/A,289,328,306,346,-1,RO-cause_of,900233-FS1,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
503460901,7/16/2014 13:36:51,,1324256503,7/16/2014 13:36:36,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],precipitate,Na,68,91,87,99,-1,RO-disease_has_finding,901567-FS1,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
503460901,7/16/2014 13:37:01,,1324256558,7/16/2014 13:36:34,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],saline lavage to dislodge,n/a,68,91,87,99,-1,RO-disease_has_finding,901567-FS1,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
503460901,7/16/2014 13:46:03,,1324259779,7/16/2014 13:45:48,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],a WET LUNG appearance,N/a,68,91,87,99,-1,RO-disease_has_finding,901567-FS1,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
503460901,7/16/2014 13:50:31,,1324261304,7/16/2014 13:50:12,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[PART_OF],[PART_OF],a,N/A,68,91,87,99,-1,RO-disease_has_finding,901567-FS1,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
503460901,7/16/2014 16:15:57,,1324320418,7/16/2014 16:14:35,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RESPIRATORY DISTRESS WET LUNG,n/a,68,91,87,99,-1,RO-disease_has_finding,901567-FS1,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
503460901,7/16/2014 16:38:24,,1324329659,7/16/2014 16:37:46,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],appearance,none,68,91,87,99,-1,RO-disease_has_finding,901567-FS1,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
503460901,7/16/2014 16:42:06,,1324331773,7/16/2014 16:41:41,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],appearance and respiratory,na,68,91,87,99,-1,RO-disease_has_finding,901567-FS1,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
503460901,7/16/2014 16:43:48,,1324332429,7/16/2014 16:41:59,instagc,1,23149109,USA,NC,Cary,24.206.38.18,[MANIFESTATION],[MANIFESTATION],RESPIRATORY DISTRESS a WET LUNG appearance,N/A,68,91,87,99,-1,RO-disease_has_finding,901567-FS1,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
503460901,7/16/2014 17:07:12,,1324340415,7/16/2014 17:04:59,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[OTHER],[OTHER],may precipitate RESPIRATORY DISTRESS,N/A,68,91,87,99,-1,RO-disease_has_finding,901567-FS1,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
503460901,7/16/2014 17:07:18,,1324340478,7/16/2014 17:07:07,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,68,91,87,99,-1,RO-disease_has_finding,901567-FS1,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
503460901,7/16/2014 18:24:54,,1324399934,7/16/2014 18:23:30,gifthulk,1,24076843,GBR,K6,Portsmouth,86.6.112.248,[MANIFESTATION],[MANIFESTATION],may precipitate RESPIRATORY DISTRESS,N/A,68,91,87,99,-1,RO-disease_has_finding,901567-FS1,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
503460901,7/16/2014 18:57:55,,1324417114,7/16/2014 18:57:33,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],may precipitate,N/A,68,91,87,99,-1,RO-disease_has_finding,901567-FS1,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
503460901,7/16/2014 20:44:03,,1324467773,7/16/2014 20:43:41,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER] [LOCATION],"[LOCATION]
[OTHER]",LUNG appearance,N/A,68,91,87,99,-1,RO-disease_has_finding,901567-FS1,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
503460901,7/16/2014 20:54:08,,1324472076,7/16/2014 20:53:36,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different conditions,68,91,87,99,-1,RO-disease_has_finding,901567-FS1,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
503460901,7/16/2014 20:54:47,,1324472333,7/16/2014 20:52:17,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[IS_A],[IS_A],RESPIRATORY DISTRESS a WET LUNG,N/A,68,91,87,99,-1,RO-disease_has_finding,901567-FS1,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
503460902,7/16/2014 13:31:57,,1324254452,7/16/2014 13:31:49,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is currently used as a test for,N/A,44,0,68,11,1,RO-may_diagnose,906617-FS1,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
503460902,7/16/2014 13:47:11,,1324260170,7/16/2014 13:46:19,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is used,N/A,44,0,68,11,1,RO-may_diagnose,906617-FS1,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
503460902,7/16/2014 13:48:36,,1324260626,7/16/2014 13:48:00,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],used as a test,na,44,0,68,11,1,RO-may_diagnose,906617-FS1,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
503460902,7/16/2014 13:50:03,,1324261089,7/16/2014 13:49:48,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ERGOMETRINE used as test for PRINZMETAL VARIANT ANGINA,N/A,44,0,68,11,1,RO-may_diagnose,906617-FS1,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
503460902,7/16/2014 14:13:50,,1324271097,7/16/2014 14:13:38,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],test,N/A,44,0,68,11,1,RO-may_diagnose,906617-FS1,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
503460902,7/16/2014 14:55:47,,1324286325,7/16/2014 14:55:29,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ERGOMETRINE PRINZMETAL VARIANT ANGINA,n/a,44,0,68,11,1,RO-may_diagnose,906617-FS1,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
503460902,7/16/2014 16:27:02,,1324324658,7/16/2014 16:24:20,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test,na,44,0,68,11,1,RO-may_diagnose,906617-FS1,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
503460902,7/16/2014 16:30:18,,1324325849,7/16/2014 16:28:57,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test,N/A,44,0,68,11,1,RO-may_diagnose,906617-FS1,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
503460902,7/16/2014 16:48:04,,1324333957,7/16/2014 16:47:24,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],ERGOMETRINE used as a test,N/A,44,0,68,11,1,RO-may_diagnose,906617-FS1,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
503460902,7/16/2014 17:33:04,,1324351591,7/16/2014 17:32:23,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,"One is being used to test the other, so no relationship is proven yet.",44,0,68,11,1,RO-may_diagnose,906617-FS1,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
503460902,7/16/2014 18:07:21,,1324385259,7/16/2014 18:06:55,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],used as a test,na,44,0,68,11,1,RO-may_diagnose,906617-FS1,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
503460902,7/16/2014 18:19:33,,1324397808,7/16/2014 18:18:51,clixsense,1,6621167,USA,"","",66.87.78.42,[ASSOCIATED_WITH],[ASSOCIATED_WITH],for,Na,44,0,68,11,1,RO-may_diagnose,906617-FS1,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
503460902,7/16/2014 18:27:33,,1324401151,7/16/2014 18:27:16,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA,N/A,44,0,68,11,1,RO-may_diagnose,906617-FS1,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
503460902,7/16/2014 19:48:52,,1324443645,7/16/2014 19:48:36,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is currently used as a test for,N/A,44,0,68,11,1,RO-may_diagnose,906617-FS1,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
503460902,7/16/2014 20:56:58,,1324473038,7/16/2014 20:56:46,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],PRINZMETAL VARIANT ANGINA,NONE,44,0,68,11,1,RO-may_diagnose,906617-FS1,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
503460903,7/16/2014 13:31:00,,1324253994,7/16/2014 13:30:50,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],degrees,N/A,94,190,111,201,-1,RO-disease_has_finding,901568-FS1,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
503460903,7/16/2014 13:34:47,,1324255730,7/16/2014 13:34:20,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],indicate,N/A,94,190,111,201,-1,RO-disease_has_finding,901568-FS1,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
503460903,7/16/2014 13:34:50,,1324255737,7/16/2014 13:34:28,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],related to,N/A,94,190,111,201,-1,RO-disease_has_finding,901568-FS1,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
503460903,7/16/2014 13:44:58,,1324259437,7/16/2014 13:44:39,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],AMYLOID DEPOSITION in AMYLOIDOSIS,N/A,94,190,111,201,-1,RO-disease_has_finding,901568-FS1,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
503460903,7/16/2014 14:49:10,,1324284219,7/16/2014 14:48:39,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],related to the,N/A,94,190,111,201,-1,RO-disease_has_finding,901568-FS1,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
503460903,7/16/2014 15:05:58,,1324290620,7/16/2014 15:05:09,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[MANIFESTATION],[MANIFESTATION],presence of,na,94,190,111,201,-1,RO-disease_has_finding,901568-FS1,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
503460903,7/16/2014 15:30:39,,1324298553,7/16/2014 15:29:59,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[LOCATION],[LOCATION],in,n/a,94,190,111,201,-1,RO-disease_has_finding,901568-FS1,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
503460903,7/16/2014 17:04:08,,1324339447,7/16/2014 17:04:03,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,94,190,111,201,-1,RO-disease_has_finding,901568-FS1,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
503460903,7/16/2014 19:10:55,,1324424935,7/16/2014 19:10:04,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[ASSOCIATED_WITH],[ASSOCIATED_WITH],presence and degrees of AMYLOID DEPOSITION would be related,N/A,94,190,111,201,-1,RO-disease_has_finding,901568-FS1,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
503460903,7/16/2014 19:43:17,,1324440799,7/16/2014 19:42:37,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[LOCATION],[LOCATION],the presence,N/A,94,190,111,201,-1,RO-disease_has_finding,901568-FS1,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
503460903,7/16/2014 19:48:19,,1324443384,7/16/2014 19:47:57,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],would be related to,N/A,94,190,111,201,-1,RO-disease_has_finding,901568-FS1,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
503460903,7/16/2014 20:02:39,,1324449497,7/16/2014 20:01:54,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],would be related to,n/a,94,190,111,201,-1,RO-disease_has_finding,901568-FS1,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
503460903,7/16/2014 20:56:12,,1324472746,7/16/2014 20:54:30,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],related to,N/A,94,190,111,201,-1,RO-disease_has_finding,901568-FS1,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
503460903,7/16/2014 21:03:30,,1324476550,7/16/2014 21:02:43,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[ASSOCIATED_WITH],[ASSOCIATED_WITH],related,n/a,94,190,111,201,-1,RO-disease_has_finding,901568-FS1,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
503460903,7/16/2014 21:09:46,,1324480221,7/16/2014 21:08:33,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION] [ASSOCIATED_WITH],"[LOCATION]
[ASSOCIATED_WITH]",AMYLOID DEPOSITION in the skeletal muscles related to amyloid proteins AMYLOIDOSIS,n/a,94,190,111,201,-1,RO-disease_has_finding,901568-FS1,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
503460904,7/16/2014 13:27:30,,1324252455,7/16/2014 13:27:00,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],influence of CISAPRIDE on,n/a,30,17,81,26,1,RO-may_treat,908361-FS1,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
503460904,7/16/2014 13:33:03,,1324254900,7/16/2014 13:32:42,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[TREATS],[TREATS],influence of,na,30,17,81,26,1,RO-may_treat,908361-FS1,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
503460904,7/16/2014 13:33:40,,1324255229,7/16/2014 13:33:32,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],The influence of on,N/A,30,17,81,26,1,RO-may_treat,908361-FS1,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
503460904,7/16/2014 13:35:40,,1324256033,7/16/2014 13:35:14,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[PREVENTS],[PREVENTS],"FOOD STIMULATED endoscopy,",asd,30,17,81,26,1,RO-may_treat,908361-FS1,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
503460904,7/16/2014 13:46:37,,1324259964,7/16/2014 13:46:21,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],The influence of CISAPRIDE on,N/a,30,17,81,26,1,RO-may_treat,908361-FS1,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
503460904,7/16/2014 13:47:04,,1324260117,7/16/2014 13:46:37,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],influence,N/A,30,17,81,26,1,RO-may_treat,908361-FS1,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
503460904,7/16/2014 14:37:44,,1324280879,7/16/2014 14:35:16,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],The influence of,N/A,30,17,81,26,1,RO-may_treat,908361-FS1,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
503460904,7/16/2014 16:08:44,,1324316763,7/16/2014 16:08:14,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[ASSOCIATED_WITH] [CAUSES] [LOCATION],"[CAUSES]
[LOCATION]
[ASSOCIATED_WITH]",on,[ASSOCIATED_WITH] [CAUSES] [LOCATION],30,17,81,26,1,RO-may_treat,908361-FS1,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
503460904,7/16/2014 16:50:01,,1324334647,7/16/2014 16:49:20,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],influence of on,N/A,30,17,81,26,1,RO-may_treat,908361-FS1,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
503460904,7/16/2014 16:51:42,,1324335202,7/16/2014 16:51:10,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],on,NONE,30,17,81,26,1,RO-may_treat,908361-FS1,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
503460904,7/16/2014 17:03:30,,1324339219,7/16/2014 17:02:52,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CISAPRIDE FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,n/a,30,17,81,26,1,RO-may_treat,908361-FS1,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
503460904,7/16/2014 18:15:23,,1324393639,7/16/2014 18:14:57,clixsense,1.0,6621167,USA,"","",66.87.78.42,[ASSOCIATED_WITH],[ASSOCIATED_WITH],on,Na,30,17,81,26,1,RO-may_treat,908361-FS1,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
503460904,7/16/2014 19:04:54,,1324421498,7/16/2014 19:03:58,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied,N/A,30,17,81,26,1,RO-may_treat,908361-FS1,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
503460904,7/16/2014 19:38:17,,1324438290,7/16/2014 19:38:05,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GASTRO OESOPHAGEAL REFLUX,N/A,30,17,81,26,1,RO-may_treat,908361-FS1,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
503460904,7/16/2014 19:56:17,,1324447112,7/16/2014 19:56:06,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],on,N/A,30,17,81,26,1,RO-may_treat,908361-FS1,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
503460905,7/16/2014 13:28:20,,1324252793,7/16/2014 13:27:57,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],spectrum of,n/a,16,59,28,91,1,RO-has_finding_site,905095-FS1,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
503460905,7/16/2014 13:30:09,,1324253554,7/16/2014 13:29:59,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],encompasses,N/A,16,59,28,91,1,RO-has_finding_site,905095-FS1,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
503460905,7/16/2014 13:42:13,,1324258534,7/16/2014 13:41:27,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],encompasses,N/A,16,59,28,91,1,RO-has_finding_site,905095-FS1,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
503460905,7/16/2014 13:43:41,,1324258978,7/16/2014 13:43:28,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],encompasses,Na,16,59,28,91,1,RO-has_finding_site,905095-FS1,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
503460905,7/16/2014 14:00:01,,1324265233,7/16/2014 13:59:33,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],spectrum of encompasses,N/A,16,59,28,91,1,RO-has_finding_site,905095-FS1,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
503460905,7/16/2014 14:17:34,,1324272544,7/16/2014 14:17:23,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[PART_OF],[PART_OF],encompasses,N/A,16,59,28,91,1,RO-has_finding_site,905095-FS1,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
503460905,7/16/2014 14:52:32,,1324285211,7/16/2014 14:51:15,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[ASSOCIATED_WITH],[ASSOCIATED_WITH],encompasses,N/A,16,59,28,91,1,RO-has_finding_site,905095-FS1,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
503460905,7/16/2014 16:34:39,,1324327436,7/16/2014 16:34:23,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],encompasses,N/A,16,59,28,91,1,RO-has_finding_site,905095-FS1,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
503460905,7/16/2014 16:39:14,,1324330233,7/16/2014 16:38:49,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],encompasses,na,16,59,28,91,1,RO-has_finding_site,905095-FS1,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
503460905,7/16/2014 16:44:54,,1324332847,7/16/2014 16:44:32,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[PART_OF],[PART_OF],SKIN DISEASES encompasses DERMATOSES OF DIVERSE ETIOLOGIES;,N/A,16,59,28,91,1,RO-has_finding_site,905095-FS1,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
503460905,7/16/2014 17:06:16,,1324339983,7/16/2014 17:05:25,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,16,59,28,91,1,RO-has_finding_site,905095-FS1,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
503460905,7/16/2014 17:22:03,,1324344972,7/16/2014 17:21:31,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[OTHER],[OTHER],spectrum of SKIN DISEASES,n/a,16,59,28,91,1,RO-has_finding_site,905095-FS1,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
503460905,7/16/2014 17:51:29,,1324368907,7/16/2014 17:51:09,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],encompasses,n/a,16,59,28,91,1,RO-has_finding_site,905095-FS1,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
503460905,7/16/2014 18:08:51,,1324386761,7/16/2014 18:08:03,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[IS_A],[IS_A],encompasses,na,16,59,28,91,1,RO-has_finding_site,905095-FS1,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
503460905,7/16/2014 18:33:26,,1324403727,7/16/2014 18:33:04,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[IS_A],[IS_A],in such patients encompasses,na,16,59,28,91,1,RO-has_finding_site,905095-FS1,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
503460906,7/16/2014 13:26:42,,1324252087,7/16/2014 13:26:24,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TENDONS,N/A,47,11,53,25,1,RO-has_finding_site,905252-FS1,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
503460906,7/16/2014 13:36:13,,1324256254,7/16/2014 13:34:48,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],found to,N/A,47,11,53,25,1,RO-has_finding_site,905252-FS1,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
503460906,7/16/2014 13:37:26,,1324256669,7/16/2014 13:36:41,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TENDON RUPTURE,n/a,47,11,53,25,1,RO-has_finding_site,905252-FS1,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
503460906,7/16/2014 13:49:21,,1324260857,7/16/2014 13:48:39,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and even,na,47,11,53,25,1,RO-has_finding_site,905252-FS1,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
503460906,7/16/2014 13:51:27,,1324261642,7/16/2014 13:51:12,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[LOCATION],[LOCATION],TENDON TENDONS,N/A,47,11,53,25,1,RO-has_finding_site,905252-FS1,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
503460906,7/16/2014 13:54:29,,1324262821,7/16/2014 13:53:33,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[LOCATION],[LOCATION],TENDON RUPTURE TENDONS,N/A,47,11,53,25,1,RO-has_finding_site,905252-FS1,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
503460906,7/16/2014 13:59:12,,1324264860,7/16/2014 13:59:05,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[PREVENTS] [SYMPTOM],"[PREVENTS]
[SYMPTOM]",RUPTURE minimal,N/A,47,11,53,25,1,RO-has_finding_site,905252-FS1,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
503460906,7/16/2014 14:11:20,,1324270030,7/16/2014 14:10:47,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],TENDON TENDONS,N/A,47,11,53,25,1,RO-has_finding_site,905252-FS1,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
503460906,7/16/2014 14:50:27,,1324284619,7/16/2014 14:49:59,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RUPTURE TENDONS,n/a,47,11,53,25,1,RO-has_finding_site,905252-FS1,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
503460906,7/16/2014 15:20:21,,1324295196,7/16/2014 15:20:08,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[LOCATION],[LOCATION],TENDONS,N/A,47,11,53,25,1,RO-has_finding_site,905252-FS1,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
503460906,7/16/2014 16:33:46,,1324327033,7/16/2014 16:32:55,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,none,47,11,53,25,1,RO-has_finding_site,905252-FS1,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
503460906,7/16/2014 16:37:17,,1324328872,7/16/2014 16:35:47,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],RUPTURE minimal,N/A,47,11,53,25,1,RO-has_finding_site,905252-FS1,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
503460906,7/16/2014 17:02:20,,1324338907,7/16/2014 17:02:14,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,47,11,53,25,1,RO-has_finding_site,905252-FS1,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
503460906,7/16/2014 18:19:06,,1324397504,7/16/2014 18:18:37,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[LOCATION],[LOCATION],TENDON RUPTURE was minimal and TENDONS found to be thinned out,N/A,47,11,53,25,1,RO-has_finding_site,905252-FS1,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
503460906,7/16/2014 18:57:32,,1324416909,7/16/2014 18:57:15,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],and,N/A,47,11,53,25,1,RO-has_finding_site,905252-FS1,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
503460907,7/16/2014 13:29:34,,1324253331,7/16/2014 13:29:26,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],serum,N/A,17,107,36,131,1,RO-may_prevent,907157-FS1,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
503460907,7/16/2014 13:34:12,,1324255452,7/16/2014 13:33:49,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],MAGNESIUM DEFICIENCY,asd,17,107,36,131,1,RO-may_prevent,907157-FS1,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
503460907,7/16/2014 13:37:25,,1324256668,7/16/2014 13:37:03,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],may be more indicative,n/a,17,107,36,131,1,RO-may_prevent,907157-FS1,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
503460907,7/16/2014 13:43:11,,1324258825,7/16/2014 13:42:28,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],more indicative of low magnesium states.,N/A,17,107,36,131,1,RO-may_prevent,907157-FS1,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
503460907,7/16/2014 13:44:30,,1324259297,7/16/2014 13:43:29,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of,N/A,17,107,36,131,1,RO-may_prevent,907157-FS1,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
503460907,7/16/2014 13:44:35,,1324259321,7/16/2014 13:44:18,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],although,N/A,17,107,36,131,1,RO-may_prevent,907157-FS1,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
503460907,7/16/2014 13:58:32,,1324264547,7/16/2014 13:58:23,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",MAGNESIUM serum although,N/A,17,107,36,131,1,RO-may_prevent,907157-FS1,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
503460907,7/16/2014 14:46:22,,1324283342,7/16/2014 14:45:36,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of may be more indicative of,N/A,17,107,36,131,1,RO-may_prevent,907157-FS1,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
503460907,7/16/2014 15:20:34,,1324295281,7/16/2014 15:20:23,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TEST,N/A,17,107,36,131,1,RO-may_prevent,907157-FS1,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
503460907,7/16/2014 18:27:12,,1324400996,7/16/2014 18:26:30,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],although the may be more indicative,na,17,107,36,131,1,RO-may_prevent,907157-FS1,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
503460907,7/16/2014 19:25:26,,1324432229,7/16/2014 19:24:57,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],The diagnosis,N/A,17,107,36,131,1,RO-may_prevent,907157-FS1,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
503460907,7/16/2014 19:57:34,,1324447582,7/16/2014 19:57:14,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TEST,n/a,17,107,36,131,1,RO-may_prevent,907157-FS1,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
503460907,7/16/2014 20:47:35,,1324469312,7/16/2014 20:46:53,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MAGNESIUM DEFICIENCY MAGNESIUM TOLERANCE TEST more indicative of low magnesium states.,n/a,17,107,36,131,1,RO-may_prevent,907157-FS1,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
503460907,7/16/2014 20:51:59,,1324471149,7/16/2014 20:50:38,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[LOCATION],[LOCATION],DEFICIENCY,NONE,17,107,36,131,1,RO-may_prevent,907157-FS1,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
503460907,7/16/2014 21:01:18,,1324475404,7/16/2014 21:01:04,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TEST,N/A,17,107,36,131,1,RO-may_prevent,907157-FS1,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
503460908,7/16/2014 13:39:29,,1324257414,7/16/2014 13:39:14,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],or,N/A,0,16,11,30,-1,RO-has_manifestation,906101-FS1,WILMS' TUMOR or NEPHROBLASTOMA is a malignant tumor of childhood and there are less than 200 cases in adults reported in the literature.,WILMS' TUMOR,NEPHROBLASTOMA
503460908,7/16/2014 13:44:52,,1324259408,7/16/2014 13:44:31,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],is a,N/A,0,16,11,30,-1,RO-has_manifestation,906101-FS1,WILMS' TUMOR or NEPHROBLASTOMA is a malignant tumor of childhood and there are less than 200 cases in adults reported in the literature.,WILMS' TUMOR,NEPHROBLASTOMA
503460908,7/16/2014 13:47:42,,1324260330,7/16/2014 13:47:29,instagc,1.0,18960682,GBR,"","",86.29.147.112,[IS_A],[IS_A],WILMS' TUMOR or NEPHROBLASTOMA,N/a,0,16,11,30,-1,RO-has_manifestation,906101-FS1,WILMS' TUMOR or NEPHROBLASTOMA is a malignant tumor of childhood and there are less than 200 cases in adults reported in the literature.,WILMS' TUMOR,NEPHROBLASTOMA
503460908,7/16/2014 13:57:48,,1324264226,7/16/2014 13:57:33,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],WILMS' TUMOR or NEPHROBLASTOMA is,N/A,0,16,11,30,-1,RO-has_manifestation,906101-FS1,WILMS' TUMOR or NEPHROBLASTOMA is a malignant tumor of childhood and there are less than 200 cases in adults reported in the literature.,WILMS' TUMOR,NEPHROBLASTOMA
503460908,7/16/2014 14:57:08,,1324286908,7/16/2014 14:55:56,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],WILMS' TUMOR NEPHROBLASTOMA,n/a,0,16,11,30,-1,RO-has_manifestation,906101-FS1,WILMS' TUMOR or NEPHROBLASTOMA is a malignant tumor of childhood and there are less than 200 cases in adults reported in the literature.,WILMS' TUMOR,NEPHROBLASTOMA
503460908,7/16/2014 16:23:54,,1324323499,7/16/2014 16:23:21,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[IS_A],[IS_A],or,N/A,0,16,11,30,-1,RO-has_manifestation,906101-FS1,WILMS' TUMOR or NEPHROBLASTOMA is a malignant tumor of childhood and there are less than 200 cases in adults reported in the literature.,WILMS' TUMOR,NEPHROBLASTOMA
503460908,7/16/2014 16:45:00,,1324332869,7/16/2014 16:44:19,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[IS_A] [OTHER],"[IS_A]
[OTHER]",WILMS' TUMOR or NEPHROBLASTOMA is tumor,N/A,0,16,11,30,-1,RO-has_manifestation,906101-FS1,WILMS' TUMOR or NEPHROBLASTOMA is a malignant tumor of childhood and there are less than 200 cases in adults reported in the literature.,WILMS' TUMOR,NEPHROBLASTOMA
503460908,7/16/2014 16:51:21,,1324335074,7/16/2014 16:50:55,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[IS_A],[IS_A],WILMS' TUMOR or NEPHROBLASTOMA,N/A,0,16,11,30,-1,RO-has_manifestation,906101-FS1,WILMS' TUMOR or NEPHROBLASTOMA is a malignant tumor of childhood and there are less than 200 cases in adults reported in the literature.,WILMS' TUMOR,NEPHROBLASTOMA
503460908,7/16/2014 17:09:47,,1324341324,7/16/2014 17:09:15,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,NONE,0,16,11,30,-1,RO-has_manifestation,906101-FS1,WILMS' TUMOR or NEPHROBLASTOMA is a malignant tumor of childhood and there are less than 200 cases in adults reported in the literature.,WILMS' TUMOR,NEPHROBLASTOMA
503460908,7/16/2014 17:47:58,,1324365228,7/16/2014 17:47:33,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[IS_A],[IS_A],or,n/a,0,16,11,30,-1,RO-has_manifestation,906101-FS1,WILMS' TUMOR or NEPHROBLASTOMA is a malignant tumor of childhood and there are less than 200 cases in adults reported in the literature.,WILMS' TUMOR,NEPHROBLASTOMA
503460908,7/16/2014 18:33:57,,1324404004,7/16/2014 18:33:38,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[IS_A],[IS_A],WILMS' TUMOR or NEPHROBLASTOMA is a malignant tumor,N/A,0,16,11,30,-1,RO-has_manifestation,906101-FS1,WILMS' TUMOR or NEPHROBLASTOMA is a malignant tumor of childhood and there are less than 200 cases in adults reported in the literature.,WILMS' TUMOR,NEPHROBLASTOMA
503460908,7/16/2014 19:01:37,,1324419404,7/16/2014 19:01:23,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[IS_A],[IS_A],or,N/A,0,16,11,30,-1,RO-has_manifestation,906101-FS1,WILMS' TUMOR or NEPHROBLASTOMA is a malignant tumor of childhood and there are less than 200 cases in adults reported in the literature.,WILMS' TUMOR,NEPHROBLASTOMA
503460908,7/16/2014 19:39:15,,1324438753,7/16/2014 19:39:08,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],TUMOR,N/A,0,16,11,30,-1,RO-has_manifestation,906101-FS1,WILMS' TUMOR or NEPHROBLASTOMA is a malignant tumor of childhood and there are less than 200 cases in adults reported in the literature.,WILMS' TUMOR,NEPHROBLASTOMA
503460908,7/16/2014 19:45:40,,1324442099,7/16/2014 19:45:15,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],or,N/A,0,16,11,30,-1,RO-has_manifestation,906101-FS1,WILMS' TUMOR or NEPHROBLASTOMA is a malignant tumor of childhood and there are less than 200 cases in adults reported in the literature.,WILMS' TUMOR,NEPHROBLASTOMA
503460908,7/16/2014 20:28:27,,1324461510,7/16/2014 20:28:07,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[IS_A],[IS_A],or,n/a,0,16,11,30,-1,RO-has_manifestation,906101-FS1,WILMS' TUMOR or NEPHROBLASTOMA is a malignant tumor of childhood and there are less than 200 cases in adults reported in the literature.,WILMS' TUMOR,NEPHROBLASTOMA
503460909,7/16/2014 13:31:30,,1324254200,7/16/2014 13:31:05,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or a history of,n/a,109,135,117,149,1,RO-disease_may_have_finding,902781-FS1,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
503460909,7/16/2014 13:40:38,,1324257880,7/16/2014 13:40:25,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or history,Na,109,135,117,149,1,RO-disease_may_have_finding,902781-FS1,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
503460909,7/16/2014 13:59:34,,1324265070,7/16/2014 13:59:25,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[PREVENTS] [SYMPTOM],"[PREVENTS]
[SYMPTOM]",screening from,N/A,109,135,117,149,1,RO-disease_may_have_finding,902781-FS1,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
503460909,7/16/2014 14:09:33,,1324269235,7/16/2014 14:08:50,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],"symptoms, such as",N/A,109,135,117,149,1,RO-disease_may_have_finding,902781-FS1,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
503460909,7/16/2014 14:41:10,,1324281971,7/16/2014 14:38:44,prodege,1.0,15508331,USA,OK,Stillwater,139.78.139.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"differs from symptoms,",N/A,109,135,117,149,1,RO-disease_may_have_finding,902781-FS1,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
503460909,7/16/2014 15:01:55,,1324288709,7/16/2014 15:01:09,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]","with symptoms, such as",N/A,109,135,117,149,1,RO-disease_may_have_finding,902781-FS1,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
503460909,7/16/2014 15:36:15,,1324300445,7/16/2014 15:35:27,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[SYMPTOM],[SYMPTOM],"symptoms,",n/a,109,135,117,149,1,RO-disease_may_have_finding,902781-FS1,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
503460909,7/16/2014 15:39:43,,1324301893,7/16/2014 15:39:11,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[SYMPTOM],[SYMPTOM],"symptoms, such as",N/A,109,135,117,149,1,RO-disease_may_have_finding,902781-FS1,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
503460909,7/16/2014 15:48:08,,1324305423,7/16/2014 15:46:21,prodege,1.0,27990290,GBR,I9,Bury Saint Edmunds,86.142.231.81,[MANIFESTATION],[MANIFESTATION],"symptoms, history",screening is different for people with a history of bladder cancer or hematuria.,109,135,117,149,1,RO-disease_may_have_finding,902781-FS1,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
503460909,7/16/2014 16:21:20,,1324322510,7/16/2014 16:19:55,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,109,135,117,149,1,RO-disease_may_have_finding,902781-FS1,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
503460909,7/16/2014 16:38:23,,1324329642,7/16/2014 16:37:49,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[SYMPTOM],[SYMPTOM],"symptoms, such as HEMATURIA or BLADDER CANCER.",N/A,109,135,117,149,1,RO-disease_may_have_finding,902781-FS1,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
503460909,7/16/2014 16:47:52,,1324333892,7/16/2014 16:47:18,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]","symptoms, such HEMATURIA or BLADDER CANCER.",N/A,109,135,117,149,1,RO-disease_may_have_finding,902781-FS1,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
503460909,7/16/2014 16:55:20,,1324336498,7/16/2014 16:54:50,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,NONE,109,135,117,149,1,RO-disease_may_have_finding,902781-FS1,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
503460909,7/16/2014 17:51:09,,1324368435,7/16/2014 17:50:34,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,They are both symptoms of the same condition but not connected to each other.,109,135,117,149,1,RO-disease_may_have_finding,902781-FS1,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
503460909,7/16/2014 18:10:44,,1324388708,7/16/2014 18:09:56,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],such as or,na,109,135,117,149,1,RO-disease_may_have_finding,902781-FS1,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
503460910,7/16/2014 13:36:18,,1324256287,7/16/2014 13:35:59,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],confirmed immunohistochemical staining,Na,158,60,169,78,-1,RO-has_manifestation,906345-FS1,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
503460910,7/16/2014 13:52:09,,1324261843,7/16/2014 13:51:43,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],confirmed by immunohistochemical staining for,N/a,158,60,169,78,-1,RO-has_manifestation,906345-FS1,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
503460910,7/16/2014 14:08:01,,1324268564,7/16/2014 14:07:24,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],confirmed by immunohistochemical staining,N/A,158,60,169,78,-1,RO-has_manifestation,906345-FS1,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
503460910,7/16/2014 15:47:03,,1324304970,7/16/2014 15:46:32,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],confirmed by,n/a,158,60,169,78,-1,RO-has_manifestation,906345-FS1,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
503460910,7/16/2014 16:07:48,,1324315983,7/16/2014 16:07:21,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],which was confirmed by,[DIAGNOSE_BY_TEST_OR_DRUG],158,60,169,78,-1,RO-has_manifestation,906345-FS1,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
503460910,7/16/2014 16:34:45,,1324327487,7/16/2014 16:34:07,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],revealed MALIGNANT MELANOMA MELANOMA PAN,N/A,158,60,169,78,-1,RO-has_manifestation,906345-FS1,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
503460910,7/16/2014 16:38:35,,1324329831,7/16/2014 16:37:56,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],immunohistochemical staining for,N/A,158,60,169,78,-1,RO-has_manifestation,906345-FS1,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
503460910,7/16/2014 17:11:01,,1324341800,7/16/2014 17:09:49,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],confirmed,NONE,158,60,169,78,-1,RO-has_manifestation,906345-FS1,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
503460910,7/16/2014 18:09:55,,1324387804,7/16/2014 18:08:52,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[MANIFESTATION],[MANIFESTATION],revealed confirmed by,na,158,60,169,78,-1,RO-has_manifestation,906345-FS1,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
503460910,7/16/2014 18:26:39,,1324400701,7/16/2014 18:26:07,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MALIGNANT MELANOMA was confirmed by immunohistochemical staining MELANOMA PAN,N/A,158,60,169,78,-1,RO-has_manifestation,906345-FS1,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
503460910,7/16/2014 19:07:01,,1324422796,7/16/2014 19:06:31,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],confirmed,N/A,158,60,169,78,-1,RO-has_manifestation,906345-FS1,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
503460910,7/16/2014 19:54:47,,1324446486,7/16/2014 19:53:59,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],was confirmed by,N/A,158,60,169,78,-1,RO-has_manifestation,906345-FS1,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
503460910,7/16/2014 20:33:06,,1324463472,7/16/2014 20:31:38,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[MANIFESTATION],[MANIFESTATION],was confirmed by immunohistochemical staining for,N/A,158,60,169,78,-1,RO-has_manifestation,906345-FS1,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
503460910,7/16/2014 20:44:48,,1324468063,7/16/2014 20:43:29,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"MALIGNANT MELANOMA which confirmed immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN",Diagnosed by test or drug,158,60,169,78,-1,RO-has_manifestation,906345-FS1,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
503460910,7/16/2014 20:58:18,,1324473597,7/16/2014 20:57:31,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MELANOMA,NONE,158,60,169,78,-1,RO-has_manifestation,906345-FS1,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
503460911,7/16/2014 13:26:51,,1324252163,7/16/2014 13:26:43,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],associated,N/A,102,131,118,148,-1,RO-cause_of,900482-FS1,"Approximately 70% of patients with allergic conjunctivitis have an associated atopic disease, such as ALLERGIC RHINITIS asthma, or ATOPIC DERMATITIS.",ALLERGIC RHINITIS,ATOPIC DERMATITIS
503460911,7/16/2014 13:30:48,,1324253874,7/16/2014 13:30:04,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"associated atopic disease, such as or",n/a,102,131,118,148,-1,RO-cause_of,900482-FS1,"Approximately 70% of patients with allergic conjunctivitis have an associated atopic disease, such as ALLERGIC RHINITIS asthma, or ATOPIC DERMATITIS.",ALLERGIC RHINITIS,ATOPIC DERMATITIS
503460911,7/16/2014 13:31:20,,1324254128,7/16/2014 13:31:07,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"associated atopic disease, such as",N/A,102,131,118,148,-1,RO-cause_of,900482-FS1,"Approximately 70% of patients with allergic conjunctivitis have an associated atopic disease, such as ALLERGIC RHINITIS asthma, or ATOPIC DERMATITIS.",ALLERGIC RHINITIS,ATOPIC DERMATITIS
503460911,7/16/2014 13:33:46,,1324255261,7/16/2014 13:32:50,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"have an associated atopic disease,",N/A,102,131,118,148,-1,RO-cause_of,900482-FS1,"Approximately 70% of patients with allergic conjunctivitis have an associated atopic disease, such as ALLERGIC RHINITIS asthma, or ATOPIC DERMATITIS.",ALLERGIC RHINITIS,ATOPIC DERMATITIS
503460911,7/16/2014 13:36:02,,1324256189,7/16/2014 13:35:43,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"associated atopic disease,",N/A,102,131,118,148,-1,RO-cause_of,900482-FS1,"Approximately 70% of patients with allergic conjunctivitis have an associated atopic disease, such as ALLERGIC RHINITIS asthma, or ATOPIC DERMATITIS.",ALLERGIC RHINITIS,ATOPIC DERMATITIS
503460911,7/16/2014 13:50:24,,1324261254,7/16/2014 13:50:04,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"associated atopic disease, such as ALLERGIC RHINITIS or ATOPIC DERMATITIS.",N/A,102,131,118,148,-1,RO-cause_of,900482-FS1,"Approximately 70% of patients with allergic conjunctivitis have an associated atopic disease, such as ALLERGIC RHINITIS asthma, or ATOPIC DERMATITIS.",ALLERGIC RHINITIS,ATOPIC DERMATITIS
503460911,7/16/2014 14:11:20,,1324270025,7/16/2014 14:11:05,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,102,131,118,148,-1,RO-cause_of,900482-FS1,"Approximately 70% of patients with allergic conjunctivitis have an associated atopic disease, such as ALLERGIC RHINITIS asthma, or ATOPIC DERMATITIS.",ALLERGIC RHINITIS,ATOPIC DERMATITIS
503460911,7/16/2014 16:09:33,,1324317247,7/16/2014 16:08:47,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ALLERGIC RHINITIS ATOPIC DERMATITIS.,n/a,102,131,118,148,-1,RO-cause_of,900482-FS1,"Approximately 70% of patients with allergic conjunctivitis have an associated atopic disease, such as ALLERGIC RHINITIS asthma, or ATOPIC DERMATITIS.",ALLERGIC RHINITIS,ATOPIC DERMATITIS
503460911,7/16/2014 16:14:50,,1324319895,7/16/2014 16:14:24,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"an associated atopic disease,",[ASSOCIATED_WITH],102,131,118,148,-1,RO-cause_of,900482-FS1,"Approximately 70% of patients with allergic conjunctivitis have an associated atopic disease, such as ALLERGIC RHINITIS asthma, or ATOPIC DERMATITIS.",ALLERGIC RHINITIS,ATOPIC DERMATITIS
503460911,7/16/2014 16:24:30,,1324323705,7/16/2014 16:24:17,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"associated atopic disease,",N/A,102,131,118,148,-1,RO-cause_of,900482-FS1,"Approximately 70% of patients with allergic conjunctivitis have an associated atopic disease, such as ALLERGIC RHINITIS asthma, or ATOPIC DERMATITIS.",ALLERGIC RHINITIS,ATOPIC DERMATITIS
503460911,7/16/2014 16:26:27,,1324324420,7/16/2014 16:26:05,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],such as,N/A,102,131,118,148,-1,RO-cause_of,900482-FS1,"Approximately 70% of patients with allergic conjunctivitis have an associated atopic disease, such as ALLERGIC RHINITIS asthma, or ATOPIC DERMATITIS.",ALLERGIC RHINITIS,ATOPIC DERMATITIS
503460911,7/16/2014 17:20:00,,1324344385,7/16/2014 17:19:09,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[OTHER],[OTHER],"associated atopic disease, such as ALLERGIC RHINITIS or ATOPIC DERMATITIS.",n/a,102,131,118,148,-1,RO-cause_of,900482-FS1,"Approximately 70% of patients with allergic conjunctivitis have an associated atopic disease, such as ALLERGIC RHINITIS asthma, or ATOPIC DERMATITIS.",ALLERGIC RHINITIS,ATOPIC DERMATITIS
503460911,7/16/2014 18:38:20,,1324406247,7/16/2014 18:37:43,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,102,131,118,148,-1,RO-cause_of,900482-FS1,"Approximately 70% of patients with allergic conjunctivitis have an associated atopic disease, such as ALLERGIC RHINITIS asthma, or ATOPIC DERMATITIS.",ALLERGIC RHINITIS,ATOPIC DERMATITIS
503460911,7/16/2014 19:16:25,,1324427978,7/16/2014 19:16:05,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"associated atopic disease, or",N/A,102,131,118,148,-1,RO-cause_of,900482-FS1,"Approximately 70% of patients with allergic conjunctivitis have an associated atopic disease, such as ALLERGIC RHINITIS asthma, or ATOPIC DERMATITIS.",ALLERGIC RHINITIS,ATOPIC DERMATITIS
503460911,7/16/2014 19:39:15,,1324438754,7/16/2014 19:38:40,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"associated atopic disease,",N/A,102,131,118,148,-1,RO-cause_of,900482-FS1,"Approximately 70% of patients with allergic conjunctivitis have an associated atopic disease, such as ALLERGIC RHINITIS asthma, or ATOPIC DERMATITIS.",ALLERGIC RHINITIS,ATOPIC DERMATITIS
503460912,7/16/2014 13:29:31,,1324253321,7/16/2014 13:29:10,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],finding of,N/A,183,157,200,161,1,RO-disease_may_have_finding,902662-FS1,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
503460912,7/16/2014 13:33:10,,1324254982,7/16/2014 13:32:51,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],subsequent finding of,n/a,183,157,200,161,1,RO-disease_may_have_finding,902662-FS1,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
503460912,7/16/2014 13:47:22,,1324260212,7/16/2014 13:46:33,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and subsequent finding of,N/A,183,157,200,161,1,RO-disease_may_have_finding,902662-FS1,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
503460912,7/16/2014 13:48:50,,1324260723,7/16/2014 13:48:26,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],finding of,N/a,183,157,200,161,1,RO-disease_may_have_finding,902662-FS1,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
503460912,7/16/2014 13:59:24,,1324264994,7/16/2014 13:59:14,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]","analysed, associations between carcinomas",N/A,183,157,200,161,1,RO-disease_may_have_finding,902662-FS1,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
503460912,7/16/2014 15:29:45,,1324298257,7/16/2014 15:28:50,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],similar associations,n/a,183,157,200,161,1,RO-disease_may_have_finding,902662-FS1,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
503460912,7/16/2014 15:45:02,,1324304176,7/16/2014 15:44:28,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and between,[ASSOCIATED_WITH],183,157,200,161,1,RO-disease_may_have_finding,902662-FS1,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
503460912,7/16/2014 16:45:46,,1324333146,7/16/2014 16:45:00,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[OTHER]",DCIS and MICROCALCIFICATION,N/A,183,157,200,161,1,RO-disease_may_have_finding,902662-FS1,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
503460912,7/16/2014 17:42:40,,1324359686,7/16/2014 17:41:53,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[OTHER],[OTHER],similar associations are seen,n/a,183,157,200,161,1,RO-disease_may_have_finding,902662-FS1,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
503460912,7/16/2014 18:20:25,,1324398206,7/16/2014 18:19:43,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two different unrelated terms,183,157,200,161,1,RO-disease_may_have_finding,902662-FS1,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
503460912,7/16/2014 18:31:54,,1324402963,7/16/2014 18:31:09,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associations are seen between finding of DCIS and MICROCALCIFICATION on previous films,N/A,183,157,200,161,1,RO-disease_may_have_finding,902662-FS1,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
503460912,7/16/2014 19:02:56,,1324420222,7/16/2014 19:02:41,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],finding,N/A,183,157,200,161,1,RO-disease_may_have_finding,902662-FS1,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
503460912,7/16/2014 19:10:03,,1324424522,7/16/2014 19:09:23,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],subsequent finding of DCIS and between MICROCALCIFICATION on previous films,N/A,183,157,200,161,1,RO-disease_may_have_finding,902662-FS1,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
503460912,7/16/2014 19:23:50,,1324431409,7/16/2014 19:23:09,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],similar associations,N/A,183,157,200,161,1,RO-disease_may_have_finding,902662-FS1,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
503460912,7/16/2014 19:42:56,,1324440639,7/16/2014 19:42:32,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and between,N/A,183,157,200,161,1,RO-disease_may_have_finding,902662-FS1,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
503460913,7/16/2014 13:33:01,,1324254871,7/16/2014 13:32:00,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],liability of,N/A,99,154,107,159,-1,RO-cause_of,900242-FS1,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
503460913,7/16/2014 13:35:42,,1324256052,7/16/2014 13:35:05,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],proved hereditary liability of,N/A,99,154,107,159,-1,RO-cause_of,900242-FS1,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
503460913,7/16/2014 13:37:39,,1324256755,7/16/2014 13:37:12,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[PREVENTS],[PREVENTS],hereditary,N/A,99,154,107,159,-1,RO-cause_of,900242-FS1,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
503460913,7/16/2014 13:40:30,,1324257841,7/16/2014 13:40:09,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],hereditary,asd,99,154,107,159,-1,RO-cause_of,900242-FS1,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
503460913,7/16/2014 13:42:26,,1324258611,7/16/2014 13:41:50,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,NOT RELATED IN ANY WAY.,99,154,107,159,-1,RO-cause_of,900242-FS1,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
503460913,7/16/2014 13:50:25,,1324261259,7/16/2014 13:49:54,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HAY FEVER with the most proved hereditary liability of ATOPY,N/a,99,154,107,159,-1,RO-cause_of,900242-FS1,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
503460913,7/16/2014 13:51:50,,1324261750,7/16/2014 13:50:44,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were observed,N/A,99,154,107,159,-1,RO-cause_of,900242-FS1,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
503460913,7/16/2014 15:12:06,,1324292692,7/16/2014 15:10:54,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[MANIFESTATION],[MANIFESTATION],liability of,N/A,99,154,107,159,-1,RO-cause_of,900242-FS1,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
503460913,7/16/2014 15:35:27,,1324300153,7/16/2014 15:34:05,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],most proved hereditary liability,n/a,99,154,107,159,-1,RO-cause_of,900242-FS1,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
503460913,7/16/2014 15:54:12,,1324307989,7/16/2014 15:51:55,prodege,1.0,27990290,GBR,I9,Bury Saint Edmunds,86.142.231.81,[ASSOCIATED_WITH],[ASSOCIATED_WITH],hereditary liability,malignancies were observed less in people with hayfever and ATOpy than in the control groups.,99,154,107,159,-1,RO-cause_of,900242-FS1,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
503460913,7/16/2014 16:25:56,,1324324236,7/16/2014 16:25:15,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],HAY FEVER ATOPY,n/a,99,154,107,159,-1,RO-cause_of,900242-FS1,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
503460913,7/16/2014 16:43:02,,1324332165,7/16/2014 16:41:59,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],HAY FEVER of ATOPY,N/A,99,154,107,159,-1,RO-cause_of,900242-FS1,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
503460913,7/16/2014 17:11:55,,1324342117,7/16/2014 17:11:02,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],with,NONE,99,154,107,159,-1,RO-cause_of,900242-FS1,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
503460913,7/16/2014 17:37:43,,1324355020,7/16/2014 17:37:16,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with the most proved hereditary liability of,n/a,99,154,107,159,-1,RO-cause_of,900242-FS1,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
503460913,7/16/2014 19:58:50,,1324448097,7/16/2014 19:58:35,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],most proved hereditary liability of,N/A,99,154,107,159,-1,RO-cause_of,900242-FS1,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
503460914,7/16/2014 13:33:22,,1324255065,7/16/2014 13:33:05,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,na,0,26,20,43,-1,RO-has_definitional_manifestation,904962-FS1,"TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect women, whereas cluster headache predominantly affects men.",TENSION TYPE HEADACHE,MIGRAINE HEADACHE
503460914,7/16/2014 13:37:52,,1324256811,7/16/2014 13:37:33,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],MIGRAINE HEADACHE,asd,0,26,20,43,-1,RO-has_definitional_manifestation,904962-FS1,"TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect women, whereas cluster headache predominantly affects men.",TENSION TYPE HEADACHE,MIGRAINE HEADACHE
503460914,7/16/2014 13:42:32,,1324258632,7/16/2014 13:41:58,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect,N/A,0,26,20,43,-1,RO-has_definitional_manifestation,904962-FS1,"TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect women, whereas cluster headache predominantly affects men.",TENSION TYPE HEADACHE,MIGRAINE HEADACHE
503460914,7/16/2014 13:46:53,,1324260077,7/16/2014 13:46:38,instagc,1.0,18960682,GBR,"","",86.29.147.112,[IS_A],[IS_A],TENSION TYPE HEADACHE and MIGRAINE HEADACHE,N/a,0,26,20,43,-1,RO-has_definitional_manifestation,904962-FS1,"TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect women, whereas cluster headache predominantly affects men.",TENSION TYPE HEADACHE,MIGRAINE HEADACHE
503460914,7/16/2014 13:48:02,,1324260438,7/16/2014 13:47:49,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],TENSION TYPE HEADACHE and MIGRAINE HEADACHE,n/a,0,26,20,43,-1,RO-has_definitional_manifestation,904962-FS1,"TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect women, whereas cluster headache predominantly affects men.",TENSION TYPE HEADACHE,MIGRAINE HEADACHE
503460914,7/16/2014 14:14:01,,1324271178,7/16/2014 14:13:51,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,0,26,20,43,-1,RO-has_definitional_manifestation,904962-FS1,"TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect women, whereas cluster headache predominantly affects men.",TENSION TYPE HEADACHE,MIGRAINE HEADACHE
503460914,7/16/2014 16:11:36,,1324318423,7/16/2014 16:11:04,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]","predominantly affect women,",[CAUSES] [MANIFESTATION],0,26,20,43,-1,RO-has_definitional_manifestation,904962-FS1,"TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect women, whereas cluster headache predominantly affects men.",TENSION TYPE HEADACHE,MIGRAINE HEADACHE
503460914,7/16/2014 16:23:04,,1324323147,7/16/2014 16:22:52,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,0,26,20,43,-1,RO-has_definitional_manifestation,904962-FS1,"TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect women, whereas cluster headache predominantly affects men.",TENSION TYPE HEADACHE,MIGRAINE HEADACHE
503460914,7/16/2014 16:35:59,,1324328148,7/16/2014 16:34:57,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TENSION TYPE HEADACHE MIGRAINE HEADACHE,n/a,0,26,20,43,-1,RO-has_definitional_manifestation,904962-FS1,"TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect women, whereas cluster headache predominantly affects men.",TENSION TYPE HEADACHE,MIGRAINE HEADACHE
503460914,7/16/2014 19:15:06,,1324427257,7/16/2014 19:14:31,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,0,26,20,43,-1,RO-has_definitional_manifestation,904962-FS1,"TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect women, whereas cluster headache predominantly affects men.",TENSION TYPE HEADACHE,MIGRAINE HEADACHE
503460914,7/16/2014 19:31:14,,1324435052,7/16/2014 19:29:42,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",predominantly affects,N/A,0,26,20,43,-1,RO-has_definitional_manifestation,904962-FS1,"TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect women, whereas cluster headache predominantly affects men.",TENSION TYPE HEADACHE,MIGRAINE HEADACHE
503460914,7/16/2014 19:40:38,,1324439528,7/16/2014 19:40:18,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,0,26,20,43,-1,RO-has_definitional_manifestation,904962-FS1,"TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect women, whereas cluster headache predominantly affects men.",TENSION TYPE HEADACHE,MIGRAINE HEADACHE
503460914,7/16/2014 19:45:00,,1324441735,7/16/2014 19:42:15,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]","TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect women,",N/A,0,26,20,43,-1,RO-has_definitional_manifestation,904962-FS1,"TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect women, whereas cluster headache predominantly affects men.",TENSION TYPE HEADACHE,MIGRAINE HEADACHE
503460914,7/16/2014 20:23:22,,1324459200,7/16/2014 20:22:48,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"predominantly affect women,",N/A,0,26,20,43,-1,RO-has_definitional_manifestation,904962-FS1,"TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect women, whereas cluster headache predominantly affects men.",TENSION TYPE HEADACHE,MIGRAINE HEADACHE
503460914,7/16/2014 21:00:33,,1324474824,7/16/2014 21:00:14,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[NONE],[NONE],N/A,N/A,0,26,20,43,-1,RO-has_definitional_manifestation,904962-FS1,"TENSION TYPE HEADACHE and MIGRAINE HEADACHE predominantly affect women, whereas cluster headache predominantly affects men.",TENSION TYPE HEADACHE,MIGRAINE HEADACHE
503460915,7/16/2014 13:32:00,,1324254474,7/16/2014 13:31:31,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[LOCATION],[LOCATION],leading to MALABSORPTION of the xylose in the,n/a,92,57,106,70,1,RO-has_finding_site,905415-FS1,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
503460915,7/16/2014 13:38:01,,1324256870,7/16/2014 13:37:40,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],xylose,N/A,92,57,106,70,1,RO-has_finding_site,905415-FS1,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
503460915,7/16/2014 13:38:10,,1324256934,7/16/2014 13:37:45,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],in the,N/A,92,57,106,70,1,RO-has_finding_site,905415-FS1,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
503460915,7/16/2014 13:48:28,,1324260600,7/16/2014 13:47:33,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION],[MANIFESTATION],accelerated,N/A,92,57,106,70,1,RO-has_finding_site,905415-FS1,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
503460915,7/16/2014 13:57:58,,1324264324,7/16/2014 13:57:49,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]","transit, xylose INTESTINE",N/A,92,57,106,70,1,RO-has_finding_site,905415-FS1,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
503460915,7/16/2014 15:19:25,,1324294918,7/16/2014 15:19:14,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[LOCATION],[LOCATION],in the,N/A,92,57,106,70,1,RO-has_finding_site,905415-FS1,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
503460915,7/16/2014 15:27:40,,1324297487,7/16/2014 15:27:24,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],in the,n/a,92,57,106,70,1,RO-has_finding_site,905415-FS1,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
503460915,7/16/2014 15:40:57,,1324302406,7/16/2014 15:40:41,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[LOCATION],[LOCATION],in the,N/A,92,57,106,70,1,RO-has_finding_site,905415-FS1,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
503460915,7/16/2014 15:47:29,,1324305135,7/16/2014 15:46:49,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",of the xylose in the,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG],92,57,106,70,1,RO-has_finding_site,905415-FS1,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
503460915,7/16/2014 16:23:19,,1324323269,7/16/2014 16:22:07,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],leading,N/A,92,57,106,70,1,RO-has_finding_site,905415-FS1,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
503460915,7/16/2014 18:23:38,,1324399432,7/16/2014 18:22:58,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,92,57,106,70,1,RO-has_finding_site,905415-FS1,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
503460915,7/16/2014 19:16:47,,1324428167,7/16/2014 19:16:27,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[LOCATION],[LOCATION],in the,N/A,92,57,106,70,1,RO-has_finding_site,905415-FS1,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
503460915,7/16/2014 19:33:41,,1324436227,7/16/2014 19:32:53,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],"accelerated small bowel transit,",N/A,92,57,106,70,1,RO-has_finding_site,905415-FS1,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
503460915,7/16/2014 19:41:26,,1324439893,7/16/2014 19:41:14,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],INTESTINE,N/A,92,57,106,70,1,RO-has_finding_site,905415-FS1,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
503460915,7/16/2014 20:41:18,,1324466796,7/16/2014 20:39:36,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[LOCATION],[LOCATION],in the,N/A,92,57,106,70,1,RO-has_finding_site,905415-FS1,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
503460916,7/16/2014 13:31:58,,1324254457,7/16/2014 13:31:16,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],STAPHYLOCOCCAL,N/A,115,202,127,227,1,RO-has_causative_agent,903638-FS1,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
503460916,7/16/2014 13:35:58,,1324256159,7/16/2014 13:35:44,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],prevalent,Na,115,202,127,227,1,RO-has_causative_agent,903638-FS1,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
503460916,7/16/2014 13:36:45,,1324256454,7/16/2014 13:36:03,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],STAPHYLOCOCCI STAPHYLOCOCCAL INFECTIONS,N/A,115,202,127,227,1,RO-has_causative_agent,903638-FS1,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
503460916,7/16/2014 13:56:22,,1324263583,7/16/2014 13:55:59,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],are prevalent in,N/A,115,202,127,227,1,RO-has_causative_agent,903638-FS1,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
503460916,7/16/2014 13:57:12,,1324263937,7/16/2014 13:56:59,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",resistant INFECTIONS include,N/A,115,202,127,227,1,RO-has_causative_agent,903638-FS1,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
503460916,7/16/2014 14:06:21,,1324267874,7/16/2014 14:05:44,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],STAPHYLOCOCCI STAPHYLOCOCCAL,N/A,115,202,127,227,1,RO-has_causative_agent,903638-FS1,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
503460916,7/16/2014 14:41:56,,1324282166,7/16/2014 14:41:26,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[CAUSES],[CAUSES],are prevalent suspected,N/A,115,202,127,227,1,RO-has_causative_agent,903638-FS1,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
503460916,7/16/2014 15:10:53,,1324292262,7/16/2014 15:09:34,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[CAUSES],[CAUSES],in,N/A,115,202,127,227,1,RO-has_causative_agent,903638-FS1,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
503460916,7/16/2014 16:14:22,,1324319642,7/16/2014 16:13:49,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],therapy of suspected,[DIAGNOSE_BY_TEST_OR_DRUG],115,202,127,227,1,RO-has_causative_agent,903638-FS1,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
503460916,7/16/2014 16:17:02,,1324320889,7/16/2014 16:16:07,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],STAPHYLOCOCCI STAPHYLOCOCCAL INFECTIONS,n/a,115,202,127,227,1,RO-has_causative_agent,903638-FS1,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
503460916,7/16/2014 16:23:53,,1324323492,7/16/2014 16:23:31,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[CAUSES],[CAUSES],are prevalent,N/A,115,202,127,227,1,RO-has_causative_agent,903638-FS1,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
503460916,7/16/2014 16:40:05,,1324330710,7/16/2014 16:39:09,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],therapy,none,115,202,127,227,1,RO-has_causative_agent,903638-FS1,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
503460916,7/16/2014 16:47:17,,1324333702,7/16/2014 16:46:48,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[ASSOCIATED_WITH],[ASSOCIATED_WITH],STAPHYLOCOCCI are prevalent in STAPHYLOCOCCAL INFECTIONS,N/A,115,202,127,227,1,RO-has_causative_agent,903638-FS1,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
503460916,7/16/2014 16:57:58,,1324337391,7/16/2014 16:57:32,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],STAPHYLOCOCCI STAPHYLOCOCCAL INFECTIONS,n/a,115,202,127,227,1,RO-has_causative_agent,903638-FS1,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
503460916,7/16/2014 17:03:31,,1324339223,7/16/2014 17:03:26,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,115,202,127,227,1,RO-has_causative_agent,903638-FS1,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
503460917,7/16/2014 13:47:09,,1324260149,7/16/2014 13:46:20,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANTIARRHYTHMIC EFFECT CARDIAC ARRHYTHMIAS,N/A,117,28,135,49,1,RO-may_prevent,907040-FS1,That naloxone both produced ANTIARRHYTHMIC EFFECT and prolonged the survival time whereas propranolol only corrected CARDIAC ARRHYTHMIAS suggests that the antiarrhythmic effect of naloxone may not result in prolongation of survival time and that different mechanisms may be involved in the antiarrhythmic effect.,CARDIAC ARRHYTHMIAS,ANTIARRHYTHMIC EFFECT
503460917,7/16/2014 13:47:57,,1324260425,7/16/2014 13:47:25,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ARRHYTHMIAS,N/A,117,28,135,49,1,RO-may_prevent,907040-FS1,That naloxone both produced ANTIARRHYTHMIC EFFECT and prolonged the survival time whereas propranolol only corrected CARDIAC ARRHYTHMIAS suggests that the antiarrhythmic effect of naloxone may not result in prolongation of survival time and that different mechanisms may be involved in the antiarrhythmic effect.,CARDIAC ARRHYTHMIAS,ANTIARRHYTHMIC EFFECT
503460917,7/16/2014 13:55:26,,1324263168,7/16/2014 13:54:30,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],prolonged,N/A,117,28,135,49,1,RO-may_prevent,907040-FS1,That naloxone both produced ANTIARRHYTHMIC EFFECT and prolonged the survival time whereas propranolol only corrected CARDIAC ARRHYTHMIAS suggests that the antiarrhythmic effect of naloxone may not result in prolongation of survival time and that different mechanisms may be involved in the antiarrhythmic effect.,CARDIAC ARRHYTHMIAS,ANTIARRHYTHMIC EFFECT
503460917,7/16/2014 13:59:33,,1324265045,7/16/2014 13:58:55,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[NONE],[NONE],N/A,"One is a positive effect of a treatment, the other a negative effect",117,28,135,49,1,RO-may_prevent,907040-FS1,That naloxone both produced ANTIARRHYTHMIC EFFECT and prolonged the survival time whereas propranolol only corrected CARDIAC ARRHYTHMIAS suggests that the antiarrhythmic effect of naloxone may not result in prolongation of survival time and that different mechanisms may be involved in the antiarrhythmic effect.,CARDIAC ARRHYTHMIAS,ANTIARRHYTHMIC EFFECT
503460917,7/16/2014 14:12:57,,1324270749,7/16/2014 14:12:38,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],corrected,N/A,117,28,135,49,1,RO-may_prevent,907040-FS1,That naloxone both produced ANTIARRHYTHMIC EFFECT and prolonged the survival time whereas propranolol only corrected CARDIAC ARRHYTHMIAS suggests that the antiarrhythmic effect of naloxone may not result in prolongation of survival time and that different mechanisms may be involved in the antiarrhythmic effect.,CARDIAC ARRHYTHMIAS,ANTIARRHYTHMIC EFFECT
503460917,7/16/2014 14:38:43,,1324281167,7/16/2014 14:37:01,prodege,1.0,15508331,USA,OK,Stillwater,139.78.139.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],both ANTIARRHYTHMIC EFFECT,N/A,117,28,135,49,1,RO-may_prevent,907040-FS1,That naloxone both produced ANTIARRHYTHMIC EFFECT and prolonged the survival time whereas propranolol only corrected CARDIAC ARRHYTHMIAS suggests that the antiarrhythmic effect of naloxone may not result in prolongation of survival time and that different mechanisms may be involved in the antiarrhythmic effect.,CARDIAC ARRHYTHMIAS,ANTIARRHYTHMIC EFFECT
503460917,7/16/2014 14:51:14,,1324284850,7/16/2014 14:50:40,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prolonged the survival time,N/A,117,28,135,49,1,RO-may_prevent,907040-FS1,That naloxone both produced ANTIARRHYTHMIC EFFECT and prolonged the survival time whereas propranolol only corrected CARDIAC ARRHYTHMIAS suggests that the antiarrhythmic effect of naloxone may not result in prolongation of survival time and that different mechanisms may be involved in the antiarrhythmic effect.,CARDIAC ARRHYTHMIAS,ANTIARRHYTHMIC EFFECT
503460917,7/16/2014 14:56:38,,1324286707,7/16/2014 14:54:51,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A],[IS_A],produced whereas propranolol only corrected,N/A,117,28,135,49,1,RO-may_prevent,907040-FS1,That naloxone both produced ANTIARRHYTHMIC EFFECT and prolonged the survival time whereas propranolol only corrected CARDIAC ARRHYTHMIAS suggests that the antiarrhythmic effect of naloxone may not result in prolongation of survival time and that different mechanisms may be involved in the antiarrhythmic effect.,CARDIAC ARRHYTHMIAS,ANTIARRHYTHMIC EFFECT
503460917,7/16/2014 15:02:28,,1324288965,7/16/2014 15:01:02,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],both produced,na,117,28,135,49,1,RO-may_prevent,907040-FS1,That naloxone both produced ANTIARRHYTHMIC EFFECT and prolonged the survival time whereas propranolol only corrected CARDIAC ARRHYTHMIAS suggests that the antiarrhythmic effect of naloxone may not result in prolongation of survival time and that different mechanisms may be involved in the antiarrhythmic effect.,CARDIAC ARRHYTHMIAS,ANTIARRHYTHMIC EFFECT
503460917,7/16/2014 16:12:46,,1324318884,7/16/2014 16:12:12,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",prolonged survival time only corrected,[PREVENTS] [TREATS],117,28,135,49,1,RO-may_prevent,907040-FS1,That naloxone both produced ANTIARRHYTHMIC EFFECT and prolonged the survival time whereas propranolol only corrected CARDIAC ARRHYTHMIAS suggests that the antiarrhythmic effect of naloxone may not result in prolongation of survival time and that different mechanisms may be involved in the antiarrhythmic effect.,CARDIAC ARRHYTHMIAS,ANTIARRHYTHMIC EFFECT
503460917,7/16/2014 16:21:50,,1324322698,7/16/2014 16:21:20,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[ASSOCIATED_WITH],[ASSOCIATED_WITH],whereas,N/A,117,28,135,49,1,RO-may_prevent,907040-FS1,That naloxone both produced ANTIARRHYTHMIC EFFECT and prolonged the survival time whereas propranolol only corrected CARDIAC ARRHYTHMIAS suggests that the antiarrhythmic effect of naloxone may not result in prolongation of survival time and that different mechanisms may be involved in the antiarrhythmic effect.,CARDIAC ARRHYTHMIAS,ANTIARRHYTHMIC EFFECT
503460917,7/16/2014 16:34:05,,1324327202,7/16/2014 16:33:11,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",both ANTIARRHYTHMIC EFFECT CARDIAC ARRHYTHMIAS,N/A,117,28,135,49,1,RO-may_prevent,907040-FS1,That naloxone both produced ANTIARRHYTHMIC EFFECT and prolonged the survival time whereas propranolol only corrected CARDIAC ARRHYTHMIAS suggests that the antiarrhythmic effect of naloxone may not result in prolongation of survival time and that different mechanisms may be involved in the antiarrhythmic effect.,CARDIAC ARRHYTHMIAS,ANTIARRHYTHMIC EFFECT
503460917,7/16/2014 16:39:39,,1324330464,7/16/2014 16:38:46,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",ANTIARRHYTHMIC EFFECT prolonged CARDIAC ARRHYTHMIAS,N/A,117,28,135,49,1,RO-may_prevent,907040-FS1,That naloxone both produced ANTIARRHYTHMIC EFFECT and prolonged the survival time whereas propranolol only corrected CARDIAC ARRHYTHMIAS suggests that the antiarrhythmic effect of naloxone may not result in prolongation of survival time and that different mechanisms may be involved in the antiarrhythmic effect.,CARDIAC ARRHYTHMIAS,ANTIARRHYTHMIC EFFECT
503460917,7/16/2014 16:43:34,,1324332306,7/16/2014 16:42:49,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANTIARRHYTHMIC EFFECT CARDIAC ARRHYTHMIAS,n/a,117,28,135,49,1,RO-may_prevent,907040-FS1,That naloxone both produced ANTIARRHYTHMIC EFFECT and prolonged the survival time whereas propranolol only corrected CARDIAC ARRHYTHMIAS suggests that the antiarrhythmic effect of naloxone may not result in prolongation of survival time and that different mechanisms may be involved in the antiarrhythmic effect.,CARDIAC ARRHYTHMIAS,ANTIARRHYTHMIC EFFECT
503460917,7/16/2014 17:38:19,,1324355549,7/16/2014 17:37:44,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,They were both part of the same experiment but not necessarily related to each other.,117,28,135,49,1,RO-may_prevent,907040-FS1,That naloxone both produced ANTIARRHYTHMIC EFFECT and prolonged the survival time whereas propranolol only corrected CARDIAC ARRHYTHMIAS suggests that the antiarrhythmic effect of naloxone may not result in prolongation of survival time and that different mechanisms may be involved in the antiarrhythmic effect.,CARDIAC ARRHYTHMIAS,ANTIARRHYTHMIC EFFECT
503460918,7/16/2014 13:31:10,,1324254049,7/16/2014 13:31:01,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],strong,N/A,39,66,52,78,1,RO-may_diagnose,906592-FS1,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
503460918,7/16/2014 14:03:19,,1324266527,7/16/2014 14:02:22,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[MANIFESTATION],[MANIFESTATION],with strong,N/A,39,66,52,78,1,RO-may_diagnose,906592-FS1,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
503460918,7/16/2014 14:54:58,,1324286002,7/16/2014 14:53:46,prodege,1.0,15508331,USA,OK,Stillwater,139.78.139.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HISTOPLASMOSIS with HISTOPLASMIN tests.,N/A,39,66,52,78,1,RO-may_diagnose,906592-FS1,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
503460918,7/16/2014 16:17:29,,1324321051,7/16/2014 16:16:59,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,39,66,52,78,1,RO-may_diagnose,906592-FS1,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
503460918,7/16/2014 16:40:06,,1324330715,7/16/2014 16:39:31,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],strong HISTOPLASMIN skin tests.,N/A,39,66,52,78,1,RO-may_diagnose,906592-FS1,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
503460918,7/16/2014 16:53:38,,1324335916,7/16/2014 16:53:00,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,N/A,39,66,52,78,1,RO-may_diagnose,906592-FS1,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
503460918,7/16/2014 17:56:55,,1324374758,7/16/2014 17:55:59,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tests.,na,39,66,52,78,1,RO-may_diagnose,906592-FS1,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
503460918,7/16/2014 18:32:49,,1324403385,7/16/2014 18:32:29,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,N/A,39,66,52,78,1,RO-may_diagnose,906592-FS1,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
503460918,7/16/2014 19:06:05,,1324422270,7/16/2014 19:05:53,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[MANIFESTATION],[MANIFESTATION],with,N/A,39,66,52,78,1,RO-may_diagnose,906592-FS1,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
503460918,7/16/2014 19:41:42,,1324440020,7/16/2014 19:41:28,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tests.,N/A,39,66,52,78,1,RO-may_diagnose,906592-FS1,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
503460918,7/16/2014 19:48:35,,1324443525,7/16/2014 19:48:20,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[OTHER]",skin tests.,N/A,39,66,52,78,1,RO-may_diagnose,906592-FS1,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
503460918,7/16/2014 20:22:11,,1324458641,7/16/2014 20:21:20,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tests.,n/a,39,66,52,78,1,RO-may_diagnose,906592-FS1,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
503460918,7/16/2014 20:28:13,,1324461411,7/16/2014 20:27:38,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],skin tests.,N/A,39,66,52,78,1,RO-may_diagnose,906592-FS1,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
503460918,7/16/2014 20:51:44,,1324471075,7/16/2014 20:51:02,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],cases of HISTOPLASMOSIS with strong HISTOPLASMIN,n/a,39,66,52,78,1,RO-may_diagnose,906592-FS1,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
503460918,7/16/2014 20:54:18,,1324472120,7/16/2014 20:53:20,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,N/A,39,66,52,78,1,RO-may_diagnose,906592-FS1,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
503460919,7/16/2014 13:30:30,,1324253738,7/16/2014 13:30:21,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],"(thymus,",N/A,91,139,114,172,-1,RO-disease_may_have_finding,903000-FS1,"of TAT gene is methylated in those cells where TAT gene does not function (thymus, spleen, ZAJDELA ASCITES HEPATOMA and is demethylated in TAT GENE EXPRESSING HEPATOMA 7777 and normal rat hepatocytes.",ZAJDELA ASCITES HEPATOMA,TAT GENE EXPRESSING HEPATOMA 7777
503460919,7/16/2014 13:37:47,,1324256784,7/16/2014 13:37:27,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[IS_A],[IS_A],and is demethylated in,n/a,91,139,114,172,-1,RO-disease_may_have_finding,903000-FS1,"of TAT gene is methylated in those cells where TAT gene does not function (thymus, spleen, ZAJDELA ASCITES HEPATOMA and is demethylated in TAT GENE EXPRESSING HEPATOMA 7777 and normal rat hepatocytes.",ZAJDELA ASCITES HEPATOMA,TAT GENE EXPRESSING HEPATOMA 7777
503460919,7/16/2014 13:40:19,,1324257788,7/16/2014 13:39:54,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],gene,N/A,91,139,114,172,-1,RO-disease_may_have_finding,903000-FS1,"of TAT gene is methylated in those cells where TAT gene does not function (thymus, spleen, ZAJDELA ASCITES HEPATOMA and is demethylated in TAT GENE EXPRESSING HEPATOMA 7777 and normal rat hepatocytes.",ZAJDELA ASCITES HEPATOMA,TAT GENE EXPRESSING HEPATOMA 7777
503460919,7/16/2014 13:53:10,,1324262255,7/16/2014 13:52:46,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],ZAJDELA ASCITES HEPATOMA and is demethylated in TAT GENE EXPRESSING HEPATOMA,N/a,91,139,114,172,-1,RO-disease_may_have_finding,903000-FS1,"of TAT gene is methylated in those cells where TAT gene does not function (thymus, spleen, ZAJDELA ASCITES HEPATOMA and is demethylated in TAT GENE EXPRESSING HEPATOMA 7777 and normal rat hepatocytes.",ZAJDELA ASCITES HEPATOMA,TAT GENE EXPRESSING HEPATOMA 7777
503460919,7/16/2014 13:55:51,,1324263332,7/16/2014 13:55:22,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],ZAJDELA ASCITES HEPATOMA TAT GENE EXPRESSING HEPATOMA,The relationship is not clear,91,139,114,172,-1,RO-disease_may_have_finding,903000-FS1,"of TAT gene is methylated in those cells where TAT gene does not function (thymus, spleen, ZAJDELA ASCITES HEPATOMA and is demethylated in TAT GENE EXPRESSING HEPATOMA 7777 and normal rat hepatocytes.",ZAJDELA ASCITES HEPATOMA,TAT GENE EXPRESSING HEPATOMA 7777
503460919,7/16/2014 13:59:04,,1324264800,7/16/2014 13:58:50,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[PREVENTS] [LOCATION] [MANIFESTATION],"[PREVENTS]
[LOCATION]
[MANIFESTATION]",methylated function ASCITES hepatocytes.,N/A,91,139,114,172,-1,RO-disease_may_have_finding,903000-FS1,"of TAT gene is methylated in those cells where TAT gene does not function (thymus, spleen, ZAJDELA ASCITES HEPATOMA and is demethylated in TAT GENE EXPRESSING HEPATOMA 7777 and normal rat hepatocytes.",ZAJDELA ASCITES HEPATOMA,TAT GENE EXPRESSING HEPATOMA 7777
503460919,7/16/2014 14:45:11,,1324283026,7/16/2014 14:44:27,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION],[LOCATION],in those cells where TAT gene does not function,N/A,91,139,114,172,-1,RO-disease_may_have_finding,903000-FS1,"of TAT gene is methylated in those cells where TAT gene does not function (thymus, spleen, ZAJDELA ASCITES HEPATOMA and is demethylated in TAT GENE EXPRESSING HEPATOMA 7777 and normal rat hepatocytes.",ZAJDELA ASCITES HEPATOMA,TAT GENE EXPRESSING HEPATOMA 7777
503460919,7/16/2014 15:26:32,,1324297223,7/16/2014 15:25:56,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],HEPATOMA,n/a,91,139,114,172,-1,RO-disease_may_have_finding,903000-FS1,"of TAT gene is methylated in those cells where TAT gene does not function (thymus, spleen, ZAJDELA ASCITES HEPATOMA and is demethylated in TAT GENE EXPRESSING HEPATOMA 7777 and normal rat hepatocytes.",ZAJDELA ASCITES HEPATOMA,TAT GENE EXPRESSING HEPATOMA 7777
503460919,7/16/2014 15:44:38,,1324303958,7/16/2014 15:43:48,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[CAUSES],[CAUSES],is,n\a,91,139,114,172,-1,RO-disease_may_have_finding,903000-FS1,"of TAT gene is methylated in those cells where TAT gene does not function (thymus, spleen, ZAJDELA ASCITES HEPATOMA and is demethylated in TAT GENE EXPRESSING HEPATOMA 7777 and normal rat hepatocytes.",ZAJDELA ASCITES HEPATOMA,TAT GENE EXPRESSING HEPATOMA 7777
503460919,7/16/2014 16:31:41,,1324326346,7/16/2014 16:30:19,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[ASSOCIATED_WITH],[ASSOCIATED_WITH],cells where TAT gene does not function ZAJDELA ASCITES HEPATOMA,N/A,91,139,114,172,-1,RO-disease_may_have_finding,903000-FS1,"of TAT gene is methylated in those cells where TAT gene does not function (thymus, spleen, ZAJDELA ASCITES HEPATOMA and is demethylated in TAT GENE EXPRESSING HEPATOMA 7777 and normal rat hepatocytes.",ZAJDELA ASCITES HEPATOMA,TAT GENE EXPRESSING HEPATOMA 7777
503460919,7/16/2014 16:36:00,,1324328156,7/16/2014 16:34:46,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],ZAJDELA ASCITES HEPATOMA is TAT GENE EXPRESSING HEPATOMA 7777,N/A,91,139,114,172,-1,RO-disease_may_have_finding,903000-FS1,"of TAT gene is methylated in those cells where TAT gene does not function (thymus, spleen, ZAJDELA ASCITES HEPATOMA and is demethylated in TAT GENE EXPRESSING HEPATOMA 7777 and normal rat hepatocytes.",ZAJDELA ASCITES HEPATOMA,TAT GENE EXPRESSING HEPATOMA 7777
503460919,7/16/2014 16:41:29,,1324331524,7/16/2014 16:40:08,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],HEPATOMA,N/A,91,139,114,172,-1,RO-disease_may_have_finding,903000-FS1,"of TAT gene is methylated in those cells where TAT gene does not function (thymus, spleen, ZAJDELA ASCITES HEPATOMA and is demethylated in TAT GENE EXPRESSING HEPATOMA 7777 and normal rat hepatocytes.",ZAJDELA ASCITES HEPATOMA,TAT GENE EXPRESSING HEPATOMA 7777
503460919,7/16/2014 17:34:24,,1324352485,7/16/2014 17:33:27,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,They are both in a list but don't seem to be related otherwise.,91,139,114,172,-1,RO-disease_may_have_finding,903000-FS1,"of TAT gene is methylated in those cells where TAT gene does not function (thymus, spleen, ZAJDELA ASCITES HEPATOMA and is demethylated in TAT GENE EXPRESSING HEPATOMA 7777 and normal rat hepatocytes.",ZAJDELA ASCITES HEPATOMA,TAT GENE EXPRESSING HEPATOMA 7777
503460919,7/16/2014 18:46:55,,1324410655,7/16/2014 18:45:54,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[PART_OF],[PART_OF],TAT gene does not function ZAJDELA ASCITES HEPATOMA,n/a,91,139,114,172,-1,RO-disease_may_have_finding,903000-FS1,"of TAT gene is methylated in those cells where TAT gene does not function (thymus, spleen, ZAJDELA ASCITES HEPATOMA and is demethylated in TAT GENE EXPRESSING HEPATOMA 7777 and normal rat hepatocytes.",ZAJDELA ASCITES HEPATOMA,TAT GENE EXPRESSING HEPATOMA 7777
503460919,7/16/2014 19:00:42,,1324418924,7/16/2014 19:00:27,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,91,139,114,172,-1,RO-disease_may_have_finding,903000-FS1,"of TAT gene is methylated in those cells where TAT gene does not function (thymus, spleen, ZAJDELA ASCITES HEPATOMA and is demethylated in TAT GENE EXPRESSING HEPATOMA 7777 and normal rat hepatocytes.",ZAJDELA ASCITES HEPATOMA,TAT GENE EXPRESSING HEPATOMA 7777
503460920,7/16/2014 13:32:32,,1324254688,7/16/2014 13:32:15,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],NOCTURNAL CRAMPS,asd,48,0,63,15,1,RO-may_prevent,907323-FS1,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
503460920,7/16/2014 13:36:46,,1324256455,7/16/2014 13:34:15,clixsense,1,6564572,USA,MI,Kalamazoo,173.46.248.170,[TREATS],[TREATS],QUININE SULFATE,na,48,0,63,15,1,RO-may_prevent,907323-FS1,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
503460920,7/16/2014 13:48:25,,1324260559,7/16/2014 13:48:12,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],is a widely prescribed drug for,N/a,48,0,63,15,1,RO-may_prevent,907323-FS1,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
503460920,7/16/2014 14:08:22,,1324268724,7/16/2014 14:08:03,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],prescribed drug,N/A,48,0,63,15,1,RO-may_prevent,907323-FS1,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
503460920,7/16/2014 15:19:13,,1324294843,7/16/2014 15:19:04,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],prescribed drug,N/A,48,0,63,15,1,RO-may_prevent,907323-FS1,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
503460920,7/16/2014 15:43:58,,1324303673,7/16/2014 15:43:44,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],widely prescribed drug for,n/a,48,0,63,15,1,RO-may_prevent,907323-FS1,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
503460920,7/16/2014 15:47:34,,1324305150,7/16/2014 15:47:04,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],prescribed,n/a,48,0,63,15,1,RO-may_prevent,907323-FS1,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
503460920,7/16/2014 16:08:42,,1324316749,7/16/2014 16:07:56,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],QUININE SULFATE NOCTURNAL CRAMPS,n/a,48,0,63,15,1,RO-may_prevent,907323-FS1,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
503460920,7/16/2014 16:45:26,,1324333013,7/16/2014 16:44:55,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[TREATS],[TREATS],QUININE SULFATE prescribed drug for NOCTURNAL CRAMPS,N/A,48,0,63,15,1,RO-may_prevent,907323-FS1,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
503460920,7/16/2014 19:05:29,,1324421849,7/16/2014 19:04:55,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[TREATS],[TREATS],is a widely prescribed drug,N/A,48,0,63,15,1,RO-may_prevent,907323-FS1,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
503460920,7/16/2014 19:40:17,,1324439281,7/16/2014 19:39:53,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],drug,N/A,48,0,63,15,1,RO-may_prevent,907323-FS1,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
503460920,7/16/2014 20:02:55,,1324449604,7/16/2014 20:02:40,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],drug for,n/a,48,0,63,15,1,RO-may_prevent,907323-FS1,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
503460920,7/16/2014 20:26:04,,1324460354,7/16/2014 20:24:54,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],widely prescribed drug for,N/A,48,0,63,15,1,RO-may_prevent,907323-FS1,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
503460920,7/16/2014 21:02:42,,1324476116,7/16/2014 21:00:25,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[TREATS],[TREATS],prescribed,n/a,48,0,63,15,1,RO-may_prevent,907323-FS1,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
503460920,7/16/2014 21:11:08,,1324481070,7/16/2014 21:10:32,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],QUININE SULFATE widely prescribed drug NOCTURNAL CRAMPS,n/a,48,0,63,15,1,RO-may_prevent,907323-FS1,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
503460921,7/16/2014 13:31:04,,1324254021,7/16/2014 13:30:50,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],treatment with,n/a,95,136,119,146,1,RO-may_treat,908138-FS1,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
503460921,7/16/2014 13:35:53,,1324256127,7/16/2014 13:35:27,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],association between,na,95,136,119,146,1,RO-may_treat,908138-FS1,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
503460921,7/16/2014 13:43:10,,1324258803,7/16/2014 13:42:59,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],treatment,Na,95,136,119,146,1,RO-may_treat,908138-FS1,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
503460921,7/16/2014 13:49:04,,1324260792,7/16/2014 13:48:51,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,N/a,95,136,119,146,1,RO-may_treat,908138-FS1,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
503460921,7/16/2014 14:12:10,,1324270398,7/16/2014 14:12:00,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],treatment,N/A,95,136,119,146,1,RO-may_treat,908138-FS1,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
503460921,7/16/2014 14:46:30,,1324283387,7/16/2014 14:45:53,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[TREATS],[TREATS],SEVERE HYPOGLYCAEMIA (SH) GLUCOSE IV.,n/a,95,136,119,146,1,RO-may_treat,908138-FS1,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
503460921,7/16/2014 15:11:03,,1324292338,7/16/2014 15:10:43,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],treatment with,na,95,136,119,146,1,RO-may_treat,908138-FS1,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
503460921,7/16/2014 15:42:50,,1324303127,7/16/2014 15:42:29,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[TREATS],[TREATS],treatment with,[TREATS],95,136,119,146,1,RO-may_treat,908138-FS1,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
503460921,7/16/2014 16:40:41,,1324331026,7/16/2014 16:40:17,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[TREATS],[TREATS],treatment,na,95,136,119,146,1,RO-may_treat,908138-FS1,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
503460921,7/16/2014 16:50:54,,1324334922,7/16/2014 16:50:33,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[TREATS],[TREATS],SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,N/A,95,136,119,146,1,RO-may_treat,908138-FS1,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
503460921,7/16/2014 17:12:37,,1324342337,7/16/2014 17:11:57,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,NONE,95,136,119,146,1,RO-may_treat,908138-FS1,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
503460921,7/16/2014 18:17:18,,1324395968,7/16/2014 18:16:29,clixsense,1.0,6621167,USA,"","",66.87.78.42,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,95,136,119,146,1,RO-may_treat,908138-FS1,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
503460921,7/16/2014 19:32:52,,1324435823,7/16/2014 19:32:33,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],association between,N/A,95,136,119,146,1,RO-may_treat,908138-FS1,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
503460921,7/16/2014 19:49:51,,1324444155,7/16/2014 19:48:53,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],treatment with,N/A,95,136,119,146,1,RO-may_treat,908138-FS1,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
503460921,7/16/2014 19:50:27,,1324444493,7/16/2014 19:47:42,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[TREATS],[TREATS],SEVERE HYPOGLYCAEMIA treatment with GLUCOSE IV.,N/A,95,136,119,146,1,RO-may_treat,908138-FS1,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
503460922,7/16/2014 13:27:12,,1324252336,7/16/2014 13:26:57,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],HEADACHES,N/A,75,22,101,48,-1,RO-has_definitional_manifestation,904971-FS1,"While Anteovin caused CLASSIC MIGRAINE HEADACHES on 0.98% of the women and ATYPICAL MIGRAINE HEADACHES on 2.3% for the women, the figures were only 0.7% and 1.4% for women on Rigevidon.",ATYPICAL MIGRAINE HEADACHES,CLASSIC MIGRAINE HEADACHES
503460922,7/16/2014 13:30:01,,1324253496,7/16/2014 13:29:48,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],0.98%,N/A,75,22,101,48,-1,RO-has_definitional_manifestation,904971-FS1,"While Anteovin caused CLASSIC MIGRAINE HEADACHES on 0.98% of the women and ATYPICAL MIGRAINE HEADACHES on 2.3% for the women, the figures were only 0.7% and 1.4% for women on Rigevidon.",ATYPICAL MIGRAINE HEADACHES,CLASSIC MIGRAINE HEADACHES
503460922,7/16/2014 13:31:38,,1324254276,7/16/2014 13:31:06,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]",and,na,75,22,101,48,-1,RO-has_definitional_manifestation,904971-FS1,"While Anteovin caused CLASSIC MIGRAINE HEADACHES on 0.98% of the women and ATYPICAL MIGRAINE HEADACHES on 2.3% for the women, the figures were only 0.7% and 1.4% for women on Rigevidon.",ATYPICAL MIGRAINE HEADACHES,CLASSIC MIGRAINE HEADACHES
503460922,7/16/2014 13:40:30,,1324257842,7/16/2014 13:39:31,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES] [IS_A],"[CAUSES]
[IS_A]",caused were,N/A,75,22,101,48,-1,RO-has_definitional_manifestation,904971-FS1,"While Anteovin caused CLASSIC MIGRAINE HEADACHES on 0.98% of the women and ATYPICAL MIGRAINE HEADACHES on 2.3% for the women, the figures were only 0.7% and 1.4% for women on Rigevidon.",ATYPICAL MIGRAINE HEADACHES,CLASSIC MIGRAINE HEADACHES
503460922,7/16/2014 13:44:17,,1324259227,7/16/2014 13:43:19,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[IS_A],[IS_A],of,N/A,75,22,101,48,-1,RO-has_definitional_manifestation,904971-FS1,"While Anteovin caused CLASSIC MIGRAINE HEADACHES on 0.98% of the women and ATYPICAL MIGRAINE HEADACHES on 2.3% for the women, the figures were only 0.7% and 1.4% for women on Rigevidon.",ATYPICAL MIGRAINE HEADACHES,CLASSIC MIGRAINE HEADACHES
503460922,7/16/2014 13:44:45,,1324259359,7/16/2014 13:44:25,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],CLASSIC MIGRAINE ATYPICAL MIGRAINE,n/a,75,22,101,48,-1,RO-has_definitional_manifestation,904971-FS1,"While Anteovin caused CLASSIC MIGRAINE HEADACHES on 0.98% of the women and ATYPICAL MIGRAINE HEADACHES on 2.3% for the women, the figures were only 0.7% and 1.4% for women on Rigevidon.",ATYPICAL MIGRAINE HEADACHES,CLASSIC MIGRAINE HEADACHES
503460922,7/16/2014 13:56:06,,1324263453,7/16/2014 13:55:54,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[LOCATION] [SYMPTOM],"[LOCATION]
[SYMPTOM]",HEADACHES 0.98% women on,N/A,75,22,101,48,-1,RO-has_definitional_manifestation,904971-FS1,"While Anteovin caused CLASSIC MIGRAINE HEADACHES on 0.98% of the women and ATYPICAL MIGRAINE HEADACHES on 2.3% for the women, the figures were only 0.7% and 1.4% for women on Rigevidon.",ATYPICAL MIGRAINE HEADACHES,CLASSIC MIGRAINE HEADACHES
503460922,7/16/2014 14:14:30,,1324271412,7/16/2014 14:14:15,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,75,22,101,48,-1,RO-has_definitional_manifestation,904971-FS1,"While Anteovin caused CLASSIC MIGRAINE HEADACHES on 0.98% of the women and ATYPICAL MIGRAINE HEADACHES on 2.3% for the women, the figures were only 0.7% and 1.4% for women on Rigevidon.",ATYPICAL MIGRAINE HEADACHES,CLASSIC MIGRAINE HEADACHES
503460922,7/16/2014 15:20:07,,1324295093,7/16/2014 15:19:52,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[IS_A],[IS_A],HEADACHES HEADACHES,N/A,75,22,101,48,-1,RO-has_definitional_manifestation,904971-FS1,"While Anteovin caused CLASSIC MIGRAINE HEADACHES on 0.98% of the women and ATYPICAL MIGRAINE HEADACHES on 2.3% for the women, the figures were only 0.7% and 1.4% for women on Rigevidon.",ATYPICAL MIGRAINE HEADACHES,CLASSIC MIGRAINE HEADACHES
503460922,7/16/2014 15:26:14,,1324297141,7/16/2014 15:25:20,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n\a,both examples of problems caused by anteovin,75,22,101,48,-1,RO-has_definitional_manifestation,904971-FS1,"While Anteovin caused CLASSIC MIGRAINE HEADACHES on 0.98% of the women and ATYPICAL MIGRAINE HEADACHES on 2.3% for the women, the figures were only 0.7% and 1.4% for women on Rigevidon.",ATYPICAL MIGRAINE HEADACHES,CLASSIC MIGRAINE HEADACHES
503460922,7/16/2014 15:45:43,,1324304489,7/16/2014 15:45:14,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[OTHER],[OTHER],caused and,N/A,75,22,101,48,-1,RO-has_definitional_manifestation,904971-FS1,"While Anteovin caused CLASSIC MIGRAINE HEADACHES on 0.98% of the women and ATYPICAL MIGRAINE HEADACHES on 2.3% for the women, the figures were only 0.7% and 1.4% for women on Rigevidon.",ATYPICAL MIGRAINE HEADACHES,CLASSIC MIGRAINE HEADACHES
503460922,7/16/2014 16:31:08,,1324326160,7/16/2014 16:30:04,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CLASSIC MIGRAINE HEADACHES ATYPICAL MIGRAINE HEADACHES,n/a,75,22,101,48,-1,RO-has_definitional_manifestation,904971-FS1,"While Anteovin caused CLASSIC MIGRAINE HEADACHES on 0.98% of the women and ATYPICAL MIGRAINE HEADACHES on 2.3% for the women, the figures were only 0.7% and 1.4% for women on Rigevidon.",ATYPICAL MIGRAINE HEADACHES,CLASSIC MIGRAINE HEADACHES
503460922,7/16/2014 16:59:19,,1324337874,7/16/2014 16:58:31,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CLASSIC MIGRAINE HEADACHES ATYPICAL MIGRAINE HEADACHES,n/a,75,22,101,48,-1,RO-has_definitional_manifestation,904971-FS1,"While Anteovin caused CLASSIC MIGRAINE HEADACHES on 0.98% of the women and ATYPICAL MIGRAINE HEADACHES on 2.3% for the women, the figures were only 0.7% and 1.4% for women on Rigevidon.",ATYPICAL MIGRAINE HEADACHES,CLASSIC MIGRAINE HEADACHES
503460922,7/16/2014 18:12:03,,1324390020,7/16/2014 18:10:45,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,na,75,22,101,48,-1,RO-has_definitional_manifestation,904971-FS1,"While Anteovin caused CLASSIC MIGRAINE HEADACHES on 0.98% of the women and ATYPICAL MIGRAINE HEADACHES on 2.3% for the women, the figures were only 0.7% and 1.4% for women on Rigevidon.",ATYPICAL MIGRAINE HEADACHES,CLASSIC MIGRAINE HEADACHES
503460922,7/16/2014 18:58:54,,1324417685,7/16/2014 18:58:35,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,75,22,101,48,-1,RO-has_definitional_manifestation,904971-FS1,"While Anteovin caused CLASSIC MIGRAINE HEADACHES on 0.98% of the women and ATYPICAL MIGRAINE HEADACHES on 2.3% for the women, the figures were only 0.7% and 1.4% for women on Rigevidon.",ATYPICAL MIGRAINE HEADACHES,CLASSIC MIGRAINE HEADACHES
503460923,7/16/2014 13:29:47,,1324253407,7/16/2014 13:29:37,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],was,N/A,118,37,148,81,-1,RO-has_causative_agent,903640-FS1,"The occurrence of ciprofloxacin  and LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS was similar, while the frequency of ERYTHROMYCIN RESISTANT S AUREUS varied widely nationwide.",ERYTHROMYCIN RESISTANT S AUREUS,LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS
503460923,7/16/2014 13:33:30,,1324255120,7/16/2014 13:33:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],while the,N/A,118,37,148,81,-1,RO-has_causative_agent,903640-FS1,"The occurrence of ciprofloxacin  and LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS was similar, while the frequency of ERYTHROMYCIN RESISTANT S AUREUS varied widely nationwide.",ERYTHROMYCIN RESISTANT S AUREUS,LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS
503460923,7/16/2014 13:36:37,,1324256404,7/16/2014 13:36:08,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ERYTHROMYCIN RESISTANT,asd,118,37,148,81,-1,RO-has_causative_agent,903640-FS1,"The occurrence of ciprofloxacin  and LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS was similar, while the frequency of ERYTHROMYCIN RESISTANT S AUREUS varied widely nationwide.",ERYTHROMYCIN RESISTANT S AUREUS,LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS
503460923,7/16/2014 13:39:21,,1324257374,7/16/2014 13:38:39,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[TREATS],[TREATS],LEVOFLOXACIN RESISTANT,na,118,37,148,81,-1,RO-has_causative_agent,903640-FS1,"The occurrence of ciprofloxacin  and LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS was similar, while the frequency of ERYTHROMYCIN RESISTANT S AUREUS varied widely nationwide.",ERYTHROMYCIN RESISTANT S AUREUS,LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS
503460923,7/16/2014 13:43:19,,1324258856,7/16/2014 13:42:53,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"was similar,",N/A,118,37,148,81,-1,RO-has_causative_agent,903640-FS1,"The occurrence of ciprofloxacin  and LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS was similar, while the frequency of ERYTHROMYCIN RESISTANT S AUREUS varied widely nationwide.",ERYTHROMYCIN RESISTANT S AUREUS,LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS
503460923,7/16/2014 13:44:03,,1324259108,7/16/2014 13:43:43,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],frequency,Na,118,37,148,81,-1,RO-has_causative_agent,903640-FS1,"The occurrence of ciprofloxacin  and LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS was similar, while the frequency of ERYTHROMYCIN RESISTANT S AUREUS varied widely nationwide.",ERYTHROMYCIN RESISTANT S AUREUS,LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS
503460923,7/16/2014 15:28:52,,1324297943,7/16/2014 15:27:50,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n\a,a list of different bacteria,118,37,148,81,-1,RO-has_causative_agent,903640-FS1,"The occurrence of ciprofloxacin  and LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS was similar, while the frequency of ERYTHROMYCIN RESISTANT S AUREUS varied widely nationwide.",ERYTHROMYCIN RESISTANT S AUREUS,LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS
503460923,7/16/2014 16:41:39,,1324331581,7/16/2014 16:41:12,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],"similar,",na,118,37,148,81,-1,RO-has_causative_agent,903640-FS1,"The occurrence of ciprofloxacin  and LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS was similar, while the frequency of ERYTHROMYCIN RESISTANT S AUREUS varied widely nationwide.",ERYTHROMYCIN RESISTANT S AUREUS,LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS
503460923,7/16/2014 17:29:21,,1324348853,7/16/2014 17:28:36,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,They appear to be involved in separate situations and not related to each other.,118,37,148,81,-1,RO-has_causative_agent,903640-FS1,"The occurrence of ciprofloxacin  and LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS was similar, while the frequency of ERYTHROMYCIN RESISTANT S AUREUS varied widely nationwide.",ERYTHROMYCIN RESISTANT S AUREUS,LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS
503460923,7/16/2014 17:59:46,,1324377612,7/16/2014 17:58:16,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"occurrence of similar, while",na,118,37,148,81,-1,RO-has_causative_agent,903640-FS1,"The occurrence of ciprofloxacin  and LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS was similar, while the frequency of ERYTHROMYCIN RESISTANT S AUREUS varied widely nationwide.",ERYTHROMYCIN RESISTANT S AUREUS,LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS
503460923,7/16/2014 18:26:00,,1324400422,7/16/2014 18:25:24,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,118,37,148,81,-1,RO-has_causative_agent,903640-FS1,"The occurrence of ciprofloxacin  and LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS was similar, while the frequency of ERYTHROMYCIN RESISTANT S AUREUS varied widely nationwide.",ERYTHROMYCIN RESISTANT S AUREUS,LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS
503460923,7/16/2014 19:34:29,,1324436595,7/16/2014 19:33:42,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"was similar, varied widely",N/A,118,37,148,81,-1,RO-has_causative_agent,903640-FS1,"The occurrence of ciprofloxacin  and LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS was similar, while the frequency of ERYTHROMYCIN RESISTANT S AUREUS varied widely nationwide.",ERYTHROMYCIN RESISTANT S AUREUS,LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS
503460923,7/16/2014 20:24:16,,1324459544,7/16/2014 20:23:34,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],while,different conditions,118,37,148,81,-1,RO-has_causative_agent,903640-FS1,"The occurrence of ciprofloxacin  and LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS was similar, while the frequency of ERYTHROMYCIN RESISTANT S AUREUS varied widely nationwide.",ERYTHROMYCIN RESISTANT S AUREUS,LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS
503460923,7/16/2014 20:43:22,,1324467531,7/16/2014 20:42:33,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"was similar, while the frequency of",N/A,118,37,148,81,-1,RO-has_causative_agent,903640-FS1,"The occurrence of ciprofloxacin  and LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS was similar, while the frequency of ERYTHROMYCIN RESISTANT S AUREUS varied widely nationwide.",ERYTHROMYCIN RESISTANT S AUREUS,LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS
503460923,7/16/2014 20:50:36,,1324470623,7/16/2014 20:48:54,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[LOCATION],[LOCATION],STAPHYLOCOCCUS,NONE,118,37,148,81,-1,RO-has_causative_agent,903640-FS1,"The occurrence of ciprofloxacin  and LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS was similar, while the frequency of ERYTHROMYCIN RESISTANT S AUREUS varied widely nationwide.",ERYTHROMYCIN RESISTANT S AUREUS,LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS
503460924,7/16/2014 13:32:41,,1324254742,7/16/2014 13:32:20,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[TREATS],[TREATS],treatment of,na,100,69,106,79,1,RO-may_treat,907842-FS1,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
503460924,7/16/2014 13:37:11,,1324256608,7/16/2014 13:36:56,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatment,N/A,100,69,106,79,1,RO-may_treat,907842-FS1,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
503460924,7/16/2014 13:44:59,,1324259435,7/16/2014 13:44:46,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],in the treatment of,n/a,100,69,106,79,1,RO-may_treat,907842-FS1,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
503460924,7/16/2014 13:48:10,,1324260489,7/16/2014 13:47:58,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],in the treatment of,N/A,100,69,106,79,1,RO-may_treat,907842-FS1,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
503460924,7/16/2014 13:48:15,,1324260502,7/16/2014 13:48:03,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[TREATS],[TREATS],treatment,N/A,100,69,106,79,1,RO-may_treat,907842-FS1,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
503460924,7/16/2014 14:13:22,,1324270882,7/16/2014 14:13:12,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],treatment,N/A,100,69,106,79,1,RO-may_treat,907842-FS1,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
503460924,7/16/2014 14:58:38,,1324287436,7/16/2014 14:57:59,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[TREATS],[TREATS],FUROSEMIDE ASCITES:,n/a,100,69,106,79,1,RO-may_treat,907842-FS1,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
503460924,7/16/2014 15:46:11,,1324304682,7/16/2014 15:45:58,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[TREATS],[TREATS],in the treatment of,N/A,100,69,106,79,1,RO-may_treat,907842-FS1,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
503460924,7/16/2014 16:30:46,,1324326026,7/16/2014 16:30:36,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treatment,N/A,100,69,106,79,1,RO-may_treat,907842-FS1,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
503460924,7/16/2014 16:37:04,,1324328787,7/16/2014 16:36:35,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],FUROSEMIDE in the treatment of ASCITES:,N/A,100,69,106,79,1,RO-may_treat,907842-FS1,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
503460924,7/16/2014 16:45:28,,1324333028,7/16/2014 16:44:41,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[TREATS],[TREATS],treatment,na,100,69,106,79,1,RO-may_treat,907842-FS1,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
503460924,7/16/2014 16:46:48,,1324333463,7/16/2014 16:46:26,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[TREATS],[TREATS],FUROSEMIDE in the treatment of ASCITES:,N/A,100,69,106,79,1,RO-may_treat,907842-FS1,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
503460924,7/16/2014 17:06:35,,1324340153,7/16/2014 17:06:27,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,100,69,106,79,1,RO-may_treat,907842-FS1,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
503460924,7/16/2014 17:38:38,,1324355777,7/16/2014 17:38:20,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],in the treatment of,n/a,100,69,106,79,1,RO-may_treat,907842-FS1,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
503460924,7/16/2014 18:38:43,,1324406373,7/16/2014 18:38:21,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],in the treatment of,na,100,69,106,79,1,RO-may_treat,907842-FS1,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
503460925,7/16/2014 13:32:12,,1324254585,7/16/2014 13:31:38,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SIDE_EFFECT],[SIDE_EFFECT],Eating Disorders Inventory,asd,173,96,184,113,-1,RO-has_definitional_manifestation,904730-FS1,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
503460925,7/16/2014 13:35:47,,1324256082,7/16/2014 13:35:08,clixsense,1,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],and number of episodes per week.,n/a,173,96,184,113,-1,RO-has_definitional_manifestation,904730-FS1,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
503460925,7/16/2014 13:41:11,,1324258072,7/16/2014 13:40:31,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",included,N/A,173,96,184,113,-1,RO-has_definitional_manifestation,904730-FS1,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
503460925,7/16/2014 13:52:20,,1324261928,7/16/2014 13:51:40,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],CONDITION (BINGE) number of BINGE EATING,N/A,173,96,184,113,-1,RO-has_definitional_manifestation,904730-FS1,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
503460925,7/16/2014 15:19:02,,1324294800,7/16/2014 15:18:50,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],number of,N/A,173,96,184,113,-1,RO-has_definitional_manifestation,904730-FS1,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
503460925,7/16/2014 15:43:47,,1324303576,7/16/2014 15:41:11,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[PART_OF],[PART_OF],and the number,n/a,173,96,184,113,-1,RO-has_definitional_manifestation,904730-FS1,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
503460925,7/16/2014 16:28:42,,1324325221,7/16/2014 16:28:04,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,173,96,184,113,-1,RO-has_definitional_manifestation,904730-FS1,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
503460925,7/16/2014 16:37:58,,1324329341,7/16/2014 16:36:53,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CONDITION (BINGE) BINGE EATING,n/a,173,96,184,113,-1,RO-has_definitional_manifestation,904730-FS1,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
503460925,7/16/2014 16:45:28,,1324333029,7/16/2014 16:43:55,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[MANIFESTATION],[MANIFESTATION],Eating Disorders,N/A,173,96,184,113,-1,RO-has_definitional_manifestation,904730-FS1,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
503460925,7/16/2014 16:46:18,,1324333277,7/16/2014 16:45:29,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,none,173,96,184,113,-1,RO-has_definitional_manifestation,904730-FS1,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
503460925,7/16/2014 17:23:34,,1324345530,7/16/2014 17:22:03,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[CAUSES],[CAUSES],included Index CONDITION (BINGE),n/a,173,96,184,113,-1,RO-has_definitional_manifestation,904730-FS1,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
503460925,7/16/2014 18:24:33,,1324399769,7/16/2014 18:21:42,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Bulimic CONDITION (BINGE) and the number of BINGE EATING episodes,N/A,173,96,184,113,-1,RO-has_definitional_manifestation,904730-FS1,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
503460925,7/16/2014 18:39:57,,1324407081,7/16/2014 18:38:44,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,173,96,184,113,-1,RO-has_definitional_manifestation,904730-FS1,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
503460925,7/16/2014 18:58:34,,1324417482,7/16/2014 18:58:15,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],number,N/A,173,96,184,113,-1,RO-has_definitional_manifestation,904730-FS1,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
503460925,7/16/2014 19:23:09,,1324431102,7/16/2014 19:22:32,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"Global Impression scores,",N/A,173,96,184,113,-1,RO-has_definitional_manifestation,904730-FS1,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
503460926,7/16/2014 13:46:19,,1324259846,7/16/2014 13:46:04,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],HYPERSENSITIVITY proved to be due to an ALLERGY,N/a,4,44,19,51,1,RO-cause_of,900099-FS1,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
503460926,7/16/2014 13:53:31,,1324262392,7/16/2014 13:53:15,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[CAUSES],[CAUSES],due to an,N/A,4,44,19,51,1,RO-cause_of,900099-FS1,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
503460926,7/16/2014 14:05:43,,1324267556,7/16/2014 14:05:14,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],"due to an ALLERGY to a reaction product,",N/A,4,44,19,51,1,RO-cause_of,900099-FS1,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
503460926,7/16/2014 14:44:25,,1324282857,7/16/2014 14:44:05,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES],[CAUSES],due to,N/A,4,44,19,51,1,RO-cause_of,900099-FS1,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
503460926,7/16/2014 15:06:34,,1324290825,7/16/2014 15:05:59,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[SYMPTOM],[SYMPTOM],due to,na,4,44,19,51,1,RO-cause_of,900099-FS1,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
503460926,7/16/2014 15:41:26,,1324302596,7/16/2014 15:41:06,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],proved to be due to,n/a,4,44,19,51,1,RO-cause_of,900099-FS1,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
503460926,7/16/2014 16:14:46,,1324319864,7/16/2014 16:14:17,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],proved,na,4,44,19,51,1,RO-cause_of,900099-FS1,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
503460926,7/16/2014 16:18:02,,1324321266,7/16/2014 16:17:30,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],due,N/A,4,44,19,51,1,RO-cause_of,900099-FS1,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
503460926,7/16/2014 16:43:39,,1324332371,7/16/2014 16:43:03,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES] [SIDE_EFFECT],"[CAUSES]
[SIDE_EFFECT]",HYPERSENSITIVITY due to ALLERGY,N/A,4,44,19,51,1,RO-cause_of,900099-FS1,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
503460926,7/16/2014 17:04:19,,1324339472,7/16/2014 17:04:09,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,4,44,19,51,1,RO-cause_of,900099-FS1,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
503460926,7/16/2014 17:49:58,,1324367259,7/16/2014 17:49:36,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[CAUSES],[CAUSES],proved to be due to,n/a,4,44,19,51,1,RO-cause_of,900099-FS1,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
503460926,7/16/2014 18:19:19,,1324397610,7/16/2014 18:18:59,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],proved to be due to an,na,4,44,19,51,1,RO-cause_of,900099-FS1,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
503460926,7/16/2014 18:25:56,,1324400364,7/16/2014 18:24:06,prodege,1,20349329,USA,CA,El Cajon,68.7.51.119,[CAUSES],[CAUSES],HYPERSENSITIVITY proved to be due to an ALLERGY,N/A,4,44,19,51,1,RO-cause_of,900099-FS1,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
503460926,7/16/2014 18:34:55,,1324404519,7/16/2014 18:34:37,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[CAUSES],[CAUSES],HYPERSENSITIVITY proved to be due to an ALLERGY,N/A,4,44,19,51,1,RO-cause_of,900099-FS1,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
503460926,7/16/2014 19:19:48,,1324429519,7/16/2014 19:16:53,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[SYMPTOM],[SYMPTOM],due to,N/A,4,44,19,51,1,RO-cause_of,900099-FS1,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
503460927,7/16/2014 13:29:15,,1324253196,7/16/2014 13:29:07,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],the,N/A,94,0,107,24,1,RO-cause_of,900255-FS1,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
503460927,7/16/2014 13:29:28,,1324253289,7/16/2014 13:29:05,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[CAUSES],[CAUSES],contribute to,na,94,0,107,24,1,RO-cause_of,900255-FS1,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
503460927,7/16/2014 13:54:19,,1324262753,7/16/2014 13:53:58,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[CAUSES],[CAUSES],contribute to,N/A,94,0,107,24,1,RO-cause_of,900255-FS1,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
503460927,7/16/2014 13:56:53,,1324263783,7/16/2014 13:56:25,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES] [OTHER],"[CAUSES]
[OTHER]",SELENIUM (SE) DEFICIENCY contribute to atrophy of the thyroid gland ENDEMIC GOITER,N/A,94,0,107,24,1,RO-cause_of,900255-FS1,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
503460927,7/16/2014 15:39:09,,1324301691,7/16/2014 15:38:54,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[CAUSES],[CAUSES],contribute to the,N/A,94,0,107,24,1,RO-cause_of,900255-FS1,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
503460927,7/16/2014 16:14:16,,1324319607,7/16/2014 16:13:37,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SIDE_EFFECT],[SIDE_EFFECT],contribute,na,94,0,107,24,1,RO-cause_of,900255-FS1,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
503460927,7/16/2014 16:41:57,,1324331729,7/16/2014 16:41:10,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[CAUSES],[CAUSES],SELENIUM (SE) DEFICIENCY contribute to ENDEMIC GOITER,N/A,94,0,107,24,1,RO-cause_of,900255-FS1,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
503460927,7/16/2014 18:34:04,,1324404090,7/16/2014 18:33:27,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],is said to contribute to the atrophy of the thyroid gland in certain,na,94,0,107,24,1,RO-cause_of,900255-FS1,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
503460927,7/16/2014 18:42:32,,1324408378,7/16/2014 18:42:00,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[CAUSES],[CAUSES],SELENIUM (SE) DEFICIENCY is said to contribute to ENDEMIC GOITER,n.a,94,0,107,24,1,RO-cause_of,900255-FS1,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
503460927,7/16/2014 18:57:13,,1324416725,7/16/2014 18:56:51,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],in certain,N/A,94,0,107,24,1,RO-cause_of,900255-FS1,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
503460927,7/16/2014 19:19:40,,1324429481,7/16/2014 19:18:14,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],contribute,N/A,94,0,107,24,1,RO-cause_of,900255-FS1,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
503460927,7/16/2014 20:24:52,,1324459788,7/16/2014 20:24:04,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[CAUSES],[CAUSES],said to contribute to,N/A,94,0,107,24,1,RO-cause_of,900255-FS1,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
503460927,7/16/2014 20:31:27,,1324462829,7/16/2014 20:29:47,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION],[LOCATION],SELENIUM (SE) DEFICIENCY certain ENDEMIC GOITER areas,Location,94,0,107,24,1,RO-cause_of,900255-FS1,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
503460927,7/16/2014 20:43:41,,1324467645,7/16/2014 20:43:11,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],areas,N/A,94,0,107,24,1,RO-cause_of,900255-FS1,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
503460927,7/16/2014 20:57:29,,1324473241,7/16/2014 20:57:12,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[LOCATION],[LOCATION],ENDEMIC,NONE,94,0,107,24,1,RO-cause_of,900255-FS1,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
503460928,7/16/2014 13:30:12,,1324253562,7/16/2014 13:30:02,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],later,N/A,89,89,117,109,-1,RO-cause_of,900138-FS1,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
503460928,7/16/2014 13:40:51,,1324257948,7/16/2014 13:39:22,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[CAUSES],[CAUSES],developed,na,89,89,117,109,-1,RO-cause_of,900138-FS1,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
503460928,7/16/2014 13:44:16,,1324259226,7/16/2014 13:44:04,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],SYMPTOMS,Na,89,89,117,109,-1,RO-cause_of,900138-FS1,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
503460928,7/16/2014 13:50:43,,1324261379,7/16/2014 13:49:59,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were exposed,N/A,89,89,117,109,-1,RO-cause_of,900138-FS1,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
503460928,7/16/2014 14:00:27,,1324265339,7/16/2014 14:00:02,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],SYMPTOMS,N/A,89,89,117,109,-1,RO-cause_of,900138-FS1,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
503460928,7/16/2014 14:44:13,,1324282804,7/16/2014 14:43:48,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[SIDE_EFFECT],[SIDE_EFFECT],developed,N/A,89,89,117,109,-1,RO-cause_of,900138-FS1,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
503460928,7/16/2014 15:19:51,,1324295040,7/16/2014 15:19:39,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and had,N/A,89,89,117,109,-1,RO-cause_of,900138-FS1,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
503460928,7/16/2014 15:40:40,,1324302224,7/16/2014 15:40:19,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[SYMPTOM],[SYMPTOM],developed had,N/A,89,89,117,109,-1,RO-cause_of,900138-FS1,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
503460928,7/16/2014 15:42:59,,1324303214,7/16/2014 15:42:42,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[SYMPTOM],[SYMPTOM],SYMPTOMS,n/a,89,89,117,109,-1,RO-cause_of,900138-FS1,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
503460928,7/16/2014 15:48:12,,1324305464,7/16/2014 15:47:32,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[MANIFESTATION] [CAUSES],"[CAUSES]
[MANIFESTATION]",during early childhood developed,[MANIFESTATION] [CAUSES],89,89,117,109,-1,RO-cause_of,900138-FS1,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
503460928,7/16/2014 16:28:55,,1324325297,7/16/2014 16:28:43,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,89,89,117,109,-1,RO-cause_of,900138-FS1,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
503460928,7/16/2014 17:21:30,,1324344818,7/16/2014 17:21:11,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[SYMPTOM],[SYMPTOM],DOG HYPERSENSITIVITY SYMPTOMS,n/a,89,89,117,109,-1,RO-cause_of,900138-FS1,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
503460928,7/16/2014 18:21:58,,1324398840,7/16/2014 18:20:26,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[MANIFESTATION],[MANIFESTATION],developed,na,89,89,117,109,-1,RO-cause_of,900138-FS1,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
503460928,7/16/2014 19:03:16,,1324420435,7/16/2014 19:02:07,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[SYMPTOM],[SYMPTOM],developed DOG HYPERSENSITIVITY SYMPTOMS and had DOG HYPERSENSITIVITY slightly more often,N/A,89,89,117,109,-1,RO-cause_of,900138-FS1,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
503460928,7/16/2014 19:21:59,,1324430567,7/16/2014 19:21:11,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],developed,N/A,89,89,117,109,-1,RO-cause_of,900138-FS1,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
503460929,7/16/2014 13:34:16,,1324255461,7/16/2014 13:33:57,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[PREVENTS],[PREVENTS],susceptible or resistant to,n/a,124,180,149,213,1,RO-may_treat,907849-FS1,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
503460929,7/16/2014 13:37:23,,1324256652,7/16/2014 13:37:09,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],susceptible,Na,124,180,149,213,1,RO-may_treat,907849-FS1,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
503460929,7/16/2014 13:45:28,,1324259616,7/16/2014 13:44:59,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],susceptible or resistant to,N/A,124,180,149,213,1,RO-may_treat,907849-FS1,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
503460929,7/16/2014 13:57:31,,1324264101,7/16/2014 13:57:12,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],MYCOBACTERIUM TUBERCULOSIS susceptible to FIRST LINE ANTITUBERCULOSIS DRUGS.,N/A,124,180,149,213,1,RO-may_treat,907849-FS1,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
503460929,7/16/2014 14:45:05,,1324283003,7/16/2014 14:44:39,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],susceptible or resistant to,N/A,124,180,149,213,1,RO-may_treat,907849-FS1,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
503460929,7/16/2014 15:44:21,,1324303841,7/16/2014 15:44:00,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[TREATS],[TREATS],susceptible or resistant to,N/A,124,180,149,213,1,RO-may_treat,907849-FS1,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
503460929,7/16/2014 15:44:24,,1324303880,7/16/2014 15:43:50,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[CONTRAINDICATES],[CONTRAINDICATES],susceptible or to,[CONTRAINDICATES],124,180,149,213,1,RO-may_treat,907849-FS1,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
503460929,7/16/2014 16:26:03,,1324324290,7/16/2014 16:24:51,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],susceptible or resistant,N/A,124,180,149,213,1,RO-may_treat,907849-FS1,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
503460929,7/16/2014 16:39:30,,1324330406,7/16/2014 16:38:36,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],susceptible or resistant,N/A,124,180,149,213,1,RO-may_treat,907849-FS1,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
503460929,7/16/2014 16:49:49,,1324334607,7/16/2014 16:49:20,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[TREATS],[TREATS],MYCOBACTERIUM TUBERCULOSIS susceptible to FIRST LINE ANTITUBERCULOSIS DRUGS.,N/A,124,180,149,213,1,RO-may_treat,907849-FS1,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
503460929,7/16/2014 16:52:01,,1324335316,7/16/2014 16:51:15,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],MYCOBACTERIUM TUBERCULOSIS to FIRST LINE ANTITUBERCULOSIS DRUGS.,N/A,124,180,149,213,1,RO-may_treat,907849-FS1,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
503460929,7/16/2014 17:36:24,,1324354062,7/16/2014 17:34:24,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],against 250 clinical isolates of,n/a,124,180,149,213,1,RO-may_treat,907849-FS1,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
503460929,7/16/2014 18:14:54,,1324392982,7/16/2014 18:14:20,clixsense,1.0,6621167,USA,"","",66.87.78.42,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,Na,124,180,149,213,1,RO-may_treat,907849-FS1,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
503460929,7/16/2014 19:16:03,,1324427804,7/16/2014 19:15:27,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[PREVENTS],[PREVENTS],susceptible or resistant to,N/A,124,180,149,213,1,RO-may_treat,907849-FS1,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
503460929,7/16/2014 19:38:36,,1324438410,7/16/2014 19:38:18,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[PREVENTS],[PREVENTS],resistant,N/A,124,180,149,213,1,RO-may_treat,907849-FS1,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
503460930,7/16/2014 13:30:08,,1324253553,7/16/2014 13:29:30,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[SYMPTOM],[SYMPTOM],caused by,na,46,103,57,136,1,RO-disease_has_finding,901623-FS1,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
503460930,7/16/2014 13:38:31,,1324257091,7/16/2014 13:38:12,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],lead to,N/A,46,103,57,136,1,RO-disease_has_finding,901623-FS1,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
503460930,7/16/2014 13:41:02,,1324258006,7/16/2014 13:40:50,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],caused,Na,46,103,57,136,1,RO-disease_has_finding,901623-FS1,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
503460930,7/16/2014 13:41:20,,1324258127,7/16/2014 13:40:59,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],may also lead to the rare syndrome,n/a,46,103,57,136,1,RO-disease_has_finding,901623-FS1,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
503460930,7/16/2014 13:45:52,,1324259730,7/16/2014 13:45:11,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],which may also lead to the rare syndrome of,N/A,46,103,57,136,1,RO-disease_has_finding,901623-FS1,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
503460930,7/16/2014 13:51:27,,1324261643,7/16/2014 13:51:05,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],may also lead to the rare syndrome of,N/a,46,103,57,136,1,RO-disease_has_finding,901623-FS1,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
503460930,7/16/2014 14:16:31,,1324272065,7/16/2014 14:16:19,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],lead to,N/A,46,103,57,136,1,RO-disease_has_finding,901623-FS1,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
503460930,7/16/2014 15:07:07,,1324291051,7/16/2014 15:06:36,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[CAUSES],[CAUSES],lead to,na,46,103,57,136,1,RO-disease_has_finding,901623-FS1,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
503460930,7/16/2014 15:32:16,,1324299106,7/16/2014 15:31:44,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],may lead to,n/a,46,103,57,136,1,RO-disease_has_finding,901623-FS1,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
503460930,7/16/2014 15:32:41,,1324299248,7/16/2014 15:32:30,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[CAUSES],[CAUSES],lead to,N/A,46,103,57,136,1,RO-disease_has_finding,901623-FS1,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
503460930,7/16/2014 15:42:13,,1324302888,7/16/2014 15:41:55,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[CAUSES],[CAUSES],may also lead to,N/A,46,103,57,136,1,RO-disease_has_finding,901623-FS1,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
503460930,7/16/2014 16:24:32,,1324323736,7/16/2014 16:23:05,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[CAUSES],[CAUSES],may also lead to,N/A,46,103,57,136,1,RO-disease_has_finding,901623-FS1,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
503460930,7/16/2014 17:03:25,,1324339192,7/16/2014 17:03:20,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,46,103,57,136,1,RO-disease_has_finding,901623-FS1,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
503460930,7/16/2014 18:30:37,,1324402334,7/16/2014 18:29:58,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],which may also lead to the rare syndrome of,na,46,103,57,136,1,RO-disease_has_finding,901623-FS1,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
503460930,7/16/2014 18:59:05,,1324417791,7/16/2014 18:58:54,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],lead,N/A,46,103,57,136,1,RO-disease_has_finding,901623-FS1,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
503460931,7/16/2014 13:28:12,,1324252730,7/16/2014 13:27:13,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],BONE,N/A,48,32,67,47,-1,RO-disease_may_have_finding,902836-FS1,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
503460931,7/16/2014 13:31:12,,1324254075,7/16/2014 13:30:51,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[MANIFESTATION],[MANIFESTATION],BONE METASTASES PATHOLOGIC FRACTURES,asd,48,32,67,47,-1,RO-disease_may_have_finding,902836-FS1,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
503460931,7/16/2014 13:46:29,,1324259938,7/16/2014 13:46:12,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[ASSOCIATED_WITH],[ASSOCIATED_WITH],METASTASES PATHOLOGIC,N/A,48,32,67,47,-1,RO-disease_may_have_finding,902836-FS1,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
503460931,7/16/2014 13:47:56,,1324260424,7/16/2014 13:47:21,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],(new,N/A,48,32,67,47,-1,RO-disease_may_have_finding,902836-FS1,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
503460931,7/16/2014 13:51:03,,1324261496,7/16/2014 13:50:46,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],BONE METASTASES PATHOLOGIC FRACTURES,All one term,48,32,67,47,-1,RO-disease_may_have_finding,902836-FS1,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
503460931,7/16/2014 15:08:48,,1324291544,7/16/2014 15:07:46,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[MANIFESTATION],[MANIFESTATION],events,N/A,48,32,67,47,-1,RO-disease_may_have_finding,902836-FS1,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
503460931,7/16/2014 15:34:36,,1324299872,7/16/2014 15:34:23,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[LOCATION],[LOCATION],Skeletal,N/A,48,32,67,47,-1,RO-disease_may_have_finding,902836-FS1,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
503460931,7/16/2014 15:43:44,,1324303568,7/16/2014 15:43:19,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Skeletal events,N/A,48,32,67,47,-1,RO-disease_may_have_finding,902836-FS1,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
503460931,7/16/2014 15:45:41,,1324304482,7/16/2014 15:44:39,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n\a,list of issues,48,32,67,47,-1,RO-disease_may_have_finding,902836-FS1,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
503460931,7/16/2014 16:07:15,,1324315509,7/16/2014 16:06:34,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[MANIFESTATION]",development progression of bone pain,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [MANIFESTATION],48,32,67,47,-1,RO-disease_may_have_finding,902836-FS1,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
503460931,7/16/2014 16:12:32,,1324318794,7/16/2014 16:11:49,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[PART_OF],[PART_OF],BONE METASTASES PATHOLOGIC FRACTURES,n/a,48,32,67,47,-1,RO-disease_may_have_finding,902836-FS1,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
503460931,7/16/2014 16:18:33,,1324321491,7/16/2014 16:18:03,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[IS_A],[IS_A],BONE METASTASES PATHOLOGIC FRACTURES,N/A,48,32,67,47,-1,RO-disease_may_have_finding,902836-FS1,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
503460931,7/16/2014 16:56:24,,1324336866,7/16/2014 16:55:23,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],events,NONE,48,32,67,47,-1,RO-disease_may_have_finding,902836-FS1,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
503460931,7/16/2014 17:02:15,,1324338885,7/16/2014 17:01:41,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BONE METASTASES PATHOLOGIC FRACTURES,n/a,48,32,67,47,-1,RO-disease_may_have_finding,902836-FS1,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
503460931,7/16/2014 17:39:50,,1324356742,7/16/2014 17:38:40,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,"They are both types of ""skeletal events"" but don't seem to be connected to each other.",48,32,67,47,-1,RO-disease_may_have_finding,902836-FS1,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
503460932,7/16/2014 13:29:05,,1324253115,7/16/2014 13:28:40,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[TREATS],[TREATS],significantly reduced,na,78,42,81,51,1,RO-may_prevent,907174-FS1,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
503460932,7/16/2014 13:31:34,,1324254244,7/16/2014 13:31:08,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],the addition of significantly reduced the,N/A,78,42,81,51,1,RO-may_prevent,907174-FS1,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
503460932,7/16/2014 13:34:32,,1324255593,7/16/2014 13:34:17,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[PREVENTS],[PREVENTS],significantly reduced the,n/a,78,42,81,51,1,RO-may_prevent,907174-FS1,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
503460932,7/16/2014 13:45:32,,1324259634,7/16/2014 13:45:04,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],significantly reduced,N/A,78,42,81,51,1,RO-may_prevent,907174-FS1,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
503460932,7/16/2014 13:45:51,,1324259725,7/16/2014 13:44:53,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],reduced,N/A,78,42,81,51,1,RO-may_prevent,907174-FS1,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
503460932,7/16/2014 13:48:19,,1324260527,7/16/2014 13:48:03,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],significantly reduced,n/a,78,42,81,51,1,RO-may_prevent,907174-FS1,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
503460932,7/16/2014 14:11:49,,1324270272,7/16/2014 14:11:38,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],reduced,N/A,78,42,81,51,1,RO-may_prevent,907174-FS1,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
503460932,7/16/2014 14:53:24,,1324285499,7/16/2014 14:52:56,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],significantly reduced the,N/A,78,42,81,51,1,RO-may_prevent,907174-FS1,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
503460932,7/16/2014 15:06:42,,1324290877,7/16/2014 15:06:07,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS],[TREATS],significantly reduced the,N/A,78,42,81,51,1,RO-may_prevent,907174-FS1,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
503460932,7/16/2014 16:27:27,,1324324759,7/16/2014 16:26:28,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],reduced,N/A,78,42,81,51,1,RO-may_prevent,907174-FS1,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
503460932,7/16/2014 16:35:29,,1324327887,7/16/2014 16:34:34,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],reduced,none,78,42,81,51,1,RO-may_prevent,907174-FS1,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
503460932,7/16/2014 16:47:16,,1324333687,7/16/2014 16:46:51,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],LIDOCAINE reduced PAIN,N/A,78,42,81,51,1,RO-may_prevent,907174-FS1,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
503460932,7/16/2014 16:56:55,,1324337034,7/16/2014 16:56:22,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LIDOCAINE PAIN,n/a,78,42,81,51,1,RO-may_prevent,907174-FS1,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
503460932,7/16/2014 17:50:33,,1324367851,7/16/2014 17:50:00,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],significantly reduced the,n/a,78,42,81,51,1,RO-may_prevent,907174-FS1,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
503460932,7/16/2014 19:06:30,,1324422537,7/16/2014 19:06:07,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SIDE_EFFECT],[SIDE_EFFECT],reduced,N/A,78,42,81,51,1,RO-may_prevent,907174-FS1,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
503460933,7/16/2014 13:27:58,,1324252658,7/16/2014 13:27:49,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,N/A,137,14,146,24,1,RO-may_treat,907692-FS1,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
503460933,7/16/2014 13:29:01,,1324253091,7/16/2014 13:28:13,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],Medication augmentation,N/A,137,14,146,24,1,RO-may_treat,907692-FS1,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
503460933,7/16/2014 13:32:29,,1324254676,7/16/2014 13:32:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],for depression,N/A,137,14,146,24,1,RO-may_treat,907692-FS1,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
503460933,7/16/2014 13:37:06,,1324256591,7/16/2014 13:36:41,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[TREATS],[TREATS],SSRIs for DEPRESSION.,asd,137,14,146,24,1,RO-may_treat,907692-FS1,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
503460933,7/16/2014 13:38:55,,1324257222,7/16/2014 13:38:32,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],for depression,N/A,137,14,146,24,1,RO-may_treat,907692-FS1,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
503460933,7/16/2014 13:42:14,,1324258535,7/16/2014 13:41:44,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],for depression Medication,n/a,137,14,146,24,1,RO-may_treat,907692-FS1,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
503460933,7/16/2014 13:42:31,,1324258628,7/16/2014 13:41:12,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],after failure,N/A,137,14,146,24,1,RO-may_treat,907692-FS1,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
503460933,7/16/2014 14:46:33,,1324283414,7/16/2014 14:46:08,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],for,N/A,137,14,146,24,1,RO-may_treat,907692-FS1,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
503460933,7/16/2014 14:47:22,,1324283647,7/16/2014 14:46:34,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[TREATS],[TREATS],SERTRALINE DEPRESSION.,n/a,137,14,146,24,1,RO-may_treat,907692-FS1,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
503460933,7/16/2014 15:02:45,,1324289158,7/16/2014 15:01:56,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",for,N/A,137,14,146,24,1,RO-may_treat,907692-FS1,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
503460933,7/16/2014 15:07:45,,1324291263,7/16/2014 15:07:01,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],Medication,N/A,137,14,146,24,1,RO-may_treat,907692-FS1,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
503460933,7/16/2014 15:24:31,,1324296698,7/16/2014 15:24:02,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],for,n\a,137,14,146,24,1,RO-may_treat,907692-FS1,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
503460933,7/16/2014 16:24:08,,1324323586,7/16/2014 16:23:00,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],SSRIs DEPRESSION.,n/a,137,14,146,24,1,RO-may_treat,907692-FS1,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
503460933,7/16/2014 16:24:19,,1324323657,7/16/2014 16:22:48,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],depression,na,137,14,146,24,1,RO-may_treat,907692-FS1,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
503460933,7/16/2014 17:15:32,,1324343151,7/16/2014 17:14:07,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[OTHER],[OTHER],SERTRALINE after failure depression Medication,n\a,137,14,146,24,1,RO-may_treat,907692-FS1,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
503460934,7/16/2014 13:33:41,,1324255230,7/16/2014 13:33:24,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[TREATS],[TREATS],effective and generally well tolerated,na,96,13,108,36,1,RO-may_treat,908025-FS1,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
503460934,7/16/2014 13:35:59,,1324256165,7/16/2014 13:35:34,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],effective,N/A,96,13,108,36,1,RO-may_treat,908025-FS1,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
503460934,7/16/2014 13:41:15,,1324258106,7/16/2014 13:41:03,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],effective,Na,96,13,108,36,1,RO-may_treat,908025-FS1,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
503460934,7/16/2014 13:43:51,,1324259041,7/16/2014 13:43:37,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],well tolerated in patients with,n/a,96,13,108,36,1,RO-may_treat,908025-FS1,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
503460934,7/16/2014 13:45:09,,1324259479,7/16/2014 13:44:43,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],is effective in patients with,N/A,96,13,108,36,1,RO-may_treat,908025-FS1,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
503460934,7/16/2014 13:59:46,,1324265142,7/16/2014 13:59:35,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[TREATS] [LOCATION],"[TREATS]
[LOCATION]",CONCLUSIONS: ACTING RISPERIDONE effective symptoms.,N/A,96,13,108,36,1,RO-may_treat,908025-FS1,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
503460934,7/16/2014 14:12:25,,1324270541,7/16/2014 14:12:11,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],effective,N/A,96,13,108,36,1,RO-may_treat,908025-FS1,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
503460934,7/16/2014 14:38:21,,1324281045,7/16/2014 14:37:46,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],is effective and generally well tolerated in patients with,N/A,96,13,108,36,1,RO-may_treat,908025-FS1,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
503460934,7/16/2014 14:57:52,,1324287190,7/16/2014 14:57:10,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CONCLUSIONS: LONG ACTING RISPERIDONE SCHIZOPHRENIA,n/a,96,13,108,36,1,RO-may_treat,908025-FS1,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
503460934,7/16/2014 15:06:05,,1324290655,7/16/2014 15:05:38,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",is effective and generally well tolerated in,N/A,96,13,108,36,1,RO-may_treat,908025-FS1,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
503460934,7/16/2014 16:27:53,,1324324945,7/16/2014 16:26:59,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],LONG ACTING RISPERIDONE SCHIZOPHRENIA,n/a,96,13,108,36,1,RO-may_treat,908025-FS1,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
503460934,7/16/2014 17:40:11,,1324357176,7/16/2014 17:39:51,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],is effective,n/a,96,13,108,36,1,RO-may_treat,908025-FS1,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
503460934,7/16/2014 18:21:41,,1324398701,7/16/2014 18:21:21,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],LONG ACTING RISPERIDONE is effective in patients with SCHIZOPHRENIA,N/A,96,13,108,36,1,RO-may_treat,908025-FS1,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
503460934,7/16/2014 19:14:31,,1324426878,7/16/2014 19:14:10,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[PREVENTS],[PREVENTS],is effective and generally well tolerated in patients with,N/A,96,13,108,36,1,RO-may_treat,908025-FS1,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
503460934,7/16/2014 19:21:10,,1324430209,7/16/2014 19:19:41,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],is effective,N/A,96,13,108,36,1,RO-may_treat,908025-FS1,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
503460935,7/16/2014 13:30:37,,1324253792,7/16/2014 13:30:23,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PREVENTS],[PREVENTS],for long term prevention,N/A,118,50,149,89,1,RO-may_prevent,907299-FS1,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
503460935,7/16/2014 13:41:58,,1324258371,7/16/2014 13:41:33,instagc,1.0,13763729,USA,"","",75.182.89.225,[PREVENTS],[PREVENTS],long term prevention,N/A,118,50,149,89,1,RO-may_prevent,907299-FS1,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
503460935,7/16/2014 13:44:28,,1324259274,7/16/2014 13:43:56,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PREVENTS],[PREVENTS],CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention,N/a,118,50,149,89,1,RO-may_prevent,907299-FS1,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
503460935,7/16/2014 13:49:38,,1324260947,7/16/2014 13:49:17,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[PREVENTS],[PREVENTS],long term prevention,N/A,118,50,149,89,1,RO-may_prevent,907299-FS1,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
503460935,7/16/2014 13:56:48,,1324263753,7/16/2014 13:56:34,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[PREVENTS] [CAUSES] [MANIFESTATION],"[PREVENTS]
[CAUSES]
[MANIFESTATION]",intensity warfarin CONVENTIONAL THROMBOEMBOLISM,N/A,118,50,149,89,1,RO-may_prevent,907299-FS1,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
503460935,7/16/2014 14:51:16,,1324284861,7/16/2014 14:50:08,prodege,1.0,15508331,USA,OK,Stillwater,139.78.139.193,[PREVENTS],[PREVENTS],therapy CONVENTIONAL INTENSITY WARFARIN THERAPY prevention RECURRENT VENOUS THROMBOEMBOLISM,N/A,118,50,149,89,1,RO-may_prevent,907299-FS1,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
503460935,7/16/2014 15:06:03,,1324290639,7/16/2014 15:05:09,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],THERAPY long term prevention,N/A,118,50,149,89,1,RO-may_prevent,907299-FS1,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
503460935,7/16/2014 15:34:02,,1324299657,7/16/2014 15:33:51,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[PREVENTS],[PREVENTS],long term prevention,N/A,118,50,149,89,1,RO-may_prevent,907299-FS1,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
503460935,7/16/2014 16:24:16,,1324323652,7/16/2014 16:24:08,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[PREVENTS],[PREVENTS],prevention,N/A,118,50,149,89,1,RO-may_prevent,907299-FS1,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
503460935,7/16/2014 17:02:46,,1324339023,7/16/2014 17:02:21,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,118,50,149,89,1,RO-may_prevent,907299-FS1,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
503460935,7/16/2014 17:02:49,,1324339037,7/16/2014 17:02:20,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[PREVENTS],[PREVENTS],CONVENTIONAL INTENSITY WARFARIN THERAPY RECURRENT VENOUS THROMBOEMBOLISM,n/a,118,50,149,89,1,RO-may_prevent,907299-FS1,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
503460935,7/16/2014 17:11:06,,1324341824,7/16/2014 17:08:44,prodege,1,15143610,USA,OH,Bucyrus,74.4.40.174,[PREVENTS],[PREVENTS],prevention,N/A,118,50,149,89,1,RO-may_prevent,907299-FS1,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
503460935,7/16/2014 19:15:26,,1324427462,7/16/2014 19:15:07,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[PREVENTS],[PREVENTS],prevention,N/A,118,50,149,89,1,RO-may_prevent,907299-FS1,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
503460935,7/16/2014 19:44:50,,1324441654,7/16/2014 19:44:30,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],for long term prevention,N/A,118,50,149,89,1,RO-may_prevent,907299-FS1,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
503460935,7/16/2014 20:37:46,,1324465309,7/16/2014 20:37:00,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[PREVENTS],[PREVENTS],CONVENTIONAL INTENSITY WARFARIN THERAPY long term prevention RECURRENT VENOUS THROMBOEMBOLISM,Prevents,118,50,149,89,1,RO-may_prevent,907299-FS1,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
503460936,7/16/2014 13:32:50,,1324254802,7/16/2014 13:32:17,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[PART_OF],[PART_OF],"hyperviscosity syndrome,",n/a,66,88,86,119,-1,RO-disease_has_finding,901594-FS1,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
503460936,7/16/2014 13:34:30,,1324255617,7/16/2014 13:33:47,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],"cryoprotein induced diseases,",N/A,66,88,86,119,-1,RO-disease_has_finding,901594-FS1,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
503460936,7/16/2014 13:35:11,,1324255879,7/16/2014 13:34:16,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA,asd,66,88,86,119,-1,RO-disease_has_finding,901594-FS1,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
503460936,7/16/2014 13:38:48,,1324257187,7/16/2014 13:38:13,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],induced,N/A,66,88,86,119,-1,RO-disease_has_finding,901594-FS1,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
503460936,7/16/2014 13:45:18,,1324259551,7/16/2014 13:44:49,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[ASSOCIATED_WITH],[ASSOCIATED_WITH],induced,N/A,66,88,86,119,-1,RO-disease_has_finding,901594-FS1,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
503460936,7/16/2014 13:50:07,,1324261137,7/16/2014 13:49:44,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[PART_OF],[PART_OF],MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA,N/A,66,88,86,119,-1,RO-disease_has_finding,901594-FS1,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
503460936,7/16/2014 14:44:03,,1324282750,7/16/2014 14:43:18,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[OTHER],[OTHER],"cryoprotein induced diseases,",N/A,66,88,86,119,-1,RO-disease_has_finding,901594-FS1,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
503460936,7/16/2014 16:06:32,,1324314898,7/16/2014 16:05:49,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]","induced diseases,",[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],66,88,86,119,-1,RO-disease_has_finding,901594-FS1,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
503460936,7/16/2014 16:17:04,,1324320910,7/16/2014 16:14:48,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION] [TREATS],"[TREATS]
[MANIFESTATION]",induced,na,66,88,86,119,-1,RO-disease_has_finding,901594-FS1,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
503460936,7/16/2014 16:37:44,,1324329229,7/16/2014 16:35:31,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"diseases,",none,66,88,86,119,-1,RO-disease_has_finding,901594-FS1,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
503460936,7/16/2014 20:39:55,,1324466226,7/16/2014 20:39:01,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA,Associated With,66,88,86,119,-1,RO-disease_has_finding,901594-FS1,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
503460936,7/16/2014 20:50:05,,1324470453,7/16/2014 20:49:38,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,list of conditions,66,88,86,119,-1,RO-disease_has_finding,901594-FS1,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
503460936,7/16/2014 20:54:22,,1324472127,7/16/2014 20:52:00,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[CAUSES],[CAUSES],WALDENSTROM'S,NONE,66,88,86,119,-1,RO-disease_has_finding,901594-FS1,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
503460936,7/16/2014 20:56:39,,1324472952,7/16/2014 20:56:12,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER] [PART_OF],"[PART_OF]
[OTHER]",MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA,N/A,66,88,86,119,-1,RO-disease_has_finding,901594-FS1,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
503460936,7/16/2014 21:01:00,,1324475199,7/16/2014 21:00:35,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA,N/A,66,88,86,119,-1,RO-disease_has_finding,901594-FS1,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
503460937,7/16/2014 13:28:44,,1324252971,7/16/2014 13:28:22,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[IS_A],[IS_A],"milder psychosis (i.e., fewer",n/a,65,11,78,24,1,RO-has_manifestation,906248-FS1,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
503460937,7/16/2014 13:32:53,,1324254833,7/16/2014 13:32:43,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],denotes a milder psychosis,N/A,65,11,78,24,1,RO-has_manifestation,906248-FS1,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
503460937,7/16/2014 13:36:20,,1324256311,7/16/2014 13:35:25,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",denotes,N/A,65,11,78,24,1,RO-has_manifestation,906248-FS1,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
503460937,7/16/2014 13:37:06,,1324256595,7/16/2014 13:36:40,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[SYMPTOM],[SYMPTOM],"denotes a milder psychosis (i.e., fewer",N/A,65,11,78,24,1,RO-has_manifestation,906248-FS1,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
503460937,7/16/2014 13:37:15,,1324256629,7/16/2014 13:36:20,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[CAUSES],[CAUSES],denotes,na,65,11,78,24,1,RO-has_manifestation,906248-FS1,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
503460937,7/16/2014 13:40:46,,1324257921,7/16/2014 13:40:20,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],denotes,N/A,65,11,78,24,1,RO-has_manifestation,906248-FS1,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
503460937,7/16/2014 13:46:06,,1324259783,7/16/2014 13:45:45,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SIDE_EFFECT],[SIDE_EFFECT],denotes milder psychosis fewer and delusions,n/a,65,11,78,24,1,RO-has_manifestation,906248-FS1,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
503460937,7/16/2014 14:50:14,,1324284553,7/16/2014 14:47:56,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES] [SYMPTOM] [MANIFESTATION],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]",denotes,N/A,65,11,78,24,1,RO-has_manifestation,906248-FS1,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
503460937,7/16/2014 16:24:50,,1324323873,7/16/2014 16:24:32,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[SIDE_EFFECT],[SIDE_EFFECT],"(i.e.,",N/A,65,11,78,24,1,RO-has_manifestation,906248-FS1,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
503460937,7/16/2014 16:50:41,,1324334864,7/16/2014 16:50:03,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[SYMPTOM],[SYMPTOM],SCHIZOPHRENIA denotes HALLUCINATIONS,N/A,65,11,78,24,1,RO-has_manifestation,906248-FS1,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
503460937,7/16/2014 17:03:00,,1324339078,7/16/2014 17:02:55,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,65,11,78,24,1,RO-has_manifestation,906248-FS1,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
503460937,7/16/2014 19:09:22,,1324424198,7/16/2014 19:08:51,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS",N/A,65,11,78,24,1,RO-has_manifestation,906248-FS1,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
503460937,7/16/2014 19:41:00,,1324439701,7/16/2014 19:39:16,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM],[SYMPTOM],denotes a milder psychosis,N/A,65,11,78,24,1,RO-has_manifestation,906248-FS1,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
503460937,7/16/2014 19:56:05,,1324447012,7/16/2014 19:55:44,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[SYMPTOM],[SYMPTOM],denotes a milder psychosis,N/A,65,11,78,24,1,RO-has_manifestation,906248-FS1,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
503460937,7/16/2014 20:07:06,,1324451464,7/16/2014 20:04:37,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[SYMPTOM],[SYMPTOM],psychosis,n/a,65,11,78,24,1,RO-has_manifestation,906248-FS1,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
503460938,7/16/2014 13:34:31,,1324255615,7/16/2014 13:33:46,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],in the LUNGS,N/A,46,59,50,70,1,RO-disease_has_primary_anatomic_site,902200-FS1,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
503460938,7/16/2014 13:52:24,,1324261948,7/16/2014 13:52:10,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],the LUNGS of ten LUNG CANCER patients,N/a,46,59,50,70,1,RO-disease_has_primary_anatomic_site,902200-FS1,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
503460938,7/16/2014 13:57:33,,1324264118,7/16/2014 13:57:23,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[PREVENTS] [CAUSES],"[PREVENTS]
[CAUSES]",ferruginous patients history asbestos evaluated.,N/A,46,59,50,70,1,RO-disease_has_primary_anatomic_site,902200-FS1,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
503460938,7/16/2014 14:49:18,,1324284266,7/16/2014 14:48:55,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LUNGS LUNG CANCER,n/a,46,59,50,70,1,RO-disease_has_primary_anatomic_site,902200-FS1,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
503460938,7/16/2014 15:43:43,,1324303561,7/16/2014 15:43:27,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],in the LUNGS,n/a,46,59,50,70,1,RO-disease_has_primary_anatomic_site,902200-FS1,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
503460938,7/16/2014 16:15:19,,1324320119,7/16/2014 16:14:53,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],of ten,[DIAGNOSE_BY_TEST_OR_DRUG],46,59,50,70,1,RO-disease_has_primary_anatomic_site,902200-FS1,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
503460938,7/16/2014 16:19:16,,1324321694,7/16/2014 16:17:06,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],in the,na,46,59,50,70,1,RO-disease_has_primary_anatomic_site,902200-FS1,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
503460938,7/16/2014 16:34:32,,1324327363,7/16/2014 16:33:48,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[LOCATION],[LOCATION],in,none,46,59,50,70,1,RO-disease_has_primary_anatomic_site,902200-FS1,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
503460938,7/16/2014 17:03:19,,1324339158,7/16/2014 17:03:14,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,46,59,50,70,1,RO-disease_has_primary_anatomic_site,902200-FS1,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
503460938,7/16/2014 18:12:47,,1324390760,7/16/2014 18:12:04,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[LOCATION],[LOCATION],in the,na,46,59,50,70,1,RO-disease_has_primary_anatomic_site,902200-FS1,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
503460938,7/16/2014 18:19:42,,1324397886,7/16/2014 18:19:21,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],in the,na,46,59,50,70,1,RO-disease_has_primary_anatomic_site,902200-FS1,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
503460938,7/16/2014 18:29:03,,1324401761,7/16/2014 18:28:44,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[LOCATION],[LOCATION],distribution of ferruginous bodies in LUNGS of LUNG CANCER patients,N/A,46,59,50,70,1,RO-disease_has_primary_anatomic_site,902200-FS1,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
503460938,7/16/2014 19:38:54,,1324438571,7/16/2014 19:38:48,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],LUNGS,N/A,46,59,50,70,1,RO-disease_has_primary_anatomic_site,902200-FS1,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
503460938,7/16/2014 19:42:36,,1324440498,7/16/2014 19:41:01,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],distribution of ferruginous bodies,N/A,46,59,50,70,1,RO-disease_has_primary_anatomic_site,902200-FS1,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
503460938,7/16/2014 20:42:49,,1324467342,7/16/2014 20:42:29,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],in,N/A,46,59,50,70,1,RO-disease_has_primary_anatomic_site,902200-FS1,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
503460939,7/16/2014 13:31:04,,1324254014,7/16/2014 13:30:42,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[IS_A],[IS_A],divided into 5 groups:,na,167,154,196,162,-1,RO-has_definitional_manifestation,904983-FS1,"Two hundred and one headache patients attending the Headache Center of the University of Turin were selected for the study and divided into 5 groups: (1) MIGRAINE (2) EPISODIC TENSION TYPE HEADACHE (3) chronic tension type headache, (4) migraine associated with episodic tension type headache and (5) migraine associated with chronic tension type headache.",EPISODIC TENSION TYPE HEADACHE,MIGRAINE
503460939,7/16/2014 13:33:17,,1324255019,7/16/2014 13:33:02,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],5 groups: (1) (2) (3) (4),N/A,167,154,196,162,-1,RO-has_definitional_manifestation,904983-FS1,"Two hundred and one headache patients attending the Headache Center of the University of Turin were selected for the study and divided into 5 groups: (1) MIGRAINE (2) EPISODIC TENSION TYPE HEADACHE (3) chronic tension type headache, (4) migraine associated with episodic tension type headache and (5) migraine associated with chronic tension type headache.",EPISODIC TENSION TYPE HEADACHE,MIGRAINE
503460939,7/16/2014 13:39:30,,1324257429,7/16/2014 13:38:49,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",were selected associated with,N/A,167,154,196,162,-1,RO-has_definitional_manifestation,904983-FS1,"Two hundred and one headache patients attending the Headache Center of the University of Turin were selected for the study and divided into 5 groups: (1) MIGRAINE (2) EPISODIC TENSION TYPE HEADACHE (3) chronic tension type headache, (4) migraine associated with episodic tension type headache and (5) migraine associated with chronic tension type headache.",EPISODIC TENSION TYPE HEADACHE,MIGRAINE
503460939,7/16/2014 13:44:43,,1324259347,7/16/2014 13:44:00,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],headache patients were divided into 5 groups: (1) (2),N/A,167,154,196,162,-1,RO-has_definitional_manifestation,904983-FS1,"Two hundred and one headache patients attending the Headache Center of the University of Turin were selected for the study and divided into 5 groups: (1) MIGRAINE (2) EPISODIC TENSION TYPE HEADACHE (3) chronic tension type headache, (4) migraine associated with episodic tension type headache and (5) migraine associated with chronic tension type headache.",EPISODIC TENSION TYPE HEADACHE,MIGRAINE
503460939,7/16/2014 13:47:06,,1324260119,7/16/2014 13:46:45,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[ASSOCIATED_WITH],[ASSOCIATED_WITH],5 groups:,N/A,167,154,196,162,-1,RO-has_definitional_manifestation,904983-FS1,"Two hundred and one headache patients attending the Headache Center of the University of Turin were selected for the study and divided into 5 groups: (1) MIGRAINE (2) EPISODIC TENSION TYPE HEADACHE (3) chronic tension type headache, (4) migraine associated with episodic tension type headache and (5) migraine associated with chronic tension type headache.",EPISODIC TENSION TYPE HEADACHE,MIGRAINE
503460939,7/16/2014 13:55:41,,1324263271,7/16/2014 13:55:25,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[PREVENTS] [LOCATION] [IS_A],"[PREVENTS]
[LOCATION]
[IS_A]",study TENSION chronic migraine episodic,N/A,167,154,196,162,-1,RO-has_definitional_manifestation,904983-FS1,"Two hundred and one headache patients attending the Headache Center of the University of Turin were selected for the study and divided into 5 groups: (1) MIGRAINE (2) EPISODIC TENSION TYPE HEADACHE (3) chronic tension type headache, (4) migraine associated with episodic tension type headache and (5) migraine associated with chronic tension type headache.",EPISODIC TENSION TYPE HEADACHE,MIGRAINE
503460939,7/16/2014 15:45:13,,1324304234,7/16/2014 15:44:51,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[ASSOCIATED_WITH],[ASSOCIATED_WITH],headache patients (1) (2),N/A,167,154,196,162,-1,RO-has_definitional_manifestation,904983-FS1,"Two hundred and one headache patients attending the Headache Center of the University of Turin were selected for the study and divided into 5 groups: (1) MIGRAINE (2) EPISODIC TENSION TYPE HEADACHE (3) chronic tension type headache, (4) migraine associated with episodic tension type headache and (5) migraine associated with chronic tension type headache.",EPISODIC TENSION TYPE HEADACHE,MIGRAINE
503460939,7/16/2014 16:34:21,,1324327313,7/16/2014 16:34:06,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],groups:,N/A,167,154,196,162,-1,RO-has_definitional_manifestation,904983-FS1,"Two hundred and one headache patients attending the Headache Center of the University of Turin were selected for the study and divided into 5 groups: (1) MIGRAINE (2) EPISODIC TENSION TYPE HEADACHE (3) chronic tension type headache, (4) migraine associated with episodic tension type headache and (5) migraine associated with chronic tension type headache.",EPISODIC TENSION TYPE HEADACHE,MIGRAINE
503460939,7/16/2014 16:39:52,,1324330536,7/16/2014 16:38:58,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MIGRAINE EPISODIC TENSION TYPE HEADACHE,n/a,167,154,196,162,-1,RO-has_definitional_manifestation,904983-FS1,"Two hundred and one headache patients attending the Headache Center of the University of Turin were selected for the study and divided into 5 groups: (1) MIGRAINE (2) EPISODIC TENSION TYPE HEADACHE (3) chronic tension type headache, (4) migraine associated with episodic tension type headache and (5) migraine associated with chronic tension type headache.",EPISODIC TENSION TYPE HEADACHE,MIGRAINE
503460939,7/16/2014 16:44:32,,1324332705,7/16/2014 16:43:49,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",MIGRAINE EPISODIC TENSION TYPE HEADACHE,N/A,167,154,196,162,-1,RO-has_definitional_manifestation,904983-FS1,"Two hundred and one headache patients attending the Headache Center of the University of Turin were selected for the study and divided into 5 groups: (1) MIGRAINE (2) EPISODIC TENSION TYPE HEADACHE (3) chronic tension type headache, (4) migraine associated with episodic tension type headache and (5) migraine associated with chronic tension type headache.",EPISODIC TENSION TYPE HEADACHE,MIGRAINE
503460939,7/16/2014 19:12:23,,1324425738,7/16/2014 19:11:52,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[ASSOCIATED_WITH],[ASSOCIATED_WITH],divided into 5 groups:,N/A,167,154,196,162,-1,RO-has_definitional_manifestation,904983-FS1,"Two hundred and one headache patients attending the Headache Center of the University of Turin were selected for the study and divided into 5 groups: (1) MIGRAINE (2) EPISODIC TENSION TYPE HEADACHE (3) chronic tension type headache, (4) migraine associated with episodic tension type headache and (5) migraine associated with chronic tension type headache.",EPISODIC TENSION TYPE HEADACHE,MIGRAINE
503460939,7/16/2014 19:36:35,,1324437480,7/16/2014 19:35:48,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MIGRAINE HEADACHE,N/A,167,154,196,162,-1,RO-has_definitional_manifestation,904983-FS1,"Two hundred and one headache patients attending the Headache Center of the University of Turin were selected for the study and divided into 5 groups: (1) MIGRAINE (2) EPISODIC TENSION TYPE HEADACHE (3) chronic tension type headache, (4) migraine associated with episodic tension type headache and (5) migraine associated with chronic tension type headache.",EPISODIC TENSION TYPE HEADACHE,MIGRAINE
503460939,7/16/2014 19:56:47,,1324447268,7/16/2014 19:56:18,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],divided into 5 groups:,different condition,167,154,196,162,-1,RO-has_definitional_manifestation,904983-FS1,"Two hundred and one headache patients attending the Headache Center of the University of Turin were selected for the study and divided into 5 groups: (1) MIGRAINE (2) EPISODIC TENSION TYPE HEADACHE (3) chronic tension type headache, (4) migraine associated with episodic tension type headache and (5) migraine associated with chronic tension type headache.",EPISODIC TENSION TYPE HEADACHE,MIGRAINE
503460939,7/16/2014 20:32:25,,1324463225,7/16/2014 20:31:28,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],headache patients Headache Center 5 groups: (1) MIGRAINE (2) EPISODIC TENSION TYPE HEADACHE,Is A,167,154,196,162,-1,RO-has_definitional_manifestation,904983-FS1,"Two hundred and one headache patients attending the Headache Center of the University of Turin were selected for the study and divided into 5 groups: (1) MIGRAINE (2) EPISODIC TENSION TYPE HEADACHE (3) chronic tension type headache, (4) migraine associated with episodic tension type headache and (5) migraine associated with chronic tension type headache.",EPISODIC TENSION TYPE HEADACHE,MIGRAINE
503460939,7/16/2014 20:56:57,,1324473032,7/16/2014 20:56:40,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[IS_A],[IS_A],MIGRAINE HEADACHE,N/A,167,154,196,162,-1,RO-has_definitional_manifestation,904983-FS1,"Two hundred and one headache patients attending the Headache Center of the University of Turin were selected for the study and divided into 5 groups: (1) MIGRAINE (2) EPISODIC TENSION TYPE HEADACHE (3) chronic tension type headache, (4) migraine associated with episodic tension type headache and (5) migraine associated with chronic tension type headache.",EPISODIC TENSION TYPE HEADACHE,MIGRAINE
503460940,7/16/2014 13:33:23,,1324255068,7/16/2014 13:32:36,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[MANIFESTATION],[MANIFESTATION],VIRUSES,asd,124,143,130,158,1,RO-has_causative_agent,903536-FS1,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
503460940,7/16/2014 13:33:56,,1324255332,7/16/2014 13:33:30,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],during the VIRAL INFECTION cycle.,n/a,124,143,130,158,1,RO-has_causative_agent,903536-FS1,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
503460940,7/16/2014 13:34:52,,1324255750,7/16/2014 13:34:32,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[PART_OF],[PART_OF],during the,N/A,124,143,130,158,1,RO-has_causative_agent,903536-FS1,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
503460940,7/16/2014 13:41:18,,1324258120,7/16/2014 13:40:47,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],VIRUSES VIRAL INFECTION,N/A,124,143,130,158,1,RO-has_causative_agent,903536-FS1,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
503460940,7/16/2014 13:45:03,,1324259453,7/16/2014 13:44:36,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],during,N/A,124,143,130,158,1,RO-has_causative_agent,903536-FS1,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
503460940,7/16/2014 13:53:51,,1324262530,7/16/2014 13:53:30,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],during the,N/a,124,143,130,158,1,RO-has_causative_agent,903536-FS1,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
503460940,7/16/2014 13:56:59,,1324263817,7/16/2014 13:56:49,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",mode the extract added VIRUSES,N/A,124,143,130,158,1,RO-has_causative_agent,903536-FS1,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
503460940,7/16/2014 15:44:25,,1324303885,7/16/2014 15:43:59,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],VIRAL,n/a,124,143,130,158,1,RO-has_causative_agent,903536-FS1,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
503460940,7/16/2014 16:38:45,,1324329962,7/16/2014 16:38:23,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],VIRUSES during VIRAL INFECTION,N/A,124,143,130,158,1,RO-has_causative_agent,903536-FS1,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
503460940,7/16/2014 16:52:59,,1324335682,7/16/2014 16:52:28,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[CAUSES],[CAUSES],VIRUSES during the VIRAL INFECTION cycle.,N/A,124,143,130,158,1,RO-has_causative_agent,903536-FS1,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
503460940,7/16/2014 16:57:48,,1324337337,7/16/2014 16:57:12,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[CAUSES],[CAUSES],added to cells during VIRAL INFECTION,N/A,124,143,130,158,1,RO-has_causative_agent,903536-FS1,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
503460940,7/16/2014 19:17:54,,1324428660,7/16/2014 19:17:35,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",VIRUSES during the VIRAL INFECTION cycle.,N/A,124,143,130,158,1,RO-has_causative_agent,903536-FS1,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
503460940,7/16/2014 19:41:13,,1324439779,7/16/2014 19:40:59,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],VIRUSES VIRAL,N/A,124,143,130,158,1,RO-has_causative_agent,903536-FS1,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
503460940,7/16/2014 19:57:42,,1324447661,7/16/2014 19:57:25,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],during the,N/A,124,143,130,158,1,RO-has_causative_agent,903536-FS1,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
503460940,7/16/2014 20:33:43,,1324463700,7/16/2014 20:33:07,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[CAUSES],[CAUSES],during the,N/A,124,143,130,158,1,RO-has_causative_agent,903536-FS1,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
503460941,7/16/2014 13:30:41,,1324253819,7/16/2014 13:30:11,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],used to analyse,na,175,242,186,261,-1,RO-disease_may_have_finding,902601-FS1,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
503460941,7/16/2014 13:34:03,,1324255388,7/16/2014 13:33:22,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],specimens,N/A,175,242,186,261,-1,RO-disease_may_have_finding,902601-FS1,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
503460941,7/16/2014 13:35:10,,1324255880,7/16/2014 13:34:53,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],specimens,Na,175,242,186,261,-1,RO-disease_may_have_finding,902601-FS1,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
503460941,7/16/2014 13:47:42,,1324260337,7/16/2014 13:47:25,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[ASSOCIATED_WITH],[ASSOCIATED_WITH],following specimens,N/A,175,242,186,261,-1,RO-disease_may_have_finding,902601-FS1,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
503460941,7/16/2014 13:49:29,,1324260904,7/16/2014 13:49:06,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],human thyroid tissue: (1) COLD NODULES; (4) MEDULLARY CARCINOMA;,N/a,175,242,186,261,-1,RO-disease_may_have_finding,902601-FS1,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
503460941,7/16/2014 13:51:38,,1324261679,7/16/2014 13:51:04,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[NONE],[NONE],N/A,"Different, unrelated types of tissue",175,242,186,261,-1,RO-disease_may_have_finding,902601-FS1,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
503460941,7/16/2014 13:58:41,,1324264613,7/16/2014 13:58:32,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]","NODULES; papillary carcinoma, Graves'",N/A,175,242,186,261,-1,RO-disease_may_have_finding,902601-FS1,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
503460941,7/16/2014 14:52:55,,1324285311,7/16/2014 14:51:24,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[ASSOCIATED_WITH] [OTHER] [LOCATION],"[LOCATION]
[ASSOCIATED_WITH]
[OTHER]",specimens of human thyroid tissue:,N/A,175,242,186,261,-1,RO-disease_may_have_finding,902601-FS1,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
503460941,7/16/2014 15:50:29,,1324306488,7/16/2014 15:49:12,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n/a,examples of problems found in the thyroid,175,242,186,261,-1,RO-disease_may_have_finding,902601-FS1,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
503460941,7/16/2014 16:22:47,,1324323027,7/16/2014 16:22:12,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM] [PREVENTS],"[PREVENTS]
[SYMPTOM]",labelling with,na,175,242,186,261,-1,RO-disease_may_have_finding,902601-FS1,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
503460941,7/16/2014 17:46:58,,1324364136,7/16/2014 17:44:02,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,They are simply two separate items in the same list.,175,242,186,261,-1,RO-disease_may_have_finding,902601-FS1,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
503460941,7/16/2014 19:42:04,,1324440252,7/16/2014 19:41:42,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(1) (2) (3) (4),N/A,175,242,186,261,-1,RO-disease_may_have_finding,902601-FS1,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
503460941,7/16/2014 19:46:00,,1324442247,7/16/2014 19:45:41,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],and,N/A,175,242,186,261,-1,RO-disease_may_have_finding,902601-FS1,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
503460941,7/16/2014 20:03:30,,1324449845,7/16/2014 20:02:56,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different specimens,175,242,186,261,-1,RO-disease_may_have_finding,902601-FS1,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
503460941,7/16/2014 20:39:00,,1324465838,7/16/2014 20:37:48,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION] [MANIFESTATION],"[LOCATION]
[MANIFESTATION]",following specimens of human thyroid tissue: COLD NODULES; MEDULLARY CARCINOMA;,Location / Manifestation,175,242,186,261,-1,RO-disease_may_have_finding,902601-FS1,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
503460942,7/16/2014 13:32:29,,1324254677,7/16/2014 13:32:03,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,COMPLETELY UNRELATED WORDS,21,0,23,12,-1,RO-disease_has_finding,901754-FS1,PREECLAMPSIA (PE) is ONE of the most severe complications of pregnancy.,ONE,PREECLAMPSIA
503460942,7/16/2014 13:38:11,,1324256957,7/16/2014 13:37:30,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],is of,N/A,21,0,23,12,-1,RO-disease_has_finding,901754-FS1,PREECLAMPSIA (PE) is ONE of the most severe complications of pregnancy.,ONE,PREECLAMPSIA
503460942,7/16/2014 13:42:47,,1324258702,7/16/2014 13:42:22,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],PREECLAMPSIA,asd,21,0,23,12,-1,RO-disease_has_finding,901754-FS1,PREECLAMPSIA (PE) is ONE of the most severe complications of pregnancy.,ONE,PREECLAMPSIA
503460942,7/16/2014 13:43:36,,1324258967,7/16/2014 13:43:08,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,there is no relationship between these two words,21,0,23,12,-1,RO-disease_has_finding,901754-FS1,PREECLAMPSIA (PE) is ONE of the most severe complications of pregnancy.,ONE,PREECLAMPSIA
503460942,7/16/2014 13:44:13,,1324259205,7/16/2014 13:43:40,instagc,1.0,13763729,USA,"","",75.182.89.225,[NONE],[NONE],N/A,One is quantitative.,21,0,23,12,-1,RO-disease_has_finding,901754-FS1,PREECLAMPSIA (PE) is ONE of the most severe complications of pregnancy.,ONE,PREECLAMPSIA
503460942,7/16/2014 15:28:49,,1324297899,7/16/2014 15:28:24,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[NONE],[NONE],n/a,wrong but highlighted,21,0,23,12,-1,RO-disease_has_finding,901754-FS1,PREECLAMPSIA (PE) is ONE of the most severe complications of pregnancy.,ONE,PREECLAMPSIA
503460942,7/16/2014 16:32:17,,1324326549,7/16/2014 16:29:45,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",severe complications,na,21,0,23,12,-1,RO-disease_has_finding,901754-FS1,PREECLAMPSIA (PE) is ONE of the most severe complications of pregnancy.,ONE,PREECLAMPSIA
503460942,7/16/2014 16:53:17,,1324335787,7/16/2014 16:52:12,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[SYMPTOM],[SYMPTOM],complications,NONE,21,0,23,12,-1,RO-disease_has_finding,901754-FS1,PREECLAMPSIA (PE) is ONE of the most severe complications of pregnancy.,ONE,PREECLAMPSIA
503460942,7/16/2014 17:02:54,,1324339050,7/16/2014 17:02:47,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,21,0,23,12,-1,RO-disease_has_finding,901754-FS1,PREECLAMPSIA (PE) is ONE of the most severe complications of pregnancy.,ONE,PREECLAMPSIA
503460942,7/16/2014 18:08:02,,1324385922,7/16/2014 18:07:21,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[IS_A],[IS_A],is,na,21,0,23,12,-1,RO-disease_has_finding,901754-FS1,PREECLAMPSIA (PE) is ONE of the most severe complications of pregnancy.,ONE,PREECLAMPSIA
503460942,7/16/2014 18:45:52,,1324410161,7/16/2014 18:44:56,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[NONE],[NONE],n/a,One is a number so it just quantifies the number of symptoms,21,0,23,12,-1,RO-disease_has_finding,901754-FS1,PREECLAMPSIA (PE) is ONE of the most severe complications of pregnancy.,ONE,PREECLAMPSIA
503460942,7/16/2014 19:21:29,,1324430365,7/16/2014 19:21:03,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[NONE],[NONE],n/a,preeclampsyia is not related to the work one,21,0,23,12,-1,RO-disease_has_finding,901754-FS1,PREECLAMPSIA (PE) is ONE of the most severe complications of pregnancy.,ONE,PREECLAMPSIA
503460942,7/16/2014 19:24:25,,1324431695,7/16/2014 19:23:51,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",severe complications,N/A,21,0,23,12,-1,RO-disease_has_finding,901754-FS1,PREECLAMPSIA (PE) is ONE of the most severe complications of pregnancy.,ONE,PREECLAMPSIA
503460942,7/16/2014 19:35:47,,1324437171,7/16/2014 19:35:36,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],is,N/A,21,0,23,12,-1,RO-disease_has_finding,901754-FS1,PREECLAMPSIA (PE) is ONE of the most severe complications of pregnancy.,ONE,PREECLAMPSIA
503460942,7/16/2014 19:46:36,,1324442568,7/16/2014 19:46:21,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],is,N/A,21,0,23,12,-1,RO-disease_has_finding,901754-FS1,PREECLAMPSIA (PE) is ONE of the most severe complications of pregnancy.,ONE,PREECLAMPSIA
503460943,7/16/2014 13:36:20,,1324256314,7/16/2014 13:35:51,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[PART_OF],[PART_OF],as increased.,N/A,100,0,108,23,1,RO-disease_has_finding,901910-FS1,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
503460943,7/16/2014 13:41:44,,1324258268,7/16/2014 13:41:20,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],reduction parenchymal positivity ANAPLASIA increased.,n/a,100,0,108,23,1,RO-disease_has_finding,901910-FS1,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
503460943,7/16/2014 13:53:57,,1324262589,7/16/2014 13:53:32,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[TREATS],[TREATS],reduction increased.,N/A,100,0,108,23,1,RO-disease_has_finding,901910-FS1,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
503460943,7/16/2014 14:01:21,,1324265646,7/16/2014 14:00:43,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],ANAPLASTIC ASTROCYTOMAS showed progressive reduction as ANAPLASIA increased.,N/A,100,0,108,23,1,RO-disease_has_finding,901910-FS1,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
503460943,7/16/2014 14:35:15,,1324279765,7/16/2014 14:34:32,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[SYMPTOM],[SYMPTOM],showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,N/A,100,0,108,23,1,RO-disease_has_finding,901910-FS1,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
503460943,7/16/2014 14:48:47,,1324284105,7/16/2014 14:48:04,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANAPLASTIC ASTROCYTOMAS ANAPLASIA,n/a,100,0,108,23,1,RO-disease_has_finding,901910-FS1,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
503460943,7/16/2014 14:58:53,,1324287538,7/16/2014 14:58:14,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS],[TREATS],showed progressive reduction of,N/A,100,0,108,23,1,RO-disease_has_finding,901910-FS1,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
503460943,7/16/2014 15:28:22,,1324297735,7/16/2014 15:28:06,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],ANAPLASTIC,n/a,100,0,108,23,1,RO-disease_has_finding,901910-FS1,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
503460943,7/16/2014 15:38:49,,1324301491,7/16/2014 15:36:59,prodege,1.0,27990290,GBR,I9,Bury Saint Edmunds,86.142.231.81,[TREATS],[TREATS],showed progressive reduction as ANAPLASIA increased.,the anaplasia treats the ANAPLASTIC ASTROCYTOMAS and glioblastomas when increased,100,0,108,23,1,RO-disease_has_finding,901910-FS1,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
503460943,7/16/2014 15:41:38,,1324302712,7/16/2014 15:41:03,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",showed progressive reduction,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],100,0,108,23,1,RO-disease_has_finding,901910-FS1,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
503460943,7/16/2014 16:19:54,,1324321969,7/16/2014 16:18:35,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as,N/A,100,0,108,23,1,RO-disease_has_finding,901910-FS1,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
503460943,7/16/2014 16:48:17,,1324334077,7/16/2014 16:47:17,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[PART_OF] [OTHER] [MANIFESTATION],"[MANIFESTATION]
[PART_OF]
[OTHER]",ANAPLASTIC ASTROCYTOMAS showed reduction as ANAPLASIA increased.,N/A,100,0,108,23,1,RO-disease_has_finding,901910-FS1,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
503460943,7/16/2014 17:06:59,,1324340339,7/16/2014 17:06:55,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,100,0,108,23,1,RO-disease_has_finding,901910-FS1,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
503460943,7/16/2014 17:41:52,,1324358911,7/16/2014 17:40:13,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],showed progressive reduction of parenchymal positivity as,n/a,100,0,108,23,1,RO-disease_has_finding,901910-FS1,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
503460943,7/16/2014 18:47:22,,1324410943,7/16/2014 18:46:55,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANAPLASTIC ASTROCYTOMAS showed progressive reduction as ANAPLASIA increased.,n/a,100,0,108,23,1,RO-disease_has_finding,901910-FS1,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
503460944,7/16/2014 13:38:07,,1324256917,7/16/2014 13:37:48,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],identify both the,n/a,73,160,111,182,-1,RO-has_causative_agent,903814-FS1,"This antigen detecting procedure has also been used to identify both the PHYLOGENETICALLY DISTANT RABIES VIRUSES from silver haired bat and vampire bat and the RABIES RELATED VIRUSES Mokola, Duvenhage, and Lagos bat.",PHYLOGENETICALLY DISTANT RABIES VIRUSES,RABIES RELATED VIRUSES
503460944,7/16/2014 13:41:26,,1324258171,7/16/2014 13:40:47,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],detecting,N/A,73,160,111,182,-1,RO-has_causative_agent,903814-FS1,"This antigen detecting procedure has also been used to identify both the PHYLOGENETICALLY DISTANT RABIES VIRUSES from silver haired bat and vampire bat and the RABIES RELATED VIRUSES Mokola, Duvenhage, and Lagos bat.",PHYLOGENETICALLY DISTANT RABIES VIRUSES,RABIES RELATED VIRUSES
503460944,7/16/2014 13:49:17,,1324260841,7/16/2014 13:48:29,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],been used to identify,N/A,73,160,111,182,-1,RO-has_causative_agent,903814-FS1,"This antigen detecting procedure has also been used to identify both the PHYLOGENETICALLY DISTANT RABIES VIRUSES from silver haired bat and vampire bat and the RABIES RELATED VIRUSES Mokola, Duvenhage, and Lagos bat.",PHYLOGENETICALLY DISTANT RABIES VIRUSES,RABIES RELATED VIRUSES
503460944,7/16/2014 13:59:58,,1324265217,7/16/2014 13:59:47,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]","both PHYLOGENETICALLY Mokola, Duvenhage,",N/A,73,160,111,182,-1,RO-has_causative_agent,903814-FS1,"This antigen detecting procedure has also been used to identify both the PHYLOGENETICALLY DISTANT RABIES VIRUSES from silver haired bat and vampire bat and the RABIES RELATED VIRUSES Mokola, Duvenhage, and Lagos bat.",PHYLOGENETICALLY DISTANT RABIES VIRUSES,RABIES RELATED VIRUSES
503460944,7/16/2014 15:25:19,,1324296917,7/16/2014 15:24:33,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n/a,both examples of viruses detected,73,160,111,182,-1,RO-has_causative_agent,903814-FS1,"This antigen detecting procedure has also been used to identify both the PHYLOGENETICALLY DISTANT RABIES VIRUSES from silver haired bat and vampire bat and the RABIES RELATED VIRUSES Mokola, Duvenhage, and Lagos bat.",PHYLOGENETICALLY DISTANT RABIES VIRUSES,RABIES RELATED VIRUSES
503460944,7/16/2014 15:40:52,,1324302380,7/16/2014 15:40:31,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RABIES,N/A,73,160,111,182,-1,RO-has_causative_agent,903814-FS1,"This antigen detecting procedure has also been used to identify both the PHYLOGENETICALLY DISTANT RABIES VIRUSES from silver haired bat and vampire bat and the RABIES RELATED VIRUSES Mokola, Duvenhage, and Lagos bat.",PHYLOGENETICALLY DISTANT RABIES VIRUSES,RABIES RELATED VIRUSES
503460944,7/16/2014 16:22:31,,1324322929,7/16/2014 16:22:17,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,73,160,111,182,-1,RO-has_causative_agent,903814-FS1,"This antigen detecting procedure has also been used to identify both the PHYLOGENETICALLY DISTANT RABIES VIRUSES from silver haired bat and vampire bat and the RABIES RELATED VIRUSES Mokola, Duvenhage, and Lagos bat.",PHYLOGENETICALLY DISTANT RABIES VIRUSES,RABIES RELATED VIRUSES
503460944,7/16/2014 16:25:10,,1324323965,7/16/2014 16:24:13,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PHYLOGENETICALLY DISTANT RABIES VIRUSES RABIES RELATED VIRUSES,n/a,73,160,111,182,-1,RO-has_causative_agent,903814-FS1,"This antigen detecting procedure has also been used to identify both the PHYLOGENETICALLY DISTANT RABIES VIRUSES from silver haired bat and vampire bat and the RABIES RELATED VIRUSES Mokola, Duvenhage, and Lagos bat.",PHYLOGENETICALLY DISTANT RABIES VIRUSES,RABIES RELATED VIRUSES
503460944,7/16/2014 16:55:13,,1324336412,7/16/2014 16:54:23,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[OTHER],[OTHER],also been used to identify both,N/A,73,160,111,182,-1,RO-has_causative_agent,903814-FS1,"This antigen detecting procedure has also been used to identify both the PHYLOGENETICALLY DISTANT RABIES VIRUSES from silver haired bat and vampire bat and the RABIES RELATED VIRUSES Mokola, Duvenhage, and Lagos bat.",PHYLOGENETICALLY DISTANT RABIES VIRUSES,RABIES RELATED VIRUSES
503460944,7/16/2014 18:14:18,,1324392344,7/16/2014 18:13:20,clixsense,1.0,6621167,USA,"","",66.87.78.42,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,73,160,111,182,-1,RO-has_causative_agent,903814-FS1,"This antigen detecting procedure has also been used to identify both the PHYLOGENETICALLY DISTANT RABIES VIRUSES from silver haired bat and vampire bat and the RABIES RELATED VIRUSES Mokola, Duvenhage, and Lagos bat.",PHYLOGENETICALLY DISTANT RABIES VIRUSES,RABIES RELATED VIRUSES
503460944,7/16/2014 18:24:55,,1324399915,7/16/2014 18:24:18,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,73,160,111,182,-1,RO-has_causative_agent,903814-FS1,"This antigen detecting procedure has also been used to identify both the PHYLOGENETICALLY DISTANT RABIES VIRUSES from silver haired bat and vampire bat and the RABIES RELATED VIRUSES Mokola, Duvenhage, and Lagos bat.",PHYLOGENETICALLY DISTANT RABIES VIRUSES,RABIES RELATED VIRUSES
503460944,7/16/2014 19:05:24,,1324421793,7/16/2014 19:03:34,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,73,160,111,182,-1,RO-has_causative_agent,903814-FS1,"This antigen detecting procedure has also been used to identify both the PHYLOGENETICALLY DISTANT RABIES VIRUSES from silver haired bat and vampire bat and the RABIES RELATED VIRUSES Mokola, Duvenhage, and Lagos bat.",PHYLOGENETICALLY DISTANT RABIES VIRUSES,RABIES RELATED VIRUSES
503460944,7/16/2014 19:18:13,,1324428847,7/16/2014 19:17:55,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[IS_A],[IS_A],and the RABIES RELATED VIRUSES,N/A,73,160,111,182,-1,RO-has_causative_agent,903814-FS1,"This antigen detecting procedure has also been used to identify both the PHYLOGENETICALLY DISTANT RABIES VIRUSES from silver haired bat and vampire bat and the RABIES RELATED VIRUSES Mokola, Duvenhage, and Lagos bat.",PHYLOGENETICALLY DISTANT RABIES VIRUSES,RABIES RELATED VIRUSES
503460944,7/16/2014 19:23:46,,1324431382,7/16/2014 19:23:25,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[SIDE_EFFECT],[SIDE_EFFECT],RABIES,both are types of rabies,73,160,111,182,-1,RO-has_causative_agent,903814-FS1,"This antigen detecting procedure has also been used to identify both the PHYLOGENETICALLY DISTANT RABIES VIRUSES from silver haired bat and vampire bat and the RABIES RELATED VIRUSES Mokola, Duvenhage, and Lagos bat.",PHYLOGENETICALLY DISTANT RABIES VIRUSES,RABIES RELATED VIRUSES
503460944,7/16/2014 19:29:40,,1324434328,7/16/2014 19:27:45,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],been used to identify,N/A,73,160,111,182,-1,RO-has_causative_agent,903814-FS1,"This antigen detecting procedure has also been used to identify both the PHYLOGENETICALLY DISTANT RABIES VIRUSES from silver haired bat and vampire bat and the RABIES RELATED VIRUSES Mokola, Duvenhage, and Lagos bat.",PHYLOGENETICALLY DISTANT RABIES VIRUSES,RABIES RELATED VIRUSES
503460945,7/16/2014 13:37:31,,1324256699,7/16/2014 13:36:56,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],IN SITU,N/A,102,119,117,136,-1,RO-disease_has_finding,901517-FS1,"Both in mice and in human material, the histological changes were classified into slight, moderate or SEVERE DYSPLASIA CARCINOMA IN SITU questionable invasive carcinoma and invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503460945,7/16/2014 13:37:57,,1324256850,7/16/2014 13:37:20,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],histological changes SEVERE DYSPLASIA CARCINOMA IN SITU,N/A,102,119,117,136,-1,RO-disease_has_finding,901517-FS1,"Both in mice and in human material, the histological changes were classified into slight, moderate or SEVERE DYSPLASIA CARCINOMA IN SITU questionable invasive carcinoma and invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503460945,7/16/2014 13:39:48,,1324257538,7/16/2014 13:39:37,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],invasive,Na,102,119,117,136,-1,RO-disease_has_finding,901517-FS1,"Both in mice and in human material, the histological changes were classified into slight, moderate or SEVERE DYSPLASIA CARCINOMA IN SITU questionable invasive carcinoma and invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503460945,7/16/2014 13:49:20,,1324260850,7/16/2014 13:49:03,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],SEVERE DYSPLASIA CARCINOMA IN SITU,All one term,102,119,117,136,-1,RO-disease_has_finding,901517-FS1,"Both in mice and in human material, the histological changes were classified into slight, moderate or SEVERE DYSPLASIA CARCINOMA IN SITU questionable invasive carcinoma and invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503460945,7/16/2014 14:46:54,,1324283530,7/16/2014 14:46:34,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[PART_OF],[PART_OF],SEVERE DYSPLASIA CARCINOMA IN SITU,N/A,102,119,117,136,-1,RO-disease_has_finding,901517-FS1,"Both in mice and in human material, the histological changes were classified into slight, moderate or SEVERE DYSPLASIA CARCINOMA IN SITU questionable invasive carcinoma and invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503460945,7/16/2014 15:00:48,,1324288255,7/16/2014 14:58:54,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[NONE],[NONE],N/A,"They are completely different classifications of histological changes, and therefore unrelated",102,119,117,136,-1,RO-disease_has_finding,901517-FS1,"Both in mice and in human material, the histological changes were classified into slight, moderate or SEVERE DYSPLASIA CARCINOMA IN SITU questionable invasive carcinoma and invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503460945,7/16/2014 15:18:49,,1324294732,7/16/2014 15:18:36,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE DYSPLASIA CARCINOMA IN SITU,N/A,102,119,117,136,-1,RO-disease_has_finding,901517-FS1,"Both in mice and in human material, the histological changes were classified into slight, moderate or SEVERE DYSPLASIA CARCINOMA IN SITU questionable invasive carcinoma and invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503460945,7/16/2014 16:11:43,,1324318454,7/16/2014 16:10:49,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[PART_OF],[PART_OF],SEVERE DYSPLASIA CARCINOMA IN SITU,n/a,102,119,117,136,-1,RO-disease_has_finding,901517-FS1,"Both in mice and in human material, the histological changes were classified into slight, moderate or SEVERE DYSPLASIA CARCINOMA IN SITU questionable invasive carcinoma and invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503460945,7/16/2014 16:35:46,,1324328029,7/16/2014 16:34:52,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],histological changes,N/A,102,119,117,136,-1,RO-disease_has_finding,901517-FS1,"Both in mice and in human material, the histological changes were classified into slight, moderate or SEVERE DYSPLASIA CARCINOMA IN SITU questionable invasive carcinoma and invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503460945,7/16/2014 17:03:43,,1324339291,7/16/2014 17:03:39,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,102,119,117,136,-1,RO-disease_has_finding,901517-FS1,"Both in mice and in human material, the histological changes were classified into slight, moderate or SEVERE DYSPLASIA CARCINOMA IN SITU questionable invasive carcinoma and invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503460945,7/16/2014 19:19:41,,1324429485,7/16/2014 19:19:03,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE DYSPLASIA CARCINOMA IN SITU,N/A,102,119,117,136,-1,RO-disease_has_finding,901517-FS1,"Both in mice and in human material, the histological changes were classified into slight, moderate or SEVERE DYSPLASIA CARCINOMA IN SITU questionable invasive carcinoma and invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503460945,7/16/2014 20:23:33,,1324459261,7/16/2014 20:22:12,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],classified into,n/a,102,119,117,136,-1,RO-disease_has_finding,901517-FS1,"Both in mice and in human material, the histological changes were classified into slight, moderate or SEVERE DYSPLASIA CARCINOMA IN SITU questionable invasive carcinoma and invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503460945,7/16/2014 20:39:36,,1324466095,7/16/2014 20:38:59,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[PART_OF],[PART_OF],SEVERE DYSPLASIA CARCINOMA IN SITU,N/A,102,119,117,136,-1,RO-disease_has_finding,901517-FS1,"Both in mice and in human material, the histological changes were classified into slight, moderate or SEVERE DYSPLASIA CARCINOMA IN SITU questionable invasive carcinoma and invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503460945,7/16/2014 20:47:41,,1324469354,7/16/2014 20:46:02,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],SEVERE DYSPLASIA CARCINOMA IN SITU,N/A,102,119,117,136,-1,RO-disease_has_finding,901517-FS1,"Both in mice and in human material, the histological changes were classified into slight, moderate or SEVERE DYSPLASIA CARCINOMA IN SITU questionable invasive carcinoma and invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503460945,7/16/2014 20:59:05,,1324474002,7/16/2014 20:58:53,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[LOCATION],[LOCATION],carcinoma.,NONE,102,119,117,136,-1,RO-disease_has_finding,901517-FS1,"Both in mice and in human material, the histological changes were classified into slight, moderate or SEVERE DYSPLASIA CARCINOMA IN SITU questionable invasive carcinoma and invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503460946,7/16/2014 13:27:41,,1324252560,7/16/2014 13:27:32,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],treated with high dose,N/A,28,60,35,72,1,RO-may_treat,908155-FS1,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
503460946,7/16/2014 13:32:16,,1324254604,7/16/2014 13:32:02,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],treated with high dose,n/a,28,60,35,72,1,RO-may_treat,908155-FS1,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
503460946,7/16/2014 13:40:49,,1324257924,7/16/2014 13:40:39,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],treated,Na,28,60,35,72,1,RO-may_treat,908155-FS1,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
503460946,7/16/2014 13:45:54,,1324259737,7/16/2014 13:45:42,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[TREATS],[TREATS],treated,N/A,28,60,35,72,1,RO-may_treat,908155-FS1,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
503460946,7/16/2014 13:47:33,,1324260271,7/16/2014 13:47:12,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],treated with,N/A,28,60,35,72,1,RO-may_treat,908155-FS1,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
503460946,7/16/2014 15:26:35,,1324297240,7/16/2014 15:26:15,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],treated,n/a,28,60,35,72,1,RO-may_treat,908155-FS1,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
503460946,7/16/2014 15:41:01,,1324302421,7/16/2014 15:40:40,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[TREATS],[TREATS],treated with high dose,[TREATS],28,60,35,72,1,RO-may_treat,908155-FS1,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
503460946,7/16/2014 15:42:18,,1324302929,7/16/2014 15:41:20,prodege,1.0,27990290,GBR,I9,Bury Saint Edmunds,86.142.231.81,[TREATS],[TREATS],treated,methotrexate treats leukemia,28,60,35,72,1,RO-may_treat,908155-FS1,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
503460946,7/16/2014 16:28:03,,1324324998,7/16/2014 16:27:53,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treated,N/A,28,60,35,72,1,RO-may_treat,908155-FS1,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
503460946,7/16/2014 16:29:19,,1324325474,7/16/2014 16:27:58,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[OTHER],[OTHER],LEUKEMIA treated with METHOTREXATE,N/A,28,60,35,72,1,RO-may_treat,908155-FS1,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
503460946,7/16/2014 18:28:05,,1324401328,7/16/2014 18:27:02,prodege,1.0,20349329,USA,CA,El Cajon,68.7.51.119,[TREATS],[TREATS],LEUKEMIA treated with METHOTREXATE,N/A,28,60,35,72,1,RO-may_treat,908155-FS1,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
503460946,7/16/2014 18:28:42,,1324401676,7/16/2014 18:28:26,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],LEUKEMIA treated with high dose METHOTREXATE,N/A,28,60,35,72,1,RO-may_treat,908155-FS1,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
503460946,7/16/2014 19:03:08,,1324420336,7/16/2014 19:02:56,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],treated,N/A,28,60,35,72,1,RO-may_treat,908155-FS1,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
503460946,7/16/2014 19:20:36,,1324429942,7/16/2014 19:20:12,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],treated with,IS TREATED BY,28,60,35,72,1,RO-may_treat,908155-FS1,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
503460946,7/16/2014 19:32:11,,1324435500,7/16/2014 19:31:51,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],treated,N/A,28,60,35,72,1,RO-may_treat,908155-FS1,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
503460947,7/16/2014 13:30:55,,1324253964,7/16/2014 13:30:37,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],"own experiences course of the lupus erythematosus visceralis and LUPUS NEPHRITIS during pregnancy,",N/A,117,172,131,202,-1,RO-has_manifestation,906012-FS1,"With the help of the literature and on the basis of own experiences course of the lupus erythematosus visceralis and LUPUS NEPHRITIS during pregnancy, the influence of the LUPUS ERYTHEMATOSUS VISCERALIS on pregnancy and development of the child, peculiarities of the treatment of lupus erythematosus visceralis during pregnancy as well as questions of prevention and interruption of pregnancy are discussed.",LUPUS NEPHRITIS,LUPUS ERYTHEMATOSUS VISCERALIS
503460947,7/16/2014 13:36:35,,1324256394,7/16/2014 13:36:20,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],influence,Na,117,172,131,202,-1,RO-has_manifestation,906012-FS1,"With the help of the literature and on the basis of own experiences course of the lupus erythematosus visceralis and LUPUS NEPHRITIS during pregnancy, the influence of the LUPUS ERYTHEMATOSUS VISCERALIS on pregnancy and development of the child, peculiarities of the treatment of lupus erythematosus visceralis during pregnancy as well as questions of prevention and interruption of pregnancy are discussed.",LUPUS NEPHRITIS,LUPUS ERYTHEMATOSUS VISCERALIS
503460947,7/16/2014 13:39:46,,1324257505,7/16/2014 13:38:52,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],"course of the lupus erythematosus visceralis and during pregnancy,",N/A,117,172,131,202,-1,RO-has_manifestation,906012-FS1,"With the help of the literature and on the basis of own experiences course of the lupus erythematosus visceralis and LUPUS NEPHRITIS during pregnancy, the influence of the LUPUS ERYTHEMATOSUS VISCERALIS on pregnancy and development of the child, peculiarities of the treatment of lupus erythematosus visceralis during pregnancy as well as questions of prevention and interruption of pregnancy are discussed.",LUPUS NEPHRITIS,LUPUS ERYTHEMATOSUS VISCERALIS
503460947,7/16/2014 13:51:52,,1324261761,7/16/2014 13:51:28,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LUPUS LUPUS,N/A,117,172,131,202,-1,RO-has_manifestation,906012-FS1,"With the help of the literature and on the basis of own experiences course of the lupus erythematosus visceralis and LUPUS NEPHRITIS during pregnancy, the influence of the LUPUS ERYTHEMATOSUS VISCERALIS on pregnancy and development of the child, peculiarities of the treatment of lupus erythematosus visceralis during pregnancy as well as questions of prevention and interruption of pregnancy are discussed.",LUPUS NEPHRITIS,LUPUS ERYTHEMATOSUS VISCERALIS
503460947,7/16/2014 13:53:26,,1324262385,7/16/2014 13:53:03,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[TREATS] [SYMPTOM],"[TREATS]
[SYMPTOM]",literature LUPUS influence the development lupus erythematosus,Helps the cause,117,172,131,202,-1,RO-has_manifestation,906012-FS1,"With the help of the literature and on the basis of own experiences course of the lupus erythematosus visceralis and LUPUS NEPHRITIS during pregnancy, the influence of the LUPUS ERYTHEMATOSUS VISCERALIS on pregnancy and development of the child, peculiarities of the treatment of lupus erythematosus visceralis during pregnancy as well as questions of prevention and interruption of pregnancy are discussed.",LUPUS NEPHRITIS,LUPUS ERYTHEMATOSUS VISCERALIS
503460947,7/16/2014 13:59:05,,1324264815,7/16/2014 13:58:12,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],LUPUS LUPUS,N/A,117,172,131,202,-1,RO-has_manifestation,906012-FS1,"With the help of the literature and on the basis of own experiences course of the lupus erythematosus visceralis and LUPUS NEPHRITIS during pregnancy, the influence of the LUPUS ERYTHEMATOSUS VISCERALIS on pregnancy and development of the child, peculiarities of the treatment of lupus erythematosus visceralis during pregnancy as well as questions of prevention and interruption of pregnancy are discussed.",LUPUS NEPHRITIS,LUPUS ERYTHEMATOSUS VISCERALIS
503460947,7/16/2014 14:49:44,,1324284389,7/16/2014 14:49:10,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[NONE],[NONE],N/A,separate conditions,117,172,131,202,-1,RO-has_manifestation,906012-FS1,"With the help of the literature and on the basis of own experiences course of the lupus erythematosus visceralis and LUPUS NEPHRITIS during pregnancy, the influence of the LUPUS ERYTHEMATOSUS VISCERALIS on pregnancy and development of the child, peculiarities of the treatment of lupus erythematosus visceralis during pregnancy as well as questions of prevention and interruption of pregnancy are discussed.",LUPUS NEPHRITIS,LUPUS ERYTHEMATOSUS VISCERALIS
503460947,7/16/2014 15:40:31,,1324302162,7/16/2014 15:40:18,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,unclear,117,172,131,202,-1,RO-has_manifestation,906012-FS1,"With the help of the literature and on the basis of own experiences course of the lupus erythematosus visceralis and LUPUS NEPHRITIS during pregnancy, the influence of the LUPUS ERYTHEMATOSUS VISCERALIS on pregnancy and development of the child, peculiarities of the treatment of lupus erythematosus visceralis during pregnancy as well as questions of prevention and interruption of pregnancy are discussed.",LUPUS NEPHRITIS,LUPUS ERYTHEMATOSUS VISCERALIS
503460947,7/16/2014 16:36:23,,1324328340,7/16/2014 16:35:03,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],influence,N/A,117,172,131,202,-1,RO-has_manifestation,906012-FS1,"With the help of the literature and on the basis of own experiences course of the lupus erythematosus visceralis and LUPUS NEPHRITIS during pregnancy, the influence of the LUPUS ERYTHEMATOSUS VISCERALIS on pregnancy and development of the child, peculiarities of the treatment of lupus erythematosus visceralis during pregnancy as well as questions of prevention and interruption of pregnancy are discussed.",LUPUS NEPHRITIS,LUPUS ERYTHEMATOSUS VISCERALIS
503460947,7/16/2014 16:39:05,,1324330146,7/16/2014 16:38:26,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],influence,none,117,172,131,202,-1,RO-has_manifestation,906012-FS1,"With the help of the literature and on the basis of own experiences course of the lupus erythematosus visceralis and LUPUS NEPHRITIS during pregnancy, the influence of the LUPUS ERYTHEMATOSUS VISCERALIS on pregnancy and development of the child, peculiarities of the treatment of lupus erythematosus visceralis during pregnancy as well as questions of prevention and interruption of pregnancy are discussed.",LUPUS NEPHRITIS,LUPUS ERYTHEMATOSUS VISCERALIS
503460947,7/16/2014 16:54:05,,1324336065,7/16/2014 16:53:18,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],LUPUS NEPHRITIS influence of LUPUS ERYTHEMATOSUS VISCERALIS,N/A,117,172,131,202,-1,RO-has_manifestation,906012-FS1,"With the help of the literature and on the basis of own experiences course of the lupus erythematosus visceralis and LUPUS NEPHRITIS during pregnancy, the influence of the LUPUS ERYTHEMATOSUS VISCERALIS on pregnancy and development of the child, peculiarities of the treatment of lupus erythematosus visceralis during pregnancy as well as questions of prevention and interruption of pregnancy are discussed.",LUPUS NEPHRITIS,LUPUS ERYTHEMATOSUS VISCERALIS
503460947,7/16/2014 17:06:25,,1324340055,7/16/2014 17:06:16,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,117,172,131,202,-1,RO-has_manifestation,906012-FS1,"With the help of the literature and on the basis of own experiences course of the lupus erythematosus visceralis and LUPUS NEPHRITIS during pregnancy, the influence of the LUPUS ERYTHEMATOSUS VISCERALIS on pregnancy and development of the child, peculiarities of the treatment of lupus erythematosus visceralis during pregnancy as well as questions of prevention and interruption of pregnancy are discussed.",LUPUS NEPHRITIS,LUPUS ERYTHEMATOSUS VISCERALIS
503460947,7/16/2014 17:47:32,,1324364749,7/16/2014 17:46:58,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[OTHER],[OTHER],influence of the,n/a,117,172,131,202,-1,RO-has_manifestation,906012-FS1,"With the help of the literature and on the basis of own experiences course of the lupus erythematosus visceralis and LUPUS NEPHRITIS during pregnancy, the influence of the LUPUS ERYTHEMATOSUS VISCERALIS on pregnancy and development of the child, peculiarities of the treatment of lupus erythematosus visceralis during pregnancy as well as questions of prevention and interruption of pregnancy are discussed.",LUPUS NEPHRITIS,LUPUS ERYTHEMATOSUS VISCERALIS
503460947,7/16/2014 18:04:43,,1324382669,7/16/2014 18:03:18,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,na,117,172,131,202,-1,RO-has_manifestation,906012-FS1,"With the help of the literature and on the basis of own experiences course of the lupus erythematosus visceralis and LUPUS NEPHRITIS during pregnancy, the influence of the LUPUS ERYTHEMATOSUS VISCERALIS on pregnancy and development of the child, peculiarities of the treatment of lupus erythematosus visceralis during pregnancy as well as questions of prevention and interruption of pregnancy are discussed.",LUPUS NEPHRITIS,LUPUS ERYTHEMATOSUS VISCERALIS
503460947,7/16/2014 18:49:24,,1324412076,7/16/2014 18:48:38,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[PART_OF],[PART_OF],"LUPUS NEPHRITIS during pregnancy, influence of the LUPUS ERYTHEMATOSUS VISCERALIS",n/a,117,172,131,202,-1,RO-has_manifestation,906012-FS1,"With the help of the literature and on the basis of own experiences course of the lupus erythematosus visceralis and LUPUS NEPHRITIS during pregnancy, the influence of the LUPUS ERYTHEMATOSUS VISCERALIS on pregnancy and development of the child, peculiarities of the treatment of lupus erythematosus visceralis during pregnancy as well as questions of prevention and interruption of pregnancy are discussed.",LUPUS NEPHRITIS,LUPUS ERYTHEMATOSUS VISCERALIS
503460948,7/16/2014 13:28:29,,1324252853,7/16/2014 13:28:20,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],ARRHYTHMIA,N/A,162,122,190,158,1,RO-may_prevent,907226-FS1,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
503460948,7/16/2014 13:29:09,,1324253136,7/16/2014 13:28:55,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],"Among the compounds tested, was the most active",N/A,162,122,190,158,1,RO-may_prevent,907226-FS1,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
503460948,7/16/2014 13:45:00,,1324259436,7/16/2014 13:44:46,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],compounds,Na,162,122,190,158,1,RO-may_prevent,907226-FS1,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
503460948,7/16/2014 14:16:56,,1324272231,7/16/2014 14:16:43,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],active,N/A,162,122,190,158,1,RO-may_prevent,907226-FS1,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
503460948,7/16/2014 14:43:47,,1324282682,7/16/2014 14:41:57,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[TREATS],[TREATS],the most active in,N/A,162,122,190,158,1,RO-may_prevent,907226-FS1,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
503460948,7/16/2014 14:45:01,,1324282992,7/16/2014 14:44:40,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY ADRENALINE INDUCED ARRHYTHMIA,n/a,162,122,190,158,1,RO-may_prevent,907226-FS1,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
503460948,7/16/2014 14:47:49,,1324283793,7/16/2014 14:45:51,prodege,1.0,15508331,USA,OK,Stillwater,139.78.139.193,[TREATS],[TREATS],most active in ANTIARRHYTHMIC ACTIVITY in INDUCED ARRHYTHMIA,N/A,162,122,190,158,1,RO-may_prevent,907226-FS1,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
503460948,7/16/2014 15:42:12,,1324302902,7/16/2014 15:41:27,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was the most active,n/a,162,122,190,158,1,RO-may_prevent,907226-FS1,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
503460948,7/16/2014 16:59:08,,1324337823,7/16/2014 16:57:49,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[LOCATION],[LOCATION],PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA,N/A,162,122,190,158,1,RO-may_prevent,907226-FS1,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
503460948,7/16/2014 17:31:58,,1324350735,7/16/2014 17:31:20,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[SYMPTOM],[SYMPTOM],was the most active in the ACTIVITY,n/a,162,122,190,158,1,RO-may_prevent,907226-FS1,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
503460948,7/16/2014 19:37:44,,1324437995,7/16/2014 19:37:27,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],ANTIARRHYTHMIC,N/A,162,122,190,158,1,RO-may_prevent,907226-FS1,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
503460948,7/16/2014 19:42:14,,1324440360,7/16/2014 19:39:25,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[PART_OF] [MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]
[PART_OF]",PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY ADRENALINE INDUCED ARRHYTHMIA,N/A,162,122,190,158,1,RO-may_prevent,907226-FS1,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
503460948,7/16/2014 20:31:22,,1324462805,7/16/2014 20:30:52,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"tested,",n/a,162,122,190,158,1,RO-may_prevent,907226-FS1,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
503460948,7/16/2014 20:48:53,,1324469932,7/16/2014 20:47:36,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY ADRENALINE INDUCED ARRHYTHMIA,n/a,162,122,190,158,1,RO-may_prevent,907226-FS1,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
503460948,7/16/2014 20:51:28,,1324470977,7/16/2014 20:50:30,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[PART_OF],[PART_OF],PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA,N/A,162,122,190,158,1,RO-may_prevent,907226-FS1,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
503460949,7/16/2014 13:29:58,,1324253469,7/16/2014 13:29:46,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],i.e.,N/A,89,59,96,79,-1,RO-has_definitional_manifestation,904631-FS1,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
503460949,7/16/2014 13:38:55,,1324257225,7/16/2014 13:38:37,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SIDE_EFFECT],[SIDE_EFFECT],i.e. the SEIZURES,n/a,89,59,96,79,-1,RO-has_definitional_manifestation,904631-FS1,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
503460949,7/16/2014 13:40:28,,1324257839,7/16/2014 13:39:47,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],i.e. the persist,N/A,89,59,96,79,-1,RO-has_definitional_manifestation,904631-FS1,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
503460949,7/16/2014 13:41:30,,1324258193,7/16/2014 13:41:16,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],develop chronic,Na,89,59,96,79,-1,RO-has_definitional_manifestation,904631-FS1,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
503460949,7/16/2014 13:43:56,,1324259085,7/16/2014 13:43:37,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SYMPTOM],[SYMPTOM],INTRACTABLE EPILEPSY,asd,89,59,96,79,-1,RO-has_definitional_manifestation,904631-FS1,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
503460949,7/16/2014 14:04:01,,1324266832,7/16/2014 14:03:21,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],i.e. the SEIZURES persist,N/A,89,59,96,79,-1,RO-has_definitional_manifestation,904631-FS1,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
503460949,7/16/2014 14:15:37,,1324271751,7/16/2014 14:15:22,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[IS_A],[IS_A],i.e.,N/A,89,59,96,79,-1,RO-has_definitional_manifestation,904631-FS1,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
503460949,7/16/2014 14:47:24,,1324283671,7/16/2014 14:46:23,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[SYMPTOM] [IS_A],"[SYMPTOM]
[IS_A]",develop chronic,N/A,89,59,96,79,-1,RO-has_definitional_manifestation,904631-FS1,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
503460949,7/16/2014 14:53:10,,1324285426,7/16/2014 14:51:18,prodege,1.0,15508331,USA,OK,Stillwater,139.78.139.193,[SYMPTOM],[SYMPTOM],INTRACTABLE EPILEPSY the SEIZURES persist despite,N/A,89,59,96,79,-1,RO-has_definitional_manifestation,904631-FS1,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
503460949,7/16/2014 15:29:59,,1324298293,7/16/2014 15:28:53,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[MANIFESTATION],[MANIFESTATION],i.e. the,n/a,89,59,96,79,-1,RO-has_definitional_manifestation,904631-FS1,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
503460949,7/16/2014 15:44:37,,1324303954,7/16/2014 15:44:21,prodege,1.0,23541832,USA,AZ,Tempe,149.169.143.104,[SYMPTOM],[SYMPTOM],i.e.,N/A,89,59,96,79,-1,RO-has_definitional_manifestation,904631-FS1,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
503460949,7/16/2014 16:37:25,,1324329012,7/16/2014 16:36:43,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[IS_A],[IS_A],INTRACTABLE EPILEPSY i.e. the SEIZURES,N/A,89,59,96,79,-1,RO-has_definitional_manifestation,904631-FS1,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
503460949,7/16/2014 16:37:55,,1324329325,7/16/2014 16:37:19,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[MANIFESTATION],[MANIFESTATION],SEIZURES persist,N/A,89,59,96,79,-1,RO-has_definitional_manifestation,904631-FS1,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
503460949,7/16/2014 16:44:39,,1324332755,7/16/2014 16:42:34,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,na,89,59,96,79,-1,RO-has_definitional_manifestation,904631-FS1,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
503460949,7/16/2014 17:58:15,,1324376179,7/16/2014 17:56:56,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[SYMPTOM],[SYMPTOM],develop i.e.,na,89,59,96,79,-1,RO-has_definitional_manifestation,904631-FS1,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
503460950,7/16/2014 13:40:55,,1324257968,7/16/2014 13:40:34,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",immunocytochemistry,asd,205,220,213,236,-1,RO-disease_has_finding,901521-FS1,"We studied the expression of Gal GalNAc by GOS reaction, lectin reactivity and immunocytochemistry in 10 normal, .45 precancerous [5 Crohn's disease, 15 ulcerative colitis (5 without dysplasia and 10 with DYSPLASIA), 25 TUBULAR ADENOMAS] and 25 adenocarcinoma cases.",DYSPLASIA,TUBULAR ADENOMAS
503460950,7/16/2014 13:44:48,,1324259371,7/16/2014 13:44:29,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],(5 without 10 with,N/a,205,220,213,236,-1,RO-disease_has_finding,901521-FS1,"We studied the expression of Gal GalNAc by GOS reaction, lectin reactivity and immunocytochemistry in 10 normal, .45 precancerous [5 Crohn's disease, 15 ulcerative colitis (5 without dysplasia and 10 with DYSPLASIA), 25 TUBULAR ADENOMAS] and 25 adenocarcinoma cases.",DYSPLASIA,TUBULAR ADENOMAS
503460950,7/16/2014 14:14:52,,1324271500,7/16/2014 14:14:31,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,205,220,213,236,-1,RO-disease_has_finding,901521-FS1,"We studied the expression of Gal GalNAc by GOS reaction, lectin reactivity and immunocytochemistry in 10 normal, .45 precancerous [5 Crohn's disease, 15 ulcerative colitis (5 without dysplasia and 10 with DYSPLASIA), 25 TUBULAR ADENOMAS] and 25 adenocarcinoma cases.",DYSPLASIA,TUBULAR ADENOMAS
503460950,7/16/2014 14:34:31,,1324279376,7/16/2014 14:34:08,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[NONE],[NONE],N/A,different terms,205,220,213,236,-1,RO-disease_has_finding,901521-FS1,"We studied the expression of Gal GalNAc by GOS reaction, lectin reactivity and immunocytochemistry in 10 normal, .45 precancerous [5 Crohn's disease, 15 ulcerative colitis (5 without dysplasia and 10 with DYSPLASIA), 25 TUBULAR ADENOMAS] and 25 adenocarcinoma cases.",DYSPLASIA,TUBULAR ADENOMAS
503460950,7/16/2014 15:37:15,,1324300832,7/16/2014 15:36:16,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n/a,list of problems the patients in the test had,205,220,213,236,-1,RO-disease_has_finding,901521-FS1,"We studied the expression of Gal GalNAc by GOS reaction, lectin reactivity and immunocytochemistry in 10 normal, .45 precancerous [5 Crohn's disease, 15 ulcerative colitis (5 without dysplasia and 10 with DYSPLASIA), 25 TUBULAR ADENOMAS] and 25 adenocarcinoma cases.",DYSPLASIA,TUBULAR ADENOMAS
503460950,7/16/2014 16:13:48,,1324319331,7/16/2014 16:12:48,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[CAUSES],[CAUSES],lectin reactivity and immunocytochemistry,[CAUSES],205,220,213,236,-1,RO-disease_has_finding,901521-FS1,"We studied the expression of Gal GalNAc by GOS reaction, lectin reactivity and immunocytochemistry in 10 normal, .45 precancerous [5 Crohn's disease, 15 ulcerative colitis (5 without dysplasia and 10 with DYSPLASIA), 25 TUBULAR ADENOMAS] and 25 adenocarcinoma cases.",DYSPLASIA,TUBULAR ADENOMAS
503460950,7/16/2014 16:27:51,,1324324921,7/16/2014 16:27:28,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,205,220,213,236,-1,RO-disease_has_finding,901521-FS1,"We studied the expression of Gal GalNAc by GOS reaction, lectin reactivity and immunocytochemistry in 10 normal, .45 precancerous [5 Crohn's disease, 15 ulcerative colitis (5 without dysplasia and 10 with DYSPLASIA), 25 TUBULAR ADENOMAS] and 25 adenocarcinoma cases.",DYSPLASIA,TUBULAR ADENOMAS
503460950,7/16/2014 16:38:45,,1324329935,7/16/2014 16:38:07,instagc,1,23149109,USA,NC,Cary,24.206.38.18,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]","10 DYSPLASIA), 25 TUBULAR ADENOMAS]",N/A,205,220,213,236,-1,RO-disease_has_finding,901521-FS1,"We studied the expression of Gal GalNAc by GOS reaction, lectin reactivity and immunocytochemistry in 10 normal, .45 precancerous [5 Crohn's disease, 15 ulcerative colitis (5 without dysplasia and 10 with DYSPLASIA), 25 TUBULAR ADENOMAS] and 25 adenocarcinoma cases.",DYSPLASIA,TUBULAR ADENOMAS
503460950,7/16/2014 18:36:13,,1324405159,7/16/2014 18:35:29,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,205,220,213,236,-1,RO-disease_has_finding,901521-FS1,"We studied the expression of Gal GalNAc by GOS reaction, lectin reactivity and immunocytochemistry in 10 normal, .45 precancerous [5 Crohn's disease, 15 ulcerative colitis (5 without dysplasia and 10 with DYSPLASIA), 25 TUBULAR ADENOMAS] and 25 adenocarcinoma cases.",DYSPLASIA,TUBULAR ADENOMAS
503460950,7/16/2014 19:05:52,,1324422151,7/16/2014 19:05:37,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[NONE],[NONE],N/A,Separate,205,220,213,236,-1,RO-disease_has_finding,901521-FS1,"We studied the expression of Gal GalNAc by GOS reaction, lectin reactivity and immunocytochemistry in 10 normal, .45 precancerous [5 Crohn's disease, 15 ulcerative colitis (5 without dysplasia and 10 with DYSPLASIA), 25 TUBULAR ADENOMAS] and 25 adenocarcinoma cases.",DYSPLASIA,TUBULAR ADENOMAS
503460950,7/16/2014 19:22:43,,1324430902,7/16/2014 19:22:08,prodege,1,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"DYSPLASIA), 25 TUBULAR ADENOMAS]",both symptoms of ulcerative colotis,205,220,213,236,-1,RO-disease_has_finding,901521-FS1,"We studied the expression of Gal GalNAc by GOS reaction, lectin reactivity and immunocytochemistry in 10 normal, .45 precancerous [5 Crohn's disease, 15 ulcerative colitis (5 without dysplasia and 10 with DYSPLASIA), 25 TUBULAR ADENOMAS] and 25 adenocarcinoma cases.",DYSPLASIA,TUBULAR ADENOMAS
503460950,7/16/2014 19:32:32,,1324435665,7/16/2014 19:32:12,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],We studied,N/A,205,220,213,236,-1,RO-disease_has_finding,901521-FS1,"We studied the expression of Gal GalNAc by GOS reaction, lectin reactivity and immunocytochemistry in 10 normal, .45 precancerous [5 Crohn's disease, 15 ulcerative colitis (5 without dysplasia and 10 with DYSPLASIA), 25 TUBULAR ADENOMAS] and 25 adenocarcinoma cases.",DYSPLASIA,TUBULAR ADENOMAS
503460950,7/16/2014 19:39:24,,1324438810,7/16/2014 19:38:32,neodev,1,20929875,USA,MA,Boston,140.241.0.20,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"(5 without dysplasia and 10 with DYSPLASIA), 25 TUBULAR ADENOMAS] and adenocarcinoma cases.",N/A,205,220,213,236,-1,RO-disease_has_finding,901521-FS1,"We studied the expression of Gal GalNAc by GOS reaction, lectin reactivity and immunocytochemistry in 10 normal, .45 precancerous [5 Crohn's disease, 15 ulcerative colitis (5 without dysplasia and 10 with DYSPLASIA), 25 TUBULAR ADENOMAS] and 25 adenocarcinoma cases.",DYSPLASIA,TUBULAR ADENOMAS
503460950,7/16/2014 19:47:38,,1324443087,7/16/2014 19:47:27,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[OTHER],[OTHER],and,N/A,205,220,213,236,-1,RO-disease_has_finding,901521-FS1,"We studied the expression of Gal GalNAc by GOS reaction, lectin reactivity and immunocytochemistry in 10 normal, .45 precancerous [5 Crohn's disease, 15 ulcerative colitis (5 without dysplasia and 10 with DYSPLASIA), 25 TUBULAR ADENOMAS] and 25 adenocarcinoma cases.",DYSPLASIA,TUBULAR ADENOMAS
503460950,7/16/2014 20:26:56,,1324460751,7/16/2014 20:26:06,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[OTHER],[OTHER],studied the expression of in,N/A,205,220,213,236,-1,RO-disease_has_finding,901521-FS1,"We studied the expression of Gal GalNAc by GOS reaction, lectin reactivity and immunocytochemistry in 10 normal, .45 precancerous [5 Crohn's disease, 15 ulcerative colitis (5 without dysplasia and 10 with DYSPLASIA), 25 TUBULAR ADENOMAS] and 25 adenocarcinoma cases.",DYSPLASIA,TUBULAR ADENOMAS
503460951,7/16/2014 13:32:08,,1324254549,7/16/2014 13:31:58,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],for the detection of antibodies to,N/A,76,133,93,141,1,RO-has_causative_agent,903820-FS1,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
503460951,7/16/2014 13:47:24,,1324260229,7/16/2014 13:46:58,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],as a screening test for,N/A,76,133,93,141,1,RO-has_causative_agent,903820-FS1,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
503460951,7/16/2014 14:01:58,,1324265932,7/16/2014 14:01:23,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TREPONEMA PALLIDUM was evaluated as screening test for SYPHILIS,N/A,76,133,93,141,1,RO-has_causative_agent,903820-FS1,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
503460951,7/16/2014 15:07:24,,1324291143,7/16/2014 15:06:43,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],as a screening test,N/A,76,133,93,141,1,RO-has_causative_agent,903820-FS1,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
503460951,7/16/2014 15:46:20,,1324304750,7/16/2014 15:45:45,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",for the detection of antibodies,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],76,133,93,141,1,RO-has_causative_agent,903820-FS1,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
503460951,7/16/2014 16:41:08,,1324331333,7/16/2014 16:40:38,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TREPONEMA PALLIDUM as screening test for SYPHILIS,N/A,76,133,93,141,1,RO-has_causative_agent,903820-FS1,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
503460951,7/16/2014 16:56:00,,1324336722,7/16/2014 16:55:14,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[CAUSES],[CAUSES],antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS,N/A,76,133,93,141,1,RO-has_causative_agent,903820-FS1,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
503460951,7/16/2014 19:08:09,,1324423503,7/16/2014 19:07:20,tremorgames,1.0,16681597,USA,IL,Chicago,76.193.178.111,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was evaluated,N/A,76,133,93,141,1,RO-has_causative_agent,903820-FS1,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
503460951,7/16/2014 19:31:50,,1324435349,7/16/2014 19:31:16,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was evaluated,N/A,76,133,93,141,1,RO-has_causative_agent,903820-FS1,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
503460951,7/16/2014 19:47:26,,1324442986,7/16/2014 19:47:01,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.7,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],as a screening test for,N/A,76,133,93,141,1,RO-has_causative_agent,903820-FS1,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
503460951,7/16/2014 20:35:14,,1324464272,7/16/2014 20:33:49,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TREPONEMA PALLIDUM evaluated as a screening test SYPHILIS,Diagnose by test or drug,76,133,93,141,1,RO-has_causative_agent,903820-FS1,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
503460951,7/16/2014 20:46:01,,1324468583,7/16/2014 20:45:00,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS,N/A,76,133,93,141,1,RO-has_causative_agent,903820-FS1,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
503460951,7/16/2014 20:46:07,,1324468668,7/16/2014 20:44:30,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[MANIFESTATION],[MANIFESTATION],was evaluated as a screening test,N/A,76,133,93,141,1,RO-has_causative_agent,903820-FS1,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
503460951,7/16/2014 20:52:12,,1324471258,7/16/2014 20:51:20,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],detection as a test for,n/a,76,133,93,141,1,RO-has_causative_agent,903820-FS1,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
503460951,7/16/2014 21:10:22,,1324480573,7/16/2014 21:08:32,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[PART_OF],[PART_OF],detection of TREPONEMA PALLIDUM for SYPHILIS,N/A,76,133,93,141,1,RO-has_causative_agent,903820-FS1,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
503460952,7/16/2014 13:43:28,,1324258920,7/16/2014 13:42:32,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],containing,N/A,104,104,111,122,1,RO-has_ingredient,905727-FS1,8  No information on transferring patients receiving extended release levodopa carbidopa preparation or LEVODOPA CARBIDOPA preparations containing a 1:10 ratio of carbidopa to LEVODOPA,LEVODOPA,LEVODOPA CARBIDOPA
503460952,7/16/2014 13:47:28,,1324260253,7/16/2014 13:47:07,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],LEVODOPA CARBIDOPA preparations containing ratio of LEVODOPA,N/a,104,104,111,122,1,RO-has_ingredient,905727-FS1,8  No information on transferring patients receiving extended release levodopa carbidopa preparation or LEVODOPA CARBIDOPA preparations containing a 1:10 ratio of carbidopa to LEVODOPA,LEVODOPA,LEVODOPA CARBIDOPA
503460952,7/16/2014 13:48:07,,1324260469,7/16/2014 13:47:27,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LEVODOPA CARBIDOPA preparations,N/A,104,104,111,122,1,RO-has_ingredient,905727-FS1,8  No information on transferring patients receiving extended release levodopa carbidopa preparation or LEVODOPA CARBIDOPA preparations containing a 1:10 ratio of carbidopa to LEVODOPA,LEVODOPA,LEVODOPA CARBIDOPA
503460952,7/16/2014 14:48:39,,1324284046,7/16/2014 14:48:10,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[PART_OF],[PART_OF],preparations containing a 1:10 ratio of carbidopa to LEVODOPA,N/A,104,104,111,122,1,RO-has_ingredient,905727-FS1,8  No information on transferring patients receiving extended release levodopa carbidopa preparation or LEVODOPA CARBIDOPA preparations containing a 1:10 ratio of carbidopa to LEVODOPA,LEVODOPA,LEVODOPA CARBIDOPA
503460952,7/16/2014 15:07:00,,1324291015,7/16/2014 15:06:04,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[PART_OF],[PART_OF],preparation containing,N/A,104,104,111,122,1,RO-has_ingredient,905727-FS1,8  No information on transferring patients receiving extended release levodopa carbidopa preparation or LEVODOPA CARBIDOPA preparations containing a 1:10 ratio of carbidopa to LEVODOPA,LEVODOPA,LEVODOPA CARBIDOPA
503460952,7/16/2014 15:08:04,,1324291349,7/16/2014 15:07:09,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[PART_OF],[PART_OF],containing,na,104,104,111,122,1,RO-has_ingredient,905727-FS1,8  No information on transferring patients receiving extended release levodopa carbidopa preparation or LEVODOPA CARBIDOPA preparations containing a 1:10 ratio of carbidopa to LEVODOPA,LEVODOPA,LEVODOPA CARBIDOPA
503460952,7/16/2014 15:36:57,,1324300736,7/16/2014 15:34:47,prodege,1.0,27990290,GBR,I9,Bury Saint Edmunds,86.142.231.81,[PART_OF],[PART_OF],1:10 ratio,there is a 1:10 ratio of carbidopa to levidopa so they are related.,104,104,111,122,1,RO-has_ingredient,905727-FS1,8  No information on transferring patients receiving extended release levodopa carbidopa preparation or LEVODOPA CARBIDOPA preparations containing a 1:10 ratio of carbidopa to LEVODOPA,LEVODOPA,LEVODOPA CARBIDOPA
503460952,7/16/2014 15:39:54,,1324301955,7/16/2014 15:38:48,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[IS_A],[IS_A],to,n/a,104,104,111,122,1,RO-has_ingredient,905727-FS1,8  No information on transferring patients receiving extended release levodopa carbidopa preparation or LEVODOPA CARBIDOPA preparations containing a 1:10 ratio of carbidopa to LEVODOPA,LEVODOPA,LEVODOPA CARBIDOPA
503460952,7/16/2014 16:38:48,,1324329996,7/16/2014 16:38:21,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],transferring,na,104,104,111,122,1,RO-has_ingredient,905727-FS1,8  No information on transferring patients receiving extended release levodopa carbidopa preparation or LEVODOPA CARBIDOPA preparations containing a 1:10 ratio of carbidopa to LEVODOPA,LEVODOPA,LEVODOPA CARBIDOPA
503460952,7/16/2014 17:07:05,,1324340367,7/16/2014 17:07:00,prodege,1.0,12944140,GBR,C8,Croydon,92.21.8.174,[NONE],[NONE],na,na,104,104,111,122,1,RO-has_ingredient,905727-FS1,8  No information on transferring patients receiving extended release levodopa carbidopa preparation or LEVODOPA CARBIDOPA preparations containing a 1:10 ratio of carbidopa to LEVODOPA,LEVODOPA,LEVODOPA CARBIDOPA
503460952,7/16/2014 17:08:10,,1324340734,7/16/2014 17:07:12,neodev,1.0,28350402,NLD,11,Hazerswoude-rijndijk,94.208.82.215,[PART_OF],[PART_OF],1:10 ratio carbidopa to LEVODOPA,N/A,104,104,111,122,1,RO-has_ingredient,905727-FS1,8  No information on transferring patients receiving extended release levodopa carbidopa preparation or LEVODOPA CARBIDOPA preparations containing a 1:10 ratio of carbidopa to LEVODOPA,LEVODOPA,LEVODOPA CARBIDOPA
503460952,7/16/2014 17:49:12,,1324366476,7/16/2014 17:48:30,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[LOCATION],[LOCATION],preparations containing a,n/a,104,104,111,122,1,RO-has_ingredient,905727-FS1,8  No information on transferring patients receiving extended release levodopa carbidopa preparation or LEVODOPA CARBIDOPA preparations containing a 1:10 ratio of carbidopa to LEVODOPA,LEVODOPA,LEVODOPA CARBIDOPA
503460952,7/16/2014 18:58:14,,1324417272,7/16/2014 18:57:56,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PART_OF],[PART_OF],containing,N/A,104,104,111,122,1,RO-has_ingredient,905727-FS1,8  No information on transferring patients receiving extended release levodopa carbidopa preparation or LEVODOPA CARBIDOPA preparations containing a 1:10 ratio of carbidopa to LEVODOPA,LEVODOPA,LEVODOPA CARBIDOPA
503460952,7/16/2014 20:59:26,,1324474153,7/16/2014 20:59:07,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[MANIFESTATION],[MANIFESTATION],LEVODOPA CARBIDOPA,NONE,104,104,111,122,1,RO-has_ingredient,905727-FS1,8  No information on transferring patients receiving extended release levodopa carbidopa preparation or LEVODOPA CARBIDOPA preparations containing a 1:10 ratio of carbidopa to LEVODOPA,LEVODOPA,LEVODOPA CARBIDOPA
503460952,7/16/2014 21:07:05,,1324478506,7/16/2014 21:05:54,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[NONE],[NONE],n/a,Talks about the make up of drug,104,104,111,122,1,RO-has_ingredient,905727-FS1,8  No information on transferring patients receiving extended release levodopa carbidopa preparation or LEVODOPA CARBIDOPA preparations containing a 1:10 ratio of carbidopa to LEVODOPA,LEVODOPA,LEVODOPA CARBIDOPA
503460953,7/16/2014 13:30:03,,1324253526,7/16/2014 13:29:33,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],no significant change,n/a,140,223,162,233,1,RO-may_diagnose,906938-FS1,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
503460953,7/16/2014 13:33:29,,1324255099,7/16/2014 13:33:02,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],followed administration,N/A,140,223,162,233,1,RO-may_diagnose,906938-FS1,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
503460953,7/16/2014 13:44:39,,1324259337,7/16/2014 13:44:13,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],administration in,N/A,140,223,162,233,1,RO-may_diagnose,906938-FS1,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
503460953,7/16/2014 13:48:02,,1324260443,7/16/2014 13:47:44,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,[TREATS],[TREATS],followed administration,N/A,140,223,162,233,1,RO-may_diagnose,906938-FS1,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
503460953,7/16/2014 14:45:49,,1324283176,7/16/2014 14:45:03,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],VARIANT ANGINA PECTORIS ERGONOVINE,n/a,140,223,162,233,1,RO-may_diagnose,906938-FS1,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
503460953,7/16/2014 14:47:13,,1324283606,7/16/2014 14:46:56,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],followed,N/A,140,223,162,233,1,RO-may_diagnose,906938-FS1,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
503460953,7/16/2014 15:04:19,,1324289891,7/16/2014 15:03:44,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],administration,na,140,223,162,233,1,RO-may_diagnose,906938-FS1,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
503460953,7/16/2014 15:27:13,,1324297394,7/16/2014 15:26:36,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],administration,n\a,140,223,162,233,1,RO-may_diagnose,906938-FS1,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
503460953,7/16/2014 15:33:33,,1324299478,7/16/2014 15:33:21,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],administration,N/A,140,223,162,233,1,RO-may_diagnose,906938-FS1,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
503460953,7/16/2014 16:29:44,,1324325639,7/16/2014 16:27:03,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],no significant change in the Q T interval followed ERGONOVINE administration,na,140,223,162,233,1,RO-may_diagnose,906938-FS1,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
503460953,7/16/2014 18:43:53,,1324409018,7/16/2014 18:42:59,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[TREATS],[TREATS],patients with VARIANT ANGINA no significant change followed ERGONOVINE administration,n/a,140,223,162,233,1,RO-may_diagnose,906938-FS1,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
503460953,7/16/2014 19:38:39,,1324438434,7/16/2014 19:37:56,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM],[SYMPTOM],chest pain,N/A,140,223,162,233,1,RO-may_diagnose,906938-FS1,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
503460953,7/16/2014 20:33:48,,1324463744,7/16/2014 20:32:26,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],patients with VARIANT ANGINA PECTORIS ERGONOVINE administration with atypical chest pain,Treats,140,223,162,233,1,RO-may_diagnose,906938-FS1,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
503460953,7/16/2014 20:51:20,,1324470933,7/16/2014 20:50:06,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],administration,n/a,140,223,162,233,1,RO-may_diagnose,906938-FS1,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
503460953,7/16/2014 20:59:36,,1324474249,7/16/2014 20:59:13,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[TREATS],[TREATS],administration,N/A,140,223,162,233,1,RO-may_diagnose,906938-FS1,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
